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Heart failure (HF) is one of the most important causes of morbidity and mortality 
both in the developed and the developing nations. Acute heart failure (AHF) is a 
syndrome characterized by hospital admission for heart failure as defined by the 
presence of acute dyspnea and the presence of heart failure signs by physical 
examination with at least 2 of the following:  rales, edema, elevated JVP, 
hepatomegaly and ascites. AHF can occur de novo or as worsening of symptoms in 
patients with chronic systolic or diastolic HF. In most sub Saharan African (SSA) 
countries, AHF has not been well studied and the incidence, prevalence, treatment 
and outcome of AHF are not well defined. HF in Africa affects young people in their 
prime of life and as such pose a huge economic burden on the population. There is 
also limited information on the characteristics, outcome and predictors of HF in 
general and AHF in particular. Study of clinical characteristics of AHF patients 
including the role of conventional and novel biomarkers in prognostication is 
therefore a research priority in this region. The findings will guide appropriate 
clinical decisions on treatment and proper monitoring.  
Methods: 
This work involved two cohorts of acute heart failure patients. The first included 
patients enrolled into a multicenter prospective observational clinical registry for 
hospitalized patients with AHF while the second included patients recruited for a 
prospective, placebo controlled double blind randomized study to compare treatment 
with hydralazine – isosorbide dinitrate versus placebo on top of standard care in 
African patients admitted with AHF. Data from each subject were obtained using a 
uniform and standardized case report forms (CRF) for the particular study. In both 
cases we collected demographic data, date of diagnosis of HF and pre-admission 
history (previous heart failure related admissions). Others included New York Heart 
Association (NYHA) functional class, symptoms, signs, self reported cardiovascular 
xi 
risk factors, aetiology of HF, precipitating factors, co-morbidities, blood 
investigations (including brain natriuretic peptide (BNP) and galectin-3 (Gal3) in the 
second cohort), Chest X-ray , 12-lead ECG, echocardiography and medications.  
The main objective of this thesis was to study the clinical characteristics and short-
term (6 months) outcome of acute heart failure as well as determine the role of 
conventional biomarker BNP and the novel biomarker Gal3 in the prognostication of 
acute heart failure patients. To achieve this, we investigated in the first cohort; 1) the 
demographic and clinical characteristic of patients with AHF, 2) their 
echocardiographic parameters and how they predict outcome, 3) the predictors of 
readmission and mortality, 4) the prevalence and impact of renal dysfunction on AHF 
and 5) the electrocardiographic pattern in AHF. The outcome measures were 
worsening renal function (WRF), length of hospital stay, HF readmissions and 
cardiovascular death within 60 days and all cause, cardiovascular or HF death 
through 180 days. In the second cohort, we investigated the demographics, clinical 
characteristics as well as the relationship between plasma levels of BNP and galectin 
3 and outcomes (cardiovascular (CV) death or HF hospitalization through week 24) 
as well as the relationship between the plasma levels of BNP and Gal3 and both left 
ventricular (LV) and right ventricular (RV) remodeling in patients with AHF. 
Results: 
The first cohort enrolled 1006 patients with AHF. The mean age was 52.3 years, 
50.8% were women, and the predominant race was black African (98.5%). HF was 
most commonly due to hypertension (45.4%), dilated cardiomyopathy (DCM) 
(18.8%) and rheumatic heart disease (RHD) (14.3%). Ischemic heart disease (IHD) 
was the cause of AHF in only 7.7%. The median hospital stay was 7 days, with an in-
hospital mortality of 4.2% and estimated 180-day mortality was 17.8%  
The main predictors of 60-day re-admission or death in a model excluding the 
geographic region were a history of malignancy, severe lung disease, admission 
systolic blood pressure, and signs of congestion (rales) and kidney function, i.e. 
abnormal blood urea nitrogen (BUN). In a model including region, the Southern 
xii 
region had a higher risk. Predictors of 180-day mortality included malignancy, severe 
lung disease, smoking history, systolic blood pressure, heart rate, and symptoms and 
signs of congestion (orthopnoea, peripheral oedema and rales) at admission, kidney 
dysfunction (BUN), anaemia, and HIV positivity. The echocardiographic predictors 
of 60-day readmission or death were left atrial size and heart rate while heart rate, LV 
posterior wall thickness in diastole (PWTd), and presence of aortic stenosis (AS) 
were associated with the risk of death through 180 days. Renal dysfunction was found 
in 31 % of the AHF patients. WRF was seen in 9.8 % of those with follow up 
creatinine values available, and has different predictors compared with Western 
cohorts. It was nevertheless, associated with the severity of congestion and clinical 
outcome. Atrial Fibrillation (AF) is present in 20.8% of AHF patients, 44% of whom 
had valvular AF. Having valvular AF predicted death through day 180.  
The second cohort randomized 133 patients; mean age was 53.2 years and 50.8 % 
were males. Eighty patients had data for biomarkers available for analysis.  In this 
cohort, both BNP and galectin-3 predicted CV death or HF hospitalization through 
week 24. While BNP was not associated both with changes in markers of LV and RV 
remodeling, Gal3 at baseline predicted changes (week 24 to baseline) in left 
ventricular ejection fraction (LVEF), left ventricular end systolic and end diastolic 
diameters as well as tricuspid annular systolic excursion (TAPSE).   
Conclusion: 
AHF in Africa affects middle-aged men and women in their productive ages, has a 
predominantly non-ischaemic cause and is associated with high mortality. Except for 
HIV status association with mortality, the main predictors of outcome are largely 
similar in sub-Saharan Africa as in the rest of the world; both renal dysfunction and 
AF are prevalent in AHF patients as they are in western cohorts. Novel biomarker 
Gal3 is valuable in predicting changes (week 24 to baseline) in markers of LV and 
RV remodeling in African AHF patients.  
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Summary of Chapters 
 
Chapter 1 of this PhD thesis is an overview of the literature, reviewing the current 
knowledge and concepts on the definition, epidemiology, pathophysiology, diagnostic 
strategy and treatment of acute heart failure with particular emphasis on SSA. This 
chapter ends with a description of the gaps in the knowledge that subsequent chapters 
attempted to address. 
Chapter 2 describes the hypothesis, aim and specific objectives of this doctoral 
research. 
Chapter 3 is a description of the two studies upon which the thesis was based. These 
are the sub Saharan African survey of heart failure (THESUS-HF), a prospective 
multicentre registry of acute heart failure and a randomised clinical trial, the bi 
treatment with hydralazine/isosorbide dinitrate (HYIS) versus placebo in Africans 
admitted with AHF (BAHEF).  
Chapters 4 to 10 present the results of this thesis including condensed publications, 
manuscripts that are still under review and those that were accepted (in press) by 
peer-reviewed journals.  
 In Chapter 4 (2 published articles), we present the demography, aetiology and 
clinical characteristics of acute heart failure in SSA. We demonstrated that 
AHF in SSA affects young men and women, caused mainly by hypertension, 
DCM and RHD. HIV infection is as yet not a significant cause of AHF in 
SSA. Unlike the western population, IHD was responsible for only a small 
percentage of AHF. Most of the patients present late with severe disease had 
significant co-morbidities, high readmission rates and mortality.  
 Chapter 5 (published article) described the predictors of readmission and 
death over 6 months in our AHF patients’ cohort. These were a history of 
malignancy, severe lung disease, admission systolic blood pressure, and signs 
of congestion (rales) as well as kidney function.  
 In chapter 6 (under review), we discussed symptoms and signs of HF at 
admission and discharge and outcomes in the SSA. Symptoms and signs of 
 
 xxviii 
HF were found to be valuable tools in predicting patients’ outcomes. Simple 
assessments including edema, rales, oxygen saturation, respiratory rate and 
asking the patient about general well-being seem to add significant prognostic 
value to baseline characteristics and lab values. 
 Chapter 7 (in press) focused on echocardiographic predictors. Left atrial (LA) 
size was associated with death or readmission within 60 days while left 
ventricular posterior wall thickness, and presence of aortic stenosis were 
associated with the risk of death through 180 days. 
 Chapter 8 (published article) addressed prevalence and impact of renal 
dysfunction in our cohort; renal dysfunction was seen in a third of our 
patients. WRF was an independent predictor of death or readmission over 60 
days and all-cause death over 180 days 
 In Chapter 9 (under review), we investigated the prevalence, clinical 
characteristics and outcomes of valvular AF. We found valvular AF was 
associated with all-cause death through day 180 but was not a significant 
predictor of all cause death or readmission through day 60.  
 Chapter 10 (ready to be submitted) investigated the prognostic value of NT-
Pro BNP and Galectin-3 in a cohort of AHF patients enrolled in the BAHEF 
trial. We showed that both N terminal pro BNP (NT pro BNP) and Gal-3 at 
baseline predicted combined CV death or HF hospitalization. Gal-3 also 
predicted changes in markers of LV remodeling and RV remodeling. 
Chapter 11 summarized the major findings of this thesis and recommended the 
potential areas of future research on AHF in SSA. 
Appendix is a collection of documents that were mandatory for the conduct of this 
work including, ethical approvals, statements of originality, the list of contributors to 







Two main studies contributed data to the analyses presented in this PhD thesis. They 
were both multicentre and multinational collaborative studies, and therefore involved 
many investigators (list provided in the Appendix).  
My specific role in relation to each of these studies is outlined below: 
The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF) 
I was the principal investigator for Aminu Kano Teaching Hospital, Kano Nigeria. I 
participated in all phases from the conception of the protocol to recruitments of 
patients, interpretation of results and drafting of all related manuscripts. My centre 
had the highest number of patients enrolled in the THESUS-HF registry. For the 
majority of the manuscripts forming part of this thesis (chapters 6, 7, 8 and 9), I am 
the lead investigator and lead author, responsible for hypothesis generation, writing of 
the protocol, planning and guidance of the statistical analyses, interpretation of 
results, writing of the manuscript, submission to journals and coordinating the 
response to reviewer’s comments.  
The Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with 
acute Heart Failure (BAHEF) 
After the success of THESUS-HF registry, we embarked on BAHEF, to answer a 
questioned that arose from THESUS. I was part of the steering committee for 
establishing the BAHEF study. I was part of the team that conceived the trial and 
generated the protocol. I was the principal investigator for my centre, the Aminu 
Kano teaching hospital, Kano, Nigeria and participated in the recruitments of patients, 
interpretation of results and drafting of all related manuscripts. Out of the 2 
manuscripts included in this thesis, I am the lead author, responsible for hypothesis 
generation, writing of the protocol, planning and guidance of the statistical analyses, 
interpretation of results, writing of the manuscript, for the biomarker paper (chapter 
10). The thesis did not include the details of the results of the BAHEF study, other 




1. Chapter 1: Introduction/Background to the Thesis 
1.1 Global Burden of Cardiovascular Disease 
 
Cardiovascular disease (CVD) constitutes a major public health problem both in the 
developed and developing countries. By the turn of the 20th century CVD was responsible 
for fewer than 10% total global deaths. CVD is now leading cause of death worldwide 
accounting for over 30% of all deaths (Figure 1). 1,2 Of the 58 million deaths from all 
causes worldwide in 2005, an estimated 17.5 million were due to CVD, 3 times more 
deaths than are caused by infectious diseases including HIV/AIDS, tuberculosis, and 
malaria combined. 2 It is estimated that non-communicable diseases (NCDs) will account 
for more than three-fourths of all deaths in the year 2030, and deaths from CVD will rise 
to 23.4 million, an approximately 37% increase from 2004 rates. Furthermore, the leading 
causes of death in the world in 2030 are predicted to be ischemic heart disease (IHD) and 
cerebrovascular disease (stroke), both components of CVD.3 
The World Health Organization (WHO) noted that CVD has no geographic, 
socioeconomic, or sex boundaries. It is the leading cause of death in both developed 
developing countries as well. Low- and middle-income countries (LMICs); defined as a 
gross national income per capita of less than $10,066 US dollars per annum in 2004, 
contribute to about 80% of CVD deaths.3,4  
According to the Global Burden of Disease (GBD) study, a 55% rise would occur in 
disability adjusted life years (DALYs) loss attributable to CVD between 1990 and 2020 
in the developing countries. 5 This would be in contrast to a 14.3% reduction in the 




countries (including both established market economies and former Socialist economies). 
The gap would widen further if the former Socialist economies, which are facing 
resurgence in CVD, were excluded.  
A recent study of five countries emphasizes that a much higher proportion of deaths 
occur in the working age population in Brazil, India, and South Africa in contrast to the 
USA and Portugal.6 
The potential results of the burden of CVD on the productive population of the 
community have far reaching implications. LMICs are confronted with a dual burden of 
communicable and degenerative diseases, which need tertiary care, and a subsequent 
diversion of inadequate resources. Apart from the loss of productive years of life, CVD 
leads to economic constraints with an impact on both the private and the public sectors.  
 
 
Figure 1.1 Proportion of global death caused by cardiovascular disease (adapted from 



















1.2 The Epidemiologic Transition 
 
The epidemiological transition provides a useful framework for understanding changes in 
the patterns of disease as a result of socioeconomic and demographic developments. 7 It 
refers to the shift that occurs in developing countries as mortality rates from infectious 
diseases and nutritional deficiencies decrease and mortality from NCDs increases. Omran 
divided this epidemiological transition into 3 basic ages: pestilence and famine, receding 
pandemics, and degenerative and man-made diseases. 8 Olshansky and Ault added a 
fourth stage, delayed degenerative diseases. 9 A fifth regressive stage caused by social 
upheaval or war, with resurgence in infectious diseases, and high mortality from both 





Table 1.1 Modified Model of the Stages of Epidemiologic Transition as it pertains to 
cardiovascular diseases (adapted from Yusuf et al. 2001) 
Stages of Development Deaths 
from CVD 
(% of Total 
Deaths) 
Prominent CVD and Risk 
Factors 
Regional Examples 
1 Age of pestilence and 
famine 
5–10 Rheumatic heart disease, 
infections, and nutritional 
cardiomyopathies 
Sub-Saharan 
Africa, rural India, 
South America 
2 Age of receding 
pandemics 
10–35 As above + hypertensive 
heart disease and 
hemorrhagic strokes 
China 
3 Age of degenerative and 
man-made diseases 
35–65 All forms of strokes, 
ischemic heart disease at 
young ages, increasing 






4 Age of delayed 
degenerative 
Diseases 
<50 Stroke and ischemic heart 





5 Age of health regression 
and 
social upheaval 
35–55 Re-emergence of deaths 
from rheumatic heart 
disease, infections, increased 
alcoholism, and violence; 
increase in ischemic and 
hypertensive diseases in the 
young 
Russia 
During Stages 1 to 4, life expectancy increases, whereas in Stage 5 life expectancy decreases 
compared with stages 4 and even 3. 
 
This shift or transition in disease and mortality rates reflects economic development, 
urbanization, industrialization, and changes in social organization within countries and 
regions with increased exposure to risk factors driven by changes in diet, physical 
activity, and environment. 8,11 The overall epidemiologic transition has been triggered by 
the “globalization” of dietary habits, characterized by increased consumption of fats and 
sugars, and urbanization. 12-15 Statistical projections suggest that by 2025, 43.5% of the 




in 1994. 7 Declining death rates from infectious diseases have also accompanied 
socioeconomic growth and improved vaccination and other primary health care services. 
Falling infant and child mortality has led to fast demographic changes leading to large 
increases in the number of individuals living until middle and older age, when chronic 
diseases become apparent—the so-called demographic transition. It is projected that by 
2025, the number of Africans over 60 years old will increase from 39 million to 80 
million.16 
In addition, while European and North American populations underwent similar changes 
in demography, determinants, and disease rates over the course of a few centuries,  
African countries are passing through similar transitions in just a few decades. This 
forced pace of globalization has resulted in the "export of risk factors" from the West 
such as tobacco, refined foods, and lifestyles with high CVD risk. 17 At any given period, 
different countries in the world or even different regions within a country are at different 
stages of the epidemiologic transition. This transition can occur not only between 
different disease categories (e.g., deaths from childhood diarrhea and malnutrition giving 
way to adult chronic diseases), but also within a particular disease category e.g., 
rheumatic heart disease (RHD) of the young giving way to chronic coronary artery 
diseases of middle age or valve calcification, degeneration, and HF of the elderly.10 
Even though countries tend to enter these stages at different times, the progression from 
one stage to the next tends to proceed in a predictable manner, with both the rate and the 





1.3 Emerging Epidemic of Cardiovascular Disease in sub Saharan Africa 
 
Sub-Saharan Africa (SSA), consisting of those countries that are fully or partially located 
south of the Sahara Desert, are currently experiencing one of the most rapid 
epidemiological transitions characterized by increasing urbanization and changing 
lifestyle factors, 19 which in turn have raised the incidence of NCDs, especially CVD. 20 
Studies indicate that urbanization and economic development have also led to the 
appearance of a nutritional transition characterized by a shift to a higher caloric content 
diet and/or reduction of physical activity. 21 Together, these transitions create enormous 
public health challenges, and failure to address the problem may impose significant 
burden for the health sector and the economy of sub-Saharan African countries.22 
The increasing epidemic in of CVD in developing countries is not only driven by the 
emergence of established risk factors, but also by other contributors to a hostile 






Figure 1.2 The potential epidemic of cardiovascular disease in Africa (modified from Gersh et al. 
2010) 
 
Based on the global burden of disease estimates in 2001, CVD and IHD were the eighth 
and ninth leading causes of death in SSA, and contributed 3.3 and 3.2%, respectively, of 
total deaths recorded in that year. 24 Overall, in 2001, 10% of all deaths in SSA occurred 
as a result of CVD, and 4% of (DALYs) were related to a CVD. CVDs and chronic 
diseases are compounding an under-resourced and understaffed public health care system 
in SSA, and there is a huge financial burden as well. 25 It has been projected that by 2030, 
IHD and cerebrovascular diseases will overtake HIV/AIDS as the leading causes of death 
in this region, contributing over 20% of total deaths and 7% of DALYs in SSA.26 
This representation is however incomplete because CVD epidemiology studies have been 
limited in the region, and complete vital registration of deaths by cause and burden of 
disease assessments have been done by only a handful of SSA countries. 27  




and 2010, based on the available data. 28 They showed that compared with all other world 
regions, the SSA region had the smallest proportion of disease burden attributed to CVD 
in 2010: 8.8% of total deaths, 3.9%of years of life lost, and 3.5% of DALYs. 28 The 
corresponding CVD proportions for combined high-income regions were 35.7%, 27.2%, 
and 16.4%. Within SSA, the Southern region had the highest proportional CVD burden 
and the Western region the lowest. 
At present, there are glaring economic forces propelling previously isolated rural groups 
into the peri-urban and urban areas. As they migrate, a pattern of increasing risk factors 
with higher rates of urbanization is observed. In South Africa, the increasing migration of 
blacks to urban centers has led to increased poverty, obesity, hypertension, and elevated 
cholesterol, and this is likely to similar in most of SSA countries. 7 As “civilization” 
spreads, so does CVD become an increasing health burden that requires skillful and cost-
effective management.18 The effect of potentially modifiable risk factors associated with 
myocardial infarction (MI) in 52 countries (INTERHEART) study has shown that 
hypertension is a strong contributor to the hazards of CVD in black Africans, with an OR 
of 7.0 versus 2.3 to 3.9 in other ethnic groups. 29 Both poverty and affluence may bring 
disease. According to the “fetal” origins of adult disease, as put forward by Barker, 
environmental factors and particularly poor maternal nutrition during pregnancy may 
program risks for adverse health that appear only later in adult life. 30 Specifically, there 
is an inverse relation between birth weight and CVD in later life, as shown in a 
longitudinal study from Scotland. 31 Fetal and infant under nutrition have recently been 
shown to be associated with significantly increased risk of hypertension and impaired 




Other major CVD in Africa include the consequences of HIV/ AIDS (often manifesting 
as tuberculous pericarditis), RHD, and cardiomyopathy (DCM), each of which has at 
least some environmental component.33-35 
With increasing CV risk factors comes increase in CVD. Many of CV risk factors when 
not effectively managed will lead to HF. HF is an important cause of death and disability 
in SSA, and unlike in the high-income countries (HICs) of North America and Europe, it 
is most often caused by hypertensive heart disease (HHD), RHD, or DCM and rarely by 
IHD. 35-37 HF is however conspicuously absent among the major CVDs in SSA on the 
GBD report. 28 This is because the GBD cause list was based on international 
classification of disease (ICD), and in the ICD, HF is not classified as an underlying 
cause of death and disability, it is assigned to its root CVD causes. 28 The limitation of 
this emphasis on primary HF prevention is that the likely benefits of treating HF cases 
and improving prevalent HF disability burden are not explicitly estimated, to some 
degree taking HF off the public health agenda for SSA. It is likely that if HF underlying 
causes were reclassified into HF burden, HF would rise to be among the major CVDs in 
SSA. 28 GBD HF burden estimates are therefore required urgently in SSA. 
 
1.4 Definition & Classifications of HF/AHF 
 
Many definitions of HF have been put forward over the last 50 years. 38 In recent years, 
most definitions have emphasized the need for both the presence of symptoms of HF and 
physical signs of fluid retention. 39-42 HF can be defined as an abnormality of cardiac 




commensurate with the requirements of the metabolizing tissues, despite normal filling 
pressures (or at the expense of increased filling pressures). 43 Table 1.2 gives a historical 
perspective on HF definitions. 44 The diagnosis of HF can be difficult and many of the 















Table 1.2 A historical perspective of heart failure definitions (adapted from Sliwa & 
Stewart 2016) 
Wood, 1968 ‘A state in which the heart fails to maintain an adequate circulation for the 
needs of the body despite a satisfactory venous filling pressure.’ 
Braunwald & 
Grossman, 1992 
‘A state in which an abnormality of cardiac function is responsible for the 
failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolising tissues or, to do so only from an elevated 
filling pressure.’ 
Packer, 1988 ‘A complex clinical syndrome characterised by abnormalities of left 
ventricular function and neurohormonal regulation which are accompanied 
by effort intolerance, fluid retention and reduced longevity.’ 
Poole-Wilson, 1987 ‘A clinical syndrome caused by an abnormality of the heart and recognised 





‘Heart failure is a complex clinical syndrome that can result from any 
structural or functional cardiac disorder that impairs the ability of the 
ventricle to fill with or eject blood.’ 
ESC  Heart Failure 
Guidelines, 200539 
‘A syndrome in which the patients should have the following features: 
symptoms of heart failure, typically breathlessness or fatigue, either at rest 
or during exertion, or ankle swelling and objective evidence of cardiac 




Definition essentially unchanged, with reinforcement of the stages of heart 
failure (see legend below – note that the first two stages are not heart 
failure) and the central importance of the following statement: “The single 
most useful diagnostic test in the evaluation of  patients with HF is the 
comprehensive 2-dimensional echocardiogram  coupled with Doppler flow 
studies to determine whether abnormalities of myocardium, heart valves, or 
pericardium are present and which chambers are involved. Three 
fundamental questions must be addressed: 1) Is the LV ejection fraction 
(EF) preserved or reduced? 2) Is the structure of the LV normal or 
abnormal? 3) Are there other structural abnormalities such as valvular, 






ESC  Heart Failure 
Guidelines, 2012 
(Update) 42  
 
‘A syndrome in which patients have typical symptoms (e.g. breathlessness, 
ankle swelling and fatigue) and signs (e.g. elevated jugular venous pressure, 
pulmonary crackles and displaced apex beat) resulting from an abnormality 
of cardiac structure or function. 
 
1.4.1 Mild, Moderate or Severe HF 
Mild, moderate, or severe HF is employed as a clinical symptomatic narrative, where 
mild is used for patients who can move around with no important restrictions from 
dyspnoea or fatigue, severe for patients who are markedly symptomatic and demand 
frequent medical attention, and moderate for those in between. Two classifications of the 
severity of HF are commonly employed. Table 1.3 shows the comparison between these 
two classifications. 48 The New York heart association (NYHA) functional classification 
is based on symptoms and exercise capacity. 49 It is clinically important and is employed 
routinely to select patients in almost all randomized treatment trials in HF and, to 
describe which patients benefit from effective therapies. Patients in NYHA class I have 
no symptoms; those in NYHA classes II, III or IV are sometimes said to have mild, 
moderate or severe symptoms, respectively.  It is important to note, however, that 
symptom severity correlates poorly with ventricular function, and that although there is a 
clear relationship between severity of symptoms and survival, patients with mild 
symptoms may still have a relatively high absolute risk of hospitalization and death.50,51 
The other classification is the American College of Cardiology (ACC) and American 
Heart Association (AHA), which designates HF in stages based on structural changes and 




Table 1.3 Comparison of the classification of heart failure by structural abnormality 
(ACC/AHA), or by symptoms relation to functional capacity (NYHA) (adapted from 
Yancy et al. 2013) 
ACC/AHA stages of heart failure 49,52 NYHA functional classification63 
Stage of heart failure based on structure and 
damage to heart muscle 




At high risk for developing 
heart failure. No identified 
structural or functional 







Developed structural heart 
disease that is strongly 
associated with the 
development of heart 







Symptomatic heart failure 
associated with underlying 
structural heart disease. 
 
Class I 
No limitation of physical 
activity. Ordinary physical 
activity does not cause 






Slight limitation of physical 
activity. Comfortable at 
rest, but ordinary physical 
activity results in fatigue, 





Marked limitation of 
physical activity. 
Comfortable at rest, but less 
than ordinary activity 
results in fatigue, 





Unable to carry on any 
physical activity without 
discomfort. 
Symptoms at rest. If any 
physical activity is 




Advanced structural heart 
disease and marked 
symptoms of heart failure 
at rest despite maximal 
medical therapy 
Class IV Unable to carry on any 
physical activity without 
discomfort. 
Symptoms at rest. If any 
physical activity is 






Regrettably, despite a lot of progress made in the treatment of HF, a significant minority 
of patients continues to do poorly with conventional therapy. These patients are classified 
to have advanced HF. Clearly, patients who are in need of inotropic therapy or left 
ventricular assist devices to sustain life are believed to be in this group. However, they 
also include a larger group of patients who may not be as critically ill but still at 
substantial risk of hospitalization and death. Therefore, the current literature suggests that 
the working definition of advanced HF should include persistence of severe clinical 
symptoms and signs despite treatment, presence of marked left ventricular (LV) systolic 
dysfunction, and poor exercise capacity. 53 Prognostic studies support the following 
specific criteria: NYHA functional class III or IV for 3 months despite attempts at 
standard therapy combined with a left ventricular ejection fraction (LVEF)  <30% and a 
peak oxygen consumption during symptom-limited exercise testing of <14 ml/kg/min 
(Table 1.4). 53 Other supplementary clinical findings give additional support for the 






Table 1.4 Diagnostic Criteria for advance heart failure (adapted from Adams & 
Zannad 1998) 
A A Major criteria (all required) 
 1 - Resting left ventricular ejection fraction <30% 
 2 - Presence of NYHA functional class III or IV or, if available, peak oxygen 
consumption <14 ml/kg/min on symptom-limited exercise testing 
B Additional criteria that contribute to the diagnosis 
 1 - Trial of standard therapy (ACE inhibitors, digoxin, diuretics) for at least 3 
months 
 2 - Plasma norepinephrine >900 pg/ml 
 3 - Noninvasive evidence of pulmonary hypertension indicated by high velocity of 
tricuspid regurgitation (>2.5 m/sec) 
 4 - Hyponatremia with serum sodium <130 mmol/L in patients not treated with 
ACE inhibitors 
 
1.4.2 Systolic vs. Diastolic HF  
Systolic dysfunction is characterized by decreased contraction and emptying of the LV so 
that stroke volume is preserved by an increase in end-diastolic volume. This results in 
dilatation of the LV and the heart ejects a smaller fraction of a larger volume. The more 
advanced the systolic dysfunction, the more the ejection fraction (EF) is reduced from 
normal and, usually, the greater the end-diastolic and end-systolic volumes. An EF below 
or above 40%, distinguishes between large or normal left end-diastolic ventricular 
volumes. 42 It is considered important in HF, not only because of its prognostic 
importance (the lower the EF the poorer the survival) but also because most clinical trials 
selected patients based upon EF (usually measured using a radionuclide technique or 
echocardiography). EF values are dependent on the imaging technique used, method of 
analysis, and operator. Because other techniques may indicate abnormalities in systolic 
function among patients with a preserved EF, it is preferable to use the terms preserved or 




symptoms and/or signs of HF and a preserved LVEF >40–50%.54 There is no consensus 
concerning the cut-off for preserved EF. Other phrases have been used to describe 
diastolic HF, such as HF with preserved ejection fraction (HFpEF) or HF with normal 
ejection fraction (HFNEF). 43   
 
1.4.3 HF with reduced EF (HFrEF) 
About half of patients with HFrEF present with variable degrees of LV enlargement may 
accompany HFrEF.55,56 The definition of HFrEF has varied, with guidelines of left 
ventricular ejection fraction (LVEF) <35%, < 40%, and <40%.41,42,57 The major trials in 
patients with HF and a reduced EF (HFrEF), or ‘systolic HF’, mainly enrolled patients 
with an EF ≤35%, and it is only in these patients that effective therapies have been 
demonstrated to date. Most patients with HFrEF commonly have evidence of diastolic 
dysfunction at rest or on exercise. 58 Although coronary artery disease (CAD) with 
antecedent MI is a major cause of HFrEF, many other risk factors may lead to LV 
enlargement and HFrEF. 
1.4.4 HF with preserved EF (HFpEF)  
In patients with clinical HF, studies estimate that the prevalence of HFpEF is 
approximately 50% (range 40% to 71%).59 These estimates vary largely because of the 
differing EF cut-off criteria and challenges in diagnostic criteria for HFpEF. HFpEF has 
been variably classified as EF >40%, >45%, >50%, and >55%.48 Some of these patients 
clearly did not have an entirely normal EF (generally considered to be >50%) neither do 
they have a major reduction in systolic function either. Because of this, the term HF with 
‘preserved’ EF (HFpEF) was created to describe these patients. Patients with an EF in the 




underlying risk factors and comorbidities. Several criteria have been proposed to define 
the syndrome of HFpEF. These include a) clinical signs or symptoms of HF; b) evidence 
of preserved or normal LVEF; and c) evidence of abnormal LV diastolic dysfunction that 
can be determined by Doppler echocardiography or cardiac catheterization. 60 Studies 
have suggested that the incidence of HFpEF is increasing and that a greater portion of 
patients hospitalized with HF have HFpEF. 61 In the general population, patients with 
HFpEF are usually older women with a history of hypertension. Obesity, CAD, diabetes 
mellitus (DM), AF, and hyperlipidemia are also highly prevalent in HFpEF in population-
based studies and registries.59,62 It has been recognized that a subset of patients with 
HFpEF previously had HFrEF. 63 These patients with recovery in EF may be clinically 
different from those with persistently preserved or reduced EF. Further research is needed 
to better characterize these patients. The diagnosis of HFpEF is more difficult than the 
diagnosis of HFrEF because it also involves exclusion of potential non-cardiac causes of 
the patient’s symptoms (such as anaemia or chronic lung disease must first be 
discounted.64,65 Usually these patients do not have a dilated heart and many have an 
increase in LV wall thickness and increased LA size. Most have evidence of diastolic 
dysfunction, which is generally accepted as the likely cause of HF in these patients 
(hence the term ‘diastolic HF’).64,65 There are few reports on HF with preserved systolic 
function from SSA. This is commonly seen due to HHD either alone or in addition to 
systolic HF.66 
 
1.4.5 Acute versus chronic HF 
The word ‘acute’ in the context of acute HF (AHF) has become confusing because some 




others use the word to indicate decompensated, recent-onset, or even new-onset HF. 67 
The word is then an indicator of time rather than severity. The words acute, advanced, 
and decompensated should not be used as synonyms when applied to HF. AHF diagnosis 
is made when a sudden onset of symptoms or signs of HF is found in a patient with no 
history of HF and previously normal cardiac function or when a patient wit established 
diagnosis of HF develops increasing signs or symptoms of the disease after a period of 
relative stability. The former syndrome is also called new-onset (‘de novo’) HF and is 
usually caused by an acute change in LV performance or in structural cardiac integrity.68 
Common examples new-onset HF would be HF associated with acute MI, mechanical 
complications such as papillary muscle rupture, or fulminant myocarditis. Therapy in 
such cases must be directed both at the underlying condition (such as MI) and at the HF 
itself. However, the majority of patients with AHF are those who present with acute 
decompensation or exacerbation of chronic heart failure (CHF) and they represent the 
majority of hospitalizations for HF. 68 After initial management and stabilization of 
patients with decompensated HF, they should no longer be considered acute but chronic 
HF. 69 Patients who have had HF for some time are often said to have CHF. A treated 
patient with symptoms and signs, which have remained generally unchanged for at least a 
month, is said to be ‘stable’. If a stable CHF patient deteriorates, it usually leads to 
hospital admission, an event of considerable prognostic importance. Although symptoms 
and signs may resolve in these patients, their underlying cardiac dysfunction may not, 
and they remain at risk of recurrent ‘decompensation’. Some other patients, particularly 
those with ‘idiopathic’ DCM, may also show substantial or even complete recovery of 




converting enzyme inhibitor (ACE-I), beta-blocker, and mineralocorticoid receptor 
antagonist (MRA)]. 42  
AHF therefore encompasses 3 different patient groups: (1) patients with worsening 
chronic systolic or diastolic HF that appears to respond to therapy; (2) patients with de 
novo HF secondary to a precipitant factor, such as a large MI or a sudden increase in 
blood pressure (BP) superimposed on a noncompliant LV; and (3) patients with 
worsening of end-stage/advanced HF (ie, HF that is refractory to therapy), with 
predominantly LV systolic dysfunction associated with a low-output state. 70 Irrespective 
of the underlying cause (e.g., ischemic event) or precipitant (e.g., severe hypertension), 
pulmonary and systemic congestion due to elevated ventricular filling pressures with or 
without a decrease in cardiac output (CO) is a nearly universal finding in AHF. 71  
 ‘Congestive HF’ is a term that is sometimes still used, and may describe acute or chronic 
HF with evidence of congestion (i.e. sodium and water retention). Congestion, though not 
other symptoms of HF (e.g. fatigue), may resolve with diuretic treatment. Many or all of 
these terms may be accurately applied to the same patient at different times, depending 
upon their stage of illness. 42 In practice, the Framingham HF criteria can apply to both 
chronic HF and acute HF.72 
The difference between new-onset AHF and acute HF on a background of chronic HF 
(including advanced HF) is in the degree of physiologic response, which is more 
pronounced in the acute de novo cases and is more subtle in the chronic cases because of 
adaptive pathophysiology. 67 Patients with new-onset AHF have strong sympathetic 
activation. The microvascular permeability can be enhanced, and therefore the clinical 




conditions, and any classification will have its limitations. The patient with AHF will 
usually present in one of six clinical categories. Pulmonary oedema may or may not 
complicate the clinical presentation. Cardiogenic pulmonary oedema is accumulation of 
fluid in the lung interstitium and alveoli due to increase in hydrostatic pressure secondary 
to elevated pulmonary venous pressure. It can result from many causes including 
excessive intravascular volume administration, pulmonary venous outflow obstruction 
(e.g. mitral stenosis and left atrial myxoma) and LV failure secondary to systolic or 
diastolic dysfunction of the LV. In contrast, acute circulatory failure or shock refers to a 
situation where there is inadequate or inappropriately distributed tissue perfusion 
resulting in generalized cellular hypoxia with associated hemodynamic disturbances, end-
organ dysfunction and elevated biochemical markers of impaired tissue perfusion. Figure 




















1.5 Epidemiology of HF/AHF  
 
HF is the end stage of all diseases of the heart and is growing at alarming proportions 
especially in the elderly. It is one of the most important causes of morbidity and mortality 
both in the developed and the developing nations.  While HF was not listed as a primary 
cause of death in the GBD studies, 28 it was included as one of the non-fatal health 
outcomes and as a significant parameter in the monitoring of population health. The GBD 
studies have been the only studies to quantify non-fatal health outcomes across an 
exhaustive set of disorders at global and regional level. Left-sided and right-sided 
symptomatic HF was one of the 289 impairments included in the GBD cause-sequelae 
list in many locations. 73 It was estimated that there were 37.7 million cases of prevalent 
HF recorded globally in 2010, leading to 4.2 years lived with disability (YDLs). More 
than two-thirds (68.7%) of HF globally was attributable to four underlying causes: IHD, 
chronic obstructive pulmonary disease (COPD), HHD and RHD.  Importantly, there were 
marked regional differences, with HHD, RHD, DCM and myocarditis making a larger 










Table 1.5 Global years lived with disability (DALYs) for heart failure from a comprehensive list of 289 causes and selected  
sequelae in 1990 and 2010for all ages, both sexes combined and per 100,000 (adapted fro Vos et al. 2012) 
 
 ALL ages YDLs (thousands) YLDs ( per 100 000) 
Cause of heart 
failure 




14 373 (11 094–18 134) 21 985 (16 947–27 516) 53.0% 53.0% 271 (209–342) 319 (246–399) 17.7% 
Rheumatic HD 290 (191–412) 420 (278–592) 45.1% 5 (4–8) 6 (4–9) 11.6% 
Ischaemic  HD 894 (609–1236) 1518 (1038–2128) 69.9% 17 (11–23) 22 (15–31) 30.8% 
Hypertensive HD 292 (202–412) 460 (315–639) 57.4%  6 (4–8) 7 (5–9) 21.1% 
HF due to 
Cardiomyopathy 
and Myocarditis 
272 (183–378) 394 (269–551) 44.8% 5 (3–7) 6 (4–8) 11.4% 
HF due to 
endocarditis 
42 (28–59) 61 (42–87) 45.8% 1 (1–1) 1 (1–1) 12.2% 
HF from other 
circulatory 
diseases 





According to the ESC, there are at least 15 million patients with HF in Europe. 42 The 
prevalence of HF is between 2 and 3% and rises sharply at about 75 years of age, so the 
prevalence in 70- to 80-year-old people is between 10 and 20%.  
In the United States of America (USA), approximately 5.1 million persons have clinically 
manifest HF. The lifetime risk of developing HF is 20% for Americans who are >40 
years of age. 74 HF incidence also increases with age, rising from approximately 20 per 
1,000 individuals 65 to 69 years of age to >80 per 1,000 individuals among those >85 
years of age. Persons younger than 50 years are hardly ever found to have HF in the west. 
In a recent US population-based study, the prevalence rate of HF was 2.2%, increasing 
with age: 0.7% in persons aged 45–54 years, 1.3% in persons aged 55–64 years, 1.5% in 
persons aged 65–74 years, and 8.4% for those aged 75 years or older. 75  
The rise in the incidence and prevalence of HF globally is the result of improved care of 
acute MI combined with the ageing of the population as well as the emerging pandemic 
of CVD in the developing countries. 76   
HF has been shown to have a significant impact on health-related quality of life, 77 and 
appears to impose a huge economic burden to all nations. 78 It is associated with shorter 
life expectancy, greater morbidity and impaired quality of life than most common 
diseases. About 30% of people die within 3 months of HF diagnosis, and annual mortality 
is 10% thereafter. Those with severe HF have an annual mortality of >50%.79,80 
AHF is the most common reason for hospital admission in patients over the age of 65 
years and is also associated with increased cost of care. Furthermore, the prognosis of 
patients admitted with AHF remains dismal, with over 20% of the patients being 




In SSA, acute decompensated heart failure (ADHF) has been found to be the most 
common primary diagnosis for patients admitted to hospital with heart disease.36,82 Even 
though AHF is common, there is limited data on their clinical presentation, 
characteristics, and outcome. This is partly because AHF has not been sufficiently 
described because various definitions have been used. In addition, previous studies were 
generally focused on a one aspect of the syndrome, such as decompensated chronic heart 
failure, heart failure following MI, acute pulmonary edema, or cardiogenic shock.  
Registries that consider AHF as a distinct clinical entity have been published. The most 
important are: (1) the Acute Decompensated Heart failure National registry (ADHERE) 
from the US, (2) the European Heart Failure Surveys (EHFS I and II), (3) national 
surveys in France, Finland, and Italy, (4) the Japan AHF registry and more recently (5) 
the Survey of Heart Failure in sun Saharan Africa (THESUS - HF).  ADHERE included 
more than 100,000 patients from 282 American. 83  EHFS I provides a description of 
clinical characteristics and management of 11, 327 patients with HF hospitalized in 115 
hospitals across 24 European Countries, 40% of whom had AHF as the primary cause of 
hospitalization. 84,85 EHFS II addressed AHF and recruited 3,580 patients from 30 
countries in Europe. 86 The Etude francaise de l’insuffisance cardiaque aigue (EFICA) 
translated as French Study of AHF included randomly selected 581 patients admitted to 
60 intensive care units (ICU) or coronary care units (CCU) in France. 87 Also from 
Europe two additional national surveys on AHF from Italy and Finland (Finnish Acute 
Heart Failure Study, FINNAKVA) have been recently published 88,89 The Italian registry 
recruited 2,807 patients from 206 cardiology centers while the Finnish study had 620 




hospitals. 88,89 In Japan, the ATTEND registry recruited a total of 4,842 patients from 52 
academic and non-academic hospitals. 90 Finally the THESUS - HF registry recruited 
1006 patients from 12 centres in 9 sub- Saharan African countries. 36  
Although there were differences in disease definitions, methods used and, recruiting 
conditions, these studies present a coherent epidemiological picture of patients 
hospitalized with AHFS. 91 It is apparent from the THESUS-HF that there are major 
differences between the epidemiology of acute decompensated heart failure in sub-
Saharan Africa, compared to North America, Europe and Asia. Table 1.6 compares the 
characteristic from patients with AHFS from the US, Europe, Asia and sub Saharan 






Table 1.6 Features of patients with acute decompensated heart failure in the 
ADHERE (USA), EHFS II (Europe), ATTENT (Asia) and THESUS -HF (sub-
Sharan Africa) registries (modified from Sliwa K. 2013) 















Registry    
(n= 4842) 
¶THESUS-
HF Registry  
(n = 1,006) 
Male, % 48 57 61 58 49 
Mean age, years 72 66 70 73 52 
Hypertension 73 64 63 69 45 
Coronary artery 
disease, % 
57 50 54 31 7 
Diabetes, % 44 45 33 34 11 
Atrial fibrillation, % 31 24 39 36 18 
Anaemia, % NA NA 15 NA 15 
Renal insufficiency,  
% 
30 NA 17 69 8 
Length of Hospital 
Stay (Median) days 
4.3 6 9 21 7 
In Hospital 
Mortality (%) 
3.8 4.8 6.7 7.7 4.2 
 
*ADHERE = Acute Decompensated Heart Failure National Registry; 
 #ADHERE-AP = ADHERE Asia Pacific;  ƗEHFS II, EuroHeart Failure Survey II;  
¶THESUS-HF = The Sub-Saharan Africa Survey of Heart Failure. 





1.6 Heart Failure in sub-Saharan Africa 
 
Earlier reports on HF in SSA were mainly from clinical and necropsy studies. The 
Heart of Soweto study is the largest clinical and echocardiographic study from SSA in 
recent times. 82 It included 1,593 patients and confirmed that 44% of patients with 
newly diagnosed CVD had heart failure, whereas only 10% had CAD. Data from 
selected urban echocardiographic centers reveals the common etiologies of HF 
include non ischemic cardiomyopathies, RHD, congenital heart disease (CHD), HHD, 
and endomyocardial fibrosis (EMF); IHD remains relatively uncommon. 93-97 
Additionally, there may be significant variation within the continent as EMF, in 
particular, appears to be more predominant in pockets of East and Central Africa.98,99 
These studies have revealed peculiarities of HF on the continent. 
First, heart failure cases in SSA are largely due to the major non-ischemic causes, 
with HHD, RHD and DCM accounting for over 75% of cases in most series. Second, 
IHD remains an uncommon cause of HF with no apparent increase in its contribution 
to the cases of HF. Thirdly, many of the causes of HF such as RHD, DCM and EMF 
present in the young and middle-aged, contrary to what happens in the developed 
countries where HF is a disease of the elderly. Finally, the contribution of cor 
pulmonale and pericarditis to about 20% of cases of HF reflects the continuing impact 
of tuberculosis on heart disease on the continent.100 
SSA is home to 70% of adults and 90% of children living with human 
immunodeficiency virus (HIV) and 75% of the 30 million who have died of acquired 
immunodeficiency syndrome (AIDS)-related illnesses. 101 As a consequence, HIV 
related heart diseases mainly HIV associated cardiomyopathy (HIVAC), pericardial 




of heart failure in many African countries.33 
Peripartum cardiomyopathy (PPCM) is a disorder associated with symptoms of HF 
and occurs between the last month of pregnancy and the first five months postpartum, 
102 has its highest incidence in northern Nigeria where it has been reported to be at a 
frequency of 1 in 100 births. 103  
Before the THESUS- HF, little is known about AHF in Africa. 37 This registry has 
shown that, in addition to the high prevalence of endemic causes of HF, Africa is 
clearly facing an additional burden of emerging causes, such as IHD and HHD, 
particularly in some countries. 36  
 
1.7 Risk Stratification Models and Predictors of Mortality in AHF 
 
Despite relatively modest in-hospital mortality, the event rate of patients with AHF 
after hospitalization is unacceptably high, higher than that of outpatients with 
advanced HF. Accurate risk stratification is required for clinical care, distribution of 
health care resources, and research. Patient management requires an appreciation of 
the risk of future events to make suitable decisions about acuteness of care (e.g, 
admission to an intensive care unit versus a less monitored setting), triaging patients 
among the available therapies, and to plan hospital discharge and intensity of follow 
up.104 This is particularly important in HF, given the need to allocate health care 
resources in the face of a rapidly increasing population of patients with high health 
care utilization. The need for accurate risk stratification for HF patients will increase 
as expensive emerging technologies, such as biventricular pacing, implantable 
defibrillators, and ventricular assist devices, become increasingly used in this patient 
population.104 There are many studies that address the long term prognostic factors in 




acute decompensated HF.107,108  
Additionally, as new therapies for the management of AHF continue to evolve, there 
is need for accurate estimation of risk through prognostic modelling to appropriately 
design and power clinical trials. The identification of high-risk subgroups allows trials 
to be designed that focus on patients with high event rates, potentially speeding the 
development of new therapies and limiting the exposure of patients to potentially 
risky experimental therapies. Lastly, risk factors that may be amenable to 
modification (such as low serum sodium or hemoglobin) may be potential targets for 
the development of new treatment strategies.104  
In a Canadian study that evaluated 153 patients who arrived at the emergency 
department with AHF, the authors identified prior admission for AHF, 
intraventricular conduction delay (IVCD), the cumulative dose of intravenous 
furosemide, and serum sodium as being associated with increased rates of 
mortality.107 An analysis of data from the Flolan International Randomized Survival 
Trial (FIRST) trial identified male sex, randomization to epoprostenol, presentation 
with NYHA class IV HF, and treatment with continuous dobutamine infusion as 
independent risk factors for mortality in a population with advanced HF. 109  
Table 1.7 110 shows emerging prognostic factors in patients admitted with AHF from 
recent clinical trials and observational studies. 104,111-119 These include SBP on 
admission and early post-discharge, 120 CAD, both related to the extent and severity of 
CAD and the presence of other comorbidities, 121 ventricular dyssynchrony, 122 
sustained ventricular or atrial arrhythmias123 and renal impairment (RI). 124,125 
Markers of RI, either BUN, Cr, BUN /Cr ratio, estimated glomerular filtration rate 
(GFR), and/or cystatin C all have important prognostic significance. 124-127 Other 




natriuretic peptide (NP) levels, elevated PCWP, liver disease, anemia, severe 
symptoms, older age, and increased heart rate appear to be markers of increased post-
discharge mortality risk. 104,130-133  
Some of these prognostic indicators can be treated (eg, elevated wedge pressure and 
hyponatremia), whereas others are not readily modifiable. The use of biochemical 
markers as prognostic indicators for HF outcomes has expanded in the last decade. 
Increases in BNP may be predictive of early readmission and mortality rates in 
patients hospitalized with AHF. 134 The combination of elevated BNP and cTn was 
associated with a 12-fold increased risk of mortality in another study. 115   
Similar clinical and biological characteristics, clinical scores as well as a large and 
ever increasing number of biomarkers have been associated with outcome and a few 
have also been developed as ‘predictors’ of outcome in HF. A non-exhaustive list of 
factors includes age, gender, ethnicity, aetiology, co-morbidity, NYHA class, exercise 
capacity, peak VO2, poor quality of life, low body weight, left bundle branch block 
(LBBB), AF, non-sustained, sustained, and inducible ventricular tachycardia (VT), 
increased PR and QRS duration, T-wave alternans, QT dispersion, low heart rate 
variability, depressed baroreflex sensitivity, history of HF hospitalization, resuscitated 
death, hyponatraemia, hypokalaemia, raised serum Cr and BUN. Others include 
transaminases, bilirubin and urates, anaemia, neuroendocrine activation, high serum 
BNP, low LVEF, abnormal diastolic function parameters, raised serum levels of 
markers of extracellular matrix metabolism, viable myocardium, and central 
haemodynamics. 135-139 Prognostic analyses have been predominantly carried out on 
populations with LV systolic dysfunction. Much less data are available for HF with 
preserved systolic function. 136 Specific predictors of sudden death have also been 




basis for indicating an implantable cardioverter defibrillator (ICD). Similarly, beyond 
low LVEF and wide QRS complex, none has a strong enough predicting value for 









Table 1.7 Potential Indicators and Potential Targets of therapy in Acute Heart 
failure (adapted from Gheorghiade et al. 2009) 
SBP Admission and early post-discharge SBP inversely correlates with post-
discharge mortality. The higher the BP, the lower both in-hospital and 
post discharge mortality. However, the readmission rate of 
approximately 30% is independent of the SBP at time of admission 
CAD  Extent and severity of CAD appears to be a predictor of poor 
prognosis. 
Associated with 2-fold increase in postdischarge mortality compared 
with patients with primary cardiomyopathy 
Troponin release  
 
30–70% of patients hospitalized with AHFS have detectable plasma 
levels of cardiac troponin. Results in a 3-fold increase in in-hospital 
mortality, a 2-fold increase in post-discharge mortality, and a 3-fold 




Increase in QRS duration occurs in approximately 40% of patients with 
reduced systolic function and is a strong predictor of early and late 
post-discharge mortality and re-hospitalization. 
Renal impairment  
 
BUN and BUN/creatinine ratio appear to be better prognostic 
indicators than creatinine. Associated with a 2- to 3-fold increase in 
post discharge mortality. Worsening renal function during 
hospitalization or soon after discharge is also associated with an 
increase in in-hospital and post-discharge mortality. 
Hyponatremia  
 
Defined as serum sodium _135 mmol/l, occurs in approximately 25% 




time of discharge 
An important predictor of post-discharge mortality and morbidity. 
 
LVEF  Similar early post-discharge event rates and mortality between reduced 
and preserved EF. 
BNP/NT-proBNP  Elevated natriuretic peptides associated with increased resource 
utilization and mortality. 
PCWP Reduction in PCWP during hospitalization, but not an increase in the 
cardiac output, has been associated with improved postdischarge 
survival Reduction in PCWP with agents such as milrinone and 
dobutamine is associated with worse outcomes 
Functional 
capacity 
at time of 
discharge 
 
Pre-discharge functional capacity, defined by the 6- min walk test, is 
emerging as an important predictor of post-discharge outcomes. 
Other Predictors Anemia, diabetes mellitus, new sustained arrhythmias, and nonuse of 
neurohormonal antagonists 
*This is not an all-inclusive list. SBP = systolic blood pressure; CAD =coronary artery 








In a recent systematic review and analysis of risk prediction in patients with HF, 
Rahimi and colleagues identified 48 studies that reported 64 main multivariable 
models (43 for prediction of risk of death, 10 for hospitalization, and 11 for death or 
hospitalization). 140 Their results showed that despite the multiple differences in 
clinical settings, population characteristics, and use of candidate variables, a few 
variables emerged as consistent and strong predictors of risk across different studies. 
For prediction of death, these variables comprised age, renal function, blood pressure, 
sodium level, EF, sex, BNP (or NT-pro BNP) level, NYHA functional class, DM, 
weight/body mass index, and exercise capacity. 140 Apart from the type of outcome to 
be predicted and the duration of follow up, none of the other study markers 
investigated were found to be significantly associated with the ability of the 
prognostic models to discriminate between those who are likely to experience an 
event and those who are not. 140  
The efficacy of the a new scoring system the Acute Physiology and Chronic Health 
Evaluation - HF (APHACHE II - HF) in comparison with second version of the 
APHACHE II scoring system for predicting outcomes has recently been evaluated in 
AHF. 141 The APHACHE II consists of three parts including the acute physiology 
score, chronic health points and age points. The total number of points for the three 
parts is calculated as APHACHE II score, which has been reported predict adverse 
outcomes in patients requiring intensive care. 142 Okazaki and colleagues constructed 
a new predictive scoring system based on eight significant APACHE II factors that 
were significantly different between the alive group and the dead group. 141 These are 
mean arterial pressure (MAP), pulse, sodium, potassium, hematocrit, Cr, age, and 
Glasgow Coma Scale (GCS); giving each one point, defined as the APACHE-HF 




They observed poorer prognosis, including all-cause death and HF events (death, re-
admission-HF), in Group 5 and Group 4 than in the other groups with lower 
APHACHE II – HF Scores. The conventional APACHE II scoring system was not 
useful in adequately predicting the prognosis of patients with AHF. However the new 
scoring system named APACHE-HF, which comprised a combination of parameters 
mentioned above, exhibited significantly higher sensitivity and specificity with an 
adequate area under the curve (AUC) and could be used to predict adverse mid-term 
outcomes in patients with AHF.141 
Finally the long-term survival of a cohort of patients discharged following 
hospitalization for AHF has recently been investigated in the Acute Heart Failure 
Database (AHEAD) registry. 143 In this study however, the authors assessed a 
population of 3438 patients, all of whom survived at least 31 days after admission. 
They showed that the highest mortality rate of discharged patients was during the first 
year following discharge. The 3-year survival rate of patients after day 30 post-
admission was 64.5% and there was no significant difference among the groups in 
terms of varying AHF syndromes. High levels of NPs were the most powerful 
predictors of high mortality risk in long-term follow-ups; other negative factors 
included older age and comorbidities, such as mild RI, anemia, DM, COPD or 
previous stroke.143 
1.8 Aetiology/Peculiarities of AHF in sub Saharan Africa 
 
The scourge of HF has been recognized in SSA for the past 60 years. 144 As 
previously mentioned, recent studies from SSA have shown that HF is mainly due to 
non-ischaemic causes, like HHD, RHD and heart muscle disease caused by infectious 
or unknown agents. This includes region-specific cardiomyopathies such as EMF; 




of HIVAC. 82,98,145 Additionally, the contribution of cor pulmonale and pericarditis to 
about 20% of cases of HF reflects the continuing impact of tuberculosis on heart 
disease on the continent.  
Table 1.8146 shows a comparison of causes of HF from various studies in sub Saharan 
Africa. Details of each of the causes will be discussed in the section on various causes 









Table 1.8 Comparison of the causes of heart failure from studies in sub-Saharan Africa (modified from Ogah et al. 2014) 


















THESUS HF36 Sub 
Saharan 
Africa 
1006 50.7 52.0 45.4 18.8 14.3 NR 7.7 7.0 4.2 
Stewart et al147 South 
Africa 
844 57 55.0 33.3 35.3 7.9 14.3 7.9 NR NR 
Ogah et al146  Nigeria 452 45 56.6 78.5 7.5 2.4 4.4 0.4 11.0 3.8 
Laabes et al148 Nigeria 102 68.6 44.8 44.1 21.6 22.5 NR 1.0 NR NR 
Ojji et al149 Nigeria 315 49.1 50.6 62.6 13.8 7.4 1.8 NR NR NR 
Oyoo & Ogola150  Kenya 91 51.6 NR 13.2 25.2 32.0 NR 2.2 NR NR 
Kingue et al95 Cameroun 167 40.7 57 54.5 26.3 24.6 NR 2.4 NR NR 
Soliman & Juma151 Malawi 3980 39.9 58.9 24.0 19.0 34.0 NR 0.08 NR NR 
Habte et al152  Ethiopia 781 47.6 43.5 24.2 20.2 32.8 3.8 12.0 NR NR 
Amoah & Kallen93 Ghana 572 NR 42.0 21.3 16.6 20.1 NR 10.0 NR NR 
Onwuchekwa & 
Asekomeh 153 
Nigeria 423 42.8 54.0 56.3 12.3 4.3 2.1 0.2 NR NR 
Kuule et al154  Uganda 157 66.2 45.0 25.1 27.3 28.2 NR 1.9 NR NR 
Ogah et al155 Nigeria 1441 48.4 54.0 56.7 3.0 3.7 1.6 0.6 NR NR 
Tantchou et al156  Cameroun 462 42.9 42.5 15.0 32.0 35.0 8.0 NR 13.0 9.2 
Karaye & Sani157  Nigeria 79 44.3 46.9 57.0 24.0 12.7 2.5 7.6 NR NR 
DCM = dilated cardiomyopathy; HHF = hypertensive heart failure; IHD = ischemic heart disease; LOS = length of stay in hospital; NR = not 








1.8.1 Hypertensive Heart Disease (HHD) 
 
The diagnosis of hypertension is based on an arbitrary cut off point for a measure that has 
a continuous and graded relation across its whole range with the risk of various CV 
diseases.158 In addition, 50% of the disease burden attributable to high BP relates to 
values below this arbitrary cut off point.159 Hypertension was therefore defined as the 
level of BP for which investigation and management do more good than harm. In most 
national and international guidelines the threshold for the diagnosis of hypertension is a 
SBP measured in a clinic or office of at least 140 mm Hg, a diastolic blood pressure 
(DBP) of at least 90 mm Hg, or both. 160,161 The latest data from the GBD project showed 
that raised BP continues to be the biggest single contributor to the GBD and to global 
mortality, leading to 9.4 million deaths each year.162 
Hypertension in SSA however has some important peculiarities. Many of studies done, 
looked at the general prevalence, not providing information on age specific prevalences. 
This is very important because African patients are younger and have very severe BP. 
Secondly, more studies are done in urban centres or tertiary hospital in big cities than in 
rural communities. The high general prevalence, the rising incidence of hypertension as 
well the premature mortality calls for more research into the details of hypertension on 
the continent. 
A recent review by Ogah et al revealed the prevalence of hypertension in the two national 
studies from SSA, was about 31% (35.7% and 37% in men and 37% and 29% in women 
in Mozambique and Malawi, respectively). They also found that, in rural areas, the 
prevalence ranged from 16% in rural Rwanda to as high as 46.4% in a rural community 




Republic of Congo to as high as 47.5% in Cameroon.163 
In their review, Twagirumukiza et al164 published the estimates of the current and 
projected prevalence of hypertension in SSA from population based studies in the region. 
The overall prevalence of hypertension in SSA for 2008 was estimated at 16.2% (95% CI 
14.2% to 20.3%). The estimated number of hypertensive individuals in the region was put 
at 74.7  million (95% CI 65.2 to 93.4 million). Furthermore, the overall prevalence of 
hypertension in SSA when adjusted to the WHO standard population was 23.3%. They 
predicted a 68% increase in numbers affected between 2008 and 2015. 199  
In SSA, hypertension commonly manifests in Africa with HF, stroke  and chronic kidney 
disease (CKD). 165 Africans also tend to present late, develop more severe hypertension 
compared to other ethnic groups and more resistant to treatment, 166,167 often leading to 
HHD and HF.  
HHD is the cardiac damage related to chronic systemic arterial hypertension. It has been 
documented that some genes are implicated in the development of cardiomyocyte 
hypertrophy in patients with hypertension which affect intracellular signaling, 
degradation of normal extracellular collagens and contractile dysfunction among other 
functions ultimately leading to left ventricular hypertrophy (LVH) and HF. 168 There is 
also the possibility that these genes interact with environment as seen in black Americans 
whereby weight gain, high salt intake and psychosocial factors may facilitate the rapid 
development of hypertension and HHD in susceptible individuals. 169 The presence of 
LVH adversely affects the prognosis of patients with arterial hypertension. In the 
Framingham Study, CV mortality among patients with arterial hypertension and 
increased LV mass measured by echocardiography was double in comparison with 




LV mass indexed to body size (LVMI) and relative wall thickness (RWT), which further 
refines CV risk assessment.  
HHF consistently ranks in the top three causes of HF from all regions of the continent 
(Table 1.9). It is diagnosed in the presence of symptoms of HF, past or presently 
documented high BP and evidence of LVH (by electrocardiogram (ECG) or 
echocardiogram).  
Ojji and colleagues171 compared 1515 consecutive HF patients with 4626 patients from 
the Heart of Soweto project. 82 They showed that hypertension contributed 60% of all 
cases presented with HF in Abuja versus 33% in Soweto. On an age- and sex-adjusted 
basis, compared with the Soweto cohort, the Abuja cohort were more likely to present 
with a primary diagnosis of hypertension (adjusted OR 2.10, 95% CI 1.85–2.42) or 
HHD/HHF (OR 2.48, 95% CI 2.18–2.83); P < 0.001 for both.  In the Heart of SOWETO 
study, HHF (682/1196 – 57%, mean age 60 ± 14 years) was the most common 
manifestation of HHD among African women with diagnosis of hypertension. 172 Table 
1.9 above showed the contribution of HHD to HF from 16 HF studies in SSA. 
 
1.8.2 Dilated Cardiomyopathy (DCM) 
 
DCM competes with HHD and RHD as leading causes of heart failure in SSA. 173 Across 
the region, DCM accounts for 3 – 35 % of causes of HF (Table 1.9). 146 DCM occurs 
commonly in the third and fourth decades of life, with men affected twice as commonly 
as women. Two-thirds of African patients with DCM, especially those who are more than 
55 years of age, have persistently low arterial blood pressure, ventricular arrhythmias 
and/or atrioventricular valve incompetence and die within five years of their first 




DCM in SSA, hospital series reveal that DCM accounts for 20% of admissions to African 
hospitals for heart failure. 176 DCM has a 4-year mortality of 34% after onset of 
symptoms. 177  
Studies from Europe and North America have long suggested that 20–50% of patients 
with DCM may have familial disease. 178 More than 40 genes have been identified with 
the most common mode of inheritance being autosomal dominant. 179 Khogali and 
colleagues from South Africa have shown an association with HLA-DR1 and DRw10 
antigens as well as a common mitochondrial polymorphism with idiopathic DCM. 180 
Also from South Africa, Ntusi et al181 were the first to determine the frequency and 
probable mode of inheritance of familial DCM in patients referred for investigation of the 
cause of DCM at a tertiary centre in Cape Town. They found that familial DCM affected 
at least a quarter of African patients with DCM, presented at a young age compared with 
idiopathic DCM (mean age of presentation 28 vs 39 years), was associated with PPCM in 
7% of cases, and followed an autosomal dominant pattern of inheritance in the majority 
of families. These findings extend the recommendation for family screening for familial 
DCM in all cases of unexplained DCM, including patients with PPCM, to African 
patients with the disease. 182  
A genetic association of the β1- and α2c-adrenoreceptor variants and G308A 
polymorphism of the tumour necrosis factor (TNF) α gene with idiopathic DCM and the 
mitochondrial DNA T16189C polymorphism has been show to occur in African 
populations. 183 These associations were noted with regard to the aldosterone synthase 
gene and improvement in LVEF in DCM and the mitochondrial DNA T16189C 
polymorphism in addition to the HLA variants in increasing the risk of DCM. 35 There 




examination of relatives, to distinguish familial from non-familial DCM on the basis of 
phenotype. 184 Myocarditis is an etiologic factor for DCM in up to 24% of cases and is 
associated with autoimmune disorder. 185 Auto-immune mediated myocarditis due to 
inappropriate immunologic responses has been identified as a possible precursor of DCM 
in SSA. 184 Commonly reported infective agents include toxoplasmosis and coxsackie 
viruses though this is not a consistent finding in studies where serology is used to 
diagnose the infections.185,186 
Echocardiography allows the evaluation of cardiac chamber sizes and wall thickness as 
well as systolic and diastolic function. It is one of the most important tools to rule out 
other causes of HF such as valvular heart disease, pericardial effusion or other 
cardiomyopathies. With DCM being a heterogeneous group of heart muscle diseases of 
diverse etiologies, idiopathic DCM is diagnosed after investigating and ruling out 
possible causes.  HIV testing is usually indicated in any patient presenting with DCM 
owing to its high prevalence. Serum viral antibody testing is occasionally done but the 
yield is low. 187 Based the clinical profile of the patient, investigations for connective 
tissue diseases may need to be carried out. Similarly, endomyocardial biopsy should be 
considered when a specific diagnosis is suspected that would influence therapy.52 
Ntusi et al188 have followed-up 120 patients with familial and idiopathic DCM over 14 
years at a tertiary centre in Cape Town. A mortality of 10% per year occurred in both 
familial and idiopathic DCM. The presence of NYHA functional class III and IV 
symptoms was an independent predictor of mortality, while heart transplantation was an 
independent predictor of survival. Digoxin use was a significant predictor of mortality in 
idiopathic DCM, which has reopened the controversy on the value of digoxin for HF. 189 




particularly without proper serum level control is associated with an increased mortality 
risk in patients with AF and with CHF.  The sensitivity analysis of the authors, however, 
suggests negative effects of digoxin particularly in the AF population but somewhat less 
unfavourable effects in the CHF population. 190 This calls for randomized trials of dose-
adjusted digoxin therapy at least in CHF patients. Until such proper randomized 
controlled trials are being completed, digoxin should be used with great caution 
(including monitoring plasma levels), particularly when administered for rate control in 
AF.190 
1.8.3 Peripartum Cardiomyopathy (PPCM)  
 
PPCM was thought to be a variant of idiopathic DCM that was unmasked by the 
haemodynamic stress of pregnancy, 191 but it now considered an independent disease, 
whose diagnosis relies on its relation to pregnancy and the exclusion of other 
cardiomyopathies. 192,193 The disease is heterogeneous and seems to have important 
phenotypic variations in different geographical regions; and is associated with high 
morbidity and mortality. 194 Recent observations from Haiti suggest that a latent form of 
PPCM without clinical symptoms might exist with asymptomatic systolic dysfunction on 
echocardiography, which subsequently either develop clinically detectable DCM, or 
improve and completely recover heart function. 195  
It seems likely that women of reproductive age all over the world have some risk of 
developing PPCM. The regions with potential hotspots are Africa (1:100 to 1: 1000) and 
Haiti (1:299). 35,194,196-198 PPCM shares many common features with other forms of non-
ischaemic cardiomyopathy. 176 The important distinction is that women with PPCM are 
younger, have a higher rate of spontaneous recovery of left ventricular function, and have 




Although the patho-mechanisms that lead to PPCM are still evolving, a number of 
contributing factors have received attention. These include general risk factors for CVD 
such as hypertension, diabetes, smoking as well as maternal age, gravidity and parity, 
African decent toxemia, malnutrition, and tocolytics (Figure 1.4). 201 A role for infectious 
agents, in particular cardiotropic enteroviruses, has been implicated in PPCM because 
selected studies have found the presence of viral transcripts in cardiac tissues of patients 
with PPCM. 202,203 In contrast, the presence of HIV infection seemed not to have an 
additional adverse effect on patients with PPCM. 185  
 
Figure 1.4 Some of the factors contributing to the pathogenesis of PPCM (adapted from 
Sliwa et al. 2006) 
 
 
The higher incidence of PPCM in certain geographic areas, that is, sub- Saharan region of 
Africa, South Africa, and Haiti, emphasize the involvement of genetic factors and/or 




and her daughter in Haiti204 and observations of PPCM in sisters in South Africa and in 
Germany.  205  Indeed, subsets of PPCM patients are carriers of mutations associated with 
familial DCM forms. 206-208 While PPCM has been described as a non-familial and non-
genetic form of HF, the reality shows that it is not easy to distinguish non-genetic PPCM 
from genetic forms of peripartum HF and therefore careful familial history should be 
taken in all PPCM patients.  
Cultural habits may be associated with increased risk for PPCM, for example, in northern 
Nigeria with 1 PPCM in every 100 women. 209 This observation of increased frequency in 
Nigeria was believed to be as a result of volume overload due to ingestion of “kanwa”, a 
high sodium containing dried lake salt and lying on heated mud beds twice daily for 40 
days postpartum.209 
Several other factors have recently been found to play key roles in the pathophysiology of 
PPCM. Oxidative stress is caused by an imbalance between the production of reactive 
oxygen species (ROS) and a biological system’s capacity to detoxify ROS or repair the 
resulting damage. The level of oxidative stress rises during pregnancy, and late 
pregnancy is associated with the formation of particles that are susceptible to oxidation 
(high LDL-cholesterol level) and an increase in oxidative damage. 210 However, in 
normal pregnancy, increased ROS production is paralleled by an increase in antioxidant 
capacity, with an early postpartum peak in healthy women. 210 A compromised 
antioxidant defense system results in a shift towards increased oxidative stress, which 
predisposes to PPCM.211,212 
PPCM, being a disease of late pregnancy and early postpartum, might be triggered by 
factors specifically present in the late-gestational period like the nursing hormone pro-




effects on angiogenesis depending on proteolytic processing of the potentially 
proangiogenic, full-length, 23 kDa form of the hormone into an antiangiogenic, 16 kDa 
derivative. 213 This prolactin variant is generated from full-length prolactin by cathepsin 
D214 or other proteolytic enzymes, such as matrix metalloproteinases (MMPs). Studies 
have shown that the serum level of MMP-2 is significantly higher in women with PPCM 
than in matched pregnant controls and the MMP-3 level was substantially increased in 
the hearts of mice with PPCM as a result of cardiomyocyte-specific knockout of Stat3 
(Stat3–/–).211,215 Interestingly, lowering of oxidative stress in mice provided only partial 
rescue from PPCM, whereas blocking prolactin with bromocriptine completely prevented 
the onset of PPCM. 211 It is known that 16 kDa prolactin enhances endothelial 
inflammation by promoting leukocyte adhesion to endothelial cells. 216 It is also known to 
activate nuclear factor kappa beta  (NF-κB) signalling in endothelial cells and thereby up 
regulates microRNA-146a (miR-146a), which mediates most of the adverse effects of 16 
kDa prolactin in endothelial cells. 217  
The role of inflammation in PPCM has also been investigated. It has been observed in a 
cohort of African women with PPCM that increased levels of prolactin and IFN-γ 
correlated with both a sustained inflammatory state and poor prognosis. 215 In addition, 
both prolactin and IFN-γ might contribute to the pathology of PPCM, because they up-
regulate the proinflammatory C–C motif chemokine 2 (CCL2) also induced CCL2 
expression in cardiomyocytes, which was mediated via activation of Akt signalling. 218 
Akt activation might be protective for the maternal heart during pregnancy, but needs to 
be down-regulated in the peripartum phase.  
AHF due to PPCM provides a challenge for treating physicians. Moreover, in patients 




mother and the foetus. Especially challenging are severe forms of PPCM, as the mortality 
of these women is quite high. The use of inotropic drugs and mechanical circulatory 
support devices may be necessary in the initial phase of severe forms of acute PPCM. 
Many patients, after initial stabilization, recover LV function.219 
PPCM is sometimes difficult to be distinguished from peripartum discomfort in healthy 
women. 192,201,220 Therefore, the choice and value of diagnostic tools is critical. In 
addition to conventional ECG, Echocardiography and Chest X ray, cardiac magnetic 
resonance imaging (CMR) in the assessment of patients with PPCM has been found to 
provide valuable information about myocardial structure and right-ventricular function 
and should be considered in more severe forms of PPCM. 221  
The management of PPCM patients is multi-disciplinary and timely diagnosis and 
treatment is crucial. Figure 1.5 219 is a pre-specified protocols of interdisciplinary work-





Figure 1.5 A pre-specified protocol of interdisciplinary work up for acute heart failure 
during pregnancy (adapted from Bauersachs et al. 2016) 
 
Although patients with PPCM have a higher rate of spontaneous recovery of LV function 
than patients with other forms of non-ischaemic cardiomyopathy, 222 normalisation of LV 
function at 6 months has been reported to occur in 23–54% of patients. 199,223 Factors 
predicting poor outcome in African patients with PPCM are increased LV systolic 
dimension, lower body mass index (BMI) and low serum cholesterol at presentation, 
while older age and smaller left ventricular end systolic diameter (LVESD) appear to be 
independently associated with a higher chance of LV recovery. 224  
There are novel therapeutic concepts that have evolved in PPCM over the last decade. A 
pilot study in South Africa reported highly beneficial effect of the prolactin-blocker 
bromocriptine on top of HF medication in patients with acute onset PPCM. 201,225 There is 




mortality and childhood outcomes in the resource-poor environment of Africa.  
PPCM patients have an increased risk for sudden death and seem to benefit from ICD and 
CRT. 215,223,226  
 
1.8.4 Rheumatic Heart Disease  
In the developed world, valvular heart disease is usually degenerative, afflicts the elderly, 
is insidious in onset and is frequently associated with other comorbidities; whereas, in 
SSA, valvular heart disease is encountered in the young, not infrequently in children of 
school-going age or in young females of child-bearing potential and with a course that is 
more rapid. 227 Recurrent pharyngeal infections with group A beta- hemolytic 
streptococci and subsequent acute rheumatic carditis predispose to the development of 
RHD. RHD remains the leading cause of acquired heart disease among the young 
worldwide.34,228 
It has been projected that more than 15 million people suffer from RHD worldwide, 34,229 
which is likely a significant underestimation according to the increasing data on 
subclinical RHD. 230 Historically, SSA has had the greatest prevalence of clinically 
detected RHD, ranging from less than 1 to 14 per 1000. 228,231-233 Since the first report of 
echocardiography as a potential screening tool, 234 surveys were carried out in 
Mozambique, and subsequently in Uganda and Senegal. 231,233,235,236 All these studies 
demonstrated that echocardiography detects a significant additional number of children 
with clinically silent RHD, estimated to 7.5–51.6 per 1000 children.34 
Whereas Africa has 10% of the world's population, as many as half of the 2.4 million 
children affected by RHD globally live on the continent. RHD accounts for a major 




of all cardiovascular disease in SSA. 237 The disease causes 400,000 deaths annually, 
mainly among children and young adults living in developing countries238 At least 2 
million patients with RHD require repeated hospitalizations and 1 million needing often 
unaffordable, heart surgery in the next 5-20 years. 239  
A large multinational African study demonstrated that RHD prevails as the most frequent 
cause of HF among children and young adults, and importantly that the 180-day mortality 
is as high as 17.8%.36 The GBD Study reports that the number of years lived with 
disability due to RHD was estimated in 2010 at 1430 (944–2067) worldwide, a figure that 
represents up to a fourth that from all neoplasms. 73 Hospital-based studies reported that 
RHD accounts for 6.6–34.0% of CVD-related hospital admissions or echocardiographic 
examinations performed in several institutions across the continent.37,97,151,156,240,241 
Further data are needed to assess the social and economic impact of RHD in sub-Saharan 
countries. 
RHD has been documented to be relatively frequent among pregnant women (up to 
2.3%), although symptomatic forms remains more rarely encountered. 242 Furthermore, 
recent data emphasise that pregnancy in patients with RHD remains a challenge bearing 
high morbidity and mortality, requiring multidisciplinary antenatal and postnatal care. 243  
The recently published Global Rheumatic Heart Disease Registry (REMEDY) enrolled 
3343 patients (median age 28 years, 66.2% female) presenting with RHD at 25 hospitals 
in 12 African countries, India, and Yemen between January 2010 and November 2012. 
The majority (63.9%) had moderate-to-severe multivalvular disease complicated by 
congestive cardiac failure (CCF) (33.4%), PH (28.8%), AF (21.8%), stroke (7.1%), 
infective endocarditis (4%), and major bleeding (2.7%). One-quarter of adults and 5.3% 




dilated LVs. Among 1825 women of childbearing age (12–51 years), only 3.6% (n. 65) 
were on contraception.244 
Rapid progression and symptomatic presentation of RHD is the rule more than the 
exception in SSA. 231,233 Even with severe mitral regurgitation, many patients will remain 
asymptomatic at rest until there is LV failure, PH or the onset of AF. The most recent 
guidelines for diagnosing RHD recommend using echocardiography and incorporating 
morphologic criteria as well as Doppler-based assessment of regurgitant flow. 
Presumably, these expanded criteria offer the possibility of correctly identifying more 
subclinical disease in time to prevent progression to clinical RHD but there is no empiric 
evidence to support this assumption. The World Heart Federation (WHF) guidelines 
categorize findings into three categories - definite RHD, borderline RHD and normal – 
with different criteria for those above and below 20 years of age.230 
Medical therapy for RHD is largely preventive or prophylactic for complications. South 
African guidelines suggest that in communities where rheumatic fever is endemic, all 
cases of sore throat among children between 3 and 15 years of age should be regarded 
and treated as streptococcal infection unless there are signs suggesting otherwise (i.e., 
oral ulceration, hoarseness, watery nasal discharge and/or conjunctivitis). 245  
Although research in vaccines using highly conserved antigens and 30-valent N-terminal 
region remains active, 246-248 no vaccine is scheduled for phase 2 clinical trials in the 
foreseeable future. The high heritability and ongoing research on genetic susceptibility 
may be particularly helpful for a better understanding of the pathogenesis of acute 
rheumatic fever (ARF) and may guide vaccine development.249 
Sadly, RHD diagnosis in SSA is usually made at an advanced stage of the disease, when 




However, percutaneous mitral dilatation, closed heart mitral commissurotomy and open 
heart surgery are limited to a few centres in Africa. 34 Valve replacement presents a 
dilemma due to the generalised lack of adequate facilities for anticoagulation. Recent 
experience from Senegal evaluated the mid-term outcome of mitral valve repair in 
children, demonstrating encouraging results, dependent on careful patient selection and 
evaluation of lesions. 251 Findings from South Africa confirm superior long-term outcome 
in patients who underwent mitral valve repair while also demonstrating reasonable long-
term results for mitral valve replacement in an indigent population.252 
 
 
1.8.5 HIV Associated Cardiomyopathy 
HIV associated cardiomyopathy (HIVAC) is a significant contributor to morbidity and 
mortality in SSA and portends a particularly poor prognosis. 253 The reported prevalence 
of cardiomyopathy in HIV infection from post-mortem studies in the pre-HAART era 
varied from 2% to over 40%.254 In developed countries, highly active anti-retroviral 
therapy (HAART) has been associated with ∼50% reduction in HIVAC, 255 possibly 
related to a reduction in opportunistic infections and myocarditis. By contrast, in 
developing countries, where the availability of HAART is limited and the potential 
pathogenic impact of nutritional factors is significant, there is ∼32% increase in the 
prevalence of HIVAC and a related high mortality from CCF. 256 Nevertheless, studies 
from Africa have reported low rates of HIVAC in series with high uptake of HAART, 
such as a recent study suggesting that, with appropriate implementation of antiretroviral 
therapy, this rising trend can be challenged. Although the true prevalence in Africa is not 
known, echocardiographic studies of HIV-infected patients found varying prevalence in 




In the Heart of Soweto Study, which defined cardiomyopathy as LVEF ≤45% in the 
absence of CAD, it was the most common cause of de novo CVD in patients with HIV 
(38%) presenting to Chris Hani Baragwanath Hospital in South Africa. 260  
There is a wide range of hypotheses regarding the pathogenesis of HIV-associated 
cardiomyopathy. 145,261-263 These include the direct results of myocardial invasion with 
HIV itself, post-viral autoimmunity and immune system dysregulation, adverse effects of 
viral proteins (including apoptosis), interference with β-adrenergic stimulation, 
endothelial dysfunction, and transcriptional activation of cellular genes. In addition to 
these effects of HIV and related immunosuppression, there is evidence that certain 
antiretroviral therapies may be responsible. Nucleoside reverse transcriptase inhibitors 
(NRTIs) are known to cause mitochondrial DNA damage through inhibition of 
mitochondrial DNA polymerase, with zalcitabine (ddC) exhibiting the greatest toxicity 
and associated with an 80% higher incidence of cardiomyopathy. 255 In a recent review, 
HAART has been shown to be widely available in SSA and the cardiac effects of 
HAART could lead to HF. 264  
Malnutrition has been postulated to be a contributory factor of HIVAC in Africa. In a 
recent study, patients with HIVAC had evidence of under-nutrition compared with HIV-
infected people without cardiomyopathy (body mass index 20.9 vs 27.0 kg/m2, p=0.02), 
and a lower BMI was the only independent anthropometric risk factor for 
cardiomyopathy (OR 0.76, 95% CI 0.64 to 0.97, p=0.02).265 
The role of genetic factors in HIVAC is largely not known. The mitochondrial DNA 
T16189C polymorphism, with a homopolymeric C-tract of 10–12 cytosines— a putative 
genetic risk factor for idiopathic DCM in the African and British populations—was not 




The role of HIV infection as a risk factor for PPCM is not known. In a study of pregnant 
Ugandan women in their third trimester and without signs of HF, HIV infection was not 
associated with any of the seven pre-specified echocardiographic signs of 
cardiomyopathy. 267 However, in recent publication, Sliwa et al223 demonstrated that 
HIV-infected women, despite having mild to moderate immunosuppression, have a 
similar 2-year prognosis to uninfected women with PPCM in South Africa.  
The link between HIV and HF in the HAART era has been described in high-income 
countries (HICs) in the last decade. 268,269 A meta-analysis of 11 studies of HF in HIV-
positive patients showed a prevalence of 8.3% for systolic dysfunction and 43.4% for 
diastolic dysfunction. 270 HIV causes damaged myocardium directly and also indirectly 
through inflammation and increased susceptibility to infections, toxins, and, eventually, 
ischemia. The endothelium serves as a reservoir of HIV and also acts to elaborate 
cytokines, such as TNF and interleukin-6 (IL-6), and free radicals in response to 





Figure 1.6 Pathophysiology of HIV associated heart failure (adapted from Remick 2014) 
 
Data from most of the LMICs implicating HIV as a cause of HF were generated before 
the widespread availability of HAART in LMICs. During this era, systolic HF was 
commonly reported in association with HIV; however, diastolic dysfunction was also 
documented in a large proportion (86%) of asymptomatic HIV-positive patients. 272  
Studies in the HAART era demonstrate that cardiomyopathy is still a relevant form of 
HIV-associated CVD. 33 Systolic dysfunction remains the most commonly investigated 
form; however, diastolic dysfunction is concurrent in 21%–46% of HIV-positive patients 
with cardiomyopathy depending on the clinical presentation.260 
The clinical presentation, chest X-ray, ECG and echocardiography of HIVAC in 




use of dobutamine stress echocardiography was found to be of incremental value to 
NYHA class in risk-stratifying risk of cardiac death in patients with HIVAC. 273 With less 
contractile reserve, there was a sevenfold increase in risk as well as less improvement in 
LVEF with standard cardiac medication and HAART. BNP may be a useful screening 
tool for underlying structural heart disease. A study of HIV-infected patients 
demonstrated higher levels of BNP with HF, cardiomyopathy and CAD. 274  
In addition to the conventional therapy of HF, other therapies such as immune 
suppressants and selenium supplementation have been suggested. ACEI may be poorly 
tolerated because of low systemic vascular resistance from diarrhoeal disease, infection 
or dehydration. Patients with myocarditis have enhanced sensitivity to digoxin, and 
anticoagulation presents risks to patients with cerebral vasculopathy and possible  
aneurysm formation. 261 Although HAART has not been shown to conclusively reverse or 
improve cardiac function once cardiomyopathy is established, there is prevention of 
deterioration, 145 although data from small series suggest that some patients may 
experience improvement on echocardiography. 275 While heart transplantation has been 
successfully performed in an HIV-infected patient with advanced cardiomyopathy, 276 this 
treatment is not readily available in a resource-poor setting such as SSA.  
 
1.8.6 Ischaemic Heart Disease (IHD) 
 
SSA, similar to many parts of rural India and South America, is mostly in the earliest 
stage of the epidemiological transition. Data for the existence of an orderly shift from one 
stage of the transition to the next are incomplete; however, evidence of a changing 
disease profile with coexistence of infectious diseases, nutritional deficiencies and NCDs 




pattern of adverse lifestyle choices and health behaviours that are now leading to a rising 
prevalence of the major coronary risk factors. 277 This increase in urbanization leads to 
concomitant rise in the prevalence of hypertension and diabetes. 278  
An important development has been the publication of the first longitudinal study, with 
the aim of examining the changing pattern of disease at the primary health level, 
conducted over a 13 year period in Agincourt, a small rural district in South Africa. 279 
This study is the first to demonstrate, longitudinally, the changing pattern of disease in an 
African setting, and shows how a rural area in SSA now has to contend with the twin 
scourges of communicable disease (mainly HIV and TB) and NCDs (hypertension, 
stroke, IHD and HHD). Despite the high morbidity and mortality from HIV and TB 
coinfection, stroke, CAD and HHD increased by 65% in those over 30 years of age, 
during the study period.  
Many previous reviews and reports have highlighted the rarity of CAD in SSA. In a study 
conducted in 1960, CAD was shown to be 'extremely rare' in Africans, 280 and, in fact, in 
a later study, Africans were declared to be 'virtually free' from CAD. 281 Between 1992 
and 1994, the Chris Hani Baragwanath hospital reported an average of 35 cases of CAD 
in African patients (prevalence of 0.2%), hence emphasizing the rarity of CAD in urban 
Africans. 282  
In Nigeria, the spectrum of cardiac disease in patients admitted to public teaching 
hospitals and the proportion with ischemic heart disease has been recently described by a 
number of authors. 155,283 Of the 5124 admissions to Aminu Kano Teaching hospital in the 
5 years prior to 2005, 1347 had cardiac disease and only 46 (0.9%) had a diagnosis of 
IHD. 283 Elsewhere in the same country, in a retrospective analysis of the spectrum of 




2007, IHD was detected in less than 1% of the 992 patients.155 
At a private hospital with modern cardiac care facilities in Nairobi, Kenya, 5.1% of the 
admissions to the ICU between 2008 and 2010 had acute coronary syndrome.284 
Reports from SSA hospitals also indicate that African patients with CAD tend to be 
younger, with males outnumbering females, and that the clinical and laboratory features 
and complications of CAD are similar to those in the white population.285,286 
In the INTERHEART Africa study, hypertension and DM were common risk factors 
among Black Africans while abdominal obesity, tobacco smoking and dyslipidemia were 
more common among European Africans. 29 Black Africans in the highest tertile of 
income had a higher risk of MI than those in the lowest tertile of income. The 
relationship was reversed among European Africans and did not exist among colored 
Africans demonstrating important differences with regard to the epidemiologic transition 
of CVD risk. The authors concluded that known CVD risk factors account for 
approximately 90% of the CAD observed in the African population, which is consistent 
with results of the overall INTERHEART study.11,29 
  The reported rarity of IHD in SSA must however be accepted cautiously, as the 
evidence was not strong enough to confirm that IHD was rare, without accounting for 
misdiagnoses, limited access to and lack of facilities for making the appropriate 
diagnosis. 37  
A recently published systematic review on worldwide risk factors for HF by Khatibzadeh 
and colleagues demonstrated that IHD was a risk factor for HF in more than 50% of 




regions. In Sub-Saharan Africa IHD contributed less than 10% to heart failure. 287 
More recently, the aetiological spectrum of 1006 patients with acute heart failure 
recruited from 12 cardiology centres in nine countries has been published. Ischemic heart 
disease was found to be the cause in 7.7% of cases 36 A potential limitation of the study 
was that coronary angiography was not used, but the results were consistent with the 
paucity of cases of acute coronary syndromes (ACS) reported in the same regions. 29 The 
Heart of Soweto Study was designed to determine the aetiological spectrum of clinically 
apparent heart disease among a predominantly black African population in one of South 
Africa’s largest urban communities. 82 Interestingly, in this contemporary cohort, despite 
high prevalence of modifiable risk factors for atherosclerosis, of 1593 consecutive 
patients with cardiac symptoms, presenting for evaluation, only 6% among those 
identified as black African had a diagnosis of CAD. 82  
The age-adjusted mortality rate provides an alternative measure of the myocardial 
infarction and stroke-related outcomes in a population. Only South Africa and the 
Seychelles, two middle-income countries thought to have a comparatively high burden of 
coronary artery and cerebrovascular disease have provided recent data on this measure of 
outcome for these diseases. 288 In the Seychelles, the age-adjusted mortality rates for 
myocardial infarction and stroke have declined substantially over the last two decades. 289 
In South Africa, estimates are that the age-standardised IHD-related mortality for the 
ethnic black majority ranges from 5.3 to 70 per 100 000, 55.1 to 171 per 100 000 in 
people of mixed ancestry and 165.3 to 230 per 100 000 in the white minority. 16,29 These 
findings have important implications for projections of the CVD epidemic elsewhere in 




 Although insightful and important, the degree to which the outcome data from these two 
countries with unique ethnic and racial mixes and relatively high per capita income levels 
are generalisable to the rest of the continent is questionable.288 
Recommendations for the treatment of ischemic cardiomyopathy apply worldwide. For 
the SSA region where access to revascularization is limited, the focus should be on 
improving the quality of medical therapy in ischaemic Cardiomyopathy. 66  
 
1.8.7 Pericardial Disease 
 
Acquired heart diseases of the pericardium manifest clinically as acute pericarditis, 
pericardial effusion or constrictive pericarditis. The latter two cause cardiac compression 
leading to HF from impaired diastolic filling. Constrictive pericarditis has traditionally 
been considered as end stage manifestation of persistent pericardial inflammation in 
which the pericardium looses elasticity through fibrosis and at times with dystrophic 
calcification.290 
In Africa, heart disease is still dominated by nonischemic causes such as RHD, HHD, 
DCM, cor pulmonale, and tuberculous pericarditis. 291,292  
Tuberculous pericarditis, which accounts for a 10th of all patients that are hospitalized for 
HF in Africa and over two thirds of patients with large pericardial effusion in developing 
countries, 293 is important to recognize because it is a potentially curable cause of heart 
disease. 294 Tuberculosis (TB) is said to be the most frequent cause of constrictive 
pericarditis in Africa and Asia. 294,295 By contrast, tuberculosis is no longer a significant 
cause of either large pericardial effusion or constrictive pericarditis in industrialized 
countries. 296,297 Pericardial tuberculosis is a serious form of extrapulmonary tuberculosis 




The incidence of tuberculous pericarditis in SSA has increased as a result of the HIV 
epidemic, and this trend is likely to occur in other parts of the world where the spread of 
HIV is leading to a resurgence of tuberculosis. 299 Pericardial disease was the second most 
common manifestation of HIV-associated CVD in the Heart of Soweto Study (12.5%),82 
although in other series, it is the most common, such as in a study of 102 patients in 
Tanzania recruited between 2009 and 2010, in whom 42% had pericardial effusion.300 
A multicenter prospective study that recruited patients from centers in Cameroon, 
Nigeria, and South Africa showed marked regional variation in the prevalence of HIV-
associated tuberculous pericarditis, with an average of about 50% of patients with 
tuberculous pericarditis infected with HIV. 301 This is in stark contrast to developed 
countries, where TB is a cause of only 4% of pericardial effusions.302 
Hospital-based studies demonstrate that tuberculous pericarditis is a common cause of 
HF in SSA, being less common than RHD, but more common than HHD and 
cardiomyopathy in the Eastern Cape Province of South Africa and in Zimbabwe. 303,304 
Echocardiography studies of the relative importance of the causes of HF in African 
hospitalized patients indicate that tuberculous pericarditis accounts for 8-13% of cases in 
South Africa and Kenya and 3% overall in the SSA region. 150,176,293  In patients with 
Tuberculous pericarditis, HIV co-infection worsens the prognosis (mortality rates 7% in 
HIV seronegative patients compared to 40% in HIV seropositive patients).305 
There are four recognized stages of TB pericarditis and two general modes of clinical 
presentation (Table 1.9). 306 In the first mode of presentation, pericardial involvement is 
asymptomatic and is an incidental finding in patients who have evidence of active 
tuberculosis elsewhere in the body. 307 Evidence for this stems from autopsy findings, 




known to have pulmonary TB. 308 Among HIV-infected patients, the proportion of 
asymptomatic involvement of the pericardium may be much higher. Both autopsy and 
observational studies show that HIV is associated with a higher prevalence of 






Table 1.9 The Four Stages of Tuberculous Pericarditis (adapted from Reuter et al 
2006) 
Stage  Pathological 
manifestation 
Clinical manifestation 
One  Dry stage (least 
common) 
Acute pericarditis (chest pain, pericardial friction rub and 
widespread ST elevation without effusion 




 (1) Moderate to large pericardial effusion with 
symptoms and signs of heart failure and/or cardiac 
tamponade 
(2) Effusive constrictive pericarditis with evidence of 
simultaneous compressive pericardial fluid and visceral 
constrictive pericarditis 
Three Adsorptive stage Symptoms and signs compatible with constrictive 
pericarditis but radiological and echocardiographic 
evidence of thick fibrinous fluid around the heart 
Four Constrictive stage Symptoms, signs and echocardiography compatible with 
constrictive pericarditis with no residual fluid in the 
Pericardium 
 
The definitive diagnosis of a tuberculous etiology in patients with pericarditis rests on 
demonstrating the presence of tubercle bacilli in stained smear or culture of pericardial 
fluid or caseating granulomata on pericardial histology. 312 These include looking for 
microbiological evidence of TB elsewhere in the body and the use biomarkers like 
adenosine deaminase (ADA) in patients with an inflammatory pericardial exudate. 312,313 
DNA-based techniques such as polymerase chain reaction (PCR) have proved to be very 
disappointing. The sensitivity is well below 30 % and is particularly poor where 
pericardial tissue is not available, as is most often the case.298,314 
Where resources are limited, a chest X-ray may often be the only imaging modality 
available to the clinician (Figure 1.7). It has been shown that chest X-ray positively 




correlated with the radiographic finding of cardiac enlargement in this study. The ECG 
shows ST-segment elevation (in acute pericarditis) that is diffuse, involving both limb 
and precordial leads. Other ECG findings include PR segment depression and electrical 
alternans. Echocardiography remains the most sensitive tool for the diagnosis of 
pericardial effusion by showing an echo-free space around the heart and variable amounts 
of fibrous strands (Figure 1.8). 316 In addition to measuring the size of the effusion, 
echocardiography allows for an assessment of any hemodynamic consequences.  
Overall, the etiology is determined in only about a quarter of patients. 316 A scoring 
system, the Tygerberg score, has been validated for tuberculous pericarditis and is 
currently being utilized in research settings. 317 One point each is allotted for the presence 
of weight loss, night sweats or fever. Two points are given for fever and three points for 
either serum globulin >40g/L or blood leukocyte count <10 x 10^9. A score of 6 or 
greater is highly suggestive of tuberculous pericarditis. 
Treatment regimens recommended for pericardial TB are the same as for pulmonary 
tuberculosis, consisting of 6 months of anti-tuberculous antibiotics. Corticosteroids are 
frequently prescribed. The effectiveness of systemic steroids in the treatment of TB 
pericarditis was evaluated in a large multi-centre trial (IMPI Trial) that involved several 
African countries. 318 There was no significant difference in the primary outcome 
(composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive 
pericarditis) between patients who received prednisolone and those who received 
placebo. Prednisolone therapy, as compared with placebo, was associated with significant 
reductions in the incidence of constrictive pericarditis and hospitalization, but was 
associated with a significant increase in the incidence of HIV associated cancer. 318 Non-




forms of pericarditis and colchicine reduces the recurrence rate. 319 Therapeutic 
pericardiocentesis is usually a life-saving intervention and is essential in patients with 
cardiac tamponade. Surgery is needed for resection of the pericardium in patients with 
calcific constrictive pericarditis and after a 6– 8 week trial of anti-tuberculosis treatment 















Figure 1.8 Echocardiographic pictures - parasternal long axis 




1.9 Pathophysiology of Acute HF 
 
AHF is characterized by an acute decrease in cardiovascular function associated with 
pulmonary congestion, injury or end-organ dysfunction, including myocardial damage, 
worsening renal function, and hepatic impairment (Figure 1.9). 322,323 This multi organ 
dysfunction has been shown to be an  independent predictor of increased mortality in 
patients with AHF. 110 Signs of unresolved congestion and its most severe manifestation, 





Figure 1.9 Multi-organ system involvement in acute heart failure (adapte from 
Teichman et al. 2014). BNP, brain natriuretic peptide; Cr, creatinine; CRP, C-reactive 
protein; CysC, cystatin C; LFTs, liver function tests; TNF, tumour necrosis factor 
 
 
 AHF is a heterogeneous clinical syndrome with complex and variable pathophysiology. 
It has many overlapping pathophysiologic mechanisms that may be operative in a given 
clinical scenario to a greater or lesser degree. The pathophysiology of AHF is said to 
result from the interaction of underlying substrate with initiating mechanisms or 
triggers, and amplifying mechanisms, all of which contribute to a common set of 
clinical signs and symptoms (primarily related to congestion or end-organ dysfunction, 




structure and function. The underlying substrate may be one of normal ventricular 
function, as in patients without a previous history of heart failure in whom AHF 
develops because of sudden changes in ventricular function from an acute insult such as 
MI, acute myocarditis or sudden rise in blood pressure. Alternatively, some patients 
may have no previous history of HF but exhibit an abnormal substrate (e.g., those with 
stage B heart failure associated with asymptomatic LV dysfunction) with a first 
presentation of HF (de novo HF). Finally, in most patients with AHF, the original 
substrate is one of compensated CHF, followed by decompensation with development 
of AHF.  
 Regardless of the substrate or initiating factors, a number of “amplifying mechanisms” 
perpetuate and contribute to the episode of decompensation. These include 
neurohormonal and inflammatory activation, oxidative stress, ongoing myocardial 
injury with progressive myocardial dysfunction, WRF, interactions with the peripheral 
vasculature, as well as factors triggering AHF may include ischemia, hypertension, 
arrhythmias, non-cardiac comorbidities, and administered drugs. 326 All these contribute 





Figure 1.10 Schematic representation of the pathophysiology of acute heart failure 
(adapted from Felker & Teerlink 2015). ACS, acute coronary syndrome; CO, cardiac 
output; RAAS, renin angiotensin aldosterone system; SNS, sympathetic nervous system 
 
 
Injury to cardiac myocytes and the extracellular matrix after myocardial injury 
results in pathological remodeling of the left ventricle with dilatation, impaired 
contractility, perfusion, fibrosis and electrical instability. 327  
 
1.9.1 Neurohormonal Activation, Inflammatory Mediators and Oxidative 
Stress  
Circulatory decompensation is characterized by neurohormonal activation, 
inflammatory activation and oxidative stress. 326 These are distinct but closely related 
mechanisms, which are initially compensatory as they improve myocardial 




detrimental, augmenting the circulatory insufficiency and impairing generalized 
homeostasis. These mechanisms are involved in the progression of heart 
dysfunction, both during the acute phase of circulatory decompensation, and also 
afterwards, as their influence far exceeds beyond the episode of AHF and contributes 
to a steady progression of CHF. 328 Finally, they are considered as strong predictors 
of poor outcome, being predictors of increased short and long-term mortality as well 
as of an increased risk of recurrent hospitalizations due to subsequent episodes of 
AHF. 326 
Neurohormonal activation includes but not limited to, the activation of the renin-
angiotensin-aldosterone system (RAAS) , the sympathetic nervous system (SNS), 
arginine vasopressin (AVP) and the system of NPs. 329 Inflammatory activation leads 
stimulation of innate immune response with increased expression of pro-
inflammatory mediators.  330  
These cascades lead to progressive myocardial dysfunction and associated structural 
abnormalities, including cardiomyocyte hypertrophy, cardiomyocyte apoptosis, 
depressed myocardial contractility, inhibited cardiomyocyte responsiveness to b-
adrenergic stimulation, fibroblast growth, fibrosis, and remodeling.  
On the other hand, myocardial ischemia and necrosis may occur during an episode of 
AHF as a consequence of a transient reduction in coronary perfusion due to 
increased left ventricular filling pressure, reduced systemic arterial BP, tachycardia, 
coronary vasoconstriction and endothelial dysfunction mediated by neurohormonal 







Figure 1.11. Mechanisms of myocardial damage in patients with acute heart 
failure (adapted from Metra et al. 2010). CO, cardiac output; LVEDP, left 




1.9.2 Renin Angiotensin Aldosterone System (RAAS) 
 
Renin is synthesized by granular cells of the juxtaglomerular apparatus and released 
by the afferent arteriole in response to decreased mean arterial pressure (MAP), 
sensed by baroreceptor cells in the arteriolar vessel wall, decreased intracellular 
chloride levels inside macula densa cells lining the renal tubules at the end of 
Henle’s loop. This is potentiated by potassium depletion; and sympathetic activation. 
Renin breaks down angiotensinogen secreted by the liver, to form angiotensin I, 




enzyme (ACE), mainly from the pulmonary vasculature (Figure 1.12). Angiotensin 
II is a strong vasoconstrictor and the most potent stimulator of aldosterone release by 
the adrenal glands. This system plays a vital role in the pathophysiology of heart 
failure. 332 Indeed, persistent and excessive RAAS activation causes adverse cardiac 
remodeling and contributes to fluid retention with signs and symptoms of 
congestion. For this reason, plasma renin activity (PRA) and plasma aldosterone 
levels are of potential interest not only as markers of disease severity but also as 
mediators of heart failure progression. Although their level notoriously variable, they 
can be accurately measured and reflect the degree of activation of the RAAS.333 
 





1.9.3 Inflammatory Activation 
Evolving evidence suggests that the RAAS and the immune system interact and 
significantly influence each other in HF in general and AHF in particular. It has been 
shown that angiotensin II activates NF-κB, the transcription factor responsible for 
up-regulating numerous inflammatory mediators. 334 In the isolated perfused heart 
and isolated cardiomyocyte studies, angiotensin II stimulation results in increased 
TNF-α messenger RNA (mRNA). 335 This effect appears mediated through the AT-1 
receptor as evidenced by lack of a similar effect under blockade by the angiotensin II 
receptor blocker losartan. 336 In a separate study, pretreatment with quinapril 
attenuated the increase in mRNA of multiple pro-inflammatory cytokines. 337 TNF-α 
has been shown to increase AT-1 receptor expression as well as cardiac angiotensin 
II concentrations in cardiac fibroblasts and in a murine model.338 
 
Apart from TNF-α, a variety of cytokines have been reported to be elevated in 
patients with HF, both systemically and within the failing myocardium. They include 
interleukins 1α, 6, and 8, interferon α, growth stimulation-expressed gene 2 (ST-2, 
also known as interleukin 1 receptor-like 1 or IL1RL1), advanced glycation end-
product (AGE), Gal-3, and C-reactive protein (CRP). These cytokines cause a 
decrease in cardiac contractility and are associated with poorer clinical outcomes. 339 
Some of these markers – specifically IL-6, CRP, and TNF-α- – were elevated in 
patients with AHF, especially in those with non-ischemic etiology. 329 It was also 
shown that the degree of activation of these inflammatory markers was correlated 
with disease severity. 340 Growth differentiation factor 15 (GDF-15) is another 




growth factor-β (TGF-β) family, 341 and elevated levels have been associated with 
acute injury, inflammation, cancer, and cardiac stretch. IL-1, TNF-α, and TGF-β in 
macrophages are known to stimulate release of GDF-15, inactivating macrophage 
inflammation and apoptosis.  
Elevated GDF-15 levels have been shown to be present in patients with end stage 
non-ischemic dilated cardiomyopathy, and levels decrease markedly one month 
following LVAD placement, in strong correlation with markers of end-organ (renal, 
hepatic) dysfunction improvement, suggesting that GDF −15 may be an important 
marker of organ perfusion. 342  
Recent studies have also suggested that relative lymphocyte count may be a strong 
marker in identifying increased risk of mortality risk in CVD. 343 Specifically, low 
(below 13 %) relative lymphocyte counts were associated with less improvement of 
dyspnea, greater worsening of HF, longer length of initial hospital stay, and fewer 
days alive and out of hospital. 344 The exact reason for these associations is not clear, 
although some studies have suggested an association between activation of a specific 
population of monocyte and liver congestion with reduced relative lymphocyte 
counts. 345 There are however no prospective studies to assess the association 
between inflammatory markers and outcomes in AHF.339 
 
1.9.4 Oxidative Stress 
Oxidative stress is associated with an excess of ROS, which reacts with nitric oxide, 
disrupt physiologic signaling, and lead to the production of toxic and reactive 




activity and subsequently serum uric acid levels and also induces an augmented 
release of myeloperoxidase by activated neutrophils and monocytes.346,347 
Hyperuricaemia is a quite reliable marker of inflammatory cytokine activation, of 
endothelial dysfunction, and of oxidative stress; in fact, uric acid synthesis also 
generates superoxide radicals, hydroxyl, and hydrogen peroxide.348 
In addition to the oxidative potential, uric acid could also induce several direct 
harmful effects, such as the stimulation of smooth muscle proliferation, renin 
synthesis, reduction of intra-myocardial NO synthesis, and reduction of calcium 
release by the sarcoplasmic reticulum in cardiomyocytes. 349 In a study of 294 
hospitalized decompensated HF patients, Anker et al, observed that uric acid levels 
above 9.5 mg/dl at 12 and 18 months of follow-up were related to a survival of 52% 
and 36% at 12 and 18 months, respectively.349 
 
1.9.5 Sympathetic Nervous System (SNS) 
The SNS activation is mediated through three receptors β 1, β 2, and α 1. In HF 
patients, both β 1 and β 2 receptors are activated and, along with the α 1 receptors, 
eventually lead to myocardial toxicity, which results in decreased EF, arrhythmias, 
and tachycardia due to overstimulation by the SNS (Figure 1.13). 350 In the 
peripheral vasculature, activation of the β-1 and α-1 receptors leads to activation of 





Figure 1.13 Activation of the sympathetic nervous system in heart failure 
 
1.9.6 Arginine Vasopressin 
Vasopressin is produced in the hypothalamus and secreted by the posterior pituitary 
gland. Its release is facilitated by angiotensin II formation and is also controlled via a 
negative feedback loop. When the MAP falls in HF, this is detected by central 
baroreceptors, which decrease their inhibitory impulses to the hypothalamus, thereby 
lifting the negative regulation and leading to an increase in vasopressin release. 
Increased vasopressin causes vasoconstriction as well as increased water retention, 
both of which augment the decrease in MAP in HF.351 
 
1.9.7 Natriuretic Peptides (NPs) 
These are atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-




vasoconstriction of the other neurohormonal systems. 352 ANP and BNP are found in 
the atria and ventricles, respectively, and are released following atrial or ventricular 
stretch. CNP is found predominantly in the central nervous system and the vascular 
endothelium. These hormones act directly on blood vessels to cause vasodilation; 
cause salt and water excretion; and inhibit secretion of renin, aldosterone, and 
vasopressin. Elevated BNP in particular is thought to be one of the first signs of 
AHF and is used to follow the progression of disease.353 
 
1.9.8 Endothelial dysfunction 
Endothelial dysfunction may be due to an imbalance within neurohormonal, 
inflammatory and oxidative milieu in the circulation and endothelial cells, as well as 
due to other unidentified factors. This leads to myocardial hypoperfusion, increased 
vascular stiffness and further aggravating myocardial damage, vasoconstriction, 
endothelin- related secondary SNS activation and catecholamine release, as well as 
renal dysfunction. 354  
 
1.9.9 Renal Dysfunction or the Cardiorenal Syndrome 
Renal dysfunction plays an important role in the complex pathophysiology of AHF, 
but its mechanism is not completely understood.355 It is believed that renal 
dysfunction can trigger or aggravate AHF episodes as well as contribute to further 
progression of HF and poor outcomes. 355 It is hypothesized that impaired intra-renal 
haemodynamics (from impaired haemodynamics regulatory mechanisms), intrinsic 
renal disease (like DM and hypertension) and drugs may contribute to the 




output, high venous pressure or vasodilatation directly influence renal function.  It is 
likely that in HF, activation of various neurohormones, even in patients with normal 
cardiac output, can cause renal dysfunction. The renal dysfunction related to cardiac 
function and/or activation of neurohormones results in sodium and water retention 
and further activation of the RAAS. 357 Sodium and water retention by the kidneys 
causes hypervolemia and hyponatremia. The increase in sodium reabsorption 
produces a parallel increase in urea reabsorption that increases BUN levels. Thus, a 
vicious cycle occurs that promotes progression of HF (i.e., the Cardiorenal 
syndrome). 
Majority patients with AHF and renal abnormalities have a component called 
vasomotor nephropathy (abnormal hemodynamics and/or activation of 
neurohormones resulting in a vasoconstriction of the afferent arteriole) that is 
partially or completely reversible. These patients are characterized by marked BUN 
elevation and modest elevations of Cr, despite having signs and symptoms of 
congestion. 357 It is becoming apparent that in addition to improving hemodynamics 
and neurohormonal profile, improving renal function is also an important target for 
therapy and for research in AHF. 
Renal dysfunction carries a poor prognosis in patients with AHF and is as powerful 
an adverse prognostic factor as are most clinical variables, including LVEF and 
NYHA class. Renal function that worsens during hospitalization is a more important 
predictor of adverse outcomes than is baseline renal function. 358,359 Recent data from 
the ADHERE registry 112 have demonstrated the important role of renal dysfunction 






1.9.10 Liver Dysfunction in AHF 
 
In AHF, there is an increased filling pressure, progressive volume overload that 
eventually leads to increased intra-abdominal pressure causing interstitial edema and 
ascites. This results in both hepatic and splenic congestion. It is likely that changes 
in distribution of WBC, with reduced lymphocyte count, are as a result of 
sequestration of lymphocytes in the spleen. Abnormalities in liver function test 
(LFT) are prevalent in patients with chronic and acute HF, with limited data for the 
AHF. In a recent analysis of the PROTECT study, abnormal LFTs are frequent in 
AHF at baseline and during hospital stay and predict worse outcomes.360 
Similarly, analysis of the Survival of Patients With Acute Heart Failure in Need of 
Intravenous Inotropic Support (SURVIVE) study, showed that abnormal LFTs in 
form of elevations in aspartate and alanine aminotransferases (AST & ALT) and 
lactate dehydrogenase (LDH) are present in 46 % of patients with AHF. 361 Other 
laboratory abnormalities include elevated bilirubin as well as prolongation of 
prothrombin time. 362 Over time, these levels gradually returned to normal in the 
majority of patients, persisting only in patients with unresolved congestion and signs 
of hypoperfusion and were associated with increased 180-day mortality. 363 In the 
RELAX-AHF study, although LFT values at baseline were not significantly 
prognostic of 180-day mortality, multivariable adjustment revealed that increases in 
AST and ALT of  ≥ 20 % at day 2 were observed in almost 10 % of patients and 






 It has been shown from large trials and registries that most hospitalizations for AHF 
occur because of congestion (rales, jugular venous distension, edema) rather than a 
low cardiac output. 83,84 Although it is thought that congestion starts as a 
compensatory mechanism in response to reduced cardiac performance, clinical and 
experimental data suggest that congestion actually contributes to the progression of 
AHF (Table 1.10). 364 Increased left ventricular filling pressures augment left 
ventricular wall stress; change the shape of the ventricle (making it more spherical), 
resulting in repositioning of papillary muscles and secondary mitral regurgitation. 365  
 
Table 1.10 Potential deleterious effects of high left ventricular filling pressure 
(adapted from Filippatos et al. 1999) 
 
 
It is very essential to distinguish between clinical congestion and hemodynamic 
congestion. Although patients present with signs and symptoms of systemic 
congestion such as dyspnea, rales, elevated jugular venous pressure, and edema, this 
state often is preceded by hemodynamic congestion, defined as high LV diastolic 
● Subendocardial ischemia/cell death by necrosis/apoptosis 
● Changes in extracellular matrix 
● Changes in left ventricular shape (spherical) resulting in: 
—Increased afterload 
—Mitral regurgitation 
● Impaired cardiac venous drainage from coronary veins (may result 
   in diastolic dysfunction) 




pressures without overt clinical signs. Similarly, clinical congestion may resolve 
with treatment but hemodynamic congestion may persist, leading to a high risk of re-
hospitalization. It has been postulated that hemodynamic congestion may contribute 
to the progression of heart failure because it may result in wall stress, as well as in 
RAAS and SNS activation. These effects may trigger a variety of molecular 
responses in the myocardium, including myocyte loss and increased fibrosis. 
Concomitant abnormal processing of the natriuretic peptides, which are the intrinsic 
counter regulatory hormones in heart failure, leads to decrease in their biologic 
activity in patients with advanced disease. 366 These mechanisms also play an 
important role in pathologic remodeling of the ventricle, a chronic process that may 
be accelerated by each episode of decompensation. This is evident by the fact that 
each hospitalization for AHF leads to worsening of the long-term prognosis, an 
effect that appears additive with recurrent hospitalizations. 367 Data from studies with 
implantable hemodynamic monitors have confirmed that chronically elevated filling 
pressures (i.e. hemodynamic congestion) are associated with increased risk of future 
events.368 
 
1.9.12 AHF and Cardiac Remodeling 
 
As outlined above AHF can occur in the presence of strictly normal heart. In this 
case, heart failure is the result of the failure of the cardiac pump while myocardial 
structure and function are normal. Examples of situations of AHF and with no 





More commonly however, often the heart and its structures may have been subjected 
previously to a longstanding remodeling process due to very diverse chronic 
pathophysiologic mechanisms. This is a more or less sudden decompensation of a 
thus far well-compensated chronically failing heart usually triggered by a 
precipitating event. In this situation the heart, ventricles, myocardium, and myocytes 
have been more or less severely remodeled by long period of a more or less severe 
biomechanical stress resulting from the originating disease. 369 Table 1.11 shows the 
common precipitating factors to consider in acute decompensated heart failure.  327  
 
Table 1.11 Precipitating factors to consider in acute decompensated heart 
failure (modified from Kraus et al. 2016) 
 Anaemia 
 Onset of a new arrhythmia (e.g. atrialfibrillation/flutter, supraventricular 




 Infective endocarditis 
 Recurrence of rheumatic fever 
 Renal failure 
 Malignant hypertension 
 Myocardial infarction 
 Pulmonary embolism 
 Excessive alcohol intake 
 Non-compliance on maintenance therapy 
 Drugs – NSAIDS, negative inotropes  
 
 
Cardiac remodeling is the alterations in the size, shape, structure, and function of the 
ventricle as a result of haemodynamic or neurohormonal stresses. 370 There are two 
types of anatomic remodeling of the LV; the concentric LV remodeling seen in 




remodeling process concerns more the ventricle itself (its shape and thickness and 
stiffness of its wall) than the myocardium and myocytes. This type of remodeling is 
essentially responsible for acute diastolic HF due to alterations in the so-called 
passive properties of the LV, with little remodeling of cardiac myocytes. The other 
type is eccentric remodeling seen in dilated cardiomyopathies of any etiology in 
which the LV dilation is associated with an insufficiently thickened and 
hypocontractile myocardium. Identification and understanding of the triggers and 
signaling mechanisms of cardiac remodeling in general is important since it will 
largely guide the therapeutic approach and determine the short and long-term 
prognosis. 
These signals activate a host of complex intracellular signal transduction pathways 
(also called cascades), often interconnected as a web, which finally activate or block 
a number of transcription factors, thus modulating gene expression, while other 
factors modulate messenger RNA (mRNA) translation into protein. These processes, 
which also take place in other cells, are responsible for myocyte/myocardial 
hypertrophy and remodeling of the extracellular matrix. In cardiac myocytes, they 
lead a specific alteration in protein phenotype known as “re-expression of the fetal 
program” (also called the hypertrophic phenotype). 371 One typical example of this 
process is the production of natriuretic peptides (ANP and BNP) by ventricular 
myocytes, a production that occurred in the fetal ventricle and ceased shortly after 
birth. This remodeling process, although possibly beneficial in the short term, is 
detrimental in the long term, being responsible for the progression to heart failure. 371 




increased wall tension and fibrosis, which eventually impair contractility. The long-
term process of remodeling also leads to an increase in myocardial apoptosis. There 
is also significant contractile dyssynchrony in the dilated and remodeled ventricle 
leading to less effective pumping. 
The results of myocyte and myocardial remodeling for LV function differ according 
to the type of remodeling considered. Concentric LV hypertrophy often associated 
with increased myocardial stiffness usually characterizes diastolic HF. In the case of 
LV dilatation and remodeling, the situation depends very much on the causal 
disease. Valvular regurgitations cause chronic volume overload and is different from 
LV dilatation and remodeling seen during sustained physical training during which 
no detrimental myocardial/myocyte remodeling is seen for a long period of time.  
 
1.9.13 LV Systolic dysfunction 
 
Left ventricular systole is defined by preload, afterload, and contractility. Impaired 
myocardial contractility occurs due to a loss of functional myocytes or a decrease in 
function of viable myocytes. These processes may be due to primary myocardial 
dysfunction, in which permanent damage to the myocytes has generally occurred, or 
other conditions that adversely affect myocardial function and are generally 
reversible if the condition can be remedied. Loss of myocytes results from either 
necrosis (ischemia, toxic damage, or myocarditis) or from the process of apoptosis. 
It is thought that the decrease in cardiac contractility that occurs in HF is an 
important compensatory mechanism that decreases energy use by the failing 




contrast to CHF, during AHF there is further worsening of hemodynamic function 
(particularly with very high end-diastolic pressures) and further activation of 
neurohormones. In addition, the medications used to treat AHF often result in 
increased contractility and/or decreased BP. These changes (high LV diastolic 
pressure, decreased BP, and increased contractility) may result in myocardial injury 
in patients with primary cardiomyopathy with viable but non-contractile 
myocardium, further worsening the HF.357 
Regardless of the underlying molecular mechanisms and triggering factors, episodes 
of AHF are postulated to be associated with marked cardiomyocyte loss (necrosis) 
and dynamic changes in the architecture of the myocardial extracellular matrix 
(remodeling). Cardiomyocyte damage can be reflected by confirmation of high 
levels of circulating cardiac troponins. 115 Cardiac troponins (cTn) in AHF are 
discussed in section on diagnosis.  
The acceleration of myocardial remodeling during AHF may be reflected by an 
increased expression of 2 groups of molecules involved in the regulation of the 
dynamically changing status of extracellular matrix, i.e. MMPs degrading fibrillar 
collagens and tissue inhibitors of metalloproteinases (TIMPs), 373 as well as Gal3, a 
b-galactoside–binding lectin produced mainly by macrophages, involved in the 
fibroblast activation and tissue fibrosis.374 
The leading causes of LV systolic dysfunction in SSA uncontrolled hypertension, 
non-ischaemic cardiomyopathy and volume overload due to valvular regurgitations.  
The consequence of LV dysfunction is decreased CO which in turn leads to global 




blood in the ventricle and therefore an increase in both end-systolic and end-diastolic 
volumes. This in turn leads to an increase in LV end-diastolic pressure (LVEDP) 
which causes elevations in left atrial pressures which in turn lead to increases in the 
pressure of the capillaries in the lungs. This elevated pressure in the lungs forces 
fluid out of the pulmonary capillaries and leads to pulmonary congestion and the 
major clinical symptom of dyspnea. These signs and symptoms of LV dysfunction 
are all the result of increased left atrial pressure and pulmonary congestion.353 
In addition to the changes described above there is also a rise in the systemic 
vascular resistance (SVR) and this is deleterious to a failing heart. This is more 
profound in hypertensives where the heart is pumping against a high resistance. This 
is the basis for the importance of reduction of afterload (or SVR) in such patients. 
 
1.9.14 LV Diastolic Dysfunction 
 
Diastolic dysfunction refers to abnormal mechanical properties of the myocardium 
and includes abnormal LV diastolic distensibility, impaired filling, and slow or 
delayed relaxation. In diastolic dysfunction, the ventricle cannot accept blood at low 
pressures and ventricular filling is slow or incomplete unless atrial pressure rises. 375 
Therefore, there is an increased dependence on filling through atrial contraction and 
there are higher atrial pressures to maintain filling or cardiac output. 376 With regards 
to relaxation, any mechanism that interferes with actin myosin cross-bridge 
detachment or with removing calcium from the cytosol can delay this process.377 
Diastolic dysfunction during the late filling phase of diastole can be a result of 




myocardial mass and myocardial composition. In fact, numerous factors can 
influence LV stiffness including age, increased LV wall thickness relative to cavity 
size (such as in hypertension or aortic stenosis (AS)), intracellular changes in titin or 
microtubules, extracellular changes in collagen, and infiltration. 377-379 In addition, 
neurohormonal and cardiac endothelial activities also modulate ventricular stiffness 
and relaxation.380 
Diastolic heart failure can be defined as a clinical syndrome characterized by the 
symptoms and signs of heart failure, a preserved ejection fraction, and diastolic 
dysfunction. The presence of a preserved ejection fraction indicates that systolic 
hemodynamic pump performance (sometimes called “global pump” performance) is 
preserved, whereas contractile function of the myocardium may already be 
compromised. From a conceptual perspective, diastolic heart failure occurs when the 
ventricular chamber is unable to accept an adequate volume of blood during diastole, 
at normal diastolic pressures, and at volumes sufficient to maintain an appropriate 
stroke volume. These abnormalities are caused by impaired ventricular relaxation or 
by an increase in ventricular stiffness, both resulting in higher filling pressures at 
rest; more frequently, these impairments may produce elevated filling pressures 
during exercise and result in exercise dyspnea or exercise intolerance. 381 Elements 
and processes intrinsic to the cardiomyocyte contributing to diastolic dysfunction are 
summarized in Table 1.12. 382 In general, these relate to processes responsible for 
calcium removal from the myocyte cytosol (calcium homeostasis), to processes 
involved in cross bridge detachment, and to cytoskeletal functional elements. 




active relaxation and passive stiffness. 377  
Recent works in animal and human models have implicated titin isoform shifts, 
oxidative stress, nitric oxide synthase dysfunction, and myosin binding protein C in 
diastolic dysfunction. Titin isoform shift, or the overexpression of the stiff isoform 
of titin, has been found in endomyocardial biopsy samples of those with HFpEF. 383 
Nitric oxide is a known mediator of cardiac relaxation, and cardiac oxidation leading 
to uncoupling of cardiac nitric oxide synthase results in diastolic dysfunction. 384 
Lastly, myosin binding protein C, a protein located in cross bridge zones of muscle 
sarcomeres, is important in regulating muscle contraction. Phosphorylation of this 
important protein leads to deregulations of cardiac muscle contraction and 
subsequent dysfunction of the ventricles. 385 Indeed, Paulus describes a paradigm 
shift in thinking of HFpEF as a process of comorbid conditions leading to a systemic 
inflammatory state and microvascular inflammation, rather than focusing on 






Table 1.12 Causes leading to diastolic dysfunction (modified from Zile & 
Brutsaert 2002) 











atrial tachyarrhythmlas Impaired inactivation 
 processes 
✓Calcium homeostasis 
✓ calcium overload 




Abnormal activity of cardiac 
endothelial system (especially 
NO) 
 ✓Myofilaments 
✓ Tn-C calcium binding 
✓ Tn-l phosphorylation 
✓myofilament calcium  








✓ ADP/ATP ratio 
✓ ADP and Pi 
concentration 
 
 Nonuniformity of load or 
inactivation processes in 




 Abnormal activity of 
RAAS, OS, ANP/BNP, 
cardiac endothelial system 
 
ADP, adenosine diphosphate; ANP, atrial natriuretic protein; ATP, adenosine triphosphate; 
BNP, B-type natriuretic protein; MMP, matrix metaloproteinase; NO, nitric oxide; OS, 
orthosympathic nerve system ; RAAS, renin-angiotensin-aldosterone system; Tn-C, 
troponin-C ; Tn-I, troponin-I.  
 
 
Modern imaging technology like tissue Doppler imaging (TDI), radionuclide 
imaging and magnetic resonance imaging (MRI) are able to detect significant 




dysfunction and failure. 381 Importantly, these systolic abnormalities occur at normal 
ventricular ejection fractions, indicating that ejection fraction and parameters 
directly or indirectly related to it are indices of the ventricular hemodynamic pump, 
insensitive for measuring the performance of ventricular muscular pump. A 
preserved ejection fraction merely indicates that the radial (or circumferential) fibers 
of the ventricle compensate for longitudinal LV dysfunction to preserve overall 
hemodynamic pump performance, but does not imply that the systolic function of 
the muscular pump is normal.387 
The observations of evidence of systolic dysfunction in patients with heart failure 
with preserved ejection fractions have further reinforced the conjecture that systolic 
and diastolic heart failure are more closely related than previously anticipated. In 
fact, HF should be thought as a continuous spectrum of phenotypes in which the two 
extremes, i.e. (pure) diastolic and (pure) systolic heart failure, do probably not exist.  
Often patients at risk of heart failure have an uneven distribution of disease 
modifiers like hypertension, diabetes and female gender, with each of these 
modifiers affecting ventricular remodeling and symptom progression during the 




1.9.15 Right Ventricular (RV) Dysfunction 
 
The RV provides low-pressure perfusion of the pulmonary circulation, but is 
sensitive to changes in loading conditions and intrinsic contractility. Factors that 
affect RV preload, RV afterload, or LV function can adversely influence the 




Pathophysiologic changes in RHF vary according to the underlying cause, and are 
shown in Figure 1.14. 391 Often, patients experience RVF secondary to a combination 




Figure 1.14 Conditions associated with right ventricular (RV) failure categorised by 
initial pathophysiology (adapted from Piazza & Goldhaber 2005). ARDS, acute 
respiratory distress syndrome 
 
 
There is also a high degree of ventricular interdependence due to the role of the 
interventricular septum in the contraction of both ventricles, which is pronounced 
due the existence of pericardium. 392 Indeed, increases in the end-diastolic volume of 




the RV, increasing the end-diastolic pressure of the RV. 393 Similarly, when RV end-
diastolic volume is increased, the interventricular septum shifts toward the left cavity 
during diastole due to restrictions imposed by the pericardium on the RV as the 
cavity volume increases. This leftward shift impairs the function of the LV due to 
the reduction in LV volume, decreasing both left ventricular filling and compliance, 
manifested as increased LV muscle stiffness.  In fact, the most common cause of RV 
failure is LV failure. As the RV fails, there is a similar increase in the amount of 
blood in the ventricle, which in turn leads to elevated right atrial pressure (RAP) and 
increased pressure in the vena caval system which impairs venous drainage from the 
body. This leads to increased pressure in the liver, the gastrointestinal tract, and the 
lower extremities and to the clinical signs and symptoms of abdominal pain, 
hepatomegaly, and peripheral edema.394 
Compared to the LV, RVF progresses quickly from compensated to end-stage heart 
failure because of a vicious cycle of auto-aggravation as shown in Figure 1.15. 394 
This is unique to the RV and is rarely seen in isolated left ventricular failure. A 
sudden increase, although modest, in RV afterload on an ischemic RV immediately 
dilates the RV, induces a tricuspid regurgitation, and decreases cardiac output. This 
cascade of events must be prevented as soon as possible and implies that any sign of 
RVF should result in an immediate treatment in order to avoid this vicious cycle.394 
The RV plays a pivotal role in hemodynamic homeostasis, and changes in its 
function can have profound effects on the pulmonary and systemic circulation. The 
principal therapeutic goals of the early management of RVF depend on its 




cardiac output. This will allow restoring adequate oxygen delivery to the 
myocardium and reducing right ventricular overload. Treatment of RVF, therefore, 
should focus on alleviating congestion (limit volume loading), increasing right 
coronary artery flow, improving RV contractility, and reducing RV afterload. 
 
 




1.10 Diagnosis of AHF 
 
1.10.1 Clinical Evaluation 
A careful history and physical examination remain the cornerstones in the 
assessment of patients with HF. The history provides information to the cause of the 




identifies opportunities for therapeutic interventions. The physical examination 
provides information about the severity of illness and allows assessment of volume 
status and adequacy of perfusion. Table 1.13 summarizes the symptoms and signs of 
acute decompensated HF. 325 Sometimes atypical symptoms can predominate, 
especially in elderly patients, in whom fatigue, depression, altered mental status, or 
sleep disruptions may be the primary complaint. 
HF remains a clinical diagnosis, and the physical examination continues to play a 
fundamental role in its detection.  BP measurement is a critical part in the evaluation 
of patients with AHF; hypotension is one of the strongest predictors of poor 
outcomes and helps to define the clinical profile of the patient and appropriate 
therapeutic interventions. Majority of the patients with AHF present with either 
normal BP or high BP. 83 The pulse pressure is also a useful measure that is an 
indirect marker of cardiac output. A low pulse pressure correlates with low cardiac 
output and confers an increased risk in patients admitted with AHF. A high pulse 
pressure may alert the physician to a high-output state, including the possibility of 
unrecognized thyrotoxicosis, aortic regurgitation, or anemia.325 
The jugular venous pressure (JVP) is literally a barometer of systemic venous 
congestion and is the single most useful physical examination finding in the 
assessment of patients with AHF. It reflects the RAP, which is an indirect measure 
of LV filling pressures in the absence of isolated RVF. Rales or inspiratory crackles 
are the most common physical examination finding and have been noted in 66% to 
87% of patients admitted for AHF. However, rales are often not heard in patients 




increased lymphatic drainage, reinforcing the important clinical pearl that the 
absence of rales does not necessarily imply normal LV filling pressures.  
Peripheral edema is present in up to 65% of patients hospitalized with AHF and is 
less common in patients presenting with predominantly low-output HF or 
cardiogenic shock. As with rales, the presence of edema has a reasonable positive 
predictive value for ADHF but a low sensitivity, so its absence does not exclude that 
diagnosis. Hepatomegaly and splenomegaly can occur acutely in patients with AHF 
as a consequence of increased central venous pressure and in such cases often result 
in significant tenderness. Ascites occurs in response to elevated central venous 
pressures by retarding emptying of the peritoneal veins and the hepatic veins. Of 






Table 1.13 Common presenting symptoms and signs of decompensated heart 
failure (adapted from Felker & Teerlink 2015) 
SYMPTOMS 
 
               SIGNS 
 
Predominantly Related to Volume Overload 
 Dyspnea (exertional, paroxysmal nocturnal 
dyspnea, orthopnea, or at rest); cough; 
wheezing 
      Rales, pleural effusion 
 
Foot and leg discomfort 
 
    Peripheral edema (legs, sacral 
 
 
 Abdominal discomfort/ bloating; early 
satiety or anorexia 
  
      Ascites/increased abdominal girth; 
right 
      upper quadrant pain or discomfort;  
      hepatomegaly/splenomegaly;  
       scleral icterus 
       Increased weight 
       Elevated jugular venous pressure, 
       abdominojugular reflux 
    Increasing S3, accentuated P2 heart 
     Sounds 
Predominantly Related to Hypoperfusion 
 Fatigue  
 
Cool extremities 
 Altered mental status, daytime 
drowsiness, confusion, or difficulty 
concentrating 
  Altered mental status, daytime 
drowsiness, confusion, or difficulty 
concentrating 
 Dizziness, presyncope, or syncope   Pulse pressure (narrow)/proportional 
pulse pressure (low) 
Pulsus alternans 
Other Signs and Symptoms of AHF 
 Depression 
 Sleep disturbances 
 Palpitations 
  Orthostatic hypotension (hypovolemia 
  S4 
  Systolic and diastolic cardiac murmurs 
 
 
1.10.2 Laboratory Investigations 
The main objectives of initial evaluation of the patient with AHF are: (1) to establish 
a definitive diagnosis of AHF as quickly and efficiently as possible; (2) to provide 




respiratory failure), (3) to identify and address any relevant clinical triggers, (4) to 
risk stratify for triage of the patient to an appropriate level of care (e.g., ICU, 
telemetry unit, observation unit); and (5) to define the clinical profile of the patient 
(based on BP, volume status, and renal function) to allow rapid implementation of 
the most appropriate therapy. Based the pathophysiology (described above), a range 
of investigations is done in AHF to supplement the symptoms and signs in achieving 
the above objectives. These include serum NPs, cTn, electrolytes, liver enzymes and 
haemoglobin. An assessment of renal function is a critical component in the manage-
ment of patients with AHF. BUN is more directly related to the severity of AHF than 
Cr and typically is elevated on admission in a large proportion of patients with AHF. 
In addition to reflecting intrinsic renal function, the BUN level is roughly 
proportional to neurohormonal activation in AHF.  
The ECG and echocardiogram are the most useful investigations, as they confirm the 
presence of underlying structural heart disease. The likelihood of a normal ECG in a 
patient presenting with HF is low, making it an extremely helpful screening tool. 327 
Echocardiography is recommended for all patients with a diagnosis of HF as it 
confirms the type of structural heart disease present and provides information on 
cardiac function. 395 A summary of the applications and limitations of cardiac 






Table 1.14 Main applications and limitations of cardiac imaging techniques in 
the diagnosis and management of acute heart failure (modified from del Villar 
et al. 2015) 
 Main Applications Limitations 
Chest X-ray  Diagnosis of HF  
Diagnosis of concurrent extra 
cardiac disease(pneumothorax, 
pleural effusion, 
 consolidation, etc.) 
Low specificity  
Limited correlation with 
 hemodynamic parameters 
Focused TTE  Global assessment of cardiac 
structure and function in acute 
situations Qualitative 
 assessment of:   
 Pericardial effusion   
 Intravascular volume   
 Ventricular size and 
        function  
Pulmonary ultrasound 
Equipment technically inferior 
Specific training  
Stressful situations  
Risk of missing important 
abnormalities  
Window 
Comprehensive  TTE Syndromic  diagnosis 
(preserved vs reduced LVEF) 
Etiological diagnosis 
(ischemia, valvular heart  
disease, cardiomyopathies, 
 etc.)  
Noninvasive hemodynamic 
 Assessment 
Specific training Window 
TEE  As with TTE  
Endocarditis, intracardiac  
thrombus, aortic dissection 
Valvular heart disease (severity 
and mechanism) Monitoring of 
therapeutic procedures  
Possibility of continuous 
monitoring (miniaturized 
probes) 
Adequate training  
Esophageal probing 
CT  Triple rule out: noninvasive 
coronary angiography, 
pulmonary thromboembolism, 
acute aortic syndrome  
Diagnosis of concurrent 





MRI  Characterization of myocardium  
Quantification of severity of 
valvular heart disease 
Aortography 
Hemodynamic instability 




CT, computed tomography; HF, heart failure; LVEF, left ventricular ejection fraction; MRI, 








1.10.3 Chest X-ray in AHF 
 
In acute left heart failure, there is a progressive increase in pulmonary venous 
pressure. At a PCWP of 10 - 15 mm Hg, blood flow is uniform from bases to apices 
of the lungs due to capillary distention and recruitment. When the PCWP increases 
to between 15 and 25 mm Hg, a vascular redistribution of blood flow to the apices is 
observed and vessels appear larger than basal vessels (upper lobe diversion on the 
chest X-ray). 396 These modest elevations in pulmonary venous pressure are 
accommodated without the development of pulmonary edema. However, at higher 
filling pressures, fluid begins to cross the microvascular barrier, and pulmonary 
edema then develops. This first involves the interstitial compartment followed by the 
interlobular septa and the peri-bronchovascular spaces, and reaches the hila. This 
gives Kerley A lines situated at the apices and Kerley B lines located at the bases on 
the chest X-ray. If the pressure raises a value above 35 mm Hg, alveolar pulmonary 
edema occurs and produces a bilateral alveolar syndrome in a medullary distribution, 
with sparing of the periphery of the lung fields known as “bat’s wing” or “butterfly” 
pattern.396 
Chest X-ray may be limited in the diagnosis of pulmonary edema when presentation 
is atypical. 397 Alveolar edema is not always uniformly distributed owing to gravity. 
Lower lobe predominance can be observed when the patient is upright, and posterior 
distribution if the patient is supine. Coexisting lung disease may obscure pulmonary 
edema. Pulmonary edema may also present differently depending on the course of 
the disease. Patients with long-standing elevations in pulmonary wedge pressure like 




which protects the lung from pulmonary edema. On the other hand, a previously 
healthy patient with AHF from acute MI or massive volume overload may show 
dense alveolar peri-hilar infiltrates. Cardiomegaly may be absent especially in 
diastolic heart failure or in iatrogenic pulmonary edema due to fluid overload. Acute 
MI and acute cardiac arrhythmias can also result in pulmonary edema of cardiac 
origin with a normal sized heart. 
 
1.10.4 Echocardiography in AHF 
Echocardiography remains a very important tool is assessing patients with AHF. The 
diagnosis of cardiogenic pulmonary edema relies on the documentation of elevated 
LV filling pressure in a suggestive clinical setting. This finding is typically 
associated with LV systolic dysfunction. In this case, echocardiography quantifies 
LV pump function and identifies the underlying cardiac disease responsible for the 
congestive heart failure. Importantly, the echocardiographic abnormalities should be 
addressed in the context of the clinical setting.  
In the presence of a preserved LV systolic function but still elevated LV filling 
pressure, the presence of a high output AHF should be ruled out. The absence of 
dilatation of left cardiac cavities is usually consistent with an acute volume overload 
(e.g., valvular regurgitation, iatrogenic volume overload). However, markedly 
dilated left cardiac chambers reflect a progressive adaptation of the heart to a chronic 
volume overload. Associated LV hypertrophy is usually interpreted as a marker of 
associated LV pressure overload (e.g., aortic regurgitation).398 
The level of PH may also help in distinguishing recent from rather chronic LV 




mm Hg, 399 higher values usually denote the presence of a sub-acute or chronic PH 
rather than an acute increase of RV output impedance. Finally, echocardiography 
may clearly identify the cause of acute LV volume overload (e.g., endocarditis, 
ruptured papillary muscle, or mitral chordae) and confirms its severity. 
 The diagnosis of pure LV diastolic dysfunction can be considered after ruling out a 
congestive and a high output AHF by echocardiography. This clinical scenario 
typically corresponds to hypertensive AHF and frequently involves elderly patients 
with a history of hypertension. 39 Standardized diagnostic criteria of LV diastolic 
dysfunction have been proposed. 60 In the setting of AHF patients presenting with 
pulmonary edema and preserved LV systolic function, echocardiography represents 
a valuable diagnostic method for assessment of LV diastolic function, measurement 
of increased LV filling pressures, and identifying cardiac abnormalities known to be 
associated with impaired LV filling e.g. LVH. In practice, the prevalence of primary 
LV diastolic dysfunction in AHF patients identified by echocardiography may reach 
38%.400 
Importantly, echocardiography should be performed as close as possible to the AHF 
event (i.e., when symptoms are still present), since LV filling pressure may rapidly 
change in response to treatment-induced variations of loading conditions (e.g., 
diuretics, nitrates, mechanical ventilation, sedation).  
Patients with right heart failure typically present with acute-onset dyspnea at rest, 
physical signs of peripheral congestion, and clear lung fields. In a patient presenting 
with systemic venous congestion but no RV dilatation, a tamponade physiology 




straightforward in the presence of a pericardial effusion with diastolic compression 
of right cardiac cavities.  
Regardless of the origin of right heart failure, echocardiography enables a 
comprehensive evaluation of both global and regional RV systolic function.401 
AHF can complicate acute aortic syndrome (AAS) especially when it involves the 
aortic root rather than the descending aorta. Accordingly, trans-thoracic 
echocardiography (TTE) plays a key role in the evaluation of these patients since it 
is accurate for the diagnosis of acute condition of the ascending aorta and better 
tolerated than trans-esophageal echocardiography (TEE) in this specific clinical 
setting. 398 Although there may be no evidence for an intimal flap or an intramural 
hematoma based on TTE examination, the presence of a dilated ascending aorta and 
findings consistent with blood extravasation (i.e. haemo-pericardium) or aortic 
regurgitation is highly suggestive of AAS. In this situation, TEE should be done and 
may be safely performed in the operating room, under general anesthesia, followed 
by pericardial decompression if needed.398 
In the absence of acute disease of the ascending aorta, echocardiographic 
documentation of a new regional wall motion abnormality (RWMA) is indicative of 
acute MI.  
Cardiogenic shock is the most severe clinical presentation of peripheral 
hypoperfusion related to AHF syndrome. 39 It is attributable to a failing cardiac 
pump, regardless of the nature of the insult. Echocardiography in cardiogenic shock 
has the unparalleled advantage of documenting and assessing the severity of cardiac 




between a low cardiac output due to a failing LV and a RHF and determining if LV 
stroke volume is mostly generated by myocardial contractility rather than LV cavity 
dilatation.402 
 
1.10.5 Coronary angiography in AHF 
 
The decision to perform a coronary angiography in acute heart failure must be well 
balanced between the need to diagnose acute coronary occlusion and 
revascularization on the one hand and the procedure’s need for recumbency and 
contrast, which increases the loading conditions and can impair renal function on the 
other hand.403 
There are several causes of CAD related cardiogenic shock that can be diagnosed 
without coronary angiography, mainly using echocardiography; these causes include 
acute mitral regurgitation, and septal or free wall rupture. AHF and particularly 
cardiogenic shock occur in 5% to 10% of patients who suffer acute MI. 404 Despite 
therapeutic advances in the management of acute MI, prior reports, including those 
from large thrombolytic trials, suggest no change in the incidence or overall 
mortality (55% to 80%) of cardiogenic shock in this setting. 405  
Two randomized clinical trials by them have examined the role of emergency 
revascularization in STEMI complicated by cardiogenic shock. Both trials showed a 
clinically important (even if statistically insignificant) absolute 9% reduction in 30-
day mortality. 406-408  
The ACC/AHA recommended (class IA) primary PCI for patients younger than 75 
years old with ST segment elevation MI (STEMI) or new LBBB who develop shock 




within 18 hours of shock, unless further support is futile because of the patient’s 
wishes or contraindications/unsuitability for further invasive care.409 
Coronary angiography is available only in a few centres in Africa and may not be 




1.10.6 Biomarkers in Heart Failure 
Biomarkers have become increasingly important in diagnoses, prognostication, risk 
stratification and achieving guideline directed medical therapy in heart failure. These 
are enzymes, hormones, biologic substances, and other markers of cardiac stress and 
malfunction, or myocyte injury. 410 Although they include serum levels of 
hemoglobin, electrolytes, liver enzymes, BUN, creatinine, thyroid hormones and 
ferritin, often biomarkers refer to conventional or novel markers derived from blood 
or urine other than those mentioned above. Figure 1.16 showed clinically available 






Figure 1.16 Clinically available circulating biomarkers and their mechanistic 
implications in heart failure (adapted from BranwauldE. 2013). BNP, B-type natriuretic 




It has been proposed that a biomarker should fulfill three criteria to be useful 
clinically. 412 First, accurate, repeated measurements must be available to the 
clinician at a reasonable cost and with short turnaround times; second, the biomarker 
must provide information that is not already available from a careful clinical 
assessment; and finally, knowing the measured level should aid in medical decision 
making. Although relatively few of the biomarkers satisfy all three criteria, many 
appear to provide important information regarding the pathogenesis of heart failure 
or the identification of subjects at risk for heart failure or appear to be useful in risk 
stratification, in the diagnosis of heart failure, or in monitoring therapy. This section 
will discuss cTn, GDF-15, BNP/NT Pro BNP and Gal3. The last two are part of the 




1.10.6.1 Brain Natriuretic Peptide (BNP) and NT Pro BNP  
 
BNP belongs to the NPs family together with other structurally similar peptides, 
namely ANP, CNP and urodilatin. The NPs have in common a characteristic 
biochemical structure, which consists of a 17 amino-acid ring and a disulfide bridge 
between two cysteine molecules. 413 Figure 1.17 shows the structure of Pro BNP and 
NT-pro BNP. 
 
Figure 1.17 Structure Pro BNP and NT-proBNP 
 
 
BNP is a hormone that is secreted by atrial and ventricular myocardial cells but 
predominantly by the ventricular cells, and reaches very high plasma concentrations 
in subjects with congestive HF or AHF. BNP’s gene is located on the short arm of 




amino acids called pro BNP that co-exist with ANP in some secretory vesicles of the 
atrial and ventricular myocardial cells. BNP is synthesized in the heart as a reaction 
to cardiac wall distension and stretching, and neurohormonal activation. The 
cardiomyocytes synthesize a pre-propeptide (prepro BNP 134 amino acids), which is 
split into a signal peptide and a propeptide (pro BNP 108 amino acids). During 
secretion from the cardiomyocytes, proBNP is split at a ratio of 1:1 into the 
physiologically active BNP (32 amino acids), which corresponds to the C-terminal 
fragment, and the biologically inactive N-terminal fragment (NT-pro BNP, 76 amino 
acids). 414     
The physiological effects of BNP are manifold and comprise natriuresis/diuresis, 
peripheral vasodilatation, and inhibition of the RAAS and the SNS. BNP is cleared 
from plasma by binding to the NP receptor type C (NPR-C) and through proteolysis 
by neutral endopeptidases. In contrast, NT-pro BNP is mainly cleared by renal 
excretion; however, recent studies suggest that there might also be other important 
clearing mechanisms for NT-pro BNP.  
 
1.10.6.2 Brain Natriuretic Peptide (BNP) and NT Pro BNP in AHF 
 
B-type Natriuretic Peptide (BNP) and its precursor N-terminal pro-BNP are very 
useful in AHF diagnosis. They add value in the setting of undifferentiated dyspnea 
by improving diagnostic discrimination, 415 and they correlate with cardiac filling 
pressures and ventricular stretch. 416 Testing for NPs is a class 1 recommendation by 
the ACC/AHA, 48 and may be particularly useful when the etiology of dyspnea is 




AHF. 415 Patients with HFpEF have a smaller LV radius and thicker walls than 
HFrEF, resulting in proportionally lower NPs levels for similar degrees of AHF, 
suggesting that different diagnostic thresholds are needed depending on whether 
LVEF is preserved or reduced. 417 At the moment, natriuretic peptide testing cannot 
reliably distinguish HFpEF from HFrEF in an individual patient. 325  
Secreted NPs levels are elevated in acute MI, LV systolic dysfunction, LV diastolic 
dysfunction and RHF. 418 Elevated peptide levels are directly correlated with 
prognosis, NYHA score, intra-ventricular pressure, pulmonary pressure, and 
inversely proportional to CO. 419 It has been proposed that patients with BNP 
concentrations of less than 20 pmol/L have less chances of suffering from HF, while 
patients with higher concentrations should have further CV investigations. 420 In 
general, changes of > 50% from baseline represent worsening HF; however, 
significant variation in NP levels can occur within the same patient, and intra-
individual differences between measurements do not necessarily represent an acute 
clinical event. 421 Recent studies in patients with normal systolic function verified by 
echocardiography have shown that BNP levels correlate well with Doppler 
measurements showing diastolic dysfunction of the LV.422 
In the Breathing Not Properly study, a BNP threshold of 100 pg/mL maximized 
sensitivity and specificity to differentiate dyspnea that was ultimately confirmed to 
be due to AHF (based on a review of clinical data by a blinded panel of 
cardiologists) from dyspnea from other causes. 325 Importantly, the negative 
predictive value of a BNP level less than 100 pg/mL was particularly high (89%), 




(79%). Subsequent studies using NT-pro BNP, such as the Pro BNP Investigation of 
Dyspnoea in the Emergency department (PRIDE) study, have shown that NT-pro 
BNP has similar diagnostic value, although the appropriate cut points are higher 
overall and vary with age.423 
Assessing BNP levels and adjusting the dosage of therapy according to its level can 
lead to achieving the best possible treatment of HF. 424 These workers suggested that 
using BNP concentrations to monitor patients with HF and managing their medical 
therapy accordingly might improve overall morbidity and mortality. 
High levels of natriuretic peptides are associated with recurrent hospitalization and 
risk of sudden death, 425 and pre discharge BNP level appears to be a strong predictor 
for identifying subsequent death or hospital admission at 6 months. 426,427 Although 
“hard targets” for pro BNP values are not entirely defined, morbidity and mortality 
in CHF appear to increase markedly with a pro BNP concentration >500 pg/ml.  
In the Australia–New Zealand HF Group study, 428 levels of pro BNP above the 
median were associated with increased risks for new decompensated HF events and 
all-cause mortality during 18 months of follow-up, independently of age, NYHA 
functional class, LVEF, previous MI, or previous HF admission. 
In the Valsartan Heart failure (Val-Heft) trial, pro BNP ranked as the first prognostic 
factor on multivariate analysis independent of and more powerful than traditional 
risk factors, such as NYHA class, age, LV dilation, or renal dysfunction. 429 The Val-
Heft study also showed NPs to be superior to several other recognized 
neurohormonal markers of risk in HF, including norepinephrine, renin activity, 





1.10.6.3 BNP Versus NT Pro BNP 
 
In practice, measuring NT-pro BNP has advantages over routine BNP. NT-pro BNP 
is more stable than BNP with a half-life of 60-120 minutes, as against a half-life of 
18-22 minutes for BNP. This explains why NT-pro BNP serum values are 
approximately six times higher than BNP values, even though both molecules are 
released in equimolar proportions. 430 Once blood is collected BNP levels are not 
stable in vitro for long periods, dropping significantly over the first 24 hours, while 
there is very little variation in the level of NT-pro BNP for at least 72 hours or even 
longer. Therefore, NT-pro BNP can be assayed from stored or delayed specimens 
with confidence that the levels have not degraded with storage. In addition, assaying 
NT-pro BNP has been found to be easier than assaying BNP and this is because of 
higher plasma concentration. NT-pro BNP has also been found to be better in 
identifying patients with HF. 431,432  
 
1.10.7 Galectin 3 (Gal3) 
Gal3 is a soluble β-galactoside-binding lectin secreted by immune cells that regulate 
fibrogenesis, inflammation, cell proliferation and tissue repair. 433 Gal3 is encoded 
by a single gene, LGALS3, which is located on chromosome 14. 434 It is a chimera-
type galectin composed of a non-lectin domain connected to a carbohydrate-
recognition domain (CRD). Galectins share remarkable sequence similarities in the 
CRD, and many family members preferentially recognize galactose-containing 
saccharide ligands. The carbohydrate recognition domain has about 130 amino acid 
residues (attached to Gal3 binding partner), the collagen-like domain is proline-, 




domain has about 30 residues. (Figure 1.18). 374 Gal3 is ubiquitously expressed and it 
is present both in the cytoplasm, nucleus and outside cells. 
  
 
Figure 1.18 Schematic drawing of the structure of galectin-3 (adapted from Filipe MD 
et al. 2015) 
 
Gal3 is recently discovered to be involved in the pathophysiology of HF through 
mediation of myocardial fibrosis and inflammation, contributing to myocardial 
remodeling. 435 The evidence for the role of Gal3 in the pathogenesis of cardiac 
fibrosis has been described in detail by McCullough and coworkers. 436 Production of 
Gal3 from local pericytes, mast cells, and macrophages, induces resident fibroblasts 
and myofibroblasts to produce procollagen which is irreversibly cross-linked to 
collagen generating cardiac fibrosis. 437 Gal3 as a paracrine protein also directs cell 
adhesion, activation, chemoattraction, growth and differentiation, up-regulation of 




growth factor β (TGFβ) to increase cell cycle (cyclin D1) of myofibroblasts, which 
results in their proliferation and synthesis of procollagen 1. 439 In total, the available 
data strongly suggest that Gal3 is a critical participant in the pathogenesis and 
progression of HF, 440 and a biomarker reflecting tissue damage, independent of 
cardiac loading conditions. 441  
1.10.7.1 Galectin-3 in AHF 
 
Due to its physiopathology, there is no clear proof of the effectiveness of Gal3 for 
the diagnosis of HF; however, the prognostic power of galectin-3 has undergone 
more assessment. Plasma Gal3 seems to be a prognostic marker of HF outcomes 
such as death and readmissions for HF442,443 and is associated with increased risk for 
incident HF. 444 Van Kimmenade and colleagues have also shown that serum Gal3 
levels are elevated in subjects with AHF and it was able to identify those HF patients 
at risk of short-term death or the combination of death or readmission within 60 days 
better than NT-proBNP.  442 However, the combination of both markers seemed to 
further refine predictive utility. In this study, compared with NT-pro BNP and all 
clinical data available, the elevated concentration of Gal3 was the best independent 
predictor of 60-day mortality (OR10.3; P < 0.01) and 60-day death/recurrent HF 
(OR 14.3;P < 0.001).  
In addition, Femann and colleagues found a subset of patients of AHF patients, 
whose Gal3 levels were elevated beyond what would be predicted by their BNP 
elevations, and these patients were more likely to have acute kidney injury (AKI), 
with a tendency towards an increased 30-day event rate. They hypothesized that 




syndrome that is not identified as high-risk when natriuretic peptides are used in 
isolation.445 
In a meta-analysis of three studies and 893 patients, that included 582 patients from 
Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart 
Failure (COACH) study, 181 patients from the PRIDE study and 129 patient 
University of Maryland Pro-BNP for Diagnosis and Prognosis in Patients Presenting 
with Dyspnea, DeBoer446 reported that patients with elevated Gal3 above 17.8 ng/ml 
were nearly three times as likely to suffer short-term re-hospitalization (OR 2.80, 
95% CI 1.41–5.57, and 3.01, 95% CI 1.79–5.05, for 30- and 90-day readmissions, 
respectively). Also, baseline Gal3 was a predictor of re-hospitalization even after 
adjustment for age, gender, estimated GFR, NYHA functional class, LVEF and NT-
pro BNP levels. The authors of this meta-analysis concluded that in acute HF, an 
elevated Gal3 during an emergency department (ED) visit, hospital admission, or at 
hospital discharge is independently associated with early HF readmission. These 
findings are of clinical significance because the results of these studies suggest that 
Gal3 may identify AHF patients with elevated risk for death and re-hospitalization 
independent of the severity of signs and symptoms at presentation. Identification of 
those AHF patients at highest risk by combined assessment of serum markers may 
help to tailor the most appropriate treatment strategy on a more individualized basis. 
The direct inhibition of Gal3 is possible by N-acetyl-seryl-aspartyl-lysyl-proline 
(Ac-SDKP). This is a naturally occurring tetra-peptide that has been shown to 
prevents and reverses inflammation and collagen deposition in the heart in 




cardiac inflammation, remodeling and dysfunction and that these effects are 
mediated by the transforming growth factor signaling pathway.447 
 
1.10.8 Growth Differentiating Factor (GDF) – 15 in AHF 
Growth Differentiaing factor 15 (GDF-15) is a member of the TGF-β cytokine 
superfamily. 448 Like TGF-β, GDF-15 is synthesized as a precursor protein that 
undergoes disulfide- linked dimerization. Proteolytic cleavage of the correctly folded 
GDF-15 precursor releases the N-terminal propeptide from the mature GDF-15 
peptide, which is then secreted as a disulfide-linked dimer with a molecular mass of 
~28 kDa. 449 
Cardiac myocytes produce and secrete large amounts of GDF-15 in response to 
oxidative stress, stimulation with angiotensin II or pro-inflammatory cytokines, 
ischemia, and mechanical stretch. 450 
The prominent anti-apoptotic, anti-hypertrophic, and anti-inflammatory actions of 
GDF-15 in CVD models indicate that GDF-15 plays an important counter-regulatory 
role in the context of acute CV injury, such as MI or acute pressure overload.451 
Patients presenting with signs and symptoms of HF, have higher GDF-15 levels than 
do patients who are haemodynamically stable. 452 GDF-15 levels are elevated in HF, 
independent to disease severity (NYHA class, BNP, peripheral edema), CV risk 
factors (age, DM), renal dysfunction, inflammation and neurohormonal activation 
(CRP, uric acid, norepinephrine), and high-sensitivity troponin T (hs-TnT). 342  GDF-
15 levels are elevated in HF with preserved ejection fraction to a similar degree as in 
HF with reduced ejection fraction.453 




enrolled in the RELAX-AHF study, baseline GDF-15 was not associated with the 
composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days 
/CV death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at 
days 2 and 14 were associated with a greater risk of 60-day HF/RF re-
hospitalizations/CV death and CV death at 180 days . 
Data also show a tight relation between GDF-15 level and other biomarkers such as 
NT-pro BNP in heart failure patients. Furthermore, the combined use of GDF-15 and 
NT-pro BNP to predict prognosis significantly improves the accuracy.341 
 
1.10.9 Cardiac  Troponin (cTn) in AHF 
Cardiac troponin (cTn) is released by cardiac myocytes when they are injured. It is 
classically considered as marker of acute myocardial infarction but now considered 
as a marker of myocardial ischaemia regardless of the cause. Studies have now 
shown that cTn is in fact increased in AHF and even minor increase in 
concentrations have been shown to independently predict disease severity as well as 
short term and long term prognosis.455 
The prognostic utility of cTn in patients presenting with ADHF was explored in the 
ADHERE trial. 456 4240 out of approximately 85,000 patients with ADHF had 
abnormal cTn. The incidence of in-hospital mortality was higher in patients with 
elevated cTn compared to patients without elevated cTn (adjusted odds ratio 2.55; 
2.24–2.98, 95% CI, p b 0.001), and among patients with detectable cTn, mortality 
increased in a stepwise fashion with cTn.  
In another study of ADHF patients, cardiac troponin T (cTnT) and NT-proBNP were 




measurements was better at stratifying long term morbidity and mortality. 457 
Patients who at admission had elevations of neither biomarker, one biomarker, or 
both biomarkers had 85%, 60%, and 34% ADHF-free re-hospitalization survival 
rates (a composite of mortality and rehospitalization for HF), respectively. Patients 
who at discharge had elevations of neither biomarker, one biomarker, or both 
biomarkers had 63%, 71%, and 26% ADHF-free re-hospitalization survival rates, 
respectively. Thus, in this study, a predictive model using admission values for both 
cTnT and NT-pro BNP appears to have the greatest prognostic value for long-term 
adverse outcomes.  
Xue et al. 458 performed serial high sensitive cardiac troponin I (hs cTnI) and BNP 
measurements in 144 patients with ADHF. Biomarkers were quantified on 
admission, during hospitalization, and at discharge and the patients were then 
followed for mortality and rehospitalization for HF for ninety days after discharge. 
cTnI was detectable in over 99% of the samples. Elevated cTnI was strongly 
associated with greater ninety-day mortality and an increased rate of 
rehospitalization and the risk of these adverse outcomes tended to increase with 
higher cTnI. Moreover, patients with increasing cTnI, defined as a peak cTnI greater 
than admission cTnI, were at higher risk of dying by the time of follow-up than those 
with stable or decreasing cTnI (hazard ratio 4.52, p = 0.047). The presence of both 
elevated cTnI and BNP was associated with the worst prognosis.  
The fore going has made the ACC/AHA Task Force on Practice Guidelines to 




Compared with conventional troponin assays, hsTn methods detect substantially 
more myocardial necrosis in patients with HF and are incrementally prognostic, 
typically providing information that is additive to the natriuretic peptides and other 
biomarkers such as soluble ST2. 459 In the context of AHF therefore, elevated hsTn 
should not be assumed to be from acute coronary syndrome (ACS) but should be 
interpreted in the overall clinical picture especially because such increase during 
hospitalization or at discharge is predictive of a worse prognosis. 460 In summary, 
troponins identify both death and recurrent AHF episodes requiring readmissions 
and the hsTn has a graded association with mortality and is of independent 
prognostic importance.455 
 
1.11 Differential Diagnoses of Acute Heart Failure Syndrome 
Acute dyspnea is mostly due to potentially life-threatening cardiac or respiratory 
conditions, and treating it promptly requires understanding of the underlying 
mechanisms. Other than AHFS, a number of disorders can present with acute 
dyspnea, including COPD, asthma, pulmonary embolism, pneumonia, metabolic 
acidosis, neuromuscular weakness, and others. Depending on the hospital setting, 
AHFS accounts for 30% to 70% of acute dyspnea in the emergency unit. 461 Rapid 
identification of AHFS remains crucial and lifesaving, and may lead to prompt 
admission of the patient into the intensive care. Early diagnosis of AHFS was shown 
to be cost-effective and to reduce the hospital length of stay. 462 Thus, a simple and 
quick way of differentiating cardiac and pulmonary causes of dyspnea is essential in 




In practice, medical history, symptoms, physical examination, chest X-ray, ECG, 
and, more recently, use of biomarkers like BNP are sufficient to recognize AHFS in 
most patients presenting with acute dyspnea. Other investigations like 
echocardiography or cardiac catheterization (discussed above) require time and 
expertise and thus cannot be used as a screening procedure. Table 1.15 identifies 

















Pulmonary Embolism Probability clinical score 




Rare cause of acute dyspnoea 
Fever,  
Purulent sputum 
Interstitial and other 
lung diseases 
 
Exacerbation of other chronic respiratory conditions 
(tuberculosis sequelae, interstitial lung diseases, cystic fi 
brosis, and others)  
Less frequent cause of acute dyspnea in the ED.  
BNP BNP level <100 pg/mL 
ARDS 
 
Presence ARDS risk factor 
Normal cardiac silhouette 
Peripheral topography of infiltrates and absence of 
Kerley’s B lines on CXR, 










ARDS, acute respiratory distress syndrome; BNP, B-type natriuretic peptide; COPD, 
chronic obstructive pulmonary disease; CT, CXR, chest x-ray; ECG, electrocardiogram; 







1.12 Treatment of Acute Heart Failure 
 
The available treatment options for AHF have been largely empirical and limited by 
an incomplete understanding of the epidemiology and pathophysiology of the 
condition. The current general approach focuses on the successful treatment of 
clinical and hemodynamic congestion, while limiting untoward effects on 
myocardial or end-organ function, identifying addressable triggers, and optimizing 
proven long-term therapies.325 
The use of invasive hemodynamic management with pulmonary artery cath-
eterization may be a useful strategy in the management of some patients with AHF. 
This is an invasive procedure that provides detailed hemodynamic data, including 
direct assessment of filling pressures and cardiac output, and calculation of 
pulmonary and systemic vascular resistance. It has the potential risks of bleeding, 
infection, arrhythmias, and rare catastrophic events, such as pulmonary artery 
rupture or infarction. 
As mentioned earlier there is a complex interaction of structural, functional, cellular, 
genetic, neurohormonal, and inflammatory factors in AHF. This makes its 
pharmacological treatment challenging especially as regards to short- and long-term 
benefits. Currently pharmacological treatment for AHF is still based on the use of 
intravenous diuretics in a combination of series drugs such as vasodilators, (nitrates , 
levosimendan), ACE inhibitors, oxygen, digoxin and morphine. Dopamine should be 
used in patients with AHF complicated by cardiogenic shock. 463 There is a growing 
evidence for and interest in the use of novel drugs that are potent vasodilators with 




acting at various levels of cardiac smooth muscle cells, arterioles or renal blood flow 
are currently being investigated. 463 Table 1.16 Summarizes the emerging medical 





Table 1.16 Emerging medical therapies in acute heart failure 
Drug Mechanism of Action Trail/Study Results 
Ularitide Natriuretic peptide TRUE-AHF Improves 
haemodynamics, 
symptoms and signs, no 
WRF 
Relaxin Peptide, a recombinant 
analog of the 
endogenous human 
hormone, relaxin 
Releases nitric oxide, 
inhibits endothelin and 
angiotensin II 
RELAX-AHF  Relief of dyspnea and 
with a decrease in the 
combined endpoint of 
cardiovascular death 





activator that increases 
the transition of the 
actin-myosin complex 
and inhibits the 
nonproductive 
hydrolysis of (ATP). 
ATOMIC AHF dose-dependent 
increases in systolic 
ejection time, fractional 
shortening, stroke 
volume, and ejection 
fraction and was well 
tolerated over a broad 
range of plasma 
concentrations. 
Cledivipine Short-acting calcium 
channel blocker  
Selectively dilates 
arterioles and has no 







over 160 mmHg 
in the emergency. 
significant dyspnea 
improvement for up to 3 
hours, and a blood 
pressure improvement 




enhances the activity 
of SR Ca/ ATPase 
type 2a 
HORIZON –HF reduced pulmonary 
wedge pressure, 
improved diastolic 
function and cardiac 
index, and increased 
systolic blood pressure 
in AHF patients 
compared with placebo 
Cinaciguat Activates soluble 
guanylate cyclase, 
thus increasing cGMP 




decrease of systolic 
blood pressure and 
improvement of cardiac 
output but causes 
hypotension 




hormone that bind 
with strong affinity to 
the corticotropin-
releasing hormone 
receptor type 2 (CRH-
R2), which is highly 
expressed in the 
myocardium Inotropic 
and Lusitropic  
patients cardiac output, heart 




Aliskiren Direct renin inhibitor ASTRONAUT No reduction in CV 
death or HF 
rehospitalization at 6 
months or 12 months 
after discharge. 
Rolofylline Reno protective agent 
- Adenosine A1 
receptor antagonists 
have been developed 
to increase renal blood 
flow and enhance 
diuresis 
PROTECT No clinical benefit, 
including renal 
protection, associated 
with more seizure and 
stroke events when 
compared with placebo 
TRUE-AHF, Trial of Ulatiride’s efficacy and safety in patients with AHF; RELAX-AHF, Relaxin in 
AHF; ATOMIC-AHF, Acute Treament with Omecamtiv Mecarbil to Increase Contractility in AHF; 
HORIZON HF, Haemodynamic Effects of Istaroxime in patients with worsening HF and reduced LV 
systolic function; COMPOSE, Efficacy and Tolerability of Cinaciguat given intravenously in patients 
with ADHF; ASTRONAUT, Aliskiren Trial on AHF; PROTECT, Placebo Controlled Randomized 
Study of the Selective A1 Adenosine receptor antagonist Rolofylline for patients hospitalized with 
ADHF.  
  
Despite recent advances in pharmacological management, the prognosis of patients 
with ADHF remains poor. Consequently, non-pharmacological approaches are being 
developed and increasingly used. Such techniques may include several modalities of 
positive airway pressure therapy, ultrafiltration, mechanical circulatory support 
(MCS), myocardial revascularization, and surgical treatment, among others. Cardiac 
transplantation can also be considered as an option in severe AHF known to have 
poor outcome. However, transplantation cannot be done until patient is stable 





1.12.1 Treatment of Acute Heart Failure in sub Saharan Africa 
The treatment of AHF in sub Saharan Africa is not different from the rest of the 
world. However, the THESUS-HF36 data provided some important observations 
about medical therapy for AHF (Figure 1.19). 36 First, there was a high incidence of 
the use of aspirin in patients with non-ischemic HF in the sub-Saharan African 
region. Secondly, the rate of beta-blocker use, even at follow-up, is relatively low. 
Although many patients in THESUS -HF have HF with preserved systolic function 
for which the use of beta blockers is less clearly indicated, the rate of beta blocker 
use in THESUS–HF is lower than that described in other regions. 83,465 Thirdly, 
despite the encouraging results of A-HeFT, 52,465 the THESUS-HF data show that 
patients in sub Saharan Africa are rarely treated with a combination of hydralazine 
and nitrates, or the fixed-dose combination BiDil that was used in A-HeFT, since 
this preparation is unavailable in Africa. 36 These observations provided an 
opportunity to improve the quality of the care of patients with HF in the region. This 
led to a randomized study (BAHEF) 466 investigating the combination treatment with 
hydralazine and nitrates (HYIS) versus placebo in Africans admitted with AHF. This 
study was planned and carried out in nine centres in 6 sub-Saharan African counties 






Figure 1.19 Prescribed oral medication in sub Saharan Africa (adapted from 




Although the primary endpoint in BAHEF was not met due to poor recruitment, 
however, the results from the limited data set for several secondary outcomes were 
consistent with expected effects of HYIS, including a lower rate of cardiovascular 
mortality through 24 weeks, a non-statistically significantly lower number of HF and 
all-cause admissions per patient, and fewer days dead or in hospital in the active 
arm. Other findings consistent with a benefit include that in the HYIS group 
compared with the placebo group, by 24 weeks systolic BP dropped more, weight 
decreased more, 6MWT improved more, and there was a larger drop in BUN. On 
echocardiographic evaluation, parameters such as improvement in the LVEF, and a 
decrease in LV end-systolic diameter and LV end-diastolic diameter all favoured the 





1.13 Knowledge gaps and implications for Sub Saharan Africa 
 
This chapter has presented a review of contemporary literature on AHF with 
emphasis on sub Saharan Africa.  
Despite advancement in medical therapeutics, AHF has remained the most common 
reason for hospital admission in patients over the age of 65 years and its prognosis 
still dismal, with over 20% of the patients being readmitted with HF and over 20% 
dying during the first year after initial admission81.  
Acute heart failure is a major health issue, accounting for a large proportion of 
patients admitted to hospitals. Patients with recent hospitalizations for AHF are at 
high risk for future cardiovascular events and death. 467  In contrast to treatments for 
chronic heart failure, advances in the management of AHF have been limited while 
its incidence has been increasing in developed countries. 
The reviewed literature showed that current knowledge on epidemiology of HF in 
general and AHF in particular is based on studies in Europe and America with very 
few studies from Africa. Africa is witnessing a population explosion, increased life 
expectancy in many countries resulting in increasing HF prevalence. The continent 
also has both endemic and emerging causes of HF. In addition, the data on HF 
obtainable from studies in SSA are limited with most of them based on clinical 
diagnosis alone with few having echocardiography or biomarkers.  
In most SSA countries, AHF has not been well studied and the incidence, 
prevalence, treatment and outcomes of AHF are not well defined. There is also 
limited information on the characteristics, outcome and its predictors of heart failure 




including the role of the conventional and novel biomarkers in diagnosis and 
outcome will guide appropriate clinical decisions on treatment and proper 
monitoring. This can also allow designing specific strategies tailored to particular 
communities or countries based on their needs, for example control of hypertension 
and adequate treatment for pharyngitis to prevent Rheumatic fever. Because HF is 
both a preventable and treatable disease, early diagnosis and treatment of heart 
failure can lead to dramatic decreases in the morbidity and mortality.  
The findings obtained will also serve as baseline data on which larger initiatives 
exploring both pathophysiology and treatment of AHF would be built upon in the 
future. They can also be the bases for adequate planning for reduction of morbidity 
and mortality from AHF. 
In the next chapter, we present the hypothesis, aims and specific questions 

















We hypothesized AHF in SSA to have significant morbidity and mortality, affecting 
young patients in their prime of life. We also hypothesize that NT-pro BNP and the 
novel biomarkers GDF-15 and Gal3 will have a role in predicting outcome in this 
setting.  
 
2.2 General Aim  
 
The primary aim of this doctoral research project is to investigate the clinical 
characteristics and short-term (6 months) outcome of acute heart failure as well as 
determine the role of conventional biomarker NT-pro BNP and the novel biomarkers 
GDF -15 and Galactin 3 in the prognostication of acute heart failure patients in sub 
Saharan Africa.  
 
2.3 Specific objectives 
 
To fulfill the aim of this project the following specific objectives were pursued as 
















To describe the demographic and clinical characteristic of patients with 
acute HF 
To study the echocardiographic parameters in AHF and how they predict 
outcome.
To determine the predictors of readmission and mortality in AHF
To determine the prevalence and impact of renal dysfunction on AHF
To determine the electrocardiographic pattern in AHF
To determine the relationship between plasma levels of NT Pro BNP, 
GDF-15 and Galactin 3 and outcomes in Patients  with AHF
To determine the relationship between the plasma levels of NT Pro BNP, 





2.4 Outcome Measures 




Figure 2.2 Outcome measures of the study 
2.5 Protocol Modification 
 
In the course of this study, there was a slight modification in the submitted protocol 
as regards the biomarker assessment. Because of limitations to obtain the funding for 
specific assays due to the weakening Rand and therefore doubling of the costs one of 
the assays, GDF – 15 assay was not carried out. This neither affected the overall aim 
of the study nor the outcomes.   















3 CHAPTER 3: OVERVIEW OF STUDY METHODS 
3.1 Introduction 
This thesis involved cohorts of AHF patients from two prospective studies. Both the 
studies were conducted in centres in SSA.  They both adhere to the Declaration of 
Helsinki. Ethical clearance for all studies was granted by the Human Research Ethics 
Committee of the University of the Cape Town as well as the ethical committees of 
the various centres involved.  
3.2 Study Populations 
The first cohort include patients recruited for the sub Saharan African Survey on 
Heart Failure (THESUS-HF), which is a multicenter prospective observational 
clinical registry for hospitalized patients with AHF. The second cohort include 
patients recruited for the Bi treatment with hydralazine/nitrates versus placebo in 
Africans admitted with acute heart Failure in (BAHEF) which is a prospective, 
placebo controlled double blind randomized study to compare treatment with 
hydralazine – isorsobide dinitrate versus placebo on top of standard care in African 
patients admitted with AHF. Patients were considered to have AHF if they were 
admitted with acute dyspnea and the presence of heart failure signs by physical 
examination with at least 2 of the following: rales, edema, elevated JVP, 
hepatomegaly and ascites. Stable outpatient chronic heart failure cases were 
excluded. Details of inclusion and exclusion criteria for THESUS-HF and BAHEF 
studies are shown in Table 3.1 and 3.3 respectively. 
 Data collected from AHF patients enrolled in both studies were analyzed. These 




collected at the time of enrollment. They included extensive documentation of their 
HF state, CV history, general medical history, and management, including careful 
recording of medication usage.  
3.3 Study Design 
3.3.1 The sub Saharan African Survey on Heart Failure (THESUS-HF) 
The study was a multicenter prospective observational clinical registry.  Patients 
hospitalized with AHF were screened and enrolled if they met entry criteria as early 
as possible following admission. 
Patients had their baseline clinical and laboratory data collected at the time of 
enrollment. In addition, daily follow-up medical data were collected concerning the 
patient's course in the hospital with particular attention to the HF symptoms and 
signs, recurrent or persistent HF events, medications administered including 
intravenous diuretics, vasodilators and inotropes.    
Patients were followed-up through telephone call 30-180 days after enrollment to 











 Inclusion crit er ia 
1. Age  > 12 years 
2. Hospital admission for acute heart failure as defined by the presence of 
acute dyspnea and the presence of heart failure signs by physical 
examination  
3. Physical findings of congestive heart failure (pedal oedema, raised 
jugular venous pressure, pulmonary congestion, and tender 
hepatomegaly) 
4. NT-proBNP >900 pg/ml, > 1800 pg/ml if the patient has Atrial fibrillation 
at screening or > 450 pg/ml if BMI > 35 kg/m2. 
5. Subjects with primary diagnosis of acute HF regardless of the cause. 
6. Availability of regular follow up  
 
Exclusion crit er ia 
1. Severe known renal failure (patient on dialysis or creatinine > 4 
mg/ml), nephrotic syndrome, hepatic failure or other cause of 
hypoalbuminaemia. 
2. Reversible etiology of acute heart failure such as myocarditis, acute 
myocardial infarction, arrhythmia 
3. Recent Acute coronary syndromes within 2 weeks from screening 
4. Non-cardiac pulmonary edema 
5. Patients’ refusal or inability to sign informed consent or patient 













First Assessment Hospitalization, discharge and 
follow up 
1. Inclusion and exclusion criteria 
2. Demographics 
3. Heart failure history (if any) and its    
      etiology 
3. Comorbidities 
4. Medications prior to admission 
5. Total IV diuretics and other vasoactive 
drugs administered during first hours of 
admission  
6. O2 saturation and vital signs (systolic and 
diastolic BP and pulse). 
7. Fever and weight. 
8. Symptoms and signs of heart failure 
(orthopnea, dyspnea at rest, dyspnea 
during exercise, fatigue, paroxysmal 
nocturnal dyspnea, NYHA class, rales on 
lung bases, JVP and peripheral edema).- 
These will be recorded based on file 
information and the first measurement of 
study coordinator after consent.  
9. NT pro BNP, troponin, renal function and 
electrolytes (sCr, Bun, K+, Mg+, Na+). 
1. O2 saturation and vital signs 
(BP and pulse) at 3,6 and 24 
hours, discharge or 7 days, 30 
days and 6 months follow up 
2. Fever, blood pressure and 
weight at 1,2 and 7 days or 
discharge, 30 days and 6 
months follow up. 
3. Symptoms and signs of heart 
failure (orthopnea, dyspnea at 
rest, dyspnea during exercise, 
fatigue, paroxysmal nocturnal 
dyspnea, NYHA class, rales on 
lung bases, JVP and peripheral 
edema) at 6, 24 and 48 hours, 7 
days or discharge and 30 days 
and 6 months follow up.  
4. NT pro BNP and troponin, 
renal function and electrolytes 
daily (sCr, Bun, K+, Mg+, 
Na+). 
5. Echo including LVEF, RVEF, 
wall motion, cavity size, 
pressures, valvular function, 
diastolic function 
6. Medical Rx at 1, 2 and 7 days 
(or discharge) as well as follow 
up.  
7. Worsening heart failure events 
or death either during the 
initial admission or leading to 





3.3.2  Bi treatment with hydralazine/nitrates versus placebo in Africans 
admitted with acute heart Failure in (BAHEF) 
 
This was a prospective, randomized, double-blind, placebo controlled trial 
comparing the combination of isosorbide dinitrate and hydralazine (HYIS) with 
placebo.  Patients were screened within 96 hours from admission for AHF.  Patients 
were evaluated for inclusion and exclusion criteria and underwent echocardiographic 
examination, serum chemistry (Cr and BUN), NT-pro-BNP. Patients willing to 
participate in the study and who signed an informed consent were randomized to 
receive either HYIS or placebo. Randomized patients underwent full clinical 
evaluation including physical examination, collection of patient’s self-report of 
dyspnea severity by a visual assessment scale (VAS), and physician’s assessment of 
heart failure signs and symptoms. At selected centers, blood was drawn for central 
assessment of inflammatory, neurohormonal and novel biomarkers.  Patients were 
started at the study drug low dose, and up-titrated to the higher dose at 2 weeks 
depending on tolerability. Patients were followed up from randomization to 
discharge; pre-discharge evaluations were conducted at the earlier of day 7 or 
discharge and included dyspnea assessment, physical examination and measurement 
of NT-pro-BNP.  Post-admission follow-up included clinic visits every 4 weeks 
through 24 weeks follow up.  Evaluations at 8 weeks and 24 weeks included dyspnea 
assessment, physical examination, and laboratory assessments.  Patients who 
discontinued the study drug prior to 24 weeks were still followed up through 24 
weeks.   
After the initial 24 weeks double-blind phase of the study, patients were given the 




were treated with active HYIS for up to an additional 24 weeks.  They were followed 
up every 4 weeks through 24 weeks. 
 
 

























Tab le 3.3 Inclusion and Exclusion cr iter ia of the BAHEF stud y  
Inclusion criteria 
≥18 years of age 
Hospital admission for acute heart failure as defined by the presence of acute dyspnea and 
the presence of heart failure signs by physical examination with at least 2 of the following:  
rales, edema, elevated JVP, hepatomegaly, ascites  
NT-proBNP >900 pg/ml, > 1800 pg/ml if the patient has Atrial fibrillation at screening or > 
450 pg/ml if BMI > 35 kg/m2. 
LVEF <45% assessed by echocardiography or other method within the previous 12 months 
Background therapy with at least ACE-inhibitor or ARB and beta-blocker (unless beta-
blocker is contraindicated due to severe volume overload, low output heart failure, or 
cardiogenic shock) 
Available for regular follow up 
 
Exclusion Criteria 
Any intravenous treatment for heart failure, except IV furosemide (e.g. IV inotropes, 
pressors, nitrates, or nesiritide) at the time of screening 
Systolic blood pressure <100 mmHg  
Greater than 96 hours after admission 
Reversible etiology of acute heart failure such as myocarditis, acute myocardial infarction, 
arrhythmia 
Hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, 
endomyocardial fibroelastosis 
Known severe congenital heart disease (such as uncorrected tetralogy of fallot or 
transposition of the aorta) 
Significant stenotic valvular disease  
Renal impairment (defined by creatinine > 3 mg/dL) at screening or on any type of dialysis  
Women who are pregnant or lactating 
History or presence of any other disease including AIDS and malignancy with life 







In both the two studies, subjects were required to provide written informed consent 
to participate in the study in question. 
3.5 Enrolment and data collection 
All hospital admissions for which dyspnea was the main complaint were screened. 
Patient adjudicated to have AHF that satisfies the inclusion criteria were enrolled in 
the studies.   
Data from each subject were obtained using a uniform and standardized CRF. The 
data obtained included: study identification number, demographic data, date of 
diagnosis of HF and pre-admission history (previous HF related admissions). Others 
include NYHA functional class, symptoms, signs, self-reported CV risk factors, 
aetiology of HF, precipitating factor, co-morbidities, blood investigations, Chest X-
ray , 12-lead ECG, echocardiography and medications.  
 
3.5.1 Anthropometric Measurements 
The height and weight of the subjects were measured. Height and weight were 
measured with the participants standing, wearing indoor clothes with no shoes. Body 
mass index was calculated as weight in kilograms divided by the square of height in 
meters.  
 
3.5.2 Blood Measurements 
Blood samples were drawn for fasting blood sugar, fasting lipid profile, electrolyte, 




In addition to the above blood tests, another 20mls were collected from each patient 
for assays of NT-pro BNP of Gal3, for patients from the second cohort of the study 
(BAHEF). The blood was transfused into EDTA tubes and samples were 
immediately centrifuged, plasma was separated and then stored at -80 degrees 
Celsius until assayed. Samples were transported from the various centres in dry ice 
and shipped to the Hatter Institute for Cardiovascular research in Africa (HICRA). 
Plasma NT-Pro BNP was measured by a standard electrochemiluminescence 
immunoassay. NT-Pro BNP levels were measured from a banked aliquot from stored 
blood samples using BNP EIA fragment kit from Biomedica Gruppe. A sensitive 
and specific non-radioactive immunoluminometric (ILMA) assay based on 
competitive ligand binding was used. Plasma Gal3 was assayed using human Gal3 
enzyme linked immunosorbent (ELISA) assay for in vitro diagnostic use (Human 
Galectin-3 Platinum Elisa, eBiosciences). Both assays were performed at the 
HICRA. 
3.5.3 Plasma NT-pro BNP Assay 
We used BNP Fragment ELISA Assay kit (Cat no: BI-20852W, Standard range: 0 to 
6400 pmol/L, Detection limit: 171 pmol/L) manufactured by Biomedica Gruppe. 
This kit quantitatively determines the human BNP Fragment (NT-pro BNP 8-29) in 
serum, citrate plasma, EDTA plasma or heparin plasma.  
Plasma NT-pro BNP was measured by a standard electrochemiluminescence 
immunoassay. NT-pro BNP levels were measured from a banked aliquot from stored 
blood samples. A sensitive and specific non-radioactive immunoluminometric 
(ILMA) assay based on competitive ligand binding was used. Stored samples were 




with 1% TFA containing 60% acetonitrile. The samples were lyophilised in a 
centrifugal evaporator and re-dissolved in assay buffer consisting of 0.1mol/L 
sodium phosphate (pH 7.4), 0.1% Triton X-100 for the measurement. NT- pro BNP 
concentrations were determined blind to the clinical details of a subject.  
The principle of the test: In a first step, sample and conjugate (sheep anti human NT-
pro BNP-HRPO) are pipetted into the wells of the microtiter strips, which are pre-
coated with polyclonal sheep anti NT-proBNP antibody. NT-proBNP present in the 
sample binds to the pre-coated antibody in the well and forms a sandwich with the 
detection antibody. In the washing step all non-specific unbound material is 
removed. In a second step, the substrate (TMB Tetramethylbenzidine) is pipetted 
into the wells. The enzyme catalysed colour change of the substrate is directly 
proportional to the amount of NT-proBNP present in the sample. This colour change 




Figure 3.2 Principle of assay of BNP Fragment (NT-pro BNP 8-29) in human serum. 





The reagents are reconstituted as follows: The wash buffer (WASHBUF) was 
reconstituted by diluting the concentrate in a ratio of 1:20 (e.g. 50 ml of WASHBUF 
concentrate to 950 ml of distilled water. This is stable at 2-8 o C until its labeled 
expiry date. Only the diluted WASHBUF was used for the assay. The standard 
(STD) was reconstituted by pipetting 200 μl of distilled water into each vial. It was 
left for 20 min at room temperature (18 – 26 o C) and swirled gently. This is stable at 
- 25o C or lower until its labeled expiry date.  The control (CTRL) was reconstituted 
by pipetting 200 μl of distilled water into the vial. It was left for 20 min at room 
temperature (18 – 26 o C) and swirled gently. This is also stable at - 25o C or lowers 
until its labeled expiry date.  For the STD and the CTRL, care was taken to avoid 
freeze – thaw cycles. Figure 3.3 showed the NT-pro BNP assay kit used for the 
study. 
 




The protocol of assay used is as follows (according to manufacturer’s intructions): 
The reagents and samples were at room temperature (18-26°C) before use in the 
assay. The positions for BLANK/STD/SAMPLE/CTRL 
(Blank/Standard/Sample/Control) were marked on the protocol sheet. The microtiter 
strips were taken out of the aluminum bag, and a blank well was chosen. The unused 
strips were stored with desiccant at 4°C (2-8°C) in the aluminum bag. The following 
steps were then followed one after another: 
1. 150 μ l of assay buffer (ASYBUF) was added to all wells except the blank 
2. 30 μl of STD/SAMPLE/CTRL (Standards/Sample/Control) in duplicate was 
added into respective well, except blank. 
3. 50 μl CONJ (Conjugate) was then added into each well, except blank and 
swirled gently. 
4. Microtiter strips were covered tightly and incubated overnight (16 -25 hours) 
at 4°C (2-8 °C) in the dark.  
5. The wells were aspirated and washed 5x with 300 μl diluted WASHBUF 
(Wash buffer), the remaining wash buffer was removed by hitting plate 
against paper towel after the last wash. 
6. 200 μl SUB (Substrate) was then added into each well and incubated for 20 
min at room temperature (18-26°C) in the dark. 
7. 50 μl of STOP (Stop solution) was added into each well and shook well. 
8. Absorbance was immediately measured at 450 nm with reference 630 nm. 
9. The optical density (OD) of all wells was read on a plate reader using 450 




10. The blank optical density (OD) was subtracted from the values of STD, 
CTRL and sample. A standard curve was constructed from the OD values of 
the STD.  The sample concentration was obtained from a standard curve. 
Dilution factors were taken into consideration for calculation of the samples. 
11. Using a graph paper, the sample concentration was obtained from this 
standard curve. The assay was evaluated with a 4PL algorithm.  
 
3.5.4 Plasma Galectin - 3 Assay 
Plasma galectin-3 was assayed using human Galectin-3 enzyme linked 
immunosorbent (ELISA) assay (eBioscience BMS279/4TEN, Plasma (EDTA) 
samples, Sensitivity: 0.29 ng/ml Range: 0.47-30 ng/ml) for in vitro diagnostic use.  
The Gal3 levels were measured from a banked aliquot from stored blood samples in 
triplicate. Prior to assay, the frozen samples were brought to room temperature 
slowly and mixed gently. Gal3 concentrations were determined blind to the clinical 
details of a subject.  
Principle of the test: An anti-human Galectin-3 coating antibody is adsorbed onto 
micro-wells. Human Gal3 present in the sample or standard binds to antibodies 
adsorbed to the micro-wells. A biotin-conjugated anti-human Galectin-3 antibody is 
added and binds to human Gal3 captured by the first antibody. Following incubation 
unbound biotin conjugated anti-human Galectin-3 antibody is removed during a 
wash step. Streptavidin- HRP is added and binds to the biotin conjugated anti-human 
Gal3 antibody. Following incubation unbound Streptavidin- HRP is removed during 




coloured product is formed in proportion to the amount of human Galectin-3 present 
in the sample or standard. The reaction is terminated by addition of acid and 
absorbance is measured at 450 nm. A standard curve is prepared from 7 human Gal3 
standard dilutions and human Gal3 sample concentration determined. 
The kit reagents were stored between 2° and 8°C. Immediately after use remaining 
reagents were returned to cold storage (2° to 8°C).  
The Buffer Concentrates were brought to room temperature and diluted according to 
the manufacturer’s recommendation before starting the test procedure. If crystals 
have formed in the Buffer Concentrates, they were gently warmed until they have 
completely dissolved. The dilution of the Buffer Concentrates was as follows: Wash 
Buffer Concentrate (20x ie 50 ml:950 ml of distilled water), Assay Buffer 
Concentrate (20x – 5ml : 95 ml of distilled water), Biotin conjugate ( 1:100 dilution 
of the concentrated Biotin-Conjugate solution with Assay Buffer (1x)) and 
Streptavidin-HRP (1:400 dilution of the concentrated Streptavidin-HRP solution 
with Assay Buffer (1x)). The Wash Buffer (1x) and the Assay Buffer (1x) are stable 
for 30 days. The Biotin-Conjugate and the Streptavidin-HRP were used within 30 
minutes of dilution, in keeping with manufacturer’s recommendation. 
The human Gal3 standard was reconstituted by addition of distilled water to give a 
concentration of 50 ng/ml. The standard was allowed to reconstitute for 10-30 
minutes before dilutions were made. The remaining standard was discarded after 
use. 
For eternal standard dilution, 7 tubes were labeled S1, S2, S3, S4, S5, S6, S7 one for 




follows: 225 μl of Sample Diluent was pipetted into each tube. Then 225 μl of 
reconstituted standard (concentration = 50 ng/ml) was pipetted into the first tube, 
labelled S1, and mix (concentration of standard 1 = 25ng/ml). Thereafter 225 μl of 
this dilution was pipetted into the second tube, labelled S2, and mix thoroughly 
before the next transfer. These serial dilutions were repeated 5 more times thus 
creating the points of the standard curve.  
 
Figure 3.4 Serial dilutions of human galectin-3 standard 
 
 
The protocol of the assay is as follows (according to manufacturer’s intructions): We 
determined the number of microwell strips required to test the desired number of 
samples plus appropriate number of wells needed for running blanks and standards. 





Table 3.4 Micro wells strips for galectin-3 assay - 7 Standard concentrations: 
25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 ng/ml 
 1 2 3 4 5 6 
A Blank STD4 Sample 1 Sample 1 Sample 5 Sample 9 
B       
C STD1 STD5 Sample 1 Sample 2 Sample 6 Sample 
10 
D       
E STD2 STD6 Sample 1 Sample 3 Sample 7 Sample 
11 
F       
G STD3 STD7 Sample 1 Sample 4 Sample 8 Sample 
12 
H       
 
The following steps were then followed: 
a. We washed the micro-well strips twice with approximately 400 μl Wash Buffer 
per well with thorough aspiration of micro-well contents between washes. The Wash 
Buffer was allowed to sit in the wells for about 10 – 15 seconds before aspiration.  
b. After the last wash step, the wells were emptied and micro-wells strips tapped on 
absorbent pad or paper towel to remove excess Wash Buffer.  Care was taken not to 
allow the wells to dry. 
c. 100 μl of Sample Diluent was added in duplicate to all standard wells. 100 μl of 
prepared standard was then pipetted in duplicate into the first 2 well in the first row 
(wells A1, A2). The contents were mixed well (concentration of standard 1, S1 = 25 
ng/ml), and 100 μl from these well was transferred to the first 2 well in the second 




two rows of human Galectin-3 standard dilutions ranging from 25.00 to 0.39 ng/ml. 
100 μl of the contents from the last microwells (G1, G2) used was discarded. 
d. 100 μl of Sample Diluent was added in duplicate to the blank wells. 
e.  50 μl of Sample Diluent was added to the sample wells. 
f. 50 μl of each sample was added in duplicate to the sample wells. 
g. 50 μl of Biotin-Conjugate was added to all wells. Biotin –Conjugate had to be 
used within 30 minutes of preparation 
h. The microwell strips were covered with an adhesive film and incubated at room 
temperature for 2 hours, on a microplate shaker set at 400 rpm. 
i. The adhesive film was removed the wells were emptied wells. The microwell 
strips were washed 3 times in accordance with the test protocol. 
j. 100 μl of diluted Streptavidin-HRP was added to all wells, including the blank 
wells. Streptavidin – HRP had to be used within 30 minutes of preparation 
k. The micro-well strips were covered with an adhesive film and incubated at room 
temperature for 1 hour, on a micro-plate shaker set at 400 rpm.  
l. The adhesive film was removed the wells were emptied wells. The microwell 
strips were washed 3 times in accordance with the test protocol. 
m. 100 μl of TMB Substrate Solution was pipetted to all wells. 
n. The micro-well strips were incubated at room temperature for about 10 min, 
avoiding direct exposure to intense light. 
o. The colour development on the plate was monitored and the substrate reaction 
stopped. The stop solution was added when the highest standard has developed a 




0.95, monitored by the ELISA reader at 620 nm (Figure 3.5).  
q. The enzyme reaction by quickly stopped by pipetting 100 μl of Stop Solution into 
each well. It was spread quickly and uniformly throughout the micro-wells to 
completely inactivate the enzyme.  
 
 
Figure 3.5 Colour change in after adding the Stop solution to the Standard 
 
r. Results were read immediately after the Stop Solution is added. The absorbance of 
each microwell was read on a spectro-photometer using 450 nm as the primary wave 
length. (optionally 620 nm as the reference wave length; 610 nm to 650 nm is 
acceptable). The absorbance of both the samples and the standards were determined. 
If incubation was done without micro-plate shaker, the obtained O.D. values may be 





Figure 3.6 Measurement of optical densities using spectrophotometer (left side of the 
picture). The values are read on the computer screen (right side) 
 
s. The average absorbance values were calculated for each set of duplicate standards 
and samples. Duplicates should be within 20 per cent of the mean value. A standard 
curve was created by plotting the mean absorbance for each standard concentration 
on the ordinate against the human Galectin-3 concentration on the abscissa. The best 
fit curve was drawn through the points of the graph (a 5-parameter curve fit is 
recommended). 
t. The concentration of circulating human Gal3 for each sample was determined, first 
by finding the mean absorbance value on the ordinate and extending a horizontal line 
to the standard curve. At the point of intersection, a vertical line was extended to the 
abscissa and the corresponding human Gal3 concentration was read 
u. The concentration read from the standard curve was multiplied by the dilution 
factor (x 2 - 50 μl sample + 50 μl Sample Diluent). 




external pre-dilution according to expected human Gal3 values with Sample Diluent 
in order to precisely quantitate the actual human Gal3 level. If this is not done, the 
values will be incorrectly low human Gal3 levels (Hook Effect).  
w. To validate the results, the laboratory control sample of known human Galectin-3 
concentration was run with each assay.  
Figure 3.7 below shows the picture of human Gal3 kits used for the project  
 
 











3.6 Transthoracic Echocardiography 
Subjects were examined in the left lateral decubitus position using standard 
parasternal, short-axis and apical views. Studies were performed according to the 
recommendations of the American Society of Echocardiography (ASE).  468  M-
mode echocardiograms were derived from 2D images. The M-mode cursor on the 
2D scan was moved to specific areas of the heart to obtain measurements, according 
to the recommendation of the committee on M-mode standardization of the ASE. 
Measurements were averaged over 3 cardiac cycles. The LV measurements taken 
include inter-ventricular septal thickness at end diastole (IVSd), the posterior wall 
thickness at end diastole (PWD), LV end diastolic diameter (LVEDD) and LV end 
systolic diameter (LVESD) (Figure 3.8). LV systolic function was calculated by 
Teichholz’s formula. 469 LV mass (LVM) was calculated using the formula of 





This has been shown to yield values closely related to necropsy left ventricular 
weight and that has good inter study reproducibility (r=0.90). The left and right atria 
areas were measured at end-ventricular systole when the atria chambers were at their 
greatest dimension, and with the bases of both atria at their greatest dimensions. 
LV inflow velocities were measured using pulsed-wave Doppler from the apical 4-
chamber view, with the sample volume located between the tips of the mitral valve 
leaflet during ventricular diastole. Peak velocity of early rapid filling (E), peak 
velocity of late filling caused by atrial contraction (A) and the interval from peak of 
E wave to its extrapolation to the baseline or deceleration time (DT) were measured. 
The ratio of peak E-wave to A- wave was calculated. Diastolic function was 
categorized using mitral inflow and Doppler Tissue Imaging parameters. Grade 3 
diastolic dysfunction or restrictive filling pattern was defined as E/A ratio greater 
than 2, with deceleration less than 130 milliseconds. Grade 1 diastolic dysfunction 
was defined as E/A ratio less than 1 and a deceleration time of 220 milliseconds, 
while grade 2 diastolic dysfunction or pseudo-normal filling was diagnosed when 
deceleration time was greater than 220 milliseconds and the E/A ratio was between 1 
and 2. 
RV remodeling was assessed using the RV size and wall thickness as well as the RV 
systolic function. RV systolic function was assessed on echocardiography using M-
mode recordings through the lateral tricuspid valve annulus for the purpose of 
measuring the tricuspid annular plane systolic excursion (TAPSE). TAPSE is a 
method used to measure the distance of systolic excursion of the RV annular 




TAPSE represents longitudinal function of the right ventricle. It is inferred that the 
greater the descent of the base in systole, the better the RV systolic function. TAPSE 
is usually acquired by placing an M-mode cursor through the tricuspid annulus and 
measuring the amount of longitudinal motion of the annulus at peak systole (Figure 
3.9). 470 A TAPSE value less than 16 mm denotes right ventricular systolic 
dysfunction. 471  
Echocardiography examinations also included assessment of valvular architecture; a 
semi-quantitative estimate of the severity of valvular regurgitation; and presence of 
pericardial effusion. Other abnormalities like evidence of pulmonary arterial 
hypertension were also noted.  The pulmonary artery systolic pressure (PASP) was 
estimated by measuring the maximum velocity of the tricuspid regurgitant velocity 
(TRV), the trans-tricuspid pressure gradient was then calculated using the modified 
Bernoulli equation 4(TRV)² (Figure 3.10). 472 The right ventricular systolic pressure 
(RVSP) was calculated using the formula: RVSP = 4(TRV)2 + Right Atrial 
Pressure(RAP). The TRV was measured from the continuous wave Doppler of 
tricuspid regurgitant jet from apical four-chamber or from the parasternal right 
ventricular inflow view if the regurgitant jet was eccentric. The PASP is equivalent 
to RVSP in the absence of pulmonary outflow obstruction. The RAP is estimated by 









Figure 3.8 Parasternal Long Axis view with the M-mode cursor at the TV and the LV. 
Left image: M-mode image showing how LV measurement is done. Right image: M-
mode showing RV measurement 
 
Figure 3.9 Apical four-chamber view with M-mode cursor at the tricuspid annulus. 
Bottom Image: M-mode image showing measurement of the tricuspid annular plane 








Figure 3.10 Continuous -wave across the TV in the four chamber view showing severe 
TR, despite the less impressive colour-flow jet seen across the valve 
 
3.7 Data analysis 
Data for both studies were processed at Momentum Research, Inc. Data were 
verified and analyzed using commercially available software (SAS, version 9.2; SAS 
Institute, Inc). Continuous data were presented as mean (SD) or median 
(interquartile range, i.e., 25th and 75th percentiles). Continuous variables were 
compared using 2-tailed, 2-sample t tests and categorical variables using Chi-square 
tests. Sex-adjusted differences between patients with the various causes were 




and ordinary linear regression for continuous characteristics. The cumulative 
survival probabilities were estimated using the method of Kaplan –Meier for all-
cause mortality, and readmission for worsening HF. 
The time to the first event was considered; times for patients without the event of 
interest were censored at the earlier of the last date the patient was known to be alive 
or the period of interest. 
The univariate proportional hazard regression was used to evaluate the relation of 
baseline measurements (age, gender, NYHA functional class, aetiology of HF, 
systolic blood pressure, LVEF, LVEDD, LVESD, serum Cr , serum biomarkers to 6-
month mortality. Prevalence of renal dysfunction at baseline and its association with 
outcome was determined. 
Univariable models of the association of each of the biomarkers (NT-pro BNP, 
Gal3) with the outcomes were carried out. A multivariable model with all 
biomarkers, adjusted for covariates associated with the outcome were done using 
those found to be significant in THESUS prognostic models. 
Correlation coefficients were calculated by linear regression analysis with NT-pro 
BNP and Gal3 log-transformed to establish normality, and correlations between NT-
pro BNP and Gal3 and continuous demographic, clinical, laboratory and 
echocardiographic values evaluated. Multivariate linear regression analyses were 
performed with log transformed NT-pro BNP and Gal3 concentrations as dependent 
variables, with inclusion of demographic, clinical, laboratory and echocardiographic 




Variable selection in multivariate modeling was based on clinical and statistical 
significance (p<0.05) 
Details of statistical analysis and modeling are described in the relevant chapters of 























4 Chapter 4: The demographic and clinical characteristic 
of patients with acute heart failure patients in sub 
Saharan Africa 
4.1  Introduction  
The problem of heart failure has been recognized in sub-Saharan Africa for over 60 
years. 144 Heart failure is an important cause of morbidity and mortality in Africa. 
The majority of the clinical studies of heart failure in sub-Saharan Africa were 
conducted in the pre-echocardiographic era or without the application of 
echocardiography in the majority of cases. 100,150 These clinical studies as well as 
necropsy studies that examined the etiology of heart failure of hospitalized Africans 
showed the vast majority of heart failure cases in sub-Saharan Africa are due to the 
major nonischemic causes, with rheumatic heart disease, hypertensive heart disease, 
and cardiomyopathy accounting for over 75% of cases in most series.100 
There was also a lack of data on the incidence, prevalence, etiology, treatment, and 
outcome of the disease in general and its geographical variation by region and 
country in Africa. We planned and conducted the THESUS-HF registry of patients 
admitted to hospital with heart failure in 9 sub Saharan African countries to address 
the gaps in knowledge mentioned above. This registry included information on the 
patients’ course before the admission, the in-hospital phase, echocardiographic 
evaluation and a short follow-up (6 to 12 months).  
THESUS-HF was followed by an RCT (BAHEF) investigating the combination 




admitted with AHF carried out in 6 sub-Saharan African countries.  
In this chapter, we describe the demographic and clinical characteristics of patients 
admitted with AHF in SSA, based on the THESUS-HF registry and the BAHEF 
clinical trial.  
Our results have demonstrated that AHF in SSA affects young men and women in 
their early fifties, predominantly of black race. The aetiologies are mainly 
hypertension, idiopathic dilated cardiomyopathy and rheumatic valvular heart 
disease. HIV infection is as yet not a significant cause of AHF in SSA, despite high 
prevalence of the disease in the continent. Unlike the western population, ischemic 
heart disease was responsible for only a small percentage of AHF. Most of the 
patients present late in NYHA functional class III and IV had significant co-
morbidities, high readmission rates and mortality.  In addition the data from 
THESUS –HF showed a high incidence of the use of aspirin in patients with non-
ischemic HF, low rates of use of beta-blockers and combination of hydralazine and 
nitrates This chapter is presented in form of two published research papers below, in 
the Archives of Internal Medicine and the European Journal of Heart Failure.  
1. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, 
Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, 
Edwards C, Davison BA, Cotter G, Sliwa K. The causes, treatment, and outcome 
of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012 
Oct 8;172(18):1386-94. 
2. Sliwa K, Damasceno A, Davison BA, Mayosi BM, Sani MU, Ogah O, Mondo 
C, Ojji D, Dzudie A, Kouam CK, Yonga G, Ba SA, Ogola E, Edwards C, Cotter 
G. Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with 
acute HEart Failure (BA-HEF). Eur J Heart Fail. 2016 May 20. doi: 
10.1002/ejhf.581.  
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ORIGINAL INVESTIGATION
The Causes, Treatment, and Outcome of Acute
Heart Failure in 1006 Africans From 9 Countries
Results of the Sub-Saharan Africa Survey of Heart Failure
Albertino Damasceno, MD, PhD; Bongani M. Mayosi, DPhil, FCP(SA); Mahmoud Sani, MBBS;
Okechukwu S. Ogah, MBBS; Charles Mondo, MBChB, PhD; Dike Ojji, MBBS; Anastase Dzudie, MD;
Charles Kouam Kouam, MD; Ahmed Suliman, MD; Neshaad Schrueder, MBChB, FCP(SA);
Gerald Yonga, MBChB; Serigne Abdou Ba, MD; Fikru Maru, MD; Bekele Alemayehu, MD;
Christopher Edwards, BS; Beth A. Davison, PhD; Gad Cotter, MD; Karen Sliwa, MD, PhD
Background: Acute heart failure (AHF) in sub-Saharan
Africa has not been well characterized. Therefore, we sought
to describe the characteristics, treatment, and outcomes of
patients admitted with AHF in sub-Saharan Africa.
Methods: The Sub-Saharan Africa Survey of Heart
Failure (THESUS–HF) was a prospective, multicenter,
observational survey of patients with AHF admitted to
12 university hospitals in 9 countries. Among patients
presenting with AHF, we determined the causes, treat-
ment, and outcomes during 6 months of follow-up.
Results: From July 1, 2007, to June 30, 2010, we en-
rolled 1006 patients presenting with AHF. Mean (SD) age
was 52.3 (18.3) years, 511 (50.8%) were women, and the
predominant race was black African (984 of 999 [98.5%]).
Mean (SD) left ventricular ejection fraction was 39.5%
(16.5%). Heart failure was most commonly due to hyper-
tension (n=453 [45.4%]) and rheumatic heart disease
(n=143 [14.3%]). Ischemic heart disease (n=77 [7.7%])
was not a common cause of AHF. Concurrent renal dys-
function (estimated glomerular filtration rate, !30 mL/
min/173 m2), diabetes mellitus, anemia (hemoglobin level,
!10 g/dL), and atrial fibrillation were found in 73 (7.7%),
114 (11.4%), 147 (15.2%), and 184 cases (18.3%), respec-
tively; 65 of 500 patients undergoing testing (13.0%) were
seropositive for the human immunodeficiency virus. The
median hospital stay was 7 days (interquartile range, 5-10),
with an in-hospital mortality of 4.2%. Estimated 180-day
mortality was 17.8% (95% CI, 15.4%-20.6%). Most pa-
tients were treated with renin-angiotensin system block-
ers but not "-blockers at discharge. Hydralazine hydro-
chloride and nitrates were rarely used.
Conclusions: In African patients, AHF has a predomi-
nantly nonischemic cause, most commonly hyperten-
sion. The condition occurs in middle-aged adults, equally
in men and women, and is associated with high mortal-
ity. The outcome is similar to that observed in non-
African AHF registries, suggesting that AHF has a dire
prognosis globally, regardless of the cause.
Arch Intern Med. 2012;172(18):1386-1394.
Published online September 3, 2012.
doi:10.1001/archinternmed.2012.3310
H EART FAILURE (HF) ANDespecia l ly acute HF(AHF) are importantcauses of morbidity andmortality in the devel-
oped world. The high rate of rehospital-
ization, the unproductive years of life,
and the price of treatment constitute an
important economic burden. Little is
known about acute and chronic HF in
sub-Saharan Africa.1 Recent studies2-5
suggested that the main underlying
causes of HF are different in Africa,
including some conditions that are
almost unique, such as endomyocardial
fibrosis and tuberculous pericarditis,6,7 as
well as a high prevalence of peripartum
cardiomyopathy and idiopathic dilated
cardiomyopathy.8 At the same time, with
a nonuniform epidemiologic transition to
a more Western way of living, preva-
lences of hypertension, obesity, and dia-
betes are increasing, particularly in urban
centers, with a possible effect on the eti-
ology of HF.9
The Sub-Saharan Africa Survey of
Heart Failure (THESUS–HF) was initi-
ated to determine the causes and treat-
See Invited Commentary
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ment of AHF and morbidity and mortality among
those with the disease in the African subcontinent.
METHODS
STUDY DESIGN AND CLINICAL SETTING
We conducted THESUS–HF as a prospective, multicenter, in-
ternational observational survey in 12 cardiology centers from
9 countries in the southern, eastern, central, and western re-
gions of sub-Saharan Africa. The countries and centers were
selected on the basis of availability of a physician trained in clini-
cal cardiology and echocardiography who had previously par-
ticipated in research projects. Ethiopia, Kenya, and Senegal
joined the study late, resulting in a shorter enrollment period.
INCLUSION AND EXCLUSION CRITERIA
Patients older than 12 years admitted with dyspnea as the main
complaint and diagnosed with AHF based on symptoms and
signs that were confirmed by echocardiography (de novo or de-
compensation of previously diagnosed HF) were enrolled in the
present study. Exclusion criteria were acute ST-elevation myo-
cardial infarction, severe known renal failure (patients under-
going dialysis or with a creatinine level of #4 mg/dL) (to con-
vert to micromoles per liter, multiply by 88.4), nephrotic
syndrome, hepatic failure, or another cause of hypoalbumin-
emia. Written informed consent was obtained from each sub-
ject who was enrolled into the study. Ethical approval was ob-
tained from the ethical review board of the participating
institutions, and the study conformed to the principles out-
lined in the Declaration of Helsinki.
DATA COLLECTION AND CASE DEFINITION
A comprehensive range of clinical data was collected on a stan-
dardized case report form. A detailed echocardiographic as-
sessment of ventricular function, valvular structure and func-
tion, and regional wall abnormalities was performed. All
echocardiographic procedures were undertaken by trained phy-
sicians, and measurements were made according to the Ameri-
can Society of Echocardiography Guidelines.10 Electrocardio-
grams were read centrally by a cardiologist at Momentum
Research, Inc, using standard reference ranges.11 Laboratory
evaluations provided by the local institution and intravenous
and oral medications were recorded at admission and on days
1, 2, and 7 (or at discharge if earlier). Symptoms and signs of
HF, vital signs, and laboratory test data (when indicated) were
collected at baseline and through day 7 (or at discharge if ear-
lier). The probable primary cause of HF was based on the Eu-
ropean Society of Cardiology guidelines12 and as recently ap-
plied in the chronic HF cohort of the Heart of Soweto Study.13
Ischemic causes were determined on the basis of accepted cri-
teria, such as history, or results of noninvasive (eg, electrocar-
diography, stress test) or invasive tests when available. Test-
ing for human immunodeficiency virus infection was only
performed when clinical findings raised suspicion and after pa-
tient consent was obtained.
Subjects underwent evaluation for symptoms and signs of HF
and laboratory testing (when indicated) at the 1- and 6-month
follow-ups. Information on readmissions and death, with respec-
tive reasons and cause, was collected through the 6-month follow-
up. We initiated telephone contact with patients who could not
attend additional clinic visits because they moved to a different
location or to another province. Patients who could not be con-
tacted were censored at the last available contact.
To better understand the changes in the pattern of AHF in
Africa, the present cohort was classified as having endemic
causes (group 1; ie, rheumatic heart disease, the cardiomy-
opathies, and infective causes, such as pericarditis and human
immunodeficiency virus–associated cardiomyopathy), and
emerging causes (group 2; ie, hypertension and ischemic
heart disease).14-17
STATISTICAL ANALYSES
All data were processed at Momentum Research, Inc. Data were
verified and analyzed using commercially available software
(SAS, version 9.2; SAS Institute, Inc). Continuous data were
presented as mean (SD) or median (interquartile range, ie, 25th
and 75th percentiles). Continuous variables were compared
using 2-tailed, 2-sample t tests and categorical variables using
$2 tests. Sex-adjusted differences between patients with emerg-
ing and endemic causes were estimated using weighted least
squares regression for dichotomous characteristics and ordi-
nary linear regression for continuous characteristics. Kaplan-
Meier estimates of mortality and readmission rates were pro-
vided. The time to the first event was considered; times for
patients without the event of interest were censored at the ear-





From July 1, 2007, to June 30, 2010, 1011 patients were
enrolled in the study, for whom 1006 case report forms
were received (Figure 1).
Table 1 shows the demographic and clinical presen-
tation on admission for the entire cohort and compares
men with women (50.8% of the cohort). Electrocardio-
graphic strips were available for 814 patients. The most
frequent arrhythmia was atrial fibrillation, which was











Cape Town, South Africa












Figure 1. Patients included in the Sub-Saharan Africa Survey of Heart Failure
per country. Case report forms were available for 1006 of 1011 patients.
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conduction abnormality was left anterior hemiblock,
present in 143 of 804 patients (17.8%). Complete left
and right bundle branch blocks were seen in 62 of 803
(7.7%) and 39 of 803 patients (4.9%), respectively.
CAUSES OF HF
Figure 2 shows the causes of HF in the entire study co-
hort. In some patients, more than 1 cause was identified.
Table 2 shows the characteristics by endemic vs emerg-
ing HF causes and interaction of those causes with sex.
Figure 3 shows the different causes of AHF by country.
THERAPIES FOR HF
The most commonly administered intravenous medi-
cation at admission was furosemide in 927 of 998
patients (92.9%), with use decreasing to only 215 of
938 patients (22.9%) at day 7 or discharge. The next
commonly administered parenteral drugs on admis-
sion were digoxin in 13.7% and nitrates in 7.9%.
Parenteral inotropes (ie, dopamine hydrochloride and
dobutamine hydrochloride) were used in 5.0% and
5.1%, respectively, on admission. Mechanical
ventilation was rarely used (0.6%). Figure 4 shows









Mean (SD) 52.3 (18.3) 54.0 (16.9) 50.7 (19.5) .005
Median (IQR) 55.0 (39.0-67.0) 55.0 (43.0-67.0) 53.0 (33.0-67.0)
Black African, No. (%) 984 (98.5) 486 (98.8) 497 (98.2) .47
Atrial fibrillation, No. (%) 184 (18.3) 77 (15.7) 107 (21.1) .03
No. of AHF admissions in last 12 mo
Mean (SD) 0.37 (0.78) 0.41 (0.77) 0.34 (0.78) .15Median (IQR) 0 (0-0) 0 (0-1) 0 (0-0)
Hyperlipidemia, No. (%)b 90 (9.2) 52 (10.8) 38 (7.6) .09
History of smoking, No. (%) 98 (9.8) 85 (17.3) 13 (2.6) !.001
History of hypertension, No. (%) 556 (55.5) 296 (60.0) 259 (51.0) .004
History of diabetes mellitus, No. (%) 114 (11.4) 58 (11.8) 56 (11.0) .68
Body mass indexc
Mean (SD) 25.2 (9.0) 24.7 (4.9) 25.7 (11.6) .08Median (IQR) 24.0 (20.9-28.1) 24.0 (21.2-27.6) 23.9 (20.5-28.6)
Systolic blood pressure, mm Hg
Mean (SD) 130.4 (33.5) 132.4 (33.7) 128.4 (33.3) .06Median (IQR) 126.5 (106.0-150.0) 130.0 (110.0-151.0) 120.0 (102.0-150.0)
Diastolic blood pressure, mm Hg
Mean (SD) 84.3 (20.9) 85.5 (21.2) 83.2 (20.7) .08Median (IQR) 80.0 (70.0-100.0) 82.0 (70.0-100.0) 80.0 (70.0-96.0)
Heart rate, bpm
Mean (SD) 103.7 (21.6) 101.6 (21.4) 105.7 (21.6) .003Median (IQR) 104.0 (90.0-116.0) 100.0 (88.0-112.0) 108.0 (90.0-120.0)
LVEF, %
Mean (SD) 39.5 (16.5) 37.8 (16.2) 41.1 (16.6) .002Median (IQR) 38.0 (27.0-50.0) 37.0 (25.0-112.0) 40.0 (28.4-53.0)
Creatinine level, mg/dL
Mean (SD) 1.44 (1.19) 1.57 (1.21) 1.30 (1.16)
!.001Median (IQR) 1.12 (0.89-1.50) 1.23 (0.96-1.65) 1.01 (0.80-1.33)
SUN level, mg/dL
Mean (SD) 35.6 (34.1) 41.1 (38.9) 30.2 (27.7)
!.001Median (IQR) 26.6 (16.5-42.0) 30.5 (20.0-49.0) 23.2 (14.3-34.5)
Sodium level, mEq/L
Mean (SD) 135.1 (6.6) 134.9 (6.5) 135.3 (6.8) .33Median (IQR) 135.8 (131.0-139.1) 135.0 (131.0-139.0) 146.0 (131.4-140.0)
Glucose level, mg/dL
Mean (SD) 109.7 (49.7) 109.7 (44.0) 109.5 (54.9) .94Median (IQR) 93.7 (84.0-117.0) 97.2 (84.6-122.0) 93.0 (82.8-111.6)
eGFR, mL/min/1.73 m2
Mean (SD) 83.3 (48.0) 85.3 (51.4) 81.4 (44.4) .20Median (IQR) 76.7 (54.0-103.5) 79.6 (55.5-106.2) 74.7 (52.6-101.3)
Renal dysfunction, No. (%)d 73 (7.7) 35 (7.5) 38 (7.8) .83
Hemoglobin level, g/dL
Mean (SD) 12.2 (2.6) 12.6 (2.6) 11.8 (2.5)
!.001Median (IQR) 12.3 (10.7-13.7) 13.0 (11.0-14.5) 11.8 (10.5-13.1)
Anemia, No. (%)e 147 (15.2) 68 (14.3) 79 (16.1) .43
Total WBC count, No./µL
Mean (SD) 7699 (4092) 7484 (3505) 7914 (4581) .10Median (IQR) 6800 (5200-8980) 6700 (5200-8900) 6900 (5200-9000)
Lymphocyte count, %
Mean (SD) 30.3 (13.4) 29.8 (12.9) 30.9 (13.8) .25Median (IQR) 30.0 (20.0-39.6) 30.0 (20.0-39.0) 30.5 (20.3-40.0)
(continued)
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prescribed oral medications on admission and
follow-up.
PATIENTS’ FOLLOW-UP AND OUTCOMES
Of 1006 patients, 1-month follow-up assessments were
completed for 578 (57.5%) and 6-month assessments for
461 (45.8%). A total of 159 of 1006 patients (15.8%) died
without completing a 6-month assessment; an addi-
tional 316 (31.4%) had a last date known alive provided
and were included in the analysis. The remaining 70 pa-
tients (7.0%) were lost to follow-up. Reasons for loss to
follow-up were provided for 35 of these patients and in-
cluded lack of telephone contact (2.3%), financial con-
straints (0.3%), unwillingness to come for follow-up
(0.3%), lack of transportation to the site (!0.1%), and
others, for example, transfer of care to other facilities
(0.5%). Table 3 reports the main clinical outcomes ob-
served in the study. The rate of death or readmission at
60 days was 15.4% (Figure 5A), and the estimated
6-month mortality rate was 17.8% (Figure 5B). Mortal-
ity rates were similar among countries, except that a some-
what lower rate was reported in the Ugandan center
(6.3%).
COMMENT
To our knowledge, our data represent Africa’s first and
largest multinational prospective registry of AHF. This
registry reveals a few unique characteristics of AHF in
sub-Saharan Africa.
One of the most striking features of this cohort of Afri-
can patients with AHF is the relative youth of the pa-
tients affected (median age, 55 years). In industrialized
countries, AHF is a disease of the elderly, with a mean
age of 72 years (median age, 66-70 years)18; hence, the
condition presents 2 decades earlier in sub-Saharan Africa.
Acute HF therefore strikes patients in the prime of their
lives in sub-Saharan Africa, with major economic impli-
cations because it affects the generation of bread-
winners and caregivers. With respect to sex, despite the
relative youth of the patients, the disease affects men and
women equally, although the characteristics and causes
Patients with acute heart failure1006
453 of 998 (45.4%) Hypertension
188 of 998 (18.8%) Idiopathic dilated cardiomyopathy
143 of 997 (14.3%) Rheumatic heart disease
77 of 999 (7.7%) Ischemic heart disease
77 of 1002 (7.7%) Peripartum cardiomyopathy
68 of 999 (6.8%) Pericardial effusion tamponade
39 of 986 (4.0%) Other endemic
34 of 986 (3.4%) Other emerging
26 of 1000 (2.6%) HIV cardiomyopathy
13 of 1000 (1.3%) Endomyocardial fibrosis
Figure 2. Causes of acute heart failure in the study cohort. Blue indicates
earlier stages of epidemiologic transition (endemic causes); pink, later stages
of epidemiologic transition (emerging causes); and HIV, human
immunodeficiency virus.









Mean (SD) 157.6 (54.2) 160.0 (59.0) 155.2 (49.1) .26Median (IQR) 152.1 (124.0-187.0) 156.0 (124.8-187.2) 152.1 (120.9-183.3)
Triglyceride level, mg/dL
Mean (SD) 106.2 (53.9) 109.8 (56.7) 102.7 (50.9) .09Median (IQR) 97.9 (71.2-124.6) 97.9 (73.5-125.0) 95.5 (71.2-124.6)
CK level, U/L
Mean (SD) 232.2 (447.7) 259.4 (412.6) 210.8 (473.9) .40Median (IQR) 88.0 (55.0-171.0) 110.0 (62.5-251.6) 83.0 (48.9-139.0)
CK-MB fraction, U/L
Mean (SD) 37.4 (76.0) 39.1 (83.9) 35.9 (68.6) .78Median (IQR) 19.0 (13.0-32.0) 19.0 (14.0-31.0) 20.0 (12.0-32.5)
Seropositive for HIV, No./No. undergoing
testing (%)
65/500 (13.0) 30/240 (12.5) 35/260 (13.5) .75f
Abbreviations: AHF, acute heart failure; CK, creatine kinase; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; IQR, interquartile
range; LVEF, left ventricular ejection fraction; SUN, serum urea nitrogen; WBC, white blood cell.
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; CK to microkatals per liter, multiply by 0.0167; creatinine to micromoles
per liter, multiply by 88.4; glucose to millimoles per liter, multiply by 0.0555; hemoglobin to grams per liter, multiply by 10.0; lymphocyte fraction to a proportion
of 1, multiply by 0.01; sodium to millimoles per liter, multiply by 1; SUN to millimoles per liter, multiply by 0.357; triglycerides to millimoles per liter, multiply
by 0.0113; WBC count to cells %109 per liter, multiply by 0.001.
aData are computed from nonmissing values, the number of which may vary from variable to variable. The sex of 1 patient was not reported.
b Indicates cholesterol level of more than 200 mg/dL, low-density lipoprotein level of at least 130 mg/dL, or high-density lipoprotein level of less than 30 mg/dL.
cCalculated as weight in kilograms divided by height in meters squared.
d Indicates eGFR of less than 30 mL/min/1.73 m2.
e Indicates hemoglobin level of less than 10 g/dL.
fCalculated as comparison of seropositivity for HIV test with negative/unknown results.
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(95% CI) P Value
Sociodemographic Profile
Age, y
Mean (SD) 52.3 (18.3) 46.8 (18.2) 41.0 (18.3) 59.0 (13.7) 62.6 (13.6) 17.0
(15.0 to 19.1) !.001Median (IQR) 55.0 (39.0-67.0) 46.0 (34.0-59.0) 36.0 (25.0-54.0) 60.0 (50.0-69.0) 64.0 (55.0-73.0)
Risk factor profile, No./
No. not missing (%)
Total cholesterol level
#193 mg/dL
112/649 (17.3) 16/129 (12.4) 21/190 (11.1) 44/185 (23.8) 30/128 (23.4) 11.9
(5.9 to 17.9)
!.001





43/197 (21.8) 60/274 (21.9) 247/286 (86.4) 189/219 (86.3) 64.5
(59.6 to 69.3)
!.001
Type 2 diabetes mellitus 114/1003
(11.4)
14/197 (7.1) 17/276 (6.2) 43/285 (15.1) 37/219 (16.9) 9.3
(5.3 to 13.3)
!.001




NYHA, No./No. not missing (%)
II 303/706 (42.9) 60/141 (42.6) 97/200 (48.5) 72/200 (36.0) 67/147 (45.6)
III 216/706 (30.6) 46/141 (32.6) 49/200 (24.5) 69/200 (34.5) 47/147 (32.0)
IV 28/706 (4.0) 4/141 (2.8) 8/200 (4.0) 13/200 (6.5) 2/147 (1.4)
Systolic blood pressure, mm Hg
Mean (SD) 130.4 (33.5) 116.1 (28.5) 115.7 (24.3) 143.8 (32.3) 143.8 (36.4)
27.9












Mean (SD) 84.3 (20.9) 76.5 (19.5) 77.1 (17.0) 92.0 (19.8) 90.9 (22.4)
14.6











Mean (SD) 103.7 (21.6) 103.8 (24.3) 109.1 (22.4) 100.2 (19.3) 101.7 (20.0)
−5.5











Mean (SD) 1.8 (1.0) 1.9 (1.0) 1.7 (1.0) 1.9 (1.1) 1.8 (1.1)
0.1












Mean (SD) 94.6 (17.9) 97.3 (18.4) 98.1 (18.9) 91.1 (17.5) 9.19 (15.9)
−6.2










Dimensions and LV Function
LV systole size, mm
Mean (SD) 46.0 (13.1) 49.3 (13.4) 45.7 (13.5) 47.3 (12.6) 42.8 (12.3)
−2.4










LV diastole size, mm
Mean (SD) 57.7 (11.6) 60.9 (11.5) 57.9 (11.9) 58.6 (11.3) 54.0 (10.7)
−3.1











Mean (SD) 39.1 (16.3) 36.9 (16.4) 40.2 (17.1) 37.3 (15.4) 40.8 (15.5)
0.6












Mean (SD) 11.2 (3.3) 10.7 (3.1) 9.8 (3.1) 12.3 (3.1) 11.8 (3.0)
1.8
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differ by sex (Tables 1 and 2), probably contributing to
slight differences in outcomes (Table 3).
Three important observations are worth noting about
medical therapy for AHF (Figure 3). First, we have ob-
served a high incidence of the use of aspirin in patients with
nonischemic HF in the sub-Saharan African region. In ad-
dition, the combination of hydralazine hydrochloride and
nitrates, which has been shown to be effective in patients
of African descent,19,20 is hardly ever used in the sub-
Saharan region. Third, the rate of "-blocker use, even at
follow-up, is relatively low. Although many patients in the
present study have HF with preserved systolic function for
which the use of "-blockers is less clearly indicated, the
rate of "-blocker use in THESUS–HF is lower than that de-
scribed in other regions.18,21,22 These observations provide
an opportunity to improve the quality of the care of pa-
tients with HF in the region. A larger randomized study
investigating the combination treatment with hydralazine
and nitrates vs placebo in Africans admitted with AHF will
commence soon in the centers that participated in the
THESUS–HF registry.
The cause of AHF remains predominantly nonis-
chemic, with hypertension, rheumatic heart disease, and
the endemic cardiomyopathies (ie, idiopathic dilated car-
diomyopathy, peripartum cardiomyopathy, and endo-
myocardial fibrosis) accounting for 75.5% of the cases
(Figure 2 and Table 2). Although the rate of ischemic heart
disease may have been underestimated owing to limited
diagnostic tools, this finding is in striking contrast to reg-
istries in Europe or the United States,18,21,22 where ische-
mic heart disease (a rarity in Africa) accounts for most
of the cases. However, Africa is clearly facing an addi-
tional burden because, in addition to the high preva-
lence of endemic diseases, we are observing a high (and
probably increasing) burden of emerging diseases, such
as ischemic heart disease and hypertension, in particu-
lar in some countries (Figure 3). As socioeconomic
changes continue to progress across the continent, the



















(95% CI) P Value
Dimensions and LV Function
Posterior wall (diastole), mm
Mean (SD) 10.7 (2.9) 10.2 (2.9) 9.5 (2.7) 11.7 (2.7) 11.2 (2.7) 1.6












Mean (SD) 47.1 (9.2) 49.1 (9.7) 47.4 (10.5) 46.9 (8.1) 45.7 (7.8) −1.9









Left atrial planimetry size, mm2
Mean (SD) 2782 (924) 3039 (1001) 2882 (1110) 2782 (770) 2532 (7808) −306









Mitral E wave, cm/s
Mean (SD) 544.2 (500.6) 537.1 (587.0) 571.3 (585.6) 529.6 (404.7) 529.4 (449.7) −25.8









E-wave deceleration time, ms
Mean (SD) 150.0 (92.1) 151.3 (146.2) 145.3 (102.9) 143.2 (54.6) 159.0 (64.4) 3.6









Mitral A wave, m/s
Mean (SD) 324.4 (330.2) 302.0 (289.3) 334.9 (396.1) 295.5 (274.9) 365.5 (344.9) 13.3









Mitral A-wave duration, ms
Mean (SD) 126.4 (45.1) 114.3 (38.1) 126.7 (57.5) 130.7 (44.1) 128.4 (34.2) 8.5









Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HF, heart failure; IQR, interquartile range; LV, left
ventricular; NYHA, New York Heart Association class.
SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259.
aStatistics are computed from nonmissing values, the number of which may vary from variable to variable. The HF causes were reported for 980 patients; sex was not
reported for one of these.
bCalculated as the sex-adjusted difference in proportions or means between endemic and emerging causes of HF.
cExamined in a dependent area, including the lower extremities and sacral area, and scored as 0 (a complete absence of skin indentation with mild digital pressure in
all dependent areas), 1& (indentation of the skin that resolves in 10-15 seconds), 2& (indentation of the skin that is easily created with limited pressure and disappears
slowly [15-30 seconds or longer]), or 3& (large areas of indentation are easily produced and slow [#30 seconds] to resolve).
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number of AHF cases (particularly in women) caused by
noncommunicable forms of heart disease may further in-
crease. Finally, human immunodeficiency virus infec-
tion, which can affect the myocardium in various ways,23
is a common condition among patients with HF in Africa.
Whether the early introduction of antiretroviral therapy
in human immunodeficiency virus–seropositive pa-
tients with HF and otherwise no indication for antiret-
roviral therapy will change their outcome remains to be






















































Figure 4. Prescribed oral medication. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; FU, follow-up.
Table 3. Clinical Outcomesa
Outcome











Length of initial hospital stay, d
Mean (SD) 9.2 (9.3) 9.4 (10.4) 9.1 (8.1) 9.8 (11.5) 8.7 (6.6)
Median (IQR) 7 (5-10) 7 (5-10) 8 (5-10) 8 (5-11) 7 (5-10)
Initial hospitalization mortality, No. (%) 42 (4.2) 24 (4.9) 18 (3.5) 28 (5.9) 14 (2.8)
Readmission to day 60 9.1 (7.3-11.3) 9.7 (7.2-13.1) 8.5 (6.2-11.6) 9.4 (6.8-12.8) 9.0 (6.6-12.2)
Death to day 60 10.6 (8.7-12.8) 11.0 (8.4-14.3) 10.2 (7.7-13.4) 12.5 (9.7-16.0) 9.0 (6.7-12.1)
Death or readmission to day 60 15.6 (13.3-18.1) 16.6 (13.5-20.5) 14.5 (11.6-18.2) 17.3 (14.0-21.2) 14.1 (11.2-17.8)
Death to day 180 17.8 (15.4-20.6) 18.3 (14.9-22.4) 17.4 (14.1-21.4) 20.5 (16.9-24.8) 15.5 (12.4-19.4)
Abbreviations: HF, heart failure; IQR, interquartile range.
aUnless otherwise indicated, data are expressed as Kaplan-Meier estimate (95% CI).
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Few studies of the outcome of HF in sub-Saharan
Africa exist.24 The outcome of AHF in this study, includ-
ing high in-hospital and 6-month mortality rates (the
latter a possible underestimation owing to higher rates
of loss to follow-up) are remarkably similar to those
observed in registries in Europe and the United
States.18,21,22 This finding is remarkable because this
almost identical outcome was registered despite large
differences in patient characteristics (eg, a 20-year differ-
ence in age) and causes of HF, suggesting that once AHF
occurs, it may have a distinct course independent of
patient characteristics. When we compared endemic and
emerging causes, AHF due to emerging causes had a
slightly better outcome, probably secondary to the better
outcome of hypertensive AHF. However, these data
should be confirmed in other studies.
Our study’s limitations deserve mention. Loss to fol-
low-up was higher in THESUS–HF than in studies con-
ducted in other regions. This finding is common in the
population studied owing to such factors as the opportu-
nity to work if the patient is still healthy (in the case of mi-
grant workers) or the need to obtain care if unhealthy. Some
inhabitants of those regions have no telephone contact.
This registry has been compiled in selected centers and
may represent only AHF patients seen in specialized cen-
ters. This limitation has to be seen in the context that
many African countries do not train cardiologists and that
access to cardiac ultrasonography is limited.
Unfortunately, there are no criterion standards for de-
finitively categorizing HF. We applied a clinically ori-
ented approach based on published criteria. As a clini-
cal registry, we did not systematically validate diagnostic
criteria. Owing to no access to cardiac catheterization in
a number of centers, we might have missed HF due to
ischemic origin.
CONCLUSIONS
Acute HF affects patients in sub-Saharan Africa at an ex-
tremely early age and is caused mostly by hypertension
and primary cardiomyopathies. The disease leads to a high
burden of readmission and death, similar to that ob-
served in other countries, affecting younger patients in
the prime of their life. These data challenge us to recog-
nize and respond to HF in Africa by responding to com-
mon precursors, such as hypertension and the urgent need
for culturally sensitive interventions. Dedicated aware-
ness programs that strive to improve the pharmacologi-
cal and nonpharmacological management of AHF (in-
cluding better follow-up) need to be developed.
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Figure 5. Kaplan-Meier estimates of study outcomes. A, Kaplan-Meier
estimates of the cumulative risk for all-cause death or readmission to 60
days. B, Kaplan-Meier estimates of the cumulative risk for all-cause death
to day 180.
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Aims Patients with acute heart failure in Africa are rarely being treated with a hydralazine/nitrates combination. Therefore
the effect of this treatment was studied here
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Methods
and results
The study was planned to enrol 500 patients during an acute heart failure (HF) admission, from nine sub-Saharan
African countries. Patients were randomized in a double-blind manner to receive 50 mg hydralazine/20 mg isosorbide
dinitrate (HYIS) t.i.d. or matching placebo for 24 weeks followed by open label HYIS for all patients. The study
was terminated after 147 patients were enrolled due mostly to issues with recruitment into a prospective,
placebo-controlled study. Most patients were recruited from Mozambique, South Africa, Kenya, and Uganda. The
primary endpoint of death or HF readmission through 24 weeks was neutral [hazard ratio (HR) 1.05, 95% confidence
interval (CI) 0.48–2.27, P= 0.90] in the 133 randomized patients included in the analyses. There were non-signficant
effects in favour of HYIS in secondary endpoints including change in dyspnoea severity at day 7 or discharge, decrease
in systolic blood pressure, greater decrease in weight, and increase in 6-min walk test distance at week 24. There were
also small changes in echocardiographic indices of cardiac size and function in favour or HYIS, but none was significant.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion The BA-HEF trial demonstrated challenges in recruiting the expected number of patients with acute HF in a number
of African countries, which highlights the need for strategic logistic support.
Trial registration: NCT01822808.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Acute heart failure (AHF) is one of the most common reasons
for admission to hospital and a major driver for health-related
costs worldwide. A number of recent studies from Soweto, South
Africa;1 Abeokuta, Nigeria;2 Abuja, Nigeria;3 and Dar-es-Salaam,










. Tanzania4 have shown the prevalence to be high, with a 6-month
mortality >15%, despite the population being two decades younger
than those in studies of higher income regions.5,6
Acute heart failure exacts a heavy social and economic burden
on families and society in Africa.2 In contrast to high-income coun-
tries where AHF affects patients with an average age of >70 years,
© 2016 The Authors
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the THESUS-HF registry7 has shown that in sub-Saharan Africa
AHF affects men and women in the most productive years of life,
at an average age of 52.3 years, and is mostly caused by hyper-
tension and not ischaemic heart disease (IHD). The THESUS-HF
registry has also observed the use of a hydralazine/isosorbide dini-
trate (HYIS) combination in <5% of patients, despite it being a
Class IIb B indication for Black African patients with chronic HF,8
and shown in previous studies to be especially effective in African
Americans with chronic HF and reduced EF. 9–11
The BA-HEF study was planned based on the limited
evidence-based therapy for AHF altogether and because HYIS is
available as a relatively affordable generic in most sub-Saharan
countries. The purpose of the study was to examine the
short-term (6 months) effects of HYIS in patients admitted
for AHF in sub-Saharan Africa and treated with HYIS during the
last days of admission through 6 months. The doses of HYIS
used in the BA-HEF study were slightly lower than those used
in the AHeFT study, and were introduced slowly through careful
up-titration (see below) in order to avoid hypotension.
Methods
Patients and data collected
The BA-HEF study was a prospective, multicentre, randomized
double-blind study which aimed to recruit a total of 500 patients
during an admission for AHF from countries in the southern, eastern,
central, and western regions of sub-Saharan Africa. AHF was diag-
nosed based on symptoms and signs, supported by echocardiographic
findings, and was confirmed by a cardiologist. Inclusion criteria were
presenting at ≥18 years of age, hospital admission for AHF, as defined
by the presence of acute dyspnoea, and the presence of HF signs
by physical examination with at least two of the following: rales,
oedema, elevated jugular venous pressure (JVP), hepatomegaly, and
ascites; LVEF <45% assessed by echocardiography or another method
within the previous 12 months; background therapy with at least
an ACE inhibitor or ARB and beta-blocker (unless a beta-blocker is
contraindicated due to severe volume overload, low output HF, or
cardiogenic shock); and availability for regular follow-up. Exclusion
criteria were any intravenous treatment for HF, except i.v. furosemide
(e.g. i.v. inotropes, vasopressors, nitrates, or nesiritide) at the time
of screening; systolic blood pressure (BP) <100 mmHg; plan for
revascularization; presentation >96 h after admission; reversible
aetiology of AHF such as myocarditis, acute myocardial infarction,
arrhythmia; hypertrophic obstructive cardiomyopathy, restrictive
or constrictive cardiomyopathy, severe congenital heart disease, or
significant stenotic valvular disease; marked renal impairment (defined
by creatinine >3 mg/dL) at screening or on any type of dialysis; known
cholestasis (total bilirubin >3 mg/dL) or increased ammonia levels
at screening; known sensitivity or intolerance to ACE inhibitors or
allergy to organic nitrates; severe cerebrovascular disease, including
acute stroke or cerebral ischaemia; women who were pregnant or
lactating; or history or presence of any other diseases (i.e. including
malignancies or AIDS) with a life expectancy of <12 months.
Primary and secondary endpoints
The study was designed to investigate the effect of the combination



















































































.. endpoint: all-cause death or re-admission for HF during 24 weeks of
therapy. The intended sample size was estimated to provide 80% power
to detect a hazard ratio (HR) of 0.61 assuming a 35% event rate in the
placebo group.
The HYIS combination was also compared with placebo with respect
to the following pre-specified secondary endpoints: (i) change in
symptoms of HF from baseline to 7 days post-randomization or
discharge, as assessed by dyspnoea severity and global well-being on
a visual analogue scale (VAS); (ii) change in systolic BP from baseline
to 7 days post-randomization or discharge, and at 8 weeks and 24
weeks post-randomization; (iii) functional status assessed by the 6-min
walk test (6MWT) at 7 days post-randomization or discharge, and at
8 weeks and 24 weeks post-randomization; (iv) changes in markers
of renal function [serum creatinine, urea, and estimated glomerular
filtration rate (eGFR)] from baseline to 7 days post-randomization or
discharge, and at 24 weeks post-randomization; and (v) change in LV
dimensions and LVEF from baseline to 24 weeks post-randomization.
Approval was obtained from the ethics committee of each partic-
ipating institution, and the study conformed to the principles of the
Declaration of Helsinki. All patients gave written, informed consent
prior to participation. The study was governed by a Steering Com-
mittee and monitored by an independent Data and Safety Monitor-
ing Committee. The membership of both committees is detailed in
Appendix 1. Investigators were trained through investigator meetings,
and study personnel monitored study conduct through remote mon-
itoring, telephone contacts, and site visits. The study is registered at
Clinicaltrials.gov as NCT01822808.
Study visits
Within 96 h of admission for AHF, and during the admission, patients
were screened and randomized into the study if the inclusion crite-
ria were met. Patients’ self-report of dyspnoea severity by VAS was
measured and a 6MWT was performed. Patients were randomized to
receive increasing doses of HYIS, starting with 25 mg hydralazine/10 mg
isosorbide dinitrate and up-titrating to 50 mg hydralazine/20 mg isosor-
bide dinitrate t.i.d. or placebo (Figure 1). The study drug was pro-
vided by Sandoz SA. The dose selection and careful up-titration were
done in order to avoid hypotension in these patients during and
immediately after an AHF admission. Patients received standard HF
therapy at the discretion of their treating physician and according
to evidence-based guideline recommendations (ACE inhibitors, ARBs,
beta-blockers, aldosterone antagonists, and diuretics). Patients were
followed by clinic visit through 6 months for the occurrence of read-
missions and death. Patients who completed the 24-week double-blind
phase were given the option of continuing open-label treatment with
active medication for up to 24 weeks.
Statistical methods
Events reported by investigators were reviewed in a blinded manner
by two independent cardiologists. Time-to-event endpoints, including
the primary outcome, were compared between treatment groups on
an intention-to-treat basis using a log-rank test. Kaplan–Meier esti-
mates of event rates and associated 95% confidence intervals (CIs) are
presented along with HRs and associated 95% CIs from Cox regres-
sion models that included only the treatment effect. The proportional
hazards assumption was tested post-hoc through inclusion of a treat-
ment× time interaction effect in the model. Patients were censored
at the earlier of the last contact date or the time period of interest.
© 2016 The Authors
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Figure 1 Schematic of the study design. AHF, acute heart failure.
For continuous outcomes, mean and standard deviation (SD) and/or
median and first and third quartiles, and absolute and relative frequen-
cies for categorical variables, are presented. The geometric mean and
corresponding 95% CIs are also included for secondary laboratory end-
points that were log-transformed. Missing values were imputed using
linear interpolation between nearest flanking non-missing values or
through last observation carried forward (LOCF) where no following
non-missing value was available. Values following a death were imputed
as the worst reported score for dyspnoea and general well-being VAS,
as zero for the 6MWT distance, as the LOCF for vital signs and lab-
oratory values, and as the baseline plus or minus the worst reported
change across all subjects for echocardiographic measures. Changes
from baseline were compared between treatment groups using analy-
sis of covariance with adjustment for the baseline value; least square
mean differences and associated 95% CIs are presented, or the ratio
of the geometric means with adjustment for the log-baseline result.
Post-hoc analyses exploring effects on rehospitalizations included a
comparison of the number of HF hospitalizations, where death was
included as an event, using negative binomial regression. Additionally,
days in hospital or dead from randomization through the earlier of 168
days or end of follow-up was compared between treatment groups
using a t-test; length of hospital stay was imputed with the overall
median (5.5 and 7 days, respectively) for three initial hospitalizations
and one rehospitalization missing the discharge date. Data from one
site in Senegal were excluded from the analyses due to major protocol
non-compliance. SAS® 9.3 (SAS Institute, Inc., Cary, NC, USA) was
used for analyses.
Results
Twelve centres from nine African countries were invited to
paticipate, of which nine centres from six African countries















































. participated. Data for 14 randomized patients from one centre in
Senegal were excluded due to non-compliance with the protocol.
This issue was reported to the site’s local ethics committee after
being discovered during routine monitoring. From March 2012
to March 2015, a total of 619 patients were screened and subse-
quently 133 patients were randomized (Figure 2) at the remaining
eight centres. The primary reasons for exclusion from the study
were (i) lack of test results, e.g. echo or laboratory, available
within 96 h of admission; (ii) kidney function too poor; (iii) lack of
background treatment with an ACE inhibitor and/or beta-blocker;
(iv) liver function too poor; and (v) not eligible due to low BP. The
study had to be terminated prematurely due to low recruitment
and expiry of the study medication. Although as described below
some patients screened failed to meet eligibility criteria, as seen
in Figure 2, most of the lag in enrolment was related to lower
than expected screening rates, in this double-blind, prospective,
randomized study. Efforts were made to overcome these enrol-
ment challenges including repeat investigators’ meetings, frequent
calls to the sites, and site visits by study personnel and the study
Principal Investigator.
Demographic characteristics of the patients were rather similar
across participating countries, except with a higher proportion of
patients of race other than Black African enrolled in South Africa
(Supplementary material online, Table S1). The randomization was
blocked by study centre, however, so randomization to the two
study arms was balanced within each country.
Baseline characteristics of the study population by treatment
group are outlined in Table 1. For convenience of comparison, the
last two columns of Table 1 contain the baseline characteristics
from the A-HeFT study.11 The mean age of the entire group was
53.2±14.8 years, with 49.2% being female. The majority (66.7%) of
patients had hypertension, while few (5.3%) had a history of IHD.
© 2016 The Authors
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Figure 2 Study flow diagram. Excludes patients (25 screened, 14 randomized, 6 to placebo and 8 to hydralazine/isosorbide dinitrate) in one
site in Senegal due to major protocol non-compliance.
Baseline characteristics were similar in the active and the placebo
groups. Twenty-nine (22%) of the 133 patients were >65 years old,
26 (92.9%) of whom did not have a history of IHD. Of the 103
patients ≤65 years old, 98 (95.1%) had no history of IHD.
A total of 111 (83.5%) of the randomized patients either
died or completed the study through week 24 (Figure 2). Twelve
(9.0%) patients were discontinued prematurely when the study was
terminated; 6 patients were lost to follow-up, and for 4 patients
who had stopped attending visits, only the vital status at week
24 was obtained. The mean follow-up was 145.0 days. Over 60%
of patients (63.5% and 67.6% in the placebo and HYIS groups,
respectively) had a final dose of 50 mg hydralazine/20 mg isosorbide
dinitrate t.i.d., while ∼75% (73.8% and 77.9% in the placebo and
HYIS groups, respectively) were on this dose at any point in the
study.
The primary endpoint was not met, with a HR for death or
HF readmission at 24 weeks of 1.05 (95% CI 0.48–2.27, P= 0.90).
Fourteen patients in the HYIS arm died or had a HF readmission
by week 24 as compared with 12 in the placebo arm. However,
this was driven by an early potential benefit [at 60 days the HR was
0.49 (95% CI 0.18–1.32)] that decreased with time (Figure 3A). By
































.. group had died or been hospitalized for HF, which was reflected by
a statistically significant treatment× time interaction (P= 0.0268).
Nine patients in each treatment group died by week 24: five in
the HYIS group and nine in the placebo group from cardiovascular
causes. One patient in the HYIS group and five patients in the
placebo group died from a cardiovascular cause by day 60. There
was a trend to benefit on cardiovascular mortality at 24 weeks
where the HR was 0.51 (95% CI 0.17–1.52, P= 0.22) (Figure 3B).
In a post-hoc analysis we observed that patients in the placebo
arm had more HF rehospitalizations per patient. The total number
of events—deaths or HF readmissions—through week 24 was
18 in the HYIS arm vs. 26 in the placebo group, giving a rate
ratio of 0.54 (95% CI 0.16–1.82, P= 0.32). Fifteen patients in the
HYIS arm died or had a readmission for any cause by week 24
as compared with 17 in the placebo arm; however, patients in
the placebo arm had more readmissions per patient. The total
number of deaths or all-cause readmissions was 21 in the HYIS
arm vs. 33 in the placebo arm (P= 0.25). The mean number of days
dead or in hospital through 24 weeks was 18.3± 36.4 days [median
6.0, interquartile range (IQR) 3.0–8.5 days] in the HYIS group
compared with 26.4± 45.9 days (median 7.0, IQR 5.0–15.0 days)
in the placebo group (P= 0.26).
© 2016 The Authors
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Table 1 Baseline characteristics of the study population
Characteristic BA-HEF AHeFT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall (n=133) Isosorbide dinitrate
plus hydralazine (n= 518)
Placebo (n = 532)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, mean (SD) 53.2 (14.76) 56.7 (12.7) 56.9 (13.3)
Male sex, % 50.8 55.8 63.9
Weight, kg, mean (SD) 74.1 (19.1) 92.5 (21.4) 94.1 (25.5)
Primary cause of heart failure, %a
Ischaemic heart disease 5.3 23.4 22.7
Hypertension 66.7 40.0 37.4
Idiopathic 13.7 24.5 27.6
Valvular cause 11.3 2.5 3.2
Other – 9.7 9.0
NYHA class at screening, %
I 1.1 0 0
II 22.2 0.2 0
III 55.6 96.7 94.7
IV 21.1 3.1 5.3
Diabetes, % 12.9 44.8 37.0
Atrial fibrillation, % 7.6 15.0 18.0
Cardiac resynchronization therapy, % 0.8 2.0 2.1
Implantable cardiac defibrillator, % 0 16.6 17.3
Ejection fraction at screening, %, mean (SD) 24.6 (10.2) 23.9 (7.3) 24.2 (7.5)
LVIDD, cm, at screening 6.3 (1.1) 6.5 (0.9) 6.5 (1.0)
Blood pressure, mmHg, mean (SD)
Systolic 130.9 (19.6) 127.2 (17.4) 125.3 (18.1)
Diastolic 85.8 (14.8) 77.6 (10.3) 75.6 (10.5)
Medication for heart failure, %
Diuretic 66.2 88.0 91.5
ACE inhibitor 85.7 69.4 69.5
ARB 9.8 17.2 16.5
Beta-blocker 43.6 74.1 73.5
Carvedilol 33.0 55.2 55.8
Digoxin 22.6 58.5 60.7
Spironolactone 27.8 40.2 37.6
Race, %
African or Black 81.5 – –
Coloured or mixed race 16.9 – –
Caucasian or White 1.6 – –
Time from presentation to randomization, hours, mean (SD) 73.1 (80.5) – –
LVIDD, left ventricular end-diastolic internal diameter.
aHistory of condition for BA-HEF.
The secondary endpoints showed non-significant trends in most
outcomes in favour of HYIS vs. placebo. Dyspnoea improved by
1.6 mm more on a 100-mm VAS in the active group from an overall
mean baseline of 57.7 mm, i.e. 3%, at day 7 or discharge (P= 0.58)
(Table 2). General well-being improved to day 7 or discharge
by 2.5 mm more in the active group (P= 0.31) from an overall
mean baseline of 59.7 mm. The 6MWT distance improved at 24
weeks by 17.2 m more in the active group (P= 0.48) (Table 2). The
overall mean baseline systolic BP was 126.7 mmHg, and decreased















. (P= 0.31) at week 24 (Figure 4). The overall mean baseline weight
was 73.7 kg and decreased by 2.7 kg (95% CI −5.52 to 0.13) more
in the active group (P= 0.06) at 24 weeks (Figure 5). There was a
similar drop in creatinine, a 13% larger drop in blood urea nitrogen
(BUN; P= 0.11), and a 3.7 mL/min/1.73 m2 greater improvement
in eGFR (P= 0.49) at 24 weeks in the active group (Table 3). On
echocardiographic evaluation, LVEF increased by 0.3% (P= 0.92),
LV end-systolic diameter decreased by 2.0 mm (P= 0.22), and LV
end-diastolic diameter decreased by 1.1 mm (P= 0.55) more in
the active group (Table 4).
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A
B
Figure 3 Kaplan–Meier curves for (A) all-cause death or heart failure rehospitalization through 24 weeks and (B) cardiovascular death trought
week 24.
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Table 2 Changes in dyspnoea, general well-being, and 6-min walk test distance
Measure Statistic Placebo (n= 65) HYIS (n= 68) LS mean
difference (95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dyspnoea VAS, mm
Baseline Mean (SD) 56.2 (18.24) 59.1 (21.58)
Median (Q1, Q3) 60.0 (50.0, 68.0) 60.0 (42.0, 73.0)
Change to Day 7 or discharge Mean (SD) 12.3 (18.57) 12.7 (19.91) 1.6 (−4.3, 7.5) 0.5842
Median (Q1, Q3) 8.0 (0.0, 24.0) 7.0 (0.0, 20.5)
Change to week 8 Mean (SD) 13.2 (25.41) 14.8 (27.29) 3.0 (−5.4, 11.5) 0.4804
Median (Q1, Q3) 10.0 (0.0, 30.0) 12.5 (0.0, 30.0)
Change to week 24 Mean (SD) 14.2 (31.79) 10.0 (32.81) −2.9 (−13.6, 7.8) 0.5932
Median (Q1, Q3) 20.0 (0.0, 36.0) 10.0 (0.0, 30.0)
General well-being VAS, mm
Baseline Mean (SD) 59.2 (17.72) 60.3 (19.67)
Median (Q1, Q3) 60.0 (47.0, 72.0) 60.0 (50.0, 77.5)
Change to Day 7 or discharge Mean (SD) 9.0 (14.79) 11.2 (15.78) 2.5 (−2.4, 7.4) 0.3066
Median (Q1, Q3) 5.0 (0.0, 19.0) 8.0 (0.0, 20.0)
Change to week 8 Mean (SD) 12.4 (22.96) 14.6 (23.76) 2.9 (−4.1, 9.9) 0.4134
Median (Q1, Q3) 15.0 (0.0, 24.0) 14.5 (0.0, 30.0)
Change to week 24 Mean (SD) 12.3 (24.66) 10.6 (29.89) −0.7 (−9.3, 7.8) 0.8661
Median (Q1, Q3) 12.0 (0.0, 30.0) 13.0 (0.0, 30.0)
6-min walk test distance, m
Baseline Mean (SD) 253.8 (115.60) 244.3 (123.37)
Median (Q1, Q3) 252.0 (170.0, 318.0) 229.0 (150.0, 333.0)
Change to Day 7 or discharge Mean (SD) 41.0 (52.93) 35.3 (101.42) −6.7 (−35.0, 21.7) 0.6412
Median (Q1, Q3) 28.0 (0.0, 74.0) 17.0 (0.0, 60.0)
Change to week 8 Mean (SD) 42.3 (104.40) 66.7 (128.48) 23.0 (−18.1, 64.0) 0.2704
Median (Q1, Q3) 45.0 (0.0, 114.0) 49.0 (8.0, 98.0)
Change to week 24 Mean (SD) 48.1 (119.76) 65.7 (149.0) 17.2 (−30.5, 65.0) 0.4764
Median (Q1, Q3) 37.0 (0.0, 129.0) 48.0 (0.0, 145.0)
CI, confidence interval; HYIS, hydralazine/isosorbide dinitrate; LS, least squares; VAS, visual analogue scale.
Rates of reported serious adverse events were similar in the
two treatment groups: 18 (27.7%) placebo and 19 (27.9%) HYIS
patients. Adverse events leading to discontinuation of study drug
were also similar and were reported for 4 (6.2%) placebo and 6
(8.8%) HYIS patients.
Discussion
The BA-HEF study was initiated on the heels of the THESUS-AF
registry where we observed low use of a HYIS combination
therapy in patients with HF in Africa.7 Based on the screening
and enrolment rates in the THESUS-AF registry, it was planned
to enrol 500 patients during an AHF admission over a period of
12 months and test whether administration of HYIS would reduce
the risk of death or HF readmission over 6 months. Regretfully,
despite our best efforts, after 4 years we managed to enrol fewer
than 150 patients and the study drug had expired and could not be
renewed further. Hence, the study was terminated, all patients in
the active part of the study crossed to active open-label HYIS, and
the database was locked.
The primary endpoint was not met. However, in this limited data

































.. expected effects of HYIS, including a lower rate of cardiovascular
mortality through 24 weeks, a non-statistically significantly lower
number of HF and all-cause admissions per patient, and fewer days
dead or in hospital in the active arm. Other findings consistent
with a benefit include that in the HYIS group compared with the
placebo group, by 24 weeks systolic BP dropped more, weight
decreased more, 6MWT improved more, and there was a larger
drop in BUN. On echocardiographic evaluation, parameters such
as improvement in the LVEF, and a decrease in LV end-systolic
diameter and LV end-diastolic diameter all favoured the active
group, although again in a statistically non-significant manner. The
interpretation of these differences should be tempered by the fact
that the study is small and recruitment was in a selected group of
hospitals, mostly advanced medical centres in each country.
The combination of hydralazine and isosorbide dinitrate has
been shown to reduce mortality, as compared with placebo, in
patients with mild to moderate HF treated with digoxin and
diuretics.9 In V-HeFT II, enalapril improved survival to a greater
extent than hydralazine and isosorbide dinitrate at 2 years, but
the difference between the treatment groups was attenuated by
the end of follow-up.10 In A-HeFT, the fixed dose combination
of hydralazine and isosorbide dinitrate improved survival, as com-
pared with placebo (6.2% vs. 10.2%, HR 0.57, P= 0.01)11 in African
© 2016 The Authors
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Figure 4 Changes in systolic blood pressure.
Figure 5 Changes in weight.
American patients. The rate of first HF hospitalization was also
reduced in the hydralazine and isosorbide dinitrate group (16.4%
vs. 24.4%, P= 0.001). Comparing the A-HeFT and BA-HEF stud-
ies highlights some important points, although one has to bear in







. recruited patients with AHF. Despite the above, the age of the
patients was similar between the two studies (mid-50s). However,
patients in A-HeFT were on average ∼20 kg heavier than patients
in BA-HEF. This may explained by the fact that patients in A-HeFT
had a higher prevalence of diabetes mellitus and IHD as compared
© 2016 The Authors
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Table 3 Changes in renal function markers
Measure Statistic Placebo (n= 65) HYIS (n= 68) Treatment effect (95% CI)a P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Creatinine, μmol/L
Baseline Mean (SD) 106.20 (30.38) 120.08 (54.12)
Median (Q1, Q3) 104.0 (82.0, 125.0) 105.2 (88.4, 140.0)
Change to week 24 Mean (SD) 4.50 (26.18) 1.78 (35.44)
Geometric mean (95% CI) 1.04 (0.98, 1.09) 1.01 (0.95, 1.09) 1.00 (0.92, 1.09) 0.9893
Median (Q1, Q3) 0.0 (−8.5, 16.9) 0.0 (−14.6, 22.9)
BUN, mmol/L
Baseline Mean (SD) 7.20 (3.40) 7.52 (4.76)
Median (Q1, Q3) 6.70 (4.60, 9.06) 6.53 (4.20, 8.50)
Change to week 24 Mean (SD) 0.48 (3.71) 0.03 (4.99)
Geometric mean (95% CI) 1.06 (0.93, 1.22) 0.93 (0.81, 1.05) 0.87 (0.73, 1.03) 0.1082
Median (Q1, Q3) 0.00 (−1.60, 2.59) 0.00 (−2.10, 1.20)
eGFR, mL/min/1.73 m2
Baseline Mean (SD) 79.21 (30.16) 73.41 (30.02)
Median (Q1, Q3) 74.56 (61.15, 90.70) 70.61 (51.37, 90.89)
Change to week 24 Mean (SD) −3.05 (20.11) 3.23 (41.50) 3.7 (−6.8, 14.3) 0.4865
Median (Q1, Q3) 0.00 (−14.26, 5.15) 0.0 (−10.54, 16.01)
BUN, blood urea nitrogen; CI, confidence interval; eGFR, estimated glomerular filtration rate; HYIS, hydralazine/isosorbide dinitrate.
aTreatment effect for creatinine and BUN is presented as the geometric least squares mean ratio. Treatment effect for eGFR is presented as the least squares mean difference.
Table 4 Changes in echocardiographic parameters
Measure Statistic Placebo (n= 65) HYIS (n= 68) LS mean
difference (95% CI)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ejection fraction, %
Baseline Mean (SD) 23.8 (9.07) 25.3 (11.26)
Median (Q1, Q3) 24.0 (18.0, 30.0) 25.0 (15.0, 34.0)
Change to week 24 Mean (SD) 8.0 (14.18) 8.0 (14.13) 0.3 (−4.6, 5.1) 0.9187
Median (Q1, Q3) 6.5 (0.0, 19.5) 4.0 (0.0, 19.5)
Left ventricular size systole, mm
Baseline Mean (SD) 55.8 (10.72) 55.8 (10.71)
Median (Q1, Q3) 55.0 (50.0, 62.3) 56.0 (46.0, 63.3)
Change to week 24 Mean (SD) −2.2 (8.62) −4.2 (9.58) −2.0 (−5.2, 1.2) 0.2189
Median (Q1, Q3) 0.0 (−7.0, 1.0) −3.5 (−11.0, 0.0)
Left ventricular size diastole, mm
Baseline Mean (SD) 62.7 (11.01) 63.1 (10.36)
Median (Q1, Q3) 63.0 (57.0, 71.0) 62.7 (55.1, 69.5)
Change to week 24 Mean (SD) 2.1 (10.12) 1.0 (10.76) −1.1 (−4.6, 2.5) 0.5502
Median (Q1, Q3) 0.0 (−3.0, 5.0) 0.0 (−3.0, 1.0)
CI, confidence interval; HYIS, hydralazine/isosorbide dinitrate; LS, least squares.
with BA-HEF. On the other hand, patients in BA-HEF had a higher
incidence of valvular heart disease possibly due to a higher inci-
dence of rheumatic heart disease. They also received on average
less diuretics, beta-blockers, and aldosterone blockers at screen-
ing, although this may be in part related to the fact that some
had new-onset HF, as reflected by the lower NYHA class at the
same time (Table 1). Interestingly, in line with the findings from the
THESUS registry,7 patients in both studies were relatively young
(mid-50s), had low prevalence of AF and IHD, and almost identical















. Despite the encouraging results of A-HeFT, the THESUS-HF data
show that patients in Africa are rarely treated with a combination of
hydralazine and nitrates, or the fixed-dose combination BiDil that
was used in A-HeFT, since this preparation is unavailable in Africa.
The efficacy of combination hydralazine and isosorbide dinitrate is
uncertain in Africans when given as individual generic agents. Finally,
hydralazine and isosorbide dinitrate had not been evaluated in AHF.
There are a number of reasons for the poor recruitment into
this study. There were only 21.5% of screened patients who were
eligible for entry into the study, which reflects the difficulty in
© 2016 The Authors
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recruiting patients for AHF trials in general. Screening failures were
mostly due to renal and hepatic dysfunction, low BP, and procedural
difficulties. Therefore, there was a need to screen 2500 patients
to achieve the original sample size of 500 patients, which was not
achieved due to the low screening at the enrolling sites and because
some of the originally planned sites never screened patients at all.
Although other studies in which more sites were activated12
have been able to reach their enrolment targets, this double-blind
prospective randomized study seems to have been challenging for
investigators, as have been other AHF studies of this kind. Many of
the centres that participated in the BA-HEF study had limited clini-
cal research facilities such as Good Clinical Practice-trained nurses
and monitors, a dedicated research office or research equipment,
and clinical staff with dedicated time to perform research. These
factors made the recruitment of patients within the specified time
interval extremely challenging. Obtaining ethics approval for cen-
tres that had limited experience with a placebo-controlled, multi-
centre randomized trial was a major challenge, causing delays of up
to 2 years at some sites. Registries which do not have these short
recruitment time intervals, or give study medication, are still pos-
sible under these circumstances, but require enthusiasm and large
investment of after-hours time, as the recently published REMEDY
study on rheumatic heart disease,13 The Heart of Soweto Study,14
and THESUS-HF7 have demonstrated.
The shortage of trained physicians and cardiologists, plus inad-
equate specialized cardiac facilities and equipment, coupled with
low levels of patient and public awareness, led to many patients not
having ready access to basic diagnostic facilities such as electrocar-
diography and echocardiography, causing a delay in recruitment. It
is therefore imperative that the research and developmental objec-
tives be specifically focused and tailored towards those disease
entities that are highly prevalent on the African continent (e.g. HF)
and upon issues and obstacles in regard to documenting their epi-
demiology, treatment, and prevention.
As stated above, a cautious interpretation of the study results
is warranted. However, this is the first study to examine the
administration of the HYIS combination in patients with AHF.
The limited results of the study suggest that HYIS treatment may
be associated with an early decrease in cardiovascular mortality
but offset by an increase in non-cardiovascular mortality and HF
readmissions. A trend towards an increase in non-cardiovascular
mortality while cardiovascular mortality decreases was observed
in recent years in HF studies, although not to the point of a lack of
decrease in all-cause mortality.15 Nonetheless, the effects observed
raise an important related question of what the effects of HYIS
combination would be in all patients with AHF regardless of race
and geographical region. As no new effective therapies have been
developed in AHF in recent decades, would it be possible that some
of the effects observed here may be replicated in larger and more
diverse populations?
Limitations
The BA-HEF study enrolled patients in almost the same centres
as in the THESUS-HF study and, as such, shares certain limi-



















































































.. were recruited in a limited number of hospitals—mainly in Kenya,
Mozambique, Nigeria, South Africa, and Uganda. As the study had
to be terminated early, it was underpowered. Loss to follow-up
and missing laboratory data and assessments of clinical signs were
higher than in studies conducted in other regions.
Conclusions
Extensive investment in research facilities in a number of African
countries is needed which would allow randomized controlled
studies for non-communicable diseases, including AHF studies.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Baseline characteristics of the study population by
country.
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5 Chapter 5: The predictors of readmission and mortality 
in acute heart failure in sub Saharan Africa: results 
from THESUS-HF registry 
5.1 Introduction 
 
Patients with heart failure (HF) are at high risk for mortality and rehospitalization in 
the early period after hospital discharge. Identification of predictors of outcomes is 
needed for risk stratification of HF patients. Patient management requires an 
understanding of risk of future events to make appropriate decisions about acuity of 
care (eg, admission to an intensive care unit versus a less monitored setting), to 
triage patients among available therapies, and to plan hospital discharge and 
intensity of follow up. 104  
Although there has been several publications on long-term prognostic factors in 
CHF, 105,106 little has been done to aid in the risk stratification of patients presenting 
with exacerbations of decompensated heart failure. 107,108  
Acute heart failure exacts a heavy social and economic burden on families and 
society in Africa. The understanding of the causes of re-admission and death is 
especially important in African population and may be relevant to other developing 
regions of the world. 
In this chapter, we present the patient characteristics associated with 60-day re-
admission or death and 180-day mortality among patients admitted with AHF and 
enrolled in the THESUS-HF registry 




model excluding the geographic region were a history of malignancy, severe lung 
disease, admission systolic blood pressure, and signs of congestion (rales) as well as 
kidney function (BUN). In a model including region, the Southern region had a 
higher risk. Predictors of 180-day mortality included malignancy, severe lung 
disease, smoking history, systolic blood pressure, heart rate, and symptoms and signs 
of congestion (orthopnoea, peripheral oedema and rales) at admission, kidney 
dysfunction (BUN), anaemia, and HIV positivity. 
This chapter is presented as a published research paper below, in the European Heart 
Journal. 
Sliwa K, Davison BA, Mayosi BM, Damasceno A, Sani M, Ogah O, Mondo C, Ojji 
D, Dzudie A, Koum Koum C, Suliman A, Schrueder N, Yonga G, Ba, SA, Maru F, 
Alemayehu B, Edwards C and Cotter G. Readmission and Death after an acute heart 
falure event: predictors and oputcomes in sub-Saharan Africa: results from the 
THESUS- HF registry.  Eur Heart J. 2013 Oct; 34(40):3151-9. doi: 
10.1093/eurheartj/eht393. Epub 2013 Sep 18. 
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Aims Contrary to elderly patients with ischaemic-related acute heart failure (AHF) typically enrolled in North American and
European registries, patients enrolled in the sub-Saharan Africa Survey of Heart Failure (THESUS-HF) were middle-aged




Prognostic models were developed from data collected on 1006 patients enrolled in THESUS-HF, a prospective registry
of AHF patients in 12 hospitals in nine sub-Saharan African countries, mostly in Nigeria, Uganda, and South Africa. The
main predictors of 60-day re-admission or death in a model excluding the geographic region were a history of malignancy
and severe lung disease, admission systolic blood pressure, heart rate and signs of congestion (rales), kidney function
(BUN), and echocardiographic ejection fraction. In a model including region, the Southern region had a higher risk.
Age and admission sodium levels were not prognostic. Predictors of 180-day mortality included malignancy, severe
lung disease, smoking history, systolic blood pressure, heart rate, and symptoms and signs of congestion (orthopnoea,
peripheral oedema and rales) at admission, kidney dysfunction (BUN), anaemia, and HIV positivity. Discrimination was
low for all models, similar to models for European and North American patients, suggesting that the main factors con-
tributing to adverse outcomes are still unknown.
Conclusion Despite the differences in age and disease characteristics, the main predictors for 6 months mortality and combined 60
days re-admission and death are largely similar in sub-Saharan Africa as in the rest of theworld, with some exceptions such
as the association of the HIV status with mortality.
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Acute heart failure (AHF) is one of the most common reasons for ad-
mission tohospital, andamajordriver forhealth-relatedcost globally.
Its prevalence is shown to be high and outcomes dire in North
America,1 Europe,2 South America,3 Southeast Asia,4 and recently
also in sub-Saharan Africa.5
Despite the huge impact of this disease until recently little progress
has been made in characterizing the pathophysiology of the disease.
The 2012 European Society of Cardiology (ESC) guidelines on acute
andchronicheart failure6 highlight the lackof evidence-based therapy
for AHF compared with the therapeutic options for chronic heart
failure. Models examining predictors of outcomes such as short-term
re-admission and death have very low ability to discriminate between
those with and without the outcome with c-indexes ranging from 0.6
to 0.7,7– 9 where 0.5 represents chance and 1.0 perfect discrimin-
ation. This lack of understanding of pathophysiology and predictors
of outcome in AHF is at the core of the lack of progress in its treat-
ment with available therapies (diuretics and nitrates), such that out-
comes have been largely unchanged over the last 30–40 years.10
Acute heart failure exacts a heavy social and economic burden on
families and society in Africa. Contrary to North America and Europe
whereAHFaffects patients with an average ageof .70yearsold,1 the
THESUS-HF registry5 has shown that in sub-Saharan Africa the
disease affects men and women in the most productive years of life,
at an average age of 52.3 years and is mostly caused by hypertension
and not ischaemic heart disease. Hence, understanding the causes for
re-admission and death is especially important in this African popula-
tion and may be relevant to other developing regions of the world.
In this work, we identify patient characteristics associated with
60-day re-admission or death and 180-day mortality in a cohort of
1006 African patients admitted with AHF and enrolled in the
THESUS-HF registry.
Methods
Patients and data collected
THESUS-HF5 was a prospective, multicentre, international observational
survey conducted in 12 hospitals from 9 countries in the southern,
eastern, central, and western regions of sub-Saharan Africa. All patients
were recruited during an admission for AHF, mostly in Nigeria,
Uganda, and South Africa. Methods and results have been previously
described indetail.5 Inbrief, fromJuly2007 to June2010patients admitted
with dyspnoea and diagnosed with AHF based on symptoms and signs
(including dyspnoea, orthopnoea, dyspnoea on exercise, rales, oedema,
jugular venous pulse, and oxygen saturation) and who provided written
informed consent were enrolled into the study. The diagnosis was sup-
ported by echocardiographical findings and was confirmed by a cardiolo-
gist. Exclusion criteria included acute ST elevation myocardial infarction,
severe renal failure (patients on dialysis or creatinine .4 mg/dL), neph-
rotic syndrome, or hepatic failure. Approval was obtained fromthe ethics
committee of each participating institution and the study conformed to
the principles of the Declaration of Helsinki.
Detailed data collected at admission onto standardized case report
forms included medical history, medication use, laboratory values, and
physical examination with symptoms and signs of heart failure. Echocar-
diography and electrocardiography were also performed. Human im-
munodeficiency virus testing was performed as clinically indicated.
Patients were followed either by clinic visit or telephone contact
through 6 months for the occurrence of re-admissions and death. As
described in the main report, patients were classified as having either
an emerging or endemic cause of heart failure. Endemic causes included
rheumatic heart disease, cardiomyopathies, and infective causes, while
emerging causes included hypertension and ischaemic heart disease.
Statistical methods
Cox regression models were constructed considering the time from ad-
mission to the first event; times for patients without the event of interest
were censored at the earlier of the last date the patient was known to be
aliveor theperiodof interest. Prognosticmodelswereconstructed for the
two outcomes of interest considering candidate predictors chosen based
on data available in THESUS-HF, variables found to be predictive in other
AHF studies, and clinical judgment. Participating countries were grouped
into three regions: East which comprised Sudan (n ¼ 72), Ethiopia (n ¼
10), Kenya (n ¼ 32), and Uganda (n ¼ 154); West which comprised
Senegal (n ¼ 15), Nigeria (n ¼ 425), and Cameroon (n ¼ 90); and
South which comprised South Africa (n ¼ 132) and Mozambique (n ¼
76). Because region was found to be significantly associated with re-
admission or death, and because regional cultural and medical practice
patterns might affect admission, we also constructed a model examining
only patient clinical characteristics.
The linearity of association between each continuous predictor and
each outcome was assessed using restricted cubic splines with four
‘knots’ with a test of the significance of the non-linear terms.11 Where
the association was non-linear, a readily interpreted transformation
was chosen through examination of plots of the predicted log hazard
ratio against the value of the predictor and changes in Akaike’s informa-
tion criterion. If little information was lost, the same transformation was
used tomodel bothoutcomes. Multiple imputation assumingmultivariate
normality (SAS PROC MI) was used to handle missing values. The imput-
ation model included all covariates under consideration for the multivari-
able models. The ranges of imputed values were restricted to the ranges
of the observed values. Seven imputation data sets were used. Parameter
estimates were averaged across these data sets using Rubin’s algorithm12
(SAS PROC MIANALYZE). SAS version 9.2 (SAS Institute, Inc, Cary, NC,
USA) was used for the analyses.
We constructed a multivariable model for each of the outcomes from
the candidate predictors listed in Table 1 (except those effects that were
dropped), with continuous variables included using the model forms indi-
cated in Tables 2–4. For the 60-day composite endpoint, one model was
assessed with the inclusion of region as a predictor and one excluding
region. Backwards selection was performed in each of the imputed
data sets, with the criterion for staying at P ¼ 0.10. Predictors that
were significant in at least four of the imputed data sets were kept in
the reduced model. The discrimination of the models was evaluated
using the c-index.13 The model fit was assessed visually using calibration
plots11 which were generated from the stacked imputation data sets.14 In
these plots, patients were grouped by deciles of predicted risk, and the
mean predicted risk for each group was compared with the Kaplan–
Meier estimate of risk in these same groups.
Results
Of the 1006 patients included in the THESUS-HF database, one
patient was excluded who had unreasonable data pertaining to
both outcomes (i.e. subject had a date of death listed before admis-
sion) giving 1005 patients for this analysis. Of the 1006 patients en-
rolled 430 were enrolled in Nigeria, 154 in Uganda and 132 in
South Africa. Patients were followed a median of 180 days.
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Ninety-five patients died and 74 were readmitted through 60 days;
138 patients experienced a death or re-admission through 60 days,
where the first event was re-admission for 74 patients and death
for 64 patients. A total of 151 patients died through 180 days after ad-
mission. A total of 38 candidate predictors were considered. The dis-
tribution and proportion of unavailable values for each predictor are
given in Table 1. A total of 522 (51.9%) patients were missing at least
one candidate variable when cholesterol was not included as a pre-
dictor; onevariablewasmissing for284 patients, two for 162patients,
three for 72 patients, and four or more for 140 patients. We also con-
sidered cholesterol as a predictor, although it is measured only when
clinically indicated in African patients with AHF. With the inclusion of
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Table 1 Candidate predictors for re-admission and death
Variable N n Distribution (%) for
dichotomous; 25th %ile, median,
75th %ile for continuous
% missing Comments
Hx of DM 1004 114 (11.4) 0.2
Hx of IHD 1004 82 (8.2) 0.2
Valvular disease 1000 272 (27.2) 0.6
HIV positive 992 65 (6.6) 1.4
Hypertension 1002 556 (55.5) 0.4
Hyperlipidaemia 981 90 (9.2) 2.5
HX of stroke 1005 25 (2.5) 0.1
HX of PVD 1003 12 (1.2) 0.3
Current or former smoker 1002 98 (9.8) 0.4
Malignancy 1003 13 (1.3) 0.3
Hx of depression 1004 33 (3.3) 0.2
Hx of dementia 1004 22 (2.2) 0.2
Hx of atrial fibrillation 998 184 (18.4) 0.8
Hx of pericardial Disease 1000 53 (5.3) 0.6
Hx of Cardiomyopathy 994 416 (41.8) 1.2
Hx of cor pulmonale 995 72 (7.2) 1.1
Age, years 996 39, 55, 67 1.0
Male sex 1005 494 (49.2) 0.1
White race 999 15 (1.5) 0.7 Dropped from consideration as
there were no events for either
outcome in 15 white subjects
Ejection fraction, % 930 27, 38, 50 7.6
BMI, kg/m2 968 20.9, 24.0, 28.0 3.8 Extreme values of 214.5 and 121.4 set
to missing for analysis
BUN, mg/dL 971 16.5, 26.6, 42.0 3.5 Values ,6 set to missing
Creatinine, mg/dL 970 0.89, 1.12, 1.5 3.6 Values ,0.4 set to missing
Glucose, mg/dL 878 84.0, 93.7, 117.0 12.7
Haemoglobin, g/dL 967 10.7, 12.3, 13.7 3.9
Lymphocytes, % 839 20.0, 30.0, 39.6 16.6
Sodium, mmol/L 946 131.0, 135.8, 139.1 6.0
Cholesterol, mg/dL 649 124.0, 152.1, 187.0 35.5 Not measured in large proportion
of study population
Total WBC, /mm3 or /cumm or/mL or /mcL 963 5200, 6800, 8980 4.3
Systolic BP, mmHg 994 106, 126.5, 150 1.2
Diastolic BP, mmHg 992 70, 80, 100 1.4 Collinear with systolic BP.
Dropped from consideration
Heart rate, b.p.m. 997 90, 104, 116 0.9
Respiration, breaths/min 989 26, 29, 34 1.7
Orthopnoea, (0/1 vs. 2/3) 838 741 (88.4) 16.7
Peripheral oedema, (0/1 vs. 2/3) 990 665 (67.2) 1.6
Rales, (0/1 vs. 2/3) 880 565 (64.2) 12.5
lifestyle (emerging ¼ 1, endemic ¼ 0) 980 507 (51.7) 2.6
Region 1006 East: 268, South: 208, West: 530 0
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cholesterol 646 (64.3%) of the patients were missing a value for at
least one predictor. Models were run for each outcome including
and excluding cholesterol as a predictor. Despite the high number
of patients with unavailable baseline cholesterol, the variables that
stayed in the model for the outcomes were the same whether or
not cholesterol was included.
Univariable associations with the composite outcome, and the
final multivariable models with and without consideration of the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 2 Models for all-cause death or re-admission through 60 days






Hx of DM Yes/no 1.29 (0.81, 2.08) 0.2862
Hx of IHD Yes/no 1.00 (0.55, 1.81) 0.9948
Valvular disease Yes/no 1.04 (0.72, 1.52) 0.8275
HIV positive Yes/no 1.57 (0.88, 2.80) 0.1241
Hypertension Yes/no 0.86 (0.62, 1.20) 0.3756
Hyperlipidaemia Yes/no 0.40 (0.17, 0.95) 0.0373 0.47 (0.20, 1.12) 0.0891
HX of stroke Yes/no 0.27 (0.04, 1.98) 0.1984
HX of PVD Yes/no 1.13 (0.27, 4.66) 0.8644
Current or former smoker Yes/no 0.76 (0.41, 1.43) 0.3995
Malignancy Yes/no 5.07 (2.25, 11.45 ,0.0001 5.04 (2.19, 11.56) 0.0001
Hx of depression Yes/no 1.21 (0.49, 2.97) 0.6831
Hx of dementia Yes/no 0.92 (0.29, 2.92) 0.8933
Hx of atrial Fibrillation Yes/no 1.34 (0.90, 1.99) 0.1509
Hx of pericardial disease Yes/no 1.29 (0.67, 2.47) 0.4423
Hx of cardiomyopathy Yes/no 0.96 (0.68, 1.35) 0.8133
Hx of cor plmonale Yes/no 2.50 (1.57, 4.00) 0.0001 1.75 (1.07, 2.87) 0.0268
Age, years 10 0.95 (0.87, 1.04) 0.2443
Male Sex Yes/no 1.16 (0.83, 1.63) 0.3756
Ejection fraction, %a 50 vs. 27 0.94 (0.73, 1.21) 0.0523 0.89 (0.79, 1.14) 0.1355
BMI, kg/m2 5 1.04 (0.90, 1.20) 0.6127
BUN, mg/dLa Doubling 1.39 (1.18, 1.63) ,0.0001 1.46 (1.23, 1.73) ,0.0001
Creatinine, mg/dLa 1.55 vs. 0.90 1.40 (1.07, 1.83) 0.0095
Glucose, mg/dL 10 0.99 (0.95, 1.03) 0.5489
Haemoglobin, g/dL 1 0.92 (0.86, 0.99) 0.0238
Lymphocytes, % 5 0.96 (0.90, 1.03) 0.2275
Sodium, mmol/L 5 0.87 (0.77, 0.98) 0.0263
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.10 (0.84, 1.43) 0.4833
Cholesterol, mg/dL 10 0.98 (0.94, 1.02) 0.2423
Systolic BP, mmHg 10 0.91 (0.86, 0.96) 0.0009 0.91 (0.86, 0.97) 0.0017
Heart rate, b.p.m. 5 1.04 (1.00, 1.08) 0.0300
Respiration, breaths/min 5 1.07 (0.97, 1.18) 0.1836
Orthopnoeab (2/3 vs. 0/1) 1.78 (0.89, 3.56) 0.1033
Peripheral oedemac (2/3 vs. 0/1) 1.60 (1.08, 2.37) 0.0194
Ralesd (2/3 vs. 0/1) 2.16 (1.38, 3.38) 0.0008 2.18 (1.36, 3.50) 0.0012
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.78 (0.56, 1.09) 0.1497
Region (South vs. West) 1.32 (0.89, 1.94) 0.0141 1.83 (1.21, 2.78) 0.0025
Region (East vs. West) 0.62 (0.39, 0.97) 0.78 (0.48, 1.27)
C-statistic (95% confidence interval) 0.6986 (0.6521–0.7451)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
identation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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geographic region are given in Tables 2 and 3, respectively. Adjusted
for geographic region malignancy, cor pulmonale, higher admission
BUN level, and presence of rales were found to significantly increase
the risk of death or re-admission within 60 days, while hyperlipid-
aemia, and higher systolic blood pressure reduced the risk
(Table 2). Unlike for other continuous predictors, the association
of ejection fraction with the log hazard ratio was non-linear, with
risk increasing for patients with ejection fraction both less than and
greater than 40%. Patients enrolled in Southern centres were at
higher risk of the composite outcome, while those enrolled in
Eastern centres were at lower risk, compared with those enrolled
in Western centres. Considering region, the c-index for the
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Table 3 Models for all-cause death or re-admission through 60 days, excluding region






Hx of DM Yes/no 1.29 (0.81, 2.08) 0.2862
Hx of IHD Yes/no 1.00 (0.55, 1.81) 0.9948
Valvular disease Yes/no 1.04 (0.72, 1.52) 0.8275
HIV positive Yes/no 1.57 (0.88, 2.80) 0.1241
Hypertension Yes/no 0.86 (0.62, 1.20) 0.3756
Hyperlipidaemia Yes/no 0.40 (0.17, 0.95) 0.0373 0.49 (0.21, 1.19) 0.1156
HX of stroke Yes/no 0.27 (0.04, 1.98) 0.1984
HX of PVD Yes/no 1.13 (0.27, 4.66) 0.8644
Current or former smoker Yes/no 0.76 (0.41, 1.43) 0.3995
Malignancy Yes/no 5.07 (2.25, 11.45) ,0.0001 4.31 (1.89, 9.82) 0.0005
Hx of depression Yes/no 1.21 (0.49, 2.97) 0.6831
Hx of dementia Yes/no 0.92 (0.29, 2.92) 0.8933
Hx of atrial Fibrillation Yes/no 1.34 (0.90, 1.99) 0.1509
Hx of pericardial disease Yes/no 1.29 (0.67, 2.47) 0.4423
Hx of cardiomyopathy Yes/no 0.96 (0.68, 1.35) 0.8133
Hx of cor pulmonale Yes/no 2.50 (1.57, 4.00) 0.0001 2.03 (1.24, 3.32) 0.0048
Age, years 10 0.95 (0.87, 1.04) 0.2443
Male sex Yes/no 1.16 (0.83, 1.63) 0.3756
Ejection fraction, %a 50 vs. 27 0.94 (0.73, 1.21) 0.0523 0.97 (0.75, 1.26) 0.0981
BMI, kg/m2 5 1.04 (0.90, 1.20) 0.6127
BUN, mg/dLa Doubling 1.39 (1.18, 1.63) ,0.0001 1.42 (1.19, 1.68) ,0.0001
Creatinine, mg/dLa 1.55 vs. 0.90 1.40 (1.07, 1.83) 0.0095
Glucose, mg/dL 10 0.99 (0.95, 1.03) 0.5489
Haemoglobin, g/dL 1 0.92 (0.86, 0.99) 0.0238
Lymphocytes, % 5 0.96 (0.90, 1.03) 0.2275
Sodium, mmol/L 5 0.87 (0.77, 0.98) 0.0263
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.10 (0.84, 1.43) 0.4833
Cholesterol, mg/dL 10 0.98 (0.94, 1.02) 0.2423
Systolic BP, mmHg 10 0.91 (0.86, 0.96) 0.0009 0.92 (0.87, 0.98) 0.0048
Heart rate, b.p.m. 5 1.04 (1.00, 1.08) 0.0300 1.04 (1.00, 1.08) 0.0723
Respiration, breaths/min 5 1.07 (0.97, 1.18) 0.1836
Orthopnoeab (2/3 vs. 0/1) 1.78 (0.89, 3.56) 0.1033
Peripheral oedemac (2/3 vs. 0/1) 1.60 (1.08, 2.37) 0.0194
Ralesd (2/3 vs. 0/1) 2.16 (1.38, 3.38) 0.0008 2.04 (1.31, 3.16) 0.0016
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.78 (0.56, 1.09) 0.1497
C-statistic (95% confidence interval) 0. 6826 (0.6375–0.7294)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
indentation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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multivariable model was 0.70, indicating a moderate degree of dis-
crimination (Table 2). The same multivariable predictors were
obtained when region was not considered, except that heart rate
also entered the model (Table 3). The C-index for this multivariable
model (0.68) was slightly less than for that including region.
Univariable associations and the multivariable model of death
through 180 days are given in Table 4. Known HIV positivity, malig-
nancy, cor pulmonale, male sex, lower haemoglobin, lower systolic
blood pressure, and presence of orthopnoea, peripheral oedema,
and rales were found to increase risk, while current or former
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Models for all-cause death through 180 days






Hx of DM Yes/no 1.25 (0.80, 1.97) 0.3260
Hx of IHD Yes/no 0.56 (0.27, 1.15) 0.1121
Valvular disease Yes/no 1.05 (0.73, 1.51) 0.7882
HIV positive Yes/no 1.98 (1.20, 3.29) 0.0081 1.62 (0.94, 2.78) 0.0805
Hypertension Yes/no 0.76 (0.55, 1.04) 0.0859
Hyperlipidaemia Yes/no 0.43 (0.20, 0.96) 0.0382
HX of stroke Yes/no 0.77 (0.24, 2.43) 0.6544
HX of PVD Yes/no 0.92 (0.22, 3.79) 0.9074
Current or former smoker Yes/no 0.57 (0.29, 1.12) 0.1050 0.51 (0.25, 1.03) 0.0592
Malignancy Yes/no 4.26 (1.76, 10.33) 0.0014 3.00 (1.22, 7.35) 0.0166
Hx of depression Yes/no 1.16 (0.47, 2.85) 0.7474
Hx of dementia Yes/no 1.48 (0.61, 3.63) 0.3883
Hx of atrial fibrillation Yes/no 1.17 (0.79, 1.74) 0.4371
Hx of pericardial disease Yes/no 0.89 (0.43, 1.81) 0.7384
Hx of cardiomyopathy Yes/no 1.18 (0.86, 1.63) 0.3060
Hx of Cor pulmonale Yes/no 2.14 (1.33, 3.44) 0.0017 1.99 (1.22, 3.24) 0.0057
Age, years 10 0.93 (0.85, 1.01) 0.0845
Male sex Yes/no 1.08 (0.78, 1.49) 0.6409 1.38 (0.97, 1.96) 0.0699
Ejection fraction, % 5 0.96 (0.92, 1.02) 0.1657
BMI, kg/m2 5 1.01 (0.88, 1.16) 0.9101
BUN, mg/dLa Doubling 1.27 (1.08, 1.50) 0.0033
Creatinine, mg/dLa 1.55 vs. 0.90 1.37 (1.14, 1.65) 0.0020 1.36 (1.12, 1.64) 0.0051
Glucose, mg/dL 10 0.98 (0.95, 1.02) 0.3820
Haemoglobin, g/dL 1 0.91 (0.85, 0.97) 0.0050 0.93 (0.87, 1.00) 0.0488
Lymphocytes, % 5 1.00 (0.93, 1.07) 0.9657
Sodium, mmol/L 5 0.87 (0.78, 0.99) 0.0294
Cholesterol, mg/dL 10 0.95 (0.91, 0.99) 0.0282
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.14 (0.89, 1.46) 0.3060
Systolic BP, mmHg 10 0.86 (0.81, 0.91) ,0.0001 0.86 (0.81, 0.91) ,0.0001
Heart rate, b.p.m.a 116 vs. 90 1.29 (0.99, 1.67) 0.0165 1.34 (1.01, 1.81) 0.0845
Respiration, breaths/min 5 1.02 (0.93, 1.13) 0.6641
Orthopnoeab (2/3 vs. 0/1) 2.69 (1.30, 5.56) 0.0079 1.86 (0.85, 4.08) 0.1194
Peripheral oedemac (2/3 vs. 0/1) 2.26 (1.50, 3.40) ,0.0001 1.91 (1.23, 2.97) 0.0043
Ralesd (2/3 vs. 0/1) 2.11 (1.41, 3.18) 0.0003 1.60 (1.03, 2.50) 0.0380
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.72 (0.52, 0.99) 0.0431
Region (South vs. West) 1.21 (0.84, 1.76) 0.0042
Region (East vs. West) 0.53 (0.34, 0.83)
C-statistic (95% confidence interval) 0.7231 (0.6849–0.7451)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
indentation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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smoking reduced risk (Table 4). The associations of creatinine and
heart rate with the log hazard ratio for mortality were non-linear
(Figure 1). Patients with a higher heart ratewere generally at increased
risk; while the model-predicted risk appears to fall again, this is likely
because of undue influence of a fewpatients with extreme heart rates
(six patients with HR .170 b.p.m.). The model-predicted associ-
ation with creatinine was an apparent inverted U shape with patients
with creatinine levels of 1.9 mg/dL at highest risk; risks appear to
decrease with values .4 mg/dL; however, very few (32) patients
had these extreme values. The C-index for the multivariable model
was 0.72.
Calibration plots, comparing observed event rates with those pre-
dicted by the models, are given in Figure 2 for death or re-admission
through Day 60 (with, Figure 2A, and without, Figure 2B consideration
of region) and in Figure 3 for mortality through Day 180. Risks pre-
dicted by the models were generally close to those observed
among patients grouped by deciles of predicted risk.
Discussion
The current manuscript is an analysis of the THESUS registry.5 As
previously noted the main finding of the THESUS registry points to
the fact that patients who present with AHF in sub-Saharan Africa
are younger, less have ischaemic heart disease or risk factors for is-
chaemic heart disease (such as smoking) and many more have valvu-
lar (mostly rheumatic) heart disease and are hypertensive. As has
been found in other studies,7– 9 the main predictors of either re-
admission or death in the model that excludes region (Table 3) are
a history of malignancy and severe lung disease, admission systolic
blood pressure, heart rate and signs of congestion (rales), kidney
function (BUN), and echocardiographic ejection fraction. In the
model in which region has been included (Table 2), the Southern
African region seems to confer a higher risk of re-admission suggest-
ing that cultural and health economics-related factors may contribute
to the decision to re-admit a patient after an AHF event, as opposed
to outpatient clinic treatment. Interestingly, some factors that rou-
tinely contribute to similar models in North America and Europe
have a lesser role in sub-Saharan Africa. These should be confirmed
in further studies in potentially larger number of patients and more
hospitals. Most notably age and sodium levels at admission may
have potentially less of a predictive effect in sub-Saharan Africa.
Age may have a lesser role in this population because these patients
are almost 20 years younger on average than AHF patients in North
American and European registries. Sodium may play a lesser role
Figure 1 Non-linear associations of continuous predictors with all-cause death through 180 days.
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since most patients are young and the most common cause of heart
failure is hypertension which may be associated with less neurohor-
monal activation than end-stage ischaemic cardiomyopathies which
are more prevalent in North America and Europe, especially
among the sickest AHF patients who are more commonly
re-admitted after discharge.
The main predictors of 180-day mortality include malignancy,
severe lung disease, smoking history, systolic blood pressure, heart
rate, and symptoms and signs of congestion (orthopnoea, peripheral
oedema, and rales) at admission, kidney dysfunction (BUN), anaemia,
and being HIV positive. Again, many of these predictors are the same
as those reported in similar studies in North America and Europe, al-
though some notable differences are apparent. Again, the interpret-
ation of these differences should be tempered by the fact that the
study is relatively small and was recruited in a selected group of hos-
pitals, mostly advance medical centres in each country. The role of
HIV positivity as a predictor of adverse outcome is important.
Sodium was not found to be a predictor of mortality in the current
study (as is the case of re-admission and death), suggesting again
that neurohormonal activation involving the renin–angiotensin
system may have a lesser role in the HF process in sub-Saharan
Africa, a finding in line with the reduced efficacy of ACEi in African
Americans,15 suggesting that other therapies such as combination
of hydralazine and nitrates should be further explored in this popula-
tion. Finally, the association of smoking with less adverse outcome
may relate to the diagnosis of AHF being wrong and the breathless-
ness was due to lung disease, and this misdiagnosis led to the asso-
ciated cigarette smoking being seen as conferring survival advantage.
Similar to other studies in which short-term re-admission and
death and intermediate-term mortality were modelled in AHF the
strength of the predictive models are modest with C-indexes in the
range of 0.68–0.72. These C-indexes suggest that although some of
the variability in outcomes can be explained by the factors examined,
Figure 2 (A) Calibration plot for multivariable model for all-cause death or re-admission through 60 days. Model including region. (B) Calibration
plot for multivariable model for all-cause death or re-admission through 60 days. Model excluding region.
Figure 3 Calibration plot for multivariable model for all-cause
death through Day 180.
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other causes for re-admission and death after an AHF are still
unknown in sub-Saharan Africa as in the rest of the world.
Limitations
The present study is an analysis of the patients enrolled in the
THESUS-HF study and as such shares certain limitations with the ori-
ginal cohort. The majority of the patients were recruited in a limited
numberofhospitals mainly in Nigeria,Uganda, andSouthAfrica.Most
importantly loss to follow-up and missing laboratory data and clinical
signs assessments were higher than in studies conducted in other
regions. Loss to follow-up is common in the population studied
due to a number of factors such as working opportunities if still
well (migrant workers), or need to be taken care of if not well.
Some tests are not performed as routinely in these institutions as
in institutions participating in other studies. Secondly, this registry
has been performed in selected centres and may represent only
AHF patients seen in specialized centres. Thirdly, HIV infection has
emerged as an important factor that predicts outcome in patients
with AHF in sub-Saharan Africa. Future studies should aim not only
to ensure testing of cases for heart failure, but also explore the con-
tribution of degree of immunosuppression (by CD4+ T cell count
testing), and the impact of anti-retroviral therapy. Finally, a larger
sample size with significant numbers of participants at each site will
be needed to provide valid comparisons between patients from
various countries in Africa. The small size of the database obviated
a split-sample approach to model validation; validation in another
sub-Saharan African cohort would provide greater confidence in
the findings.
Conclusions
Despite being one of the most common causes for hospital admis-
sions both globally and in sub-Saharan Africa, our knowledge of the
pathophysiologyof AHF is limited. In the present study, the predictive
models for60-day re-admission ordeathand 180-day mortality are of
the modest predictive value suggesting that some of the factors con-
tributing to the morbidity and mortality in AHF are unknown. For the
most part, the main predictors for these adverse outcomes are
similar in sub-Saharan Africa as in the rest of the world although
with some notable exceptions such as the association of the HIV
status with mortality and lack of prediction by sodium on both re-
admission and deaths.
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6 Chapter 6: Symptoms and signs of heart failure at 
admission and discharge and outcomes in the Sub-
Saharan Acute Heart Failure (THESUS-HF) registry 
6.1 Introduction 
Because of their importance symptoms and signs of HF have been the mainstay of 
assessments aimed at determining the severity of disease, as well as response to 
therapy in patients admitted for AHF.  Such assessments are done at least daily in 
hospitals all over the world.  However, their importance and additive value to other 
characteristics have been debated. The challenge relates to both the exact symptoms 
and signs to be assessed which vary widely around the world, as well as variability 
in severity determination driven by different standards and differences between 
assessors.474 
The Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with 
Tolvaptan (EVEREST) investigators474 conducted an analysis of outcomes in 
patients admitted with AHF and determined that more congestion at discharge 
predicted more adverse outcomes, after adjusting for baseline characteristics, 
suggesting that non-resolution of symptoms and signs of HF during a AHF 
admission may be a strong marker for adverse outcome. However, the EVEREST 
study was limited to patients with AHF due to systolic dysfunction who met the 
strict inclusion and exclusion criteria of the study. The value of assessing changes in 
symptoms and signs of HF was not previously assessed in more real life AHF 




the relation between symptoms and signs of congestion and prognosis in African 
patients with AHF.  
6.2 Methods 
The data were collected in the THESUS study, a prospective, multicenter, 
international observational survey of AHF in 12 cardiology centers, from 9 countries 
in sub-Saharan Africa. 36  
Details of data collection have been previously described.3 Symptoms and signs of 
heart failure, including oxygen saturation, degree of edema and rales, body weight 
and levels of orthopnea were assessed at admission and on days 1, 2, and 7 (or on 
discharge if earlier).   Changes in dyspnea and well-being relative to admission were 
assessed on days 1, 2, and 7 (or on discharge if earlier). These assessments were 
done using structured scales as shown in Table 6.1. Oxygen saturation was assessed 
using pulse oximeters available at the sites and respiratory rate was defined as 




















+1 = Minimally better 0 = No change -1 Minimally 
worse 
-2 = Moderately 
Worse 










+1 = Minimally better 0 = No change -1 Minimally 
worse 
-2 = Moderately 
Worse 
 - 3 Markedly worse 
Orthopnea 
(number of 
pillow used by 
the patient 
0= None  +1 = 1 pillow     
(10 cm) 
+2 = 2 pillow      (20 
cm) 
+3 = 3 pillow 
(>30 cm). 
















2+: Indentation easily 
produced and goes 
slowly (15–30 
seconds) 
3+: Large areas 
of indentation 
easily produced 
and slow to 
resolve (> 30 
seconds). 
   
Presence of 
Rales 
0: No rales 
after clearing 
with cough  
1: Moist or 
dry rales 
heard in 
lower ⅓ of 1 




2: Moist or dry rales 
heard throughout the 
lower half to ⅔ of 1 
or both lung fields 








6.2.1 Statistical Analysis 
Data were analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
Symptoms and signs and their changes were analyzed on a continuous scale with 
summary statistics (mean, SD, median, min, and max) provided.  
Cox regression models were constructed to examine univariable and multivariable 
associations of baseline symptoms and signs and changes from baseline to day 7 (or 
discharge) with all-cause death through day 180 and a composite endpoint of all-cause 
death or readmission through 60 days. The time to first event from admission was used. 
Patients with no event were censored at the earlier of the last date the patient was known 
to be alive or the period of interest. Linearity was assessed for each sign/symptom change 
that was included as a potential predictor, using restricted cubic splines (RCS) with 4 
‘knots’ and examining the significance of the non-linear terms. None of the predictors 
were found to have a significantly non-linear association with either outcome so each 
predictor was entered as a linear term. 
Multivariable models were adjusted for clinical covariates included in multivariable 
prognostic models in the overall THESUS-HF registry. 475 For the outcome all-cause 
death or readmission to 60 days, these included history of hyperlipidemia, malignancy, or 
cor pulmonale, systolic BP, left ventricular ejection fraction, oxygen saturation, rales, 
blood urea nitrogen, and region. For the outcome all-cause death to day 180, clinical 
covariates included sex, history of malignancy, cor pulmonale, smoking, human 
immunodeficiency virus, systolic blood pressure (BP), heart rate, oxygen saturation, 
orthopnea, rales, edema, creatinine, and hemoglobin. Multiple imputations using seven 
imputed datasets and assuming multivariate normality was used to handle missing values. 




performed on each imputation dataset, which also included adjustment for the baseline 
value of each sign/symptom change in the model. Predictors that remained in ≥ 4 of the 
imputation datasets after backwards selection with a p < 0.1   were then included in the 
final model. Change values found to be predictive after model selection included an 
adjustment for the baseline value in the final model if the baseline value was not already 
included from the original prognostic model. Bootstrapping methods were used to 
examine the difference in c-statistics when the changes of symptoms and signs that were 
found to be predictive of outcome were added to the original prognostic model. 
6.3 Results 
There were a total of 1006 patients in the THESUS HF registry. Twenty-three subjects 
who died during the index hospitalization before day 7 and five patients who were 
censored before day 7, and did not have day7/discharge data, were excluded from the 
multivariable models. The mean (SD) age of the patients was 52.4 (18.3) years, 498 
(51.0%) were women, and the predominant race was black African 961 (99.0%). Left 
ventricular EF (LVEF) was 39.4 ± 16.4%.  
The majority of patients had data on changes in dyspnea, general well-being, edema, 
rales, and respiratory rate, while a lower proportion had data on changes in orthopnea, 
oxygen saturation, and weight (Tables 2 and 3).  
 
Changes in symptoms and signs of HF from baseline to day 2 and to discharge/day 7 are 
presented in Table 6.2 for patients who had changes available at both follow-up time 
points. The symptoms of dyspnea as well as general well-being improved, compared to 
admission at both day 2 and day 7 or discharge. For the most part, patients had significant 




The final signs of HF at day 7/discharge are presented in Table 6.3.  It shows that the 
patients have their symptoms improved with medians of absent rales and oedema among 
them. The mean respiratory rate was 20 cycles per minute and the mean oxygen 



















Table 6.2 Summary of changes in heart failure symptoms and signs from baseline to 
day 2 and the earlier of day 7 or discharge 
HF sign or symptom Statistic Change from baseline 
to Day 2* 
Change from Baseline to 
Day 7 or Discharge* 
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*Restricted to patients having reported values at baseline, day 2 and day 7/discharge 
†Restricted to patients having reported values at day 2 and day 7/discharge (reported value is 










Table 6.3 Heart failure symptoms and signs at the earlier of day 7 or discharge 




































































Univariable associations of baseline heart failure symptoms and signs with clinical 
outcomes are shown in Table 6.4. Rales and, to a lesser extent, respiratory rate and 
oxygen saturation were predictive of death or HF hospitalization through day 60 while 






Table 6.4 Univariable associations of baseline heart failure symptoms and signs with 
clinical outcomes 
Variable Death or HF readmission 
through day 60 
Death through day 180 
HR (95% CI) P-value HR (95% CI) P-value 
Orthopnea*   1.07 (0.84, 1.35) 0.5948 1.14 (0.91, 1.41) 0.2495 
Edema*   1.22 (0.92, 1.61) 0.1704 1.60 (1.23, 2.07) 0.0004 
Rales*   1.53 (1.14, 2.04) 0.0042 1.79 (1.36, 2.35) <.0001 
Respiration Rate† 1.04 (1.00, 1.08) 0.0502 1.08 (1.04, 1.12) <.0001 
Oxygen Saturation† 0.94 (0.89, 1.01) 0.0758 0.96 (0.90, 1.02) 0.1832 
Weight† 0.99 (0.93, 1.05) 0.7244 1.00 (0.95, 1.06) 0.9168 
 
 
*Adjusted for baseline dichotomized value (2/3 vs. 0/1) 
†Adjusted for baseline value  
 
 
Multivariable associations of symptoms and signs at admission and their changes to day 
7/discharge with death or HF hospitalization through day 60, and with death through day 
180 are presented in Tables 6.5 and 6.6, respectively. Baseline rales, baseline oxygen 
saturation and changes to day 7 or discharge in general well-being predicted death or HF 
hospitalization through day 60. For death through day 180, baseline orthopnea, rales, 
oedema and oxygen saturation and changes to day 7 or discharge in respiratory rate, and 






Table 6.5 Multivariable associations of baseline heart failure symptoms and signs 
and their changes to day 7 or discharge with death or heart failure readmission 
through 60 days 
Parameter Unit Change HR 95% CI P-value 
Hyperlipidemia Yes/No 0.39 (0.14, 1.05) 0.0638 
Malignancy Yes/No 4.71 (1.69, 
13.09) 
0.0031 
Cor Pulmonale Yes/No 1.46 (0.81, 2.65) 0.2113 
Ejection Fraction, %* 50 vs. 27 0.94 (0.69, 1.26) 0.4126 
BUN, mg/dL† Doubling 1.40 (1.15, 1.70) 0.0006 
Systolic BP, mmHg 10 0.94 (0.89, 1.00) 0.0670 
Baseline Rales (2/3 vs. 0/1) 2.30 (1.33, 3.98) 0.0032 
Region (South vs. 
West) 
1.55 (0.96, 2.50) 0.0302 
Region (East vs. 
West) 
0.69 (0.40, 1.18) 
Baseline Oxygen Saturation, % 1 0.94 (0.87, 1.01) 0.1189 
Change in Oxygen Saturation to 
Discharge/Day 7 
1 0.95 (0.88, 1.04) 0.2745 
Change in General Well-Being 
to Discharge/Day 7 
1 0.83 (0.70, 0.98) 0.0327 
Bias Corrected C-Statistic (95% 
CI) 
 0.6922 (0.6496, 0.7348) 






Table 6.6 Multivariable associations of baseline heart failure symptoms and signs 
and their changes to day 7 or discharge with death through 180 days 
Parameter Unit 
Change 
HR 95% CI P-value 
HIV Positive Yes/No 1.75 (0.97, 3.15) 0.0619 
Current/Former Smoker Yes/No 0.54 (0.26, 1.10) 0.0898 
Malignancy Yes/No 3.42 (1.04, 11.23) 0.0430 
Cor Pulmonale Yes/No 1.51 (0.84, 2.70) 0.1661 
Male Yes/No 1.34 (0.91, 1.97) 0.1431 
Creatinine, mg/dL* 1.54 vs. 
0.89 
1.42 (1.13, 1.78) 0.0085 
Hemoglobin, g/dL 1 0.90 (0.83, 0.97) 0.0042 
Systolic BP, mmHg 10 0.89 (0.83, 0.95) 0.0003 
Heart Rate, bpm* 116 vs. 90 1.57 (1.07, 2.30) 0.1230 
Orthopnea (Baseline) (2/3 vs. 0/1) 1.75 (0.91, 5.64) 0.0783 
Edema (Baseline) (2/3 vs. 0/1) 1.75 (1.05, 2.91) 0.0321 
Rales (Baseline) (2/3 vs. 0/1) 1.83 (1.09, 3.08) 0.0226 
Baseline Oxygen Saturation 1 0.94 (0.88, 1.01) 0.0921 
Change in Oxygen Saturation to 
Discharge/Day 7 
1 0.95 (0.89, 1.03) 0.1995 
Baseline Respiration Rate 1 1.01 (0.97, 1.06) 0.6093 
Change in Respiration Rate to 
Discharge/Day 7 
1 1.06 (1.01, 1.11) 0.0269 
Change in General Well Being 
Discharge/Day 7 
1 0.77 (0.65, 0.92) 0.0032 
Bias Corrected C-Statistic (95% 
CI) 
 0.7392 (0.7040, 0.7745) 







The addition of signs and symptoms add incremental prognostic information beyond 
other clinical variables previously found to be predictive of these outcomes. 475 The C-
index for the model for all-cause 180-day mortality significantly improved from 0.69 to 
0.74, an increase of 0.05 (95% CI 0.02-0.08), and for 60-day HF readmission or death 
significantly improved from 0.64 to 0.69, an increase of 0.05 (95% CI 0.01-0.08). 
  
6.4 Discussion 
Symptoms and signs of HF assessed at admission and thereafter daily to discharge have 
been the mainstay of assessment and follow-up for patients admitted for AHF. The main 
purpose of these repeat assessments is to determine the severity of the patients’ 
symptoms and the main reason patients seek medical help and are admitted - leading to 
changes in medical therapy, mainly targeting symptom relief.  
The addition of symptoms and signs of HF during admission to the models predicting 
readmission or death resulted in significant improvement in C-indexes, suggesting that 
important additional information was added, improving our ability to discriminate 
between patients with good and bad outcomes. This result is in line with the analysis of 
the EVEREST study, 474 which found similar strong associations between lack of 
improvement of symptoms and signs of HF and adverse outcomes in patients admitted 
for AHF who have systolic dysfunction. Interestingly, the symptoms and signs that were 
found to be most predictive are somehow different from what would have been 
traditionally believed to be of importance. For instance the model generated in the 
EVEREST study combined three parameters – orthopnea, JVP and pedal edema.   
Although JVP was not systematically collected in the THESUS-HF registry, rales and 




compared to orthopnea and edema in EVEREST). The presence of rales depicts raised 
left-sided filling pressure and resultant alveolar oedema while leg oedema, which is the 
simplest sign of right-sided congestion, reflects elevation of right atrial pressure. 476,477 
Damy and colleagues found that having right- and left-sided congestion was associated 
with a worse prognosis than having either side alone, perhaps reflecting more severe 
congestion. 478  This was independent of other factors. In a post-hoc analysis of patients 
enrolled in the Atrial Fibrillation and Congestive Heart Failure (AFCHF) trial to evaluate 
the prognostic value of baseline physical examination findings, including elevated JVP, 
third heart sound, rales and peripheral edema, in patients with systolic heart failure, 
Caldentey et al 479 confirmed that physical signs of congestion, defined by any of the 4 
physical findings, is associated with increased mortality and heart failure–related 
hospitalizations. 
 
In addition the THESUS-HF registry found two other important variables to be predictive 
of outcomes. First, oxygen saturation, which may be an accurate measure of congestion. 
Second, patient reported general well-being, which may be an accurate way to gauge 
congestion and the overall severity of heart failure, may add important information on 
severity of disease.  
Because AHF affects pulmonary function, 396 gas exchange can be altered even in mild 
forms. The finding of oxygen saturation predicting outcome was in accordance with 
previous trials, which showed a close correlation between the defects in gas exchange and 
the severity of AHF or the pulmonary capillary wedge pressures. 480 Hypoxemia in AHF 
can be explained by an increase in veno-arterial shunting and ventilation perfusion 




decrease in special situations such as severe hypoxemia, anemia, acidosis, pigmentation, 
low perfusion states, and the use of vasoactive drugs.482,483 
The addition of these variables had a small yet significant effect on the C-indexes of the 
models, suggesting that the addition of symptoms and signs assessment improves our 
ability to risk stratify patients with AHF, albeit to a small degree. This limited additional 
value may relate to the value of other variables now routinely collected in AHF patients, 
such as medical history and laboratory evaluation, or to the possibility that severity of 
congestion may not be as strong a predictor of outcome in AHF as previously 
hypothesized.   
Symptoms and signs of congestion are important in assessment and prognostication of 
AHF patients and interventions to treat congestion are class I recommendations for both 
acute and chronic management of heart failure.48 
The THESUS-HF study enrolled patients with AHF in Sub-Saharan Africa and therefore 
the conclusions may be limited by the patient population, which was younger and had 
more hypertension and rheumatic heart disease-driven AHF.  Furthermore, the study was 
small (approximately 1,000 patients were enrolled), follow-up was not complete and the 
investigators assessment of symptoms and signs of HF was only partially standardized. 
6.5 Conclusion 
In patients with AHF from Sub-Saharan Africa, symptoms and signs of HF improved 
over time and repeat assessments of these symptoms and signs of HF are a valuable tool 
in predicting patients’ outcomes. Simple assessments including edema, rales, oxygen 
saturation, respiratory rate and asking the patient about general well-being seem to add 




7 Chapter 7: Echocardiographic predictors of outcome in 
Acute Heart failure patients in Sub-Saharan Africa: 
Insights from THESUS-HF 
7.1 Introduction 
 
Recent data clearly indicate that HF is an important health care problem in Africa, where 
it is estimated to constitute about 3–7 % of all medical admissions. The causes of HF in 
Africa are different from those outside of Africa. 150 The recent THESUS-HF registry36 
showed that in sub-Saharan Africa, the disease affects men and women in the most 
productive years of life, at an average age of 52 years. Furthermore, HF in Africa is 
mostly caused by hypertension and not by CAD, as is seen in Western countries.83 
Patients with HF are heterogeneous in terms of risk of cardiac death and re-admission for 
decompensated HF. Therefore, assessment of prognosis is a fundamental step in 
individual patient management. Analysis of clinical variables has helped in identifying 
the most significant predictors of mortality in the HF population.484 
Echocardiography has become the gold standard for the evaluation of patients with heart 
failure because it is an inexpensive, highly reproducible, widely available, and relatively 
extensive method for assessing left ventricular systolic and diastolic function.485In fact, 
the recent HF guidelines of the European Society of Cardiology state that 
”echocardiography is the method of choice in patients with suspected HF for reasons of 
accuracy, availability (including portability), safety, and cost.”42 
More than 20 echocardiographic parameters have been proposed as predictors of outcome 




in the assessment and risk stratification of acute HF has been less clear. Some small 
studies have found little correlation between echocardiographic and hemodynamic 
variables in acute HF, and little change in these variables from admission to follow up. 487 
In large registries and trials, echocardiographic parameters were not found in many cases 
to be associated with outcomes. 488 Therefore, it is not clear which echocardiographic 
variables are of importance in patients with acute HF. 484,489  
THESUS-HF36 provides a unique opportunity to study the echocardiographic predictors 
of outcome in patients admitted with acute HF in this part of the world. To our 
knowledge, no similar study has been previously published in Africans with acute HF.  
7.2 Methods 
THESUS-HF was a prospective, multicenter, international observational survey of acute 
HF in 12 cardiology centers from 9 countries sub-Saharan Africa. 36 All participating 
centers had a physician trained in clinical cardiology and echocardiography.  
Details of data collection have been previously described in chapter 3.  
7.2.1 Echocardiography 
Echocardiographic procedures, and measurements were performed according to the 
American Society of Echocardiography (ASE) Guidelines. 468 M-mode echocardiograms 
were derived from 2D images. The M-mode cursor on the 2D scan was moved to specific 
areas of the heart to obtain measurements, according to the recommendation of the 
committee on M-mode standardization of the ASE. Doppler indices of left ventricular 
(LV) diastolic filling were obtained. Complete Doppler studies were performed according 
to the recommendations of the ASE (Figure 7.1). From the M-mode measurements, LV 
dimensions and function (LV ejection fraction) were derived. LV mass was calculated 




[LVIDD]3) -13,6 g.490 
For diastolic function, left atrial (LA) size (both antero–posterior diameter and 
planimetry) and pulse wave mitral valve (MV) inflow (early and late peak diastolic 
velocities which measure the E/A ratio and the deceleration time and MV A-wave 
duration) were measured. Echocardiography examinations also included assessment of 
valvular architecture, a semi-quantitative estimate of the severity of valvular 
regurgitation, and determination of presence of pericardial effusion. Other abnormalities, 






Figure 7.1 Echocardiography images depicting methods of echo assessment in study 
 
 
7.2.2 Statistical Methods and Modeling 
Patients whose echocardiograph was performed within 4 weeks prior to and 2 weeks post 
enrollment were included in this analysis. Continuous parameters are summarized by the 
mean and standard deviation, and categorical parameters by absolute and relative 
frequencies.  
For patients who had their E/A ratios recorded, Grade 1 was defined as E/A < 0.8, Grade 




E/A ratio then the grade was defined using the E-wave deceleration time as follows: 
Grade 1 as E-wave > 200 msec, Grade 2 as E-wave between 160 msec and 200 msec, and 
Grade 3 as E-wave < 160 msec. 
The associations between echo parameters and clinical outcomes were examined using 
Cox regression models. The univariable associations between each predictor and outcome 
were examined. The linearity of associations between continuously distributed predictors 
and each outcome was assessed using restricted cubic splines with 4 knots with a test of 
the significance of the non-linear terms. If the association was non-linear, a readily 
interpretable transformation was chosen through examination of plots of the predicted log 
hazard ratio against the value of the predictor and changes in Akaike’s Information 
Criterion. For the outcome of 180-day mortality, the associations with creatinine, heart 
rate, and posterior wall thickness were all significantly non-linear. We chose to model 
creatinine as a quadratic polynomial, and heart rate and posterior wall thickness using 
linear splines with one knot where the association between predictor and outcome 
appeared to change. 
Univariable associations between echo parameters and outcomes are presented for the 
whole analysis population as well as by key diagnosis groups. Diagnoses were grouped as 
hypertension, cardiomyopathy, valvular, and others. Valvular was defined as having 
rheumatic heart disease or at least one of the following classified as severe: aortic 
stenosis or regurgitation, mitral stenosis or regurgitation.  To assess whether an 
association between an echo parameter and outcomes differed by diagnosis group, we 
tested for the significance of the diagnosis-by-echo parameter interaction term in the Cox 




The number of events in the analysis population limited development of multivariable 
models for 180-day mortality and 60-day death or readmission. Because of this, we chose 
a few echo parameters in addition to predictors known to be associated with each 
outcome in this study population.  
Multiple imputations were used with a method that assumes multivariate normality (SAS 
PROC MI) to handle missing values. The imputation model included all covariates under 
consideration for the multivariable models. The ranges of imputed values were restricted 
to the ranges of the observed values. Seven imputation datasets were used. Parameter 
estimates were averaged across these datasets using Rubin’s algorithm (SAS PROC 
MIANALYZE). Backwards selection was used in each of the seven imputation datasets, 
with the criterion for staying at p<0.10. Predictors that were significant in the majority of 
the imputed datasets were kept in the final model.  SAS release 9.2 (SAS Institute, Cary, 
NC, USA) was used for analyses. 
7.3  Results 
There were a total of 1006 patients in the THESUS-HF registry of whom 954 had an 
echocardiogram performed within 4 weeks before to 2 weeks after enrollment. Among 
these 954 patients, the mean ± SD age of the patients was 52.3 ±18.2 years, 469 (49.2%) 
were men, the predominant race was black African (99.1%), 11.4% of patients had 
diabetes mellitus and 9.0% had hyperlipidemia. The mean + SD left ventricular EF was 
39.4 ± 16.4%, the initial systolic blood pressure was 130.7 ± 33.5 mm Hg, and heart rate 





Table 7.1 Patients' characteristics, overall and by LV ejection fraction 
Patient characteristics  
Overall 
n = 954 
LV Ejection 
Fraction <50 




n = 243 
P-
value 
Age, years, mean ± SD 52.3 ± 18.24 52.3 ± 17.64 53.0 ± 19.58 0.62 
Male sex, n (%) 469 (49.2%) 342 (52.3%) 101 (41.7%) 0.0050 
Black Africans, n (%) 939 (99.1%) 646 (99.1%) 242 (99.6%) 0.68 
Hypertension, n (%) 532 (56.0%) 369 (56.7%) 138 (57.0%) 0.93 
Hyperlipidemia, n (%) 84 (9.0%) 58 (9.1%) 23 (9.6%) 0.80 
History of Smoking, n (%) 93 (9.8%) 64 (9.8%) 17 (7.1%) 0.20 
Malignancy, n (%) 13 (1.4%) 10 (1.5%) 3 (1.2%) 1.00 
History of Cor Pulmonale, n (%) 67 (7.1%) 34 (5.2%) 30 (12.4%) 0.0002 
Diabetes Mellitus, n (%) 109 (11.4%) 72 (11.0%) 26 (10.7%) 0.88 
Peripheral edema, n (%) 631 (67.1%) 448 (69.6%) 146 (60.8%) 0.014 
Rales, n (%) 533 (63.8%) 382 (65.3%) 130 (59.6%) 0.14 
Body Mass Index, kg/m2, mean ±  SD 24.9 ± 5.84 24.8 ± 5.62 24.7 ± 6.10 0.82 
Systolic Blood Pressure, mm Hg, mean ±  SD 130.7 ± 
33.51 
127.9 ± 32.16 137.2 ± 36.35 0.0006 
Diastolic Blood Pressure, mm Hg, mean ±  SD 84.5 ± 21.04 84.0 ± 20.52 85.5 ± 22.04 0.34 
Heart Rate, BPM, mean ±  SD 104.0 ± 
21.35 
105.0 ± 21.02 101.1 ± 22.69 0.016 
LVEF %, mean ±  SD 39.4 ± 16.43 31.8 ± 10.04 60.6 ± 9.65 <.0001 
Creatinine level, mg/dL, mean ± SD 1.4 ± 0.99 1.4 ± 0.99 1.3 ± 1.07 0.54 
BUN, mg/dL, mean ± SD 34.7 ± 31.59 35.1 ± 29.58 35.9 ± 38.35 0.79 
Sodium level, mEq/L, mean ± SD 135.2 ± 6.57 135.0 ± 6.72 135.5 ± 6.3 0.27 
eGFR, ml/min/1.73m2, mean ±  SD 84.4 ± 47.91 81.7 ± 44.08 90.8 ± 57.97 0.032 
Hemoglobin, g/dL, mean ± SD 12.1 ± 2.41 12.3 ± 2.30 11.8 ± 2.64 0.019 
Glucose level, mg/dL, mean ± SD 109.8 ± 
49.92 
110.4 ± 51.95 106.1 ± 41.93 0.22 
Prior medication use, n (%)     
ACE inhibitor 180 (32.4%) 134 (34.9%) 40 (24.8%) 0.022 
Loop diuretics 215 (39.4%) 152 (40.1%) 57 (36.5%) 0.44 
b-blockers 97 (17.9%) 69 (18.3%) 26 (16.7%) 0.65 




Hydralazine 3 (0.6%) 2 (0.5%) 1 (0.6%) 1.00 
Nitrates 10 (1.8%) 8 (2.1%) 2 (1.3%) 0.73 
Aldosterone Inhibitor 101 (18.5%) 77 (20.4%) 22 (13.8%) 0.075 
Statins 27 (5.0%) 18 (4.8%) 9 (5.7%) 0.68 
Aspirin 122 (22.2%) 91 (24.0%) 29 (18.1%) 0.13 
Anticoagulants 31 (5.7%) 22 (5.9%) 7 (4.4%) 0.49 
Etiology heart failure, n (%)     
Hypertensive CMP 380 (40.9%) 274 (42.5%) 86 (37.6%)  
Idiopathic Dilated CMP 129 (13.9%) 120 (18.6%) 2 (0.9%)  
Rheumatic heart disease 133 (14.3%) 75 (11.6%) 55 (24.0%)  
Ischemic heart disease 71 (7.6%) 57 (8.8%) 10 (4.4%)  
Peripartum cardiomyopathy 72 (7.8%) 59 (9.2%) 2 (0.9%)  
Pericardial effusion tamponade 45 (4.8%) 22 (3.4%) 23 (10.0%)  
HIV cardiomyopathy 22 (2.4%) 12 (1.9%) 8 (3.5%)  
Endomyocardial fibrosis 11 (1.2%) 2 (0.3%) 8 (3.5%)  
Other 66 (7.1%) 24 (3.7%) 35 (15.3%)  
ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; CMP, cardiomyopathy; eGFR, 
estimated glomerular filtration rate; LVEF, left ventricular ejection fraction 
 
Heart failure was most commonly due to hypertension (n=380 [40.9%]) followed by 
rheumatic valvular heart disease (n=133 [14.3%]) and idiopathic dilated cardiomyopathy 
(n=129 [13.9%]).  Ischemic heart failure was present in only 71 (7.6%) patients (Table 1).  
The distribution and proportion of missing values for each echocardiographic parameter 
are presented in Table 7.2.  LVEF was available for 897 patients and was missing for 
6.0% of patients. LVEF was < 50% in 654 (73%) patients and ≥ 50% in 243 (27%) 
patients.  Patients’ characteristics according to LVEF are presented in Table 7.1. Patients 
with HFrEF had higher proportions of males and peripheral oedema, and lower systolic 








Table 7.2 Distribution and proportion of missing values for each echocardiographic 
parameter 
Echocardiographic parameter N (% 
missing) 
Min, 25th, Median, 75th, Max for 
continuous 
 
n (%) for dichotomous 
Heart rate 753 (21.07%) 30.00, 84.00, 94.00, 104.00, 177.00 
LVEDD (mm) 946 (0.84%) 27.00, 50.00, 58.00, 65.00, 104.00 
LVESD (mm) 943 (1.15%) 14.00, 37.00, 47.00, 55.00, 95.00 
IVSd (mm) 927 (2.83%) 3.00, 9.00, 11.00, 13.00, 25.00 
PWTd (mm) 904 (5.24%) 3.00, 9.00, 10.15, 12.90, 22.00 
LV mass 902 (5.45%) 42.17, 186.79, 256.15, 335.05,  914.37 
LV Ejection Fraction (%) 897 (5.97%) 10.00, 26.90, 38.00, 50.00, 78.00 
Left Atrial size (A- P) (mm) 910 (4.61%) 21.80, 41.00, 47.00, 53.00, 87.00 
Left Atrial size (Planimetry) mm2 528 (44.65%) 526.00, 2200.00, 2620.00, 3260.00, 
6840.00 
E/A ratio 651 (31.76%) 0.08, 0.98, 1.64, 2.42, 37.88 
E wave deceleration time (ms) 758 (20.55%) 10.00, 100.00, 130.00, 171.00, 1212.00 
MV A-wave duration 535 (43.92%) 24.00, 100.00, 123.00, 150.00, 540.00 
Mitral Valve E/A ratio grades   
Grade 1: Impaired relaxation 784 (17.82%) 144 (18.37%) 
Grade 2: Pseudonormal 204 (26.02%) 
Grade 3: Restrictive Filling 436 (55.61%) 
Aortic Stenosis (moderate –severe) 930 (2.52%) 24 (2.58%) 
Aortic regurgitation (moderate –severe) 938 (1.68%) 83 (8.85%) 
Mitral Stenosis (moderate – severe) 920 (3.56%) 51 (5.54%) 
Mitral regurgitation (moderate – severe) 945 (0.94%) 366 (38.73%) 
Tricuspid regurgitation (moderate- 
severe) 
943 (1.15%) 266 (28.21%) 
LV – left ventricle; LVEDD – left ventricular end diastolic diameter; LVESD – left ventriculat 
end systolic diameter; IVSd – interventricular septum in diastole; PWTd – posterior wall 





Univariable associations between the echo predictors and the outcomes by diagnosis 
groups (hypertensive heart disease, valvular heart disease and other) suggest that none of 
the associations of echo parameters with outcomes differed significantly among the 






Table 7.3 Univariable associations between echo predictors and 60-day mortality or 































LVEDD (mm) 0.98 
(0.95, 
1.01) 
0.15 1.02 (0.99, 
1.05) 
0.29 1.01 (0.99, 
1.03) 
0.49 0.17 







0.47 1.00 (0.98, 
1.02) 
0.92 0.20 
IVSd (mm) 0.98 
(0.89, 
1.09) 
0.76 0.98 (0.88, 
1.10) 
0.77 0.93 (0.85, 
1.02) 
0.12 0.64 
PWTd (mm) 1.03 
(0.91, 
1.15) 
0.68 0.97 (0.85, 
1.10) 
0.59 0.93 (0.84, 
1.04) 
0.19 0.47 
LV mass 1.00 
(1.00, 
1.00) 
0.44 1.00 (1.00, 
1.00) 









0.16 0.99 (0.89, 
1.11) 
0.86 0.99 (0.91, 
1.08) 
0.82 0.42 





0.46 1.01 (0.98, 
1.05) 
0.57 1.00 (0.97, 
1.03) 
0.97 0.83 



















0.67 1.67 (0.75, 
3.75) 











0.65 1.00 (0.99, 
1.00) 















Mitral Valve E/A 
ratio grades 























-- 1.13 (0.49, 
2.58) 
 
IVSd, interventricular septal thickness in diastole; LV, left ventricle; LVEDD, left ventricular end 
diastolic diameter, LVESD, left ventricular end systolic diameter, PWTd, posterior wall thickness 
in diastole. Note: HRs are for an increment of 1 unit in the predictor unless otherwise noted. 









































LVEDD (mm) 0.98 (0.96, 
1.01) 
0.25 1.01 (0.98, 
1.04) 
0.47 1.02 (1.00, 
1.04) 
0.12 0.17 
LVESD (mm) 0.99 (0.96, 
1.01) 
0.28 1.01 (0.99, 
1.04) 
0.32 1.01 (0.99, 
1.03) 
0.19 0.20 
IVSd (mm) 0.95 (0.85, 
1.06) 
0.34 0.99 (0.89, 
1.09) 
0.80 0.91 (0.84, 
1.00) 
0.041 0.50 
PWTd (mm)        
     ≤ 9 mm 0.58 (0.42, 
0.80) 
0.0011 0.79 (0.57, 
1.10) 
0.32 0.82 (0.67, 
1.00) 
0.072 0.30 






LV mass 1.00 (0.99, 
1.00) 
0.097 1.00 (1.00, 
1.00) 
0.85 1.00 (1.00, 
1.00) 
0.62 0.36 
LV Ejection Fraction (%), 
per 5% increment 
1.00 (0.90, 
1.11) 
0.99 0.95 (0.85, 
1.06) 
0.36 0.93 (0.86, 
1.02) 
0.11 0.59 




1.03) 1.04) 1.02) 




0.70 1.00 (1.00, 
1.00) 
0.78 1.00 (1.00, 
1.00) 
0.34 0.72 
E/A ratio, per doubling 1.03 (0.74, 
1.43) 
0.89 2.07 (1.01, 
4.26) 
0.049 1.13 (0.86, 
1.49) 
0.38 0.21 




0.23 1.00 (1.00, 
1.00) 
0.42 1.00 (0.99, 
1.00) 
0.15 0.68 




0.63 1.01 (1.00, 
1.01) 
0.12 1.00 (0.99, 
1.01) 
0.47 0.26 
Mitral Valve E/A ratio 
grades 
       
























IVSd, interventricular septal thickness in diastole; LV, left ventricle; LVEDD, left ventricular end diastolic diameter, LVESD, left 
ventricular end systolic diameter, PWTd, posterior wall thickness in diastole. Note: HRs are for an increment of 1 unit in the predictor 







Univariable associations of echo predictors with 60-day death or readmission and with 
180-day death are shown in Tables 7.5 and 7.6, respectively. Heart rate and left atrial size 
were associated with death or readmission within 60 days. Heart rate, left ventricular 
posterior wall thickness, and presence of aortic stenosis were associated with the risk of 











Hazard Ratio  
(95% CI) 
p-value 
Heart rate, per increment 
of 5 
1.07 (1.02, 1.13) 0.0088 
LVEDD (mm) 1.00 (0.99, 1.02) 0.81 
LVESD (mm) 1.00 (0.98, 1.01) 0.63 
IVSd (mm) 0.96 (0.91, 1.01) 0.14 
PWTd (mm)  0.97 (0.91, 1.03) 0.34 
LV mass 1.00 (1.00, 1.00) 0.63 
LV Ejection Fraction (%), 
per 5% increment 
1.02 (0.96, 1.07) 0.58 
Left Atrial size (A- P) 
(mm) 
1.01 (0.99, 1.03) 0.57 
Left Atrial size 
(Planometry) mm2 
1.00 (1.00, 1.00) 0.030 
E/A ratio, per doubling 1.07 (0.86, 1.34) 0.53 
E wave deceleration time 
(ms) 
1.00 (0.99, 1.00) 0.13 
MV A-wave duration 1.00 (1.00, 1.01) 0.43 
Mitral Valve E/A ratio 
grades 
  
Grade 1: Impaired 
relaxation 
(reference group) 0.61 
Grade 2: Pseudo-normal 1.07 (0.55, 2.06) 
Grade 3: Restrictive 
Filling 




Aortic Stenosis   
     None, Mild (reference group) 0.69 
     Moderate 1.83 (0.45, 7.41) 
     Severe 0.90 (0.22, 3.65) 
Aortic regurgitation   
     None, Mild (reference group) 0.072 
     Moderate 1.20 (0.61, 2.36) 
     Severe 2.42 (1.13, 5.19) 
Mitral Stenosis   
     None, Mild (reference group) 0.50 
     Moderate 1.56 (0.58, 4.22) 
     Severe 0.64 (0.20, 2.00) 
Mitral regurgitation   
     None, Mild (reference group) 0.95 
     Moderate 0.95 (0.63, 1.41) 
     Severe 1.03 (0.60, 1.76) 
Tricuspid regurgitation   
     None, Mild (reference group) 0.23 
     Moderate 1.41 (0.94, 2.11) 
     Severe 1.21 (0.66, 2.21) 
IVSd, interventricular septal thickness in diastole; LV, left ventricle; LVEDD, left  
ventricular end diastolic diameter, LVESD, left ventricular end systolic diameter,  
PWTd, posterior wall thickness in diastole. Note: HRs are for an increment of 1  
















Hazard Ratio  
(95% CI) 
p-value 
Heart rate   
     ≤ 80 bpm, per change of 5 0.90 (0.76, 1.06) 0.0001 
     > 80 bpm, per change of 5 1.25 (1.03, 1.52)  
LVEDD (mm) 1.01 (0.99, 1.02) 0.39 
LVESD (mm) 1.01 (0.99, 1.02) 0.38 
IVSd (mm) 0.94 (0.89, 0.99) 0.025 
PWTd (mm)   
     ≤ 9 mm 0.77 (0.67, 0.89) 0.0009 
     > 9 mm 1.32 (1.08, 1.61)  
LV mass 1.00 (1.00, 1.00) 0.22 
LV Ejection Fraction (%), per 
5% increment 
0.96 (0.91, 1.01) 0.12 
Left Atrial size (A- P) (mm) 1.00 (0.98, 1.01) 0.64 
Left Atrial size (Planimetry) 
mm2 
1.00 (1.00, 1.00) 0.50 
E/A ratio, per doubling 1.13 (0.92, 1.39) 0.23 
E wave deceleration time (ms) 1.00 (0.99, 1.00) 0.070 
MV A-wave duration 1.00 (1.00, 1.01) 061 
Mitral Valve E/A ratio grades   
Grade 1: Impaired 
relaxation 
(reference group) 0.19 
Grade 2: Pseudonormal 1.77 (0.92, 3.38) 
Grade 3: Restrictive Filling 1.67 (0.92, 3.03) 




     None, Mild (reference group) 0.039 
     Moderate 3.60 (1.33, 9.74)  
     Severe 0.83 (0.21, 3.36) 
Aortic regurgitation   
     None, Mild (reference group) 0.096 
     Moderate 0.93 (0.46, 1.90)  
     Severe 2.30 (1.07, 4.92) 
Mitral Stenosis   
     None, Mild (reference group) 0.89 
     Moderate 0.99 (0.31, 3.10)  
     Severe 0.79 (0.29, 2.12) 
Mitral regurgitation   
     None, Mild (reference group) 0.87 
     Moderate 0.92 (0.62, 1.34)  
     Severe 1.05 (0.63, 1.74) 
Tricuspid regurgitation   
     None, Mild (reference group) 0.53 
     Moderate 1.26 (0.85, 1.86)  
     Severe 1.04 (0.57, 1.89) 
 
IVSd, interventricular septal thickness in diastole; LV, left ventricle; LVEDD, left  
ventricular end diastolic diameter, LVESD, left ventricular end systolic  
diameter, PWTd, posterior wall thickness in diastole. Notes. HRs are for an  
increment of 1 unit in the predictor unless otherwise noted 
 
 
The multivariable models suggest LVESD, IVSd, PWTd, left atrial size, E/A ratio do not 
add significantly to prediction of 60-day death or readmission, while left ventricular 
posterior wall thickness added to clinical variables in the prediction of 180-day mortality 






Table 7.7 Univariable and multivariable Cox regression models for 60-mortality or readmission 
Predictors  Univariable Models Multivariable Model Reduced Multivariable Model 













95% CI p-value 
Baseline 
predictors 
          




<.0001 5.16 (2.23, 
11.92) 







2.60 (1.61, 4.19) <.0001 1.88 (1.11, 
3.17) 
0.018 1.99 (1.21, 3.25) 0.0064 
log2BUN Doubling 1.44 (1.22, 1.71) <.0001 1.49 (1.23, 
1.79) 
<.0001 1.47 (1.23, 1.77) <.0001 
Systolic BP 10 0.92 (0.87, 0.97) 0.0035 0.92 (0.87, 
0.98) 
0.0083 0.91 (0.87, 0.97) 0.0019 
Rales (2/3 vs. 
0/1) 
2.43 (1.55, 3.80) 0.0001 2.40 (1.49, 
3.89) 
0.0004 2.39 (1.48, 3.86) 0.0004 
Region (South vs. 
West) 
1.26 (0.85, 1.88) 0.012 1.73 (1.13, 
2.67) 
0.0052 1.71 (1.11, 2.61) 0.0040 




Region (East vs. 
West) 
0.56 (0.35, 0.91) 0.73 (0.43, 
1.23) 
0.70 (0.42, 1.15) 
Echo predictors           
LVESD, mm 1 1.00 (0.98, 1.01) 0.58 0.99 (0.97, 
1.00) 
0.17    
IVSd, mm 1 0.96 (0.91, 1.01) 0.13 0.98 (0.89, 
1.08) 
0.66    
PWTd, mm 1 0.97 (0.91, 1.03) 0.28 0.99 (0.89, 
1.10) 
0.89    
Left Atrial Size 
(A-P), mm 
1 1.00 (0.99, 1.02) 0.62 1.01 (0.99, 
1.03) 
0.49    
E/A ratio Doubling 1.07 (0.86, 1.34) 0.51 1.06 (0.84, 
1.33) 
0.64    
E wave deceler. 
time, ms 
1 1.00 (1.00, 1.00) 0.29 1.00 (1.00, 
1.00) 
0.50    
 BP, blood pressure; BUN, blood urea nitrogen; Hx, history, IVSd, interventricular septal thickness in diastole; LV, left ventricle; LVEDD, left 






Table 7.8 Univariable and multivariable Cox regression models for 180 mortality 
Predictors  Univariable Models Multivariable Model Reduced Multivariable Model 












95% CI p-value 
Baseline 
predictors 
          




0.0013 3.65 (1.47, 
9.06) 







0.0042 1.89 (1.10, 
3.23) 
0.021 2.06 (1.24, 3.43) 0.0057 
Hemoglobin 1 0.89 (0.84, 
0.96) 
0.0011 0.93 (0.86, 
1.00) 
0.038 0.92 (0.86, 0.99) 0.029 




0.0004 1.45 (1.19, 
1.77) 
0.0006 1.43 (1.18, 1.74) 0.0009 
Systolic BP 10 0.87 (0.82, 
0.92) 
<.0001 0.86 (0.81, 
0.92) 







<.0001 1.83 (1.15, 
2.90) 
0.011 1.75 (1.11, 2.76) 0.015 




0.0001 1.89 (1.20, 
2.97) 
0.0059 1.85 (1.18, 2.91) 0.0074 




LVESD, mm 1 1.01 (0.99, 
1.02) 
0.38 0.99 (0.98, 
1.01) 
0.39    
IVSd, mm 1 0.94 (0.89, 
0.99) 
0.025 1.01 (0.93, 
1.11) 
0.74    
PWTd, mm           
≤ 9 1 0.78 (0.67, 
0.90) 
0.0008 0.77 (0.64, 
0.92) 
0.0039 0.79 (0.68, 0.91) 0.0019 
> 9 1 1.01 (0.93, 
1.10) 
0.82 1.05 (0.93, 
1.18) 
0.44 1.06 (0.97, 1.16) 0.17 
Left Atrial Size 
(A-P), mm 
1 1.00 (0.98, 
1.01) 
0.69 0.99 (0.97, 
1.01) 
0.56    
E/A ratio Doubling 1.07 (0.89, 
1.27) 
0.48 1.08 (0.89, 
1.32) 




1 1.00 (1.00, 
1.00) 
0.15 1.00 (1.00, 
1.00) 
0.86    
* Creatinine was modeled as a quadratic polynomial.  BP, blood pressure; Hx, history, IVSd, interventricular septal thickness in diastole;  LVESD, 






A thorough and complete echocardiographic examination has been shown to be a useful 
diagnostic test in the evaluation of patients with HF.491Although it is widely used to 
evaluate cardiac structure and function in patients with HF, few data are available 
regarding its ability to predict outcomes. 492 In the case of acute HF, the precise 
association of LVEF with cardiovascular outcomes in patients with acute decompensated 
HF is controversial. 112 Because the LVEF measure is load-dependent and varies with 
hemodynamic status, it may underestimate or overestimate true myocardial function in 
various pathophysiologic conditions and precipitants of acute decompensation. A 
prospective study reported that LVEF was weakly correlated with hemodynamic 
measures and clinical outcomes in patients with acute HF.493 
Various therapeutic interventions can reduce the risk of readmissions and death in 
patients admitted with HF. Therefore, identification of patients at the highest risk of 
readmission or death could help provide targeted cost-effective interventions. Although 
several studies have assessed potential echocardiographic predictors, the results have 
been inconsistent. 494,495 A large number of variables can be measured or calculated by 
echocardiographic and Doppler imaging. Thus, it is not clear which echocardiographic 
measurements provide independent prognostic information.  
In the current study, echocardiographic parameters showed only limited associations 
between echocardiographic measures and outcomes. Heart rate (which can be obtained by 
simple physical examination) and left atrial size were associated with death or 




aortic stenosis were associated with the risk of death through 180 days. In agreement with 
the results of the PROTECT study modeling, 488 LVEF was not associated with 60-day 
death or readmission or with 180 day mortality. This finding contrasts data from the 
ESCAPE study, where echocardiographic measures of LV size and function did change 
from baseline to follow up and were associated with some outcomes. 496  However, the 
ESCAPE study enrolled patients with end stage cardiomyopathy who had very significant 
LV dysfunction at baseline. These patients are different from the majority of acute HF 
patients, particularly those enrolled in the THESUS registry. The results of the current 
study confirming the preliminary findings of Gandhi et al487 and the retrospective 
analysis of PROTECT study488 raised the question of why in the general population of 
patients admitted for acute HF, echocardiographic measures of left ventricular function 
and size are not associated with outcomes. This puzzling finding suggests that the 
pathophysiology of acute HF may differ from that of chronic HF by being less dependent 
on systolic function and, as suggested by Gandhi et al, 487 more driven by factors that 
cause cardiac and vascular stiffening manifesting as diastolic dysfunction  
Left ventricular hypertrophy (LVH) is a recognized complication of systemic 
hypertension and the best-studied marker of hypertensive heart disease. 497 LVH strongly 
predicts cardiovascular morbidity and mortality in hypertensive patients, and is an 
independent risk factor for overall cardiovascular mortality and morbidity. 498 It is known 
to cause a reduction in myocardial coronary reserve, which predisposes to myocardial 
ischaemia and left ventricular dysfunction, thereby causing increased incidence of 
coronary heart disease among hypertensives. 499 This finding should encourage increased 




throughout the world, to prevent the progression of hypertension to LVH. The increased 
risk of patients with severe valvular heart disease, particularly aortic stenosis, is well 
documented; 500 the confirmation in the current study of the increased risk of these 
patients when admitted for acute HF is important, adding to the evidence encouraging a 
low threshold for evaluation and treatment of patients with suspected aortic stenosis.   
Left atrial enlargement has been increasingly suggested in recent years to be an important 
indicator of increased risk for an adverse clinical outcome. Left atrial enlargement may 
serve as an indicator for persistent increased pressure within the cardiovascular system, 
possibly representing longer term changes, such as the role of HbA1c in diabetes 
mellitus. Furthermore, the left atrium modulates left ventricular filling and cardiovascular 
performance by functioning as a reservoir for pulmonary venous return during ventricular 
systole, a conduit for pulmonary venous return during early ventricular diastole, and a 
booster pump that augments ventricular filling during late ventricular diastole. Therefore, 
left atrial enlargement (and possibly associated dysfunction) may play an important role 
not only in the marking of cardiovascular dysfunction but also in its enhancement. The 
finding that left atrial size is associated with adverse outcomes begs the question of why 
measures of diastolic dysfunction were not predictive of such adverse outcomes in the 
current cohort. Although the reasons for that cannot be ascertained given the limitations 
of the study (see below), it is possible that as described by Gandhi et al487 measures of 
diastolic dysfunction improve rapidly after admission in patients with acute HF. Because 
the echocardiographic evaluations performed in the current study were not done close to 
the time of admission in many patients, the worst measures may have been missed. It is 




contributed to this lack of association. 
Increased resting heart rate is a known predictor for cardiovascular mortality and 
morbidity in a variety of cardiovascular diseases, including heart failure. 501 In patients 
with reduced LVEF, with or without signs or symptoms of HF, high heart rate has 
predicted adverse outcomes, irrespective of other known risk factors. 502 Several 
pathophysiologic mechanisms, including blunting of the force-frequency relationship, the 
induction of myocardial ischemia, precipitation of rhythm disturbances, and acceleration 
of atherosclerosis have been proposed to explain the association between higher heart rate 
and worse outcomes in patients with HF. 501 Higher heart rate might also be a marker of 
greater neurohormonal activation.  The SHIFT study showed that heart rate is important 
in the pathophysiology of HF with reduced LVEF, and that heart rate reduction per se is a 
mechanism responsible for improvement of clinical outcomes. 503 The CHARM 
investigators also found that the value of resting heart rate in predicting worse outcomes 
was independent of baseline left ventricular systolic function in heart failure. 504 A higher 
heart rate was associated with a greater risk of HF hospital stay, both in patients with 
reduced and preserved LVEF in a post hoc analysis of the DIG (Digitalis Investigation 
Group) trial. In predicting mortality, however, higher heart rate was only significant in 
patients with a reduced LVEF.505 
Similar to our findings, left atrial size or its surrogates have been shown to predict HF 
hospitalization and death in other studies. 506 Left atrial size predicts death among high-
risk groups, such as patients with dilated cardiomyopathy, LV dysfunction, atrial 
arrhythmias, acute myocardial infarction as well as in in the general population.507 




predicting outcome in our cohort. This may suggest that early diagnosis and treatment of 
hypertension and valvular heart disease in Sub Saharan Africa should be emphasized to 
improve outcome.  
Our data should be interpreted in the context of their limitations. Unobserved variables 
may have confounded the results. Not all echocardiographic parameters were available in 
all patients, limiting the number of parameters for analysis. The variable timing of the 
echocardiogram, and inter-observer variability may have affected the specific results 
obtained. Furthermore, the number of events was small. Thus, both the variable selection 
and the parameter estimates for the selected variables are subject to instability. We also 
looked at echo predictors of acute heart failure from various causes. Even though, there is 
no statistically significant interaction between the echo variables, different conditions and 
outcomes, there could still be dilutional effect of grouping heterogeneous conditions 
together. Finally, our results are drawn from a population of young acute HF patients 
predominantly with systolic dysfunction. Consequently, these findings may not apply to 
older patients or to those with preserved LVEF. 
 
7.5 Conclusions 
In accordance with previous studies, echocardiographic variables, especially those of left 
ventricular size and function, were found to have little or no additional predictive value in 
patients admitted for acute HF. Left atrial size was associated with death or readmission 
within 60 days while left ventricular posterior wall thickness, and presence of aortic 
stenosis were associated with the risk of death through 180 days. There is need for further 





































8 Chapter 8: Renal Dysfunction in African patients with 
acute heart failure 
8.1 Introduction 
Studies from Europe and North America have shown that more than half of the patients 
hospitalized for heart failure have some degree of impairment of renal function, and 
moderate to severe impairment has been reported in 30–35% of cases .508 
An association between impaired renal function and unfavorable outcomes has also been 
reported in HF patients. 358  In addition hospitalization for acute heart failure is also 
associated with further WRF in 30–50% of patients. 116,509  
Patients with WRF have been shown to have longer lengths of stay, higher in-hospital 
costs, increased in-hospital mortality, and greater likelihood of readmission. 358  
In this chapter, we describe the prevalence, predictors and clinical outcome of renal 
dysfunction in younger, mainly hypertensive AHF patients in sub-Saharan Africa 
enrolled in the THESUS-HF registry. 
We found one third of the patients had renal dysfunction on admission in this cohort. 
WRF during hospitalization was detected in 53 (9.8 %) of 543 patients with a follow-up 
creatinine value, and was independently associated with the Western sub-Saharan region, 
body mass index, and the presence of rales. WRF was an independent predictor of death 







This chapter in presented as a published research paper in the European Journal of Heart 
Failure. 
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Aims In Western countries with typically elderly ischaemic acute heart failure patients, predictors and clinical outcome of
renal dysfunction and worsening renal function are well described. However, the prevalence, predictors and clinical
outcome of renal dysfunction in younger, mainly hypertensive acute heart failure patients from Africa, have not been
described.
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Methods
and results
From 1006 patients enrolled in the sub-Saharan Africa Survey of Heart Failure (THESUS-HF), renal function was
determined by the estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD)
formula. Worsening renal function was defined as an increase in creatinine ≤0.3 mg/dL (26.5 μmol/L) from baseline
to day 7/discharge. The mean (SD) age of the patients was 52.4 (18.2) years, 481 (50.8%) were women and the
predominant race was black African [932 of 946 (98.5%)]. Heart failure was most commonly a result of hypertension
(n= 363, 39.5%) and only 7.8% had ischaemic heart failure. At hospital admission, 289 patients (30.6%) had an
estimated glomerular filtration rate ≤60 ml/min.1.73m2. Worsening renal function during hospitalization was detected
in 53 (9.8 %) of 543 patients with a follow-up creatinine value, and was independently associated with the Western
sub-Saharan region, body mass index, and the presence of rales. Worsening renal function was an independent
predictor of death or readmission over 60 days [multivariable hazard ratio= 2.06 (1.10, 3.38); P= 0.023] and all-cause
death over 180 days [multivariable hazard ratio=1.92 (1.08, 3.38); P= 0.025].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions Renal dysfunction is also prevalent in younger non-ischaemic acute heart failure patients in Africa, but worsening renal
function is less prevalent and has different predictors compared with Western cohorts. Nevertheless, worsening renal
function is strongly and independently related with clinical outcome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Heart failure is generally considered a typical disease of Western
countries. However, recent data clearly indicate that heart failure
is also an important health-care problem in Africa, where it is
estimated to contribute about 3–7% of all medical admissions.1,2
The causes of heart failure in Africa are different from those outside










. of Africa. The recent sub-Saharan Africa Survey of Heart Failure
(THESUS-HF) registry3 showed that in sub-Saharan Africa the
disease affects men and women in the most productive years of life,
at an average age of 52 years and is mostly caused by hypertension
and not ischaemic heart disease, as is seen in Western countries.4
Other studies have confirmed that hypertension accounts for more
than half of cases, followed by cardiomyopathies and rheumatic
© 2014 The Authors
European Journal of Heart Failure © 2014 European Society of Cardiology
2 M. U. Sani et al.
heart disease.5 In a recent study from Abuja, Nigeria, hypertension
was the cause of heart failure in 64% of patients.6 In addition,
the patients mostly present in late stages of heart failure [New
York Heart Association (NYHA) class III and class IV], which
may significantly worsen prognosis and increase morbidity and
mortality.
Studies from Europe and North America have shown that
more than half of the patients hospitalized for heart failure have
some degree of impairment of renal function, and moderate to
severe impairment has been reported in 30–35% of cases.7–10
Hospitalization for acute heart failure is also associated with
further worsening renal function (WRF) in 30–50% of patients,
depending on the definition used.8,9 Typical predictors of WRF
in these patients are baseline chronic kidney disease, history of
hypertension and diabetes, age, and use of diuretics.11
However, the prevalence, predictors and clinical outcome of
renal dysfunction in younger, mainly hypertensive acute heart
failure (AHF) patients in sub-Saharan African are not known.
We therefore studied renal dysfunction at admission and WRF,
the association between WRF and 180-day mortality, and 60-day
death/readmission in a cohort of 1006 African patients admitted
with AHF and enrolled in the THESUS-HF registry.
Methods
THESUS-HF3 was a prospective, multicentre, international observa-
tional survey conducted in 12 hospitals from nine countries in the
southern, eastern, central, and western regions of sub-Saharan Africa.
All patients were recruited during an admission for AHF, mostly in
Nigeria, Uganda, and South Africa. Methods and results have been
described in detail previously.3 In brief, from July 2007 to June 2010
patients admitted with dyspnoea and diagnosed with AHF based on
symptoms and signs (including dyspnoea, orthopnoea, dyspnoea on
exercise, rales, oedema, jugular venous pulse, and oxygen saturation),
and who provided written informed consent, were enrolled into the
study. The diagnosis was supported by echocardiographic findings and
was confirmed by a cardiologist. Approval was obtained from the ethics
committee of each participating institution and the study conformed to
the principles of the Declaration of Helsinki.
Detailed data collected on standardized case report forms at
admission included medical history, medication use, laboratory val-
ues, and physical examination with symptoms and signs of heart fail-
ure. Echocardiography and electrocardiography were also performed.
Human immunodeficiency virus testing was performed as clinically
indicated. Patients were followed either by clinic visit or telephone
contact over 6 months for the occurrence of readmissions and death.
As described in the main report, patients were classified as hav-
ing either an emerging or endemic cause of heart failure. Endemic
causes included rheumatic heart disease, cardiomyopathies, and infec-
tive causes, while emerging causes included hypertension and ischaemic
heart disease.
Renal function and worsening renal
function
Patients presenting with heart failure are routinely checked for renal
dysfunction at presentation. More detailed investigations and follow



















































































.. resources. The estimated glomerular filtration rate (eGFR) was calcu-
lated using the simplified Modification of Diet in Renal Disease (MDRD)
formula (186.3× (serum creatinine (mg/dl))–1.154 × age–0.203 × (0.742
if female)× (1.212 if black African) (mL/min.1.73 m2).12,13 Worsen-
ing renal function was defined as an absolute increase in creatinine≥0.3 mg/dL (26.5 μmol/l)14,15 from baseline to the earlier of day 7 or
hospital discharge.
The relation between clinical variables, renal function and worsening
renal function was evaluated. Finally, we examined clinical outcomes of
patients with worsening renal function and its prognostic significance.
Statistical methods
Means± standard deviations (SD) are presented for continuous vari-
ables, and absolute and relative frequencies for categorical variables.
Differences in continuous variables between groups were compared
using two-sample t-tests, or one-way ANOVA tests where there were
more than two groups. Categorical variables were compared using
chi-square tests or Fisher’s exact tests where at least one group had
an absolute frequency <5. To evaluate the predictors of WRF, we
first examined the univariable associations between each covariate and
WRF. Patients with baseline and follow-up creatinine values at day 7
(or discharge) were included in this analysis. The linearity of associa-
tion between each continuously distributed predictor and WRF was
assessed using restricted cubic splines (RCS) with four ‘knots’ with a
test of the significance of the non-linear terms. Where the associa-
tion was non-linear, a readily interpretable transformation was chosen
through examination of plots of the predicted log hazard ratio against
the value of the predictor and changes in Akaike’s Information Crite-
rion (AIC). The only non-linear predictor was body mass index (BMI).
A linear spline was chosen with a single knot at 18.5 kg/m2 (the lower
cut-off for a normal BMI).
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for
analyses. Multiple imputations were used with a method that assumes
multivariate normality (SAS PROC MI) to handle missing values. The
imputation model included all covariates under consideration for the
multivariable models. The ranges of imputed values were restricted
to the ranges of the observed values. Seven imputation datasets
were used. Parameter estimates were averaged across these datasets
using Rubin’s algorithm (SAS PROC MIANALYZE). With only 53
WRF events, the number of predictors that could be entered into a
multivariable model was limited. We selected predictors that had a
strong univariable association with WRF and used backwards selection
in each of the seven imputation datasets, with the criterion for staying
P< 0.10. Predictors that were significant in the majority of the imputed
datasets were kept in the final model.
We assessed the associations between WRF and clinical outcomes
using a two-sided two-sample t-tests for length of initial hospital stay
and a log-rank test for time-to-event outcomes. The associations
between WRF and 60-day death or readmission and 180-day mor-
tality were then assessed after adjusting for predictors known to be
associated with each outcome in this study population (no backwards
selection was done here).16
Results
There were a total of 1006 patients in the THESUS-HF registry.
Serum creatinine on admission was available in 964 (96%) of
the 1006 patients. The mean (SD) age of the patients was 52.4
© 2014 The Authors
European Journal of Heart Failure © 2014 European Society of Cardiology
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Table 2 Baseline characteristics of patients with and without a follow-up creatinine value





but no FU, N= 441
P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .





Male sex, n (%) 264 (48.6%) 218 (49.5%) 0.77
Black Africans, n (%) 532 (98.0%) 430 (99.1%) 0.20
Hypertension, n (%) 286 (52.8%) 257 (58.7%) 0.0643
Hyperlipidaemia, n (%) 49 (9.2%) 41 (9.7%) 0.789
History of smoking, n (%) 53 (9.8%) 44 (10.0%) 0.91
Malignancy, n (%) 3 (0.6%) 9 (2.1%) 0.034
History of cor pulmonale 38 (7.1%) 30 (6.8%) 0.88
Diabetes, n (%) 64 (11.8%) 50 (11.4%) 0.83
Peripheral oedema, n (%) 371 (69.0%) 279 (64.7%) 0.16
Rales, n (%) 340 (70.7%) 210 (55.3%) <0.0001

























LVEF <40%, n (%) 289 (32.5%) 182 (20.5%) 0.006






























Medication use (1-month before)
ACE inhibitor, n (%) 89 (37.2%) 95 (28.2%) 0.022
Loop diuretics, n (%) 103 (43.6%) 120 (36.4%) 0.081
Beta blockers, n (%) 44 (18.6%) 56 (17.2%) 0.68
Digoxin, n (%) 48 (20.1%) 58 (17.7%) 0.47
Hydralazine, n (%) 3 (1.3%) 0 (0.0%) 0.074
Nitrates, n (%) 8 (3.4%) 2 (0.6%) 0.021
Aldosterone inhibitor, n (%) 57 (24.2%) 51 (15.5%) 0.0099
Statins, n (%) 21 (8.9%) 7 (2.2%) 0.0003
Aspirin, n (%) 71 (29.8%) 55 (16.7%) 0.0002
Anticoagulants, n (%) 24 (10.1%) 11 (3.4%) 0.0011
Aetiology of heart failure
Endomyocardial fibroelastosis 9 (1.7%) 4 (0.9%)
HIV CMP 10 (1.9%) 13 (3.0%)
Hypertensive CMP 201 (37.9%) 184 (43.0%)
Idiopathic dilated CMP 81 (15.3%) 55 (12.9%)
Ischemic heart disease 37 (7.0%) 40 (9.4%)
Pericardial effusion /tamponade 31 (5.9%) 14 (3.3%)
Peripartum CMP 46 (8.7%) 26 (6.1%)
Rheumatic heart disease 79 (14.9%) 59 (13.8%)
Other 36 (6.8%) 33 (7.7%)
© 2014 The Authors
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Table 2 Continued





but no FU, N= 441
P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Region
East 99 (70.7%) 168 (38.1%) <0.0001
South 143 (26.3%) 64 (14.5%)
West 301 (55.4%) 209 (47.4%)
Country
Cameroon 10 (1.8%) 77 (17.5%)
Ethiopia 9 (1.7%) 1 (0.2%)
Kenya 17 (3.1%) 15 (3.4%)
Mozambique 72 (13.3%) 4 (0.9%)
Nigeria 285 (52.5%) 125 (28.3%)
Senegal 6 (1.1%) 7 (1.6%)
South Africa 71 (13.1%) 60 (13.6%)
Sudan 68 (12.5%) 4 (0.9%)
Uganda 5 (0.9%) 148 (33.6%)
BL, baseline; FU, follow up; BMI, body mass index; SBP, systolic blood pressure, DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; BUN, blood urea nitrogen;
eGFR, estimated glomerular filtration rate; CMP, cardiomyopathy; HIV, human immunodeficiency virus.
*P-value is from two-sided t-tests for continuous variables, or chi-square tests for categorical variables (Fisher’s exact if at least one cell count is <5).
Table 3 Clinical outcomes in patients with and without a follow-up creatinine value
Patients with BL and FU
creatinine, N= 523
Patients with BL creatinine,
but no FU. N= 441
P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Length of initial hospital stay (days),






Initial hospitalization mortality, n (%) 22 (15.1%) 15 (5.8%) 0.91
Rehospitalization to day 60, n (%) 45 (10.4%) 23 (6.6%) 0.070
Death to day 60, n (%) 50 (10.6%) 36 (9.3%) 0.66
Death of readmission to day 60, n (%) 77 (16.5%) 47 (12.3%) 0.13
Death to day 180, n (%) 90 (20.4%) 50 (13.5%) 0.029
BL, baseline; FU, follow up.
*P-value is from two-sided t-test for length of stay (LOS), log-rank test for time to event outcomes. %’s represent Kaplan-Meier event rates for time to event outcomes.
(18.2) years, 481 (50.8%) were women, and the predominant race
was black African (98.5%).3
The comorbid conditions present were 11.5% of patients
with diabetes, 18.8% with atrial fibrillation, 9.2% with hyperlip-
idaemia and 15.2% with anaemia. Left ventricular ejection frac-
tion (LVEF) was 39.2± 16.3%, with 465 (53.0%) of patients with
an LVEF of less than 40%. The initial systolic blood pressure was
129.7± 33.2 mmHg and heart rate was 103.6± 21.7 bpm.
Heart failure was most commonly caused by hypertension
(n= 363, 39.5%) followed by idiopathic dilated cardiomyopathy
(n= 136, 14.8%) and rheumatic valvular heart disease (n=137,
14.9%). Ischaemic heart failure was present in only 72 (7.8%) of
the patients.
Mean creatinine at admission was 123.0± 93.43 μmol/L [median
99.0 μmol/L, interquartile range (IQR) 78.0–132.6 μmol/L] and


























.. Table 1 shows the patients characteristic according to the
eGFR. They were categorized as follows: eGFR ≤ 30 mL/
min.1.73m2, 30–≤60 mL/min.1.73m2, 60–≤90 mL/min.1.73m2
and >90 mL/min.1.73m2. Patients with a lower eGFR (≤60 ml/
min.1.73m2; n= 289, 30.6%) were significantly older and had more
hypertension, diabetes, and hyperlipidaemia. They also showed
more evidence of congestion (rales and peripheral oedema), and
had higher body mass indices. Laboratory results showed that
they had higher creatinine and blood urea nitrogen and lower
haemoglobin levels.
Five hundred and forty-three (53%) patients had baseline and
follow-up creatinine. This group was significantly younger, had
more evidence of congestion (rales), a higher heart rate, and
lower eGFR, LVEF, and haemoglobin levels compared with those
with only a baseline value. They were also more likely to
receive renin–angiotensin aldosterone system inhibition (n= 453;
Table 2).
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Table 4 Characteristics of patients with and without worsening renal function (WRF)
Patient characteristics WRF, N= 53 no WRF, N= 470 Total, N= 523 P-value*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, mean± SD median








Male sex, n (%) 30 (56.6%) 223 (47.5%) 253 (48.4%) 0.21
Black Africans, n (%) 52 (98.1%) 461 (98.1%) 513 (98.1%) 1.00
Hypertension, n (%) 30 (56.6%) 239 (51.0%) 269 (51.5%) 0.44
Hyperlipidaemia, n (%) 4 (7.8%) 44 (9.5%) 48 (9.3%) 1.0
History of smoking, n (%) 4 (7.5%) 46 (9.8%) 50 (9.6%) 0.81
Malignancy, n (%) 0 (0.0%) 3 (0.6%) 3 (0.6%) 1.0
History of cor pulmonale, n (%) 6 (11.3%) 31 (6.7%) 37 (7.2%) 0.22
History of atrial fibrillation, n (%) 6 (11.3%) 86 (18.4%) 92 (17.7%) 0.20
Diabetes mellitus, n (%) 6 (11.3%) 56 (11.9%) 62 (11.9%) 0.90
Peripheral oedema, n (%) 43 (81.1%) 312 (67.1%) 355 (68.5%) 0.037
Rales, n (%) 43 (91.5%) 281 (67.7%) 324 (70.1% ) <.0001
Body mass index, kg/m2, mean± SD, median








Systolic blood pressure, mmHg, mean± SD,








Diastolic blood pressure, mmHg, mean± SD,
























LVEF % <40, n (%) 27 (5.3%) 262 (51.6%) 289 (56.9%) 0.45
Creatinine level, μmol/L, mean± SD, median

















Sodium level, mmol/L, mean± SD, median








eGFR, ml/min.1.73m2, mean± SD, median


























Previous medication use, n (%)
ACE inhibitor 9 (37.5%) 77 (36.7%) 86 (36.8%) 0.94
Loop diuretics 13 (54.2%) 87 (42.0%) 100 (43.3%) 0.26
𝛽-Blockers 4 (16.7%) 37 (17.8%) 41 (17.7%) 1.0
Digoxin 6 (25.0%) 40 (19.0%) 46 (19.7%) 0.49
Hydralazine 0 (0.0%) 3 (1.4%) 3 (1.3%) 1.0
Nitrates 0 (0.0%) 8 (3.8%) 8 (3.5%) 1.0
Aldosterone Inhibitor 6 (25.0%) 49 (23.8%) 55 (23.9%) 0.90
Statins 2 (8.7%) 18 (8.6%) 20 (8.6%) 1.0
Aspirin 7 (29.2%) 62 (29.7%) 69 (29.6%) 0.96
Anticoagulants 2 (8.3%) 22 (10.6%) 24 (10.4%) 1.0
Aetiology heart failure
Hypertensive CMP, n (%) 21 (41.2%) 167 (36.4%) 188 (36.0%)
Idiopathic dilated CMP, n (%) 9 (17.7%) 72 (15.7%) 81 (15.5%)
Rheumatic heart disease, n (%) 8 (15.7%) 71 (15.5%) 79 (15.1%)
Ischaemic heart disease, n (%) 3 (5.9%) 32 (7.0%) 35 (6.7%)
Peripartum cardiomyopathy, n (%) 3 (5.9%) 43 (9.4%) 46 (8.8%)
Pericardial effusion tamponade, n (%) 3 (5.9%) 25 (5.5%) 28 (5.4%)
HIV cardiomyopathy, n (%) 2 (3.9%) 8 (1.7%) 10 (1.9%)
Endomyocardial fibrosis, n (%) 0 (0.0%) 9 (2.0%) 9 (1.7%)
Other, n (%) 2 (3.9%) 32 (7.0%) 34 (6.1%)
Region
East 5 (9.4%) 93 (19.8%) 98 (18.7%) 0.048
South 11 (20.8%) 129 (27.5%) 140 (26.8%)
West 37 (69.8%) 248 (52.8%) 285 (54.5%)
ACE, angiotensin converting enzyme; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; LVEF, left ventricular ejection fraction.
*P-value for categorical variables from chi-square test or Fisher’s exact test if at least one cell count <5 P-value for continuous variables from ANOVA.
© 2014 The Authors
European Journal of Heart Failure © 2014 European Society of Cardiology
8 M. U. Sani et al.
Table 5 Predictors of worsening renal function
Predictor Unit increase Univariable models Multivariable model
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OR (95% CI) P-value OR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline Creatinine, μmol/L 88.4 0.95 (0.69, 1.31) 0.7720 0.77 (0.53, 1.11) 0.16
History of cor pulmonale Yes vs. No 1.73 (0.68, 4.41) 0.2497
Male sex Male vs. Female 1.45 (0.82, 2.56) 0.2079 1.81 (0.97, 3.39) 0.062
BMI, ≤18.5 kg/m2 5 0.10 (0.02, 0.42) 0.0018 0.06 (0.01, 0.29) 0.0005
BMI, >18.5 kg/m2 5 1.58 (1.27, 1.98) <0.0001 1.78 (1.39, 2.28) <0.0001
History of atrial fibrillation Yes vs. No 0.57 (0.23, 1.36) 0.2050
Systolic blood pressure,, mmHg 10 1.07 (0.99, 1.16) 0.0908
Peripheral oedema 2/3 vs. 0/1 2.13 (1.04, 4.38) 0.0395
Rales 2/3 vs. 0/1 3.50 (1.48, 8.28) 0.0043 3.56 (1.38, 9.17) 0.0088
Region South vs. West 0.57 (0.28, 1.16) 0.0559 0.60 (0.27, 1.35) 0.060
East vs. West 0.36 (0.14, 0.94) 0.31 (0.11, 0.87)
BMI, body mass index; CI, confidence interval; OR, odds ratio.
Patients with a follow-up creatinine value also had a longer length
of stay, and had a higher rate of readmission and death (Table 3). In
particular, a higher proportion of patients with follow-up creatinine
values than without follow-up creatinine values died in-hospital (22
or 15.1% versus 15 or 5.8%).
Worsening renal function was evident in 53 (9.8%) patients
with follow-up creatinine values available. The characteristics of
patients with and without WRF are shown in Table 4. Patients
with WRF were essentially similar to those without WRF in their
characteristics, except that they had more evidence of congestion
(peripheral oedema and rales).
Univariable and multivariable predictors of worsening renal
function are presented in Table 5. Upon multivariable adjustment,
significant predictors of WRF were BMI, the presence of rales, and
geographic region. The risk of WRF decreased with increasing BMI
until approximately 18.5 kg/m2, above which the risk increased with
increasing BMI.
Clinical outcomes by the occurrence of WRF are shown in
Table 6. Those with WRF had a similar length of hospital stay
as those without WRF, but a higher rate of 60-day mortality or
readmission and a higher 180-day mortality rate. Figure 1 is a
Kaplan–Meier plot of cumulative incidence of death by worsening
renal function to day 180.
Univariable and multivariable models predicting clinical outcome
are presented in the Supporting Information Tables S1 and S2. After
multivariable adjustment for other prognostic factors, worsening
renal function was an independent predictor of death or readmis-
sion over 60 days [adjusted hazard ratio (HR)= 2.06 (1.10, 3.82);
P= 0.023] and all-cause death over 180 days [adjusted HR=1.92
(1.08, 3.38); P= 0.025].
Discussion
Our study is the first multicentre registry from sub-Saharan Africa
that provides insight into the prevalence, predictors, and clinical
outcome of the renal dysfunction in AHF patients on this continent.











































































5 (18.8%) 17 (14.6%) 0.10
Rehospitalization to
day 60, n (%)
6 (14.5%) 39 (10.0%) 0.39
Death to day 60, n (%) 11 (22.8%) 39 (9.2%) 0.0034
Death or readmission
to day 60, n (%)
13 (26.9%) 64 (15.3%) 0.032
Death to day 180, n
(%)
15 (32.0%) 75 (19.1%) 0.020
WRF: ≥0.3 mg/dL (26.5 μmol/l) increase in creatinine compared with baseline.
*p-value is from two-sided t-test for LOS, log-rank test for time to event
outcomes.
also frequently found at hospital admission for heart failure in this
younger, mostly non-ischaemic patients. Although data for WRF
was available in half of the patients studied, it was less prevalent
and has different predictors compared with Western cohorts.
Nevertheless, WRF was strongly and independently related to
clinical outcome.
The prevalence of renal dysfunction (31% of patients with a
eGFR <60 mL/min/1.73m2) in our cohort was similar to Western
countries,7–10,17 despite younger age. This relatively high preva-
lence might be related to the large number of patients with
hypertensive heart failure, as the deleterious effects of hyperten-
sion on the kidneys are well known. In addition, AHF affects the
haemodynamic and neurohormonal milieu, which leads to func-
tional impairment or permanent kidney damage, regardless of the
© 2014 The Authors
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Figure 1 Kaplan–Meier plot of cumulative incidence of death by worsening renal function (WRF) to day 180.
comorbidities.18 The presence of comorbidities such as diabetes,
atrial fibrillation, and anaemia as well as the serum creatinine val-
ues on admission of our patients were similar to those documented
in previous studies.8,15,19 Inglis and co- workers20 found renal dys-
function in only 12% of African heart failure patients with idiopathic
dilated cardiomyopathy, which might be explained by the less dele-
terious effect of non-hypertension-related heart failure on the kid-
neys.
Concomitant renal dysfunction is one of the main independent
risk factors for prolonged hospitalization, rehospitalization, and
short- and long-term mortality in AHF.21–23 In patients with
chronic heart failure, baseline eGFR has been demonstrated to be
a stronger predictor for all-cause mortality than LVEF and NYHA
functional class.24 Similarly, a decrease in GFR is directly associated
with the rate of in-hospital mortality. In a meta-analysis, Smith et al.7
reported that annual mortality rates were 26% in patients without
renal dysfunction, 41% in the patients with any impairment of renal
function. and 51% in patients with moderate to severe impairment.
Overall, they found that any degree of renal impairment was
associated with a 56% increase in relative mortality risk. Renal
dysfunction was found to be a predictor of outcome both in heart
failure patients with reduced ejection fraction (HFrEF) and heart
failure patients with preserved ejection fraction (HFpEF) and was
suggested to be a more powerful predictor of outcome in patients
with HFpEF.11
Although the prevalence of renal dysfunction at baseline was









































. prevalent than that reported in many previous studies.8,9,25,26 This
is likely to be because our patients were younger, had less previous
myocardial infarctions, and probably less atherosclerotic kidneys.
Although they had a high prevalence of chronic kidney disease,
the kidneys could probably handle acute hypoperfusion better than
atherosclerotic kidneys. However, this prevalence may still be an
overestimation as there might have been selection in favour of
more severe heart failure patients with poorer renal function, in
whom renal function was more frequently measured.
The predictors of WRF in this study were BMI, signs of con-
gestion (peripheral oedema and rales) and being in the West-
ern African region. These are different from the factors found
by other workers, which include diabetes15,27,28 elevated systolic
blood pressure,7,27,28 NYHA class,7,19 tachycardia, and female sex.25
In a recent updated meta-analysis of WRF and outcomes in heart
failure by Damman and colleagues,11 other predictors found were
age, diuretic use, baseline GFR, anaemia, vascular disease/ischaemic
heart disease, and LVEF. Only one previous study showed a higher
BMI to be a predictor of WRF.11 We found both lower BMI and
higher BMI to be predictors of WRF. Patients with a very low BMI
might be cachectic, which carries a poor prognosis by itself, and
WRF may be a marker of a poor functional and clinical status of
cachectic heart failure patients. We cannot explain why a higher
BMI was related to a higher risk of WRF, although it is well known
that obese patients tend to hyperfiltrate, which might result in a
limited ‘spare capacity’ when kidneys are challenged with hypoper-
fusion during an episode of AHF.
© 2014 The Authors
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Similar to the findings of other studies conducted mostly in
Europe and North America,15,25,29,30 we found that patients who
presented with signs of congestion were more likely to develop
WRF than those who had a less severe congestion The sys-
temic/pulmonary congestion increases central venous pressure,
which is directly transmitted to the renal vein affecting renal perfu-
sion pressure. Different reports have highlighted that higher cen-
tral venous pressure is associated with decreasing GFR.17,31,32 In
addition, a direct effect on renal perfusion pressure—high renal
venous pressure—results in increased intrarenal pressure because
the kidney has a tight capsule. This increased pressure causes
collapsing of tubules and directly opposes filtration, resulting in
decreased GFR.33 How autoregulation responds to increased renal
venous pressure is unknown, although higher levels of intrarenal
angiotensin II and activation of the sympathetic nervous system
have been proposed, which could indirectly influence arteriolar
tone.34 However, the association between WRF and venous con-
gestion remains complex, as was recently described by Testani and
Damman.35
In a recent meta-analysis of WRF during renin-angiotensin-
aldosterone system (RAAS) inhibitor initiation and long-term out-
comes in patients with left ventricular systolic dysfunction by Clark
and colleagues,36 WRF was associated with poorer outcome in
both RAAS inhibitor and placebo groups, compared with patients
who did not develop WRF. In addition the RAAS inhibitor group,
despite having more frequent WRF, was associated with lower
overall mortality than the placebo group and that benefit was
attained in patients both with and without WRF. This may indi-
cate that WRF by itself is a biased prognosticator.37 In our study,
even though the frequency of WRF is low, there was no difference
in RAAS inhibition between those with WRF and those without
(angiotensin-converting enzyme inhibition was 36.7% vs. 37.5% ,
P= 0.94; aldosterone inhibition 23.8% vs. 25.0%, P= 0.9).
Although the length of hospital stay of our patients was com-
parable to that found in other European registries,38–41 there was
no difference between those who developed WRF and those who
did not. Other studies have shown that the development of WRF
is associated with prolonged hospital stay.15,21 The reason for this
difference is not apparent but result from different management
strategies in diverse medical centres as well as economic reasons,
as in many hospitals in sub-Saharan Africa how long a patient
remains on admission is determined by the affordability of the
services.
Worsening renal function was an independent predictor of death
or readmission over 60 days and all-cause death over 180 days. It
has been shown that WRF is associated with a poor prognosis
in most previous studies.8–10,25,42 The cause of WRF in AHF has
not been completely elucidated but is thought to result from
decreased renal perfusion and venous congestion, while endothelial
dysfunction, neurohormonal activation, and inflammation play a
mediating role.31,43 These patients also generally have more severe
disease, developing a vicious cycle with more congestion leading to












































































































The present study is an analysis of the patients enrolled in the
THESUS-HF study and as such shares certain limitations with the
original cohort.3 The majority of the patients were recruited in a
limited number of hospitals, mainly in Nigeria, Uganda, and South
Africa. Most importantly, loss to follow-up, missing laboratory
data, and clinical signs assessments were higher than in studies
conducted in other regions.
This registry was performed in selected centres and may rep-
resent only AHF patients seen in specialized centres. In addition,
we did not measure renal haemodynamics or GFR by clearance
methods, the eGFR formula used is only a surrogate marker of
real GFR, but has been shown to be the most accurate in heart
failure.12 Finally, almost half of the patients do not have follow up
creatinine values and as a result, WRF could not be calculated. This
calls for caution in interpreting the WRF data.
Conclusion
The present study shows that renal dysfunction is frequently
present in younger non-ischaemic AHF patients in Africa. Wors-
ening renal function, although calculated in half of the patients with
available follow-up creatinine values, is less prevalent and has differ-
ent predictors compared with Western cohorts. Nevertheless, in
these patients, WRF was associated with the severity of congestion
and appeared to be a strong and independent predictor of adverse
clinical outcomes.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. Predictors of death or readmission through 60 days
Table S2. Predictors of all-cause death through 180 days
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9 Chapter 9 Prevalence, clinical characteristics and outcomes 
of valvular atrial fibrillation in a cohort of African patients 
with acute heart failure: Insights from THESUS-HF 
Registry 
9.1 Introduction 
Rheumatic heart disease (RHD) remains an important cause of heart failure in SSA36,82 
and RHD associated with valvular AF is also common on the continent. 510 Among the 
regions enrolled in Randomized Evaluation of Long-Term Anticoagulation Therapy in 
atrial fibrillation (AF) (RE-LY- AF), a global prospective registry that enrolled patients 
presenting to an emergency department with AF, RHD was present in 22% of African 
patients compared 2% in North American patients. 510  
The risk of AF increases multiple folds in the presence of HF and valvular disease. 511 
The prognostic influence of the presence of AF in HF remains controversial, with some 
studies illustrating an independent adverse effect on mortality. 512,513 In recent 
metanalysis of 16 studies comprising of more than 50,000 patients with chronic HF, 
Mamas and colleagues showed that AF was associated with an adverse effect on total 
mortality. 514  
From a cohort of 1006 African patients admitted with AHF and enrolled in the THESUS-
HF registry, we analysed the burden, clinical characteristics and outcomes of AF in 







THESUS-HF was a prospective, multicenter, international observational survey of acute 
HF in 12 cardiology centers from 9 countries sub-Saharan Africa. 36  
Details of data collection have been previously described in chapter 3. In brief and 
relevant to this chapter, all ECGs were read centrally at the Momentum Research Inc. by 
one cardiologist and reviewed by another one. ECGs were analyzed for conduction or 
rhythm disturbances, evidence of myocardial ischemia/infarction or hypertrophy. AF was 
defined as either a history of documented AF or a finding of AF on the admission ECG.  
The information obtained was entered in the database registry together with other clinical 
data. A detailed echocardiographic assessment of ventricular contractility, valvular 
structure and function as well as regional wall abnormalities was performed.   
 
9.2.1 Statistical analyses  
All data were processed at the central coordinating center at Momentum Research, 
Durham, North Carolina, USA. Data were analyzed with the use of SAS version 9.3 
(SAS Institute, Cary, North Carolina). Summary statistics (mean, SD, median, and 25th 
and 75th percentiles) are provided for continuous variables and frequencies for categorical 
variables. Unless otherwise stated, a chi-square test was used for categorical variables, 
Cochran-Mantel-Haenszel test for ordinal variables, and Wilcoxon test for continuous 
variables to examine comparisons between groups. 
Atrial fibrillation classification was based on subjects either having a history of AF or the 
presence of AF on an ECG taken at admission. Baseline characteristics by AF status are 




Comparisons between valvular and non-valvular AF patients are presented to examine 
differences in the following outcomes: length of index hospitalization, time to first 
rehospitalization through 60 days, all-cause mortality through 180 days, and the 
composite endpoint of time to all-cause mortality or rehospitalization through 60 days. 
For length of index hospitalization, least square means and the difference between least 
square means are presented. For time-to event outcomes, Cox regression models were 
used with times for patients without the event of interest being censored at the earlier of 
the last date the patient was known to be alive or the period of interest for the specific 
outcome. Kaplan-Meier estimates, hazard ratios and 95% confidence intervals are given 
with the log rank test used for comparison between groups. Two patients who were 
classified with AF but were missing valvular-disease status were excluded from tables 
comparing valvular disease in only those patients with AF. For multivariable modeling 
these two patients were counted as having neither valvular-AF nor non-valvular AF. 
Anticoagulation use over time is also presented as the frequency of use by AF and by 
valvular/non-valvular disease in only those patients with AF by time point. 
The prognostic value of valvular and non-valvular AF was examined in multivariable 
models for the outcomes all-cause mortality through day 180 and the composite endpoint 
all-cause mortality or rehospitalization through day 60. The multivariable models were 
adjusted for significant clinical covariates from multivariable prognostic models 
previously constructed for these outcomes in the overall THESUS-HF registry. 475 To 
account for missing data, multiple imputations were used with 7 imputed datasets. 





9.3 Results  
There were a total of 1006 patients in the THESUS HF registry. The mean (SD) age of 
the patients was 52.3 (18.3) years, 511 (50.8%) were women, and the predominant race 
was black African (98.5%). As reported previously, 517 the primary etiology of heart 
failure was most commonly hypertension (n=363 [39.5%]) followed by idiopathic dilated 
cardiomyopathy (n=136[14.8%]) and rheumatic valvular heart disease (n=137[14.9%]), 
with ischemic heart failure in only 72 (7.8%) patients. Left ventricular EF was 39.5 ± 
16.5%, with 606 (65.2%) patients with LVEF less than 45%. 
AF was present in 209 (20.8%) of the 1006 patients. In the previous THESUS-HF 
publication, 36 prevalence was documented to be 18.3% because only those who had AF 
on the admission ECG were analysed. Table 9.1 shows the baseline patient characteristics 
by AF status. In both the AF and non-AF groups about 80% of the patients were in 
NYHA class II or III one month prior to admission.  Compared to the patients without 
AF, the patients with AF were older (mean age 57.1 versus 51.1 years) and more likely to 
be female (57.4% versus 49.1 %). They also had significantly lower systolic (125 versus 
132 mmHg) and diastolic (81 versus 85 mmHg) blood pressures and higher mean heart 











Table 9.1 Baseline patient clinical characteristics by atrial fibrillation status 
Variables Atrial fibrillation 
N = 209 [1] 
No Atrial fibrillation 
N = 797 [1] 
P-Value 
[2] 
Age (years) 57.1 (17.73), 60.0 (46.0, 70.0) 51.1 (18.26), 52.0 (36.0, 65.0) <.0001 
Gender: Females 120 (57.4) 391 (49.1) 0.0328 
Country    
Cameroon 27 (12.9) 63 (7.9)  
Ethiopia 3 (1.4) 7 (0.9)  
Kenya 5 (2.4) 27 (3.4)  
Mozambique 20 (9.6) 56 (7.0)  
Nigeria 73 (34.9) 352 (44.2) 0.0508 
Senegal 3 (1.4) 12 (1.5)  
South Africa 31 (14.8) 101 (12.7)  
Sudan 9 (4.3) 63 (7.9)  
Uganda 38 (18.2) 116 (14.6)  
Region    
East 55 (26.3) 213 (26.7)  
South 51 (24.4) 157 (19.7) 0.3071 
West 103 (49.3) 427 (53.6)  
Black African 203 (97.6) 781 (98.7) 0.2291 
BMI (Kg/m2) 24.94 (5.712), 24.73 (21.02, 28.08) 24.85 (5.836), 23.88 (20.83, 27.99) 0.4736 
SBP (mmHg) 124.5 (29.86), 120.0 (102.0, 145.0) 131.9 (34.27), 130.0 (108.0, 150.0) 0.0128 
DBP (mmHg) 80.6 (19.54), 80.0 (67.0, 90.0) 85.3 (21.19), 82.0 (70.0, 100.0) 0.0032 
History of Smoke 14 (6.7) 84 (10.6) 0.0962 
History of Diabetes mellitus 15 (7.2) 99 (12.4) 0.0344 




Malignancy 1 (0.5) 12 (1.5) 0.2429 
History of Depression 8 (3.8) 25 (3.1) 0.6114 
Dementia 7 (3.4) 15 (1.9) 0.1939 
No. of AHF admission in the 
last 12 months 
0.33 (0.621), 0.00 (0.00, 1.00) 0.38 (0.812), 0.00 (0.00, 0.00) 0.7840 
Heart Rate 109.3 (28.02), 108.0 (90.0, 124.0) 102.2 (19.29), 103.0 (90.0, 114.0) 0.0021 
NYHA 1-Month Prior to 
Admission 
   
I 21 (13.6) 100 (19.4)  
II 77 (50.0) 226 (43.9) 0.2940 
III 47 (30.5) 170 (33.0)  
IV 9 (5.8) 19 (3.7)  
History of Hypertension 110 (52.9) 446 (56.2) 0.3959 
Hyperlipidemia 9 (4.5) 81 (10.4) 0.0109 
Stroke 7 (3.4) 18 (2.3) 0.3613 
    
    
Orthopnea    
0 4 (2.3) 23 (3.5)  
1 15 (8.7) 55 (8.3) 0.3764 
2 69 (40.1) 289 (43.4)  
3 84 (48.8) 299 (44.9)  
Ischemic heart disease 11 (5.3) 71 (8.9) 0.0849 
Valvular disease 92 (44.4) 180 (22.7) <.0001 
Rales    
0 28 (15.9) 93 (13.2)  
1+ 47 (26.7) 147 (20.9) 0.1524 
2+ 70 (39.8) 341 (48.4)  
3+ 31 (17.6) 123 (17.5)  




Anemia 99 (49.0) 390 (51.0) 0.6183 
Pericardial disease 9 (4.3) 44 (5.6) 0.4815 
Cardiomyopathy 80 (38.8) 336 (42.6) 0.3243 
LVEF (%) 42.31 (15.721), 41.90 (31.00, 52.00) 38.74 (16.623), 37.00 (25.40, 50.00) 0.0022 
LVEF < 40% 82 (41.6) 405 (55.3) 0.0155 
BUN (mg/dL) 33.853 (28.017), 27.450 (17.000, 40.000) 36.048 (34.309), 26.764 (16.806, 42.015) 0.8963 
Creatinine (mg/dL) 1.310 (0.7359), 1.136 (0.900, 1.541) 1.414 (1.1182), 1.120 (0.880, 1.500) 0.5950 
Glucose (mg/dL) 106.12 (48.532), 93.600 (83.000, 111.60) 110.65 (49.991), 94.000 (84.000, 120.00) 0.3072 
eGFR (mL/min/1.73m2) 78.257 (40.114), 70.782 (49.422, 98.271) 84.685 (49.838), 77.735 (55.929, 104.20) 0.0522 
Renal dysfunction 10 (5.0) 63 (8.4) 0.1020 
Hemoglobin level (g/dL) 12.321 (2.0335), 12.350 (11.400, 13.400) 12.115 (2.5161), 12.200 (10.500, 13.800) 0.3460 
Total WBC count (No./µL) 7861.5 (4332.8), 7000.0 (5450.0, 9020.0) 7656.0 (4026.8), 6750.0 (5100.0, 8930.0) 0.3096 
Lymphocytes count (%) 30.87 (13.360), 30.70 (21.55, 38.55) 30.18 (13.368), 30.00 (20.00, 39.70) 0.5524 
Cholesterol level (mg/dL) 146.49 (43.853), 148.21 (117.00, 168.00) 160.40 (56.197), 153.86 (124.80, 187.21) 0.0154 
Triglycerides level (mg/dL) 96.924 (40.492), 92.000 (64.970, 115.70) 108.60 (56.625), 97.900 (71.200, 127.27) 0.0464 
Sodium level (mmol/L) 136.23 (6.506), 136.20 (132.00, 140.20) 134.83 (6.627), 135.00 (131.00, 139.00) 0.0097 
 
[1] Mean (SD), Median (first quartile- third quartile) for a continuous variable and frequency (percent) for a categorical variable. 









Ninety-two (44%) of the 207 AF patients had valvular heart disease. Compared with 
those without valvular disease, these patients were younger (mean age 52 versus 61 
years), had lower systolic blood pressure (120 versus 128 mmHg) and higher LVEF (47% 
versus 38%). Fifty seven percent of them had LVEF ≥45%. Among patients with non-
valvular AF, 61% had hypertensive heart disease. The other baseline characteristics were 





Table 9.2 Baseline patients clinical characteristics by valvular and non valvular atrial fibrillation 
Variables Valvular Afib 
N = 92 [1] 
Non-Valvular Afib 
N = 115 [1] 
P-Value 
[2] 
Age (years) 52.2 (18.98), 52.0 (38.5, 65.5) 60.8 (15.74), 64.0 (53.0, 72.0) 0.0005 
Gender: Females 59 (64.1) 60 (52.2) 0.0838 
Country    
Cameroon 7 (7.6) 20 (17.4)  
Ethiopia 0 (0.0) 3 (2.6)  
Kenya 2 (2.2) 3 (2.6)  
Mozambique 6 (6.5) 14 (12.2)  
Nigeria 15 (16.3) 57 (49.6) <.0001 
Senegal 1 (1.1) 2 (1.7)  
South Africa 20 (21.7) 10 (8.7)  
Sudan 8 (8.7) 1 (0.9)  
Uganda 33 (35.9) 5 (4.3)  
Region    
East 43 (46.7) 12 (10.4)  
South 26 (28.3) 24 (20.9) <.0001 
West 23 (25.0) 79 (68.7)  
Black African 91 (98.9) 111 (97.4) 0.4245 
BMI (Kg/m2) 24.89 (6.482), 24.76 (20.91, 27.91) 24.90 (5.005), 24.52 (21.23, 28.11) 0.7187 
SBP (mmHg) 119.9 (24.39), 112.0 (100.0, 133.0) 127.9 (33.38), 124.5 (108.0, 150.0) 0.0699 
DBP (mmHg) 78.4 (17.01), 79.0 (65.0, 90.0) 82.2 (21.29), 80.0 (68.0, 94.0) 0.2521 
History of Smoke 7 (7.7) 6 (5.2) 0.4682 
History of Diabetes mellitus 5 (5.4) 9 (7.9) 0.4855 




Malignancy 1 (1.1) 0 (0.0) 0.2598 
History of Depression 4 (4.4) 4 (3.5) 0.7350 
Dementia 3 (3.3) 4 (3.5) 0.9431 
No. of AHF admission in the 
last 12 months 
0.40 (0.734), 0.00 (0.00, 1.00) 0.27 (0.506), 0.00 (0.00, 0.00) 0.3873 
Heart Rate 111.7 (29.68), 109.0 (92.0, 127.0) 107.4 (26.86), 107.0 (90.0, 120.0) 0.4319 
NYHA 1-Month Prior to 
Admission 
   
I 12 (15.4) 9 (11.8)  
II 44 (56.4) 33 (43.4) 0.0320 
III 20 (25.6) 27 (35.5)  
IV 2 (2.6) 7 (9.2)  
History of Hypertension 38 (41.8) 70 (60.9) 0.0064 
Hyperlipidemia 4 (4.6) 4 (3.6) 0.7244 
Stroke 3 (3.3) 3 (2.6) 0.7706 
    
    
Orthopnea    
0 2 (2.5) 2 (2.2)  
1 10 (12.3) 5 (5.6) 0.4206 
2 30 (37.0) 38 (42.2)  
3 39 (48.1) 45 (50.0)  
Ischemic heart disease 4 (4.3) 6 (5.2) 0.7719 
Valvular disease 92 (100.0) 0 (0.0) <.0001 
Rales    
0 18 (25.4) 10 (9.6)  
1+ 16 (22.5) 31 (29.8) 0.0836 
2+ 25 (35.2) 44 (42.3)  
3+ 12 (16.9) 19 (18.3)  




Anemia 46 (51.7) 51 (45.9) 0.4196 
Pericardial disease 3 (3.3) 6 (5.2) 0.5030 
Cardiomyopathy 29 (32.2) 50 (43.5) 0.1003 
LVEF (%) 47.21 (14.440), 46.00 (40.00, 58.00) 38.20 (15.506), 36.50 (27.00, 45.70) <.0001 
LVEF < 40% 22 (24.7) 59 (55.7) <.0001 
BUN (mg/dL) 32.102 (24.442), 24.369 (16.806, 40.334) 35.694 (30.840), 29.000 (18.487, 40.000) 0.2820 
Creatinine (mg/dL) 1.312 (0.7082), 1.171 (0.878, 1.570) 1.316 (0.7660), 1.125 (0.900, 1.544) 1.0000 
Glucose (mg/dL) 102.92 (47.079), 91.800 (82.800, 105.20) 108.77 (50.132), 98.600 (84.000, 115.10) 0.1777 
eGFR (mL/min/1.73m2) 78.731 (39.738), 74.123 (48.772, 92.796) 77.676 (40.914), 69.039 (49.709, 100.88) 0.7990 
Renal dysfunction 4 (4.3) 6 (5.6) 0.6961 
Hemoglobin level (g/dL) 12.325 (2.0718), 12.600 (11.000, 13.400) 12.331 (2.0279), 12.300 (11.500, 13.600) 0.7053 
Total WBC count (No./µL) 8424.9 (5562.6), 7120.0 (5160.0, 9600.0) 7431.0 (2991.6), 7000.0 (5500.0, 8800.0) 0.6228 
Lymphocytes count (%) 29.27 (14.264), 29.60 (18.00, 38.00) 31.79 (12.234), 32.00 (24.00, 38.10) 0.1728 
Cholesterol level (mg/dL) 143.77 (41.704), 148.21 (109.20, 171.61) 147.93 (45.413), 143.00 (120.90, 167.71) 0.9203 
Triglycerides level (mg/dL) 100.63 (41.320), 91.390 (69.420, 124.60) 93.792 (39.999), 93.000 (62.300, 110.02) 0.4499 
Sodium level (mmol/L) 136.63 (6.729), 137.00 (132.20, 141.00) 135.78 (6.314), 136.00 (132.00, 140.00) 0.3750 
[1] Mean (SD), Median (first quartile- third quartile) for a continuous variable and frequency (percent) for a categorical variable. 




Anticoagulation prescription rates were low in this cohort of patients and decreased 
progressively over time.  At 6 months only 22% of patients with AF were on oral 
anticoagulant. For the AF patients, 33% of the patients with valvular AF and 12% of 
those with non-valvular AF were on anticoagulants at 6 months follow up (Table 9.3).  
For Aspirin, a greater proportion of patients with AF than without AF were on aspirin 1 
month prior to admission (29 versus 20%), but on and after admission the proportions did 
not differ significantly. At 6 months similar proportions of patients with AF and without 
AF were on aspirin.  Among patients with AF, the proportion on aspirin did not differ 
significantly except at discharge/day 7 and day 30, when a smaller proportion of patients 
with valvular AF than with non-valvular were on aspirin (48 versus 62% and 39 versus 













Table 9.3 Patients use of anticoagulation and aspirin by time 












       
















































 22/326 ( 
6.8) 














  P-value1 0.0013 <0.0001 <0.0001 <0.0001 <0.0001 0.0003 <0.0001 




       
 Valvular 
(N=92) 



































































  P-value1 0.0168 0.8915 0.3217 0.1090 <0.0001 <0.0001 0.0117 
  P-value2 0.4420 0.3667 0.5775 0.7548 0.0394 0.0073 0.7035 
1: Chi-square test for comparison of anticoagulation use. 






As shown in Table 9.4, the mean length of the hospital stay was 1.6 days longer in 
patients with valvular AF than for patients with non-valvular AF, although this was not 
statistically significant (p=0.14).  The unadjusted risk of 180-day mortality in patients 
with valvular AF was twice that in patients with non-valvular AF (HR 2.11, 95% CI 1.05-
















Table 9.4 Outcomes by valvular disease status in patients with atrial fibrillation 







95% CI [3] 
P-value 
Length of Index Hospitalization [1] 11.2 9.6  1.63 (-0.56, 3.83) 0.1438 
Rehospitalization through 60 Days [2] 6.0 11.3 0.48 (0.15, 1.52) 0.2046 
Death through Day 180 [2] 24.8 13.2 2.11 (1.05, 4.24) 0.0320 
Death or Rehospitalization through 60 Days [2] 19.1 15.5 1.32 (0.66, 2.65) 0.4268 
[1] LS Means 
[2] Kaplan-Meier event rate   
[3] Hazard Ratio from cox regression model presented for Rehospitalization, death, and death/Rehospitalization outcome.       





Without adjustment for potential confounding factors, neither valvular nor non-valvular 
AF was associated with 60-day readmission (Table 9.5), while valvular but not non-
valvular AF was associated with 180-day all-cause mortality (Table 9.6). Multivariable 
models previously developed475 showed that renal dysfunction, lower blood pressure, 
congestion and presence of malignancy and history of cor pulmonale were associated 
with all cause death or readmission within 60 days. Similar factors as well as lower 
haemoglobin and HIV status were associated with all cause death through 180 days.  
Multivariable adjustment for these prognostic markers had little effect on the estimated 
associations of valvular and non-valvular AF with either outcome. Valvular AF was not a 
significant predictor of all cause death or readmission through day 60 (Figure 9.1) (HR 
1.39, 95% CI 0.80-2.42, p=0.24) but was associated with all-cause death through day 180 
(HR 1.61, 95% CI 0.99-2.62, p=0.056) (Figure 9.2). On the other hand, non-valvular AF 
was not a significant predictor of either all cause death or readmission through day 60 
(HR 0.99, 95% CI 0.58-1.68, p=0.96) (Figure 9.1) or the outcome all-cause death through 






Table 9.5 Associations of  valvular and non-valvular atrial fibrillation with all-cause death or readmission through 60 days 
  Unadjusted  Multivariable-adjusted 
Variable HR for a  
change of 
Hazard ratio 
95% CI [1] 
P-value  Hazard ratio 
95% CI [1] 
P-value 
Valvular Atrial Fibrillation Yes vs. No 1.35 (0.80, 2.27) 0.2593  1.39 (0.80, 2.42) 0.2388 
Non-Valvular Atrial Fibrillation Yes vs. No 0.98 (0.58, 1.65) 0.9440  0.99 (0.58, 1.68) 0.9630 
BUN [2] Double in BUN --- ---  1.39 (1.17, 1.66) 0.0002 
SBP 10 units increase --- ---  0.92 (0.87, 0.98) 0.0050 
Malignancy Yes vs. No --- ---   4.48 (1.96, 10.27) 0.0004 
Hx of cor pulmonale Yes vs. No --- ---  2.03 (1.24, 3.32) 0.0047 
Rales Yes vs. No --- ---  2.12 (1.37, 3.29) 0.0008 
Hyperlipidaemia Yes vs. No --- ---  0.46 (0.19, 1.09) 0.0793 
Ejection fraction, % [2] 50 vs. 27 --- ---  0.94 (0.72, 1.23) 0.1746 
[1] Hazard Ratio from cox regression model 






Table 9.6 Associations of valvular and non-valvular atrial fibrillation with all-cause death through 180 days 
  Unadjusted  Multivariable-Adjusted 
Variable HR for a  
change of 
Hazard ratio 
95% CI [1] 
P-value  Hazard ratio 
95% CI [1] 
P-value 
Valvular Atrial Fibrillation Yes vs. No 1.61 (1.00, 2.58) 0.0475  1.61 (0.99, 2.62) 0.0563 
Non-Valvular Atrial Fibrillation Yes vs. No 0.69 (0.39, 1.21) 0.1949  0.70 (0.39, 1.26) 0.2331 
Male sex Yes vs. No --- ---  1.36 (0.96, 1.92) 0.0859 
Hemoglobin, g/dL 1 unit increase --- ---  0.93 (0.87, 1.00) 0.0551 
HIV positive Yes vs. No --- ---  1.82 (1.08, 3.06) 0.0239 
Current or former smoker Yes vs. No --- ---  0.49 (0.24, 0.99) 0.0479 
Malignancy Yes vs. No --- ---  3.05 (1.24, 7.54) 0.0157 
Hx of cor pulmonale Yes vs. No --- ---  2.04 (1.26, 3.30) 0.0038 
SBP, mmHg 10 units increase --- ---  0.85 (0.80, 0.90) <.0001 
Orthopnoea (2/3 vs. 0/1) --- ---  2.32 (1.06, 5.10) 0.0360 
Peripheral Oedema (2/3 vs. 0/1) --- ---  1.76 (1.15, 2.69) 0.0094 
Rales (2/3 vs. 0/1) --- ---  1.71 (1.11, 2.63) 0.0155 
Creatinine, mg/dL [2] 1.55 vs. 0.90 --- ---  1.37 (1.06, 1.77) 0.0239 
[1] Hazard Ratio from cox regression model 







                                                                        (HR 1.39, 95% CI 0.80-2.42, p=0.24) 




                                                                         (HR 1.61, 95% CI 0.99-2.62, p=0.056) 











We found AF to be present in 20.8% of acute HF patients.  Forty four percent of the 
patients with AF had valvular heart disease. Sixty-one percent of the patients with non-
valvular AF had hypertension. The presence of AF was not associated with the primary 
end points, but having valvular AF predicted death through day 180. 
To the best of our knowledge, this is the first sub Saharan African study to assess the 
prevalence and clinical characteristics of AF in patients hospitalized for acute HF.  
Importantly this study describes an important subpopulation of patients with AF, namely 
those due to valvular (mostly rheumatic) heart disease, which are still relatively prevalent 
in sub-Saharan Africa. 97,244,518,321,519 
The prevalence of AF was 21%, which is generally lower than that reported in previous 
studies, ranging between 23 – 41%.520-523 Among acutely decompensated HF patients, 
20% to 35% will be in AF at presentation. 83 This difference may be due to the fact that in 
Sub Saharan Africa patients with AHF are younger and have less ischemic heart disease. 
Indeed in the Heart of Soweto HF cohort, AF occurred in only 6.6% of all 2393 HF cases 
within the entire study cohort. 518 This however was not in the acute decompensated HF 
setting.  
Rheumatic heart disease is the 3rd commonest cause of HF in the THESUS HF after 
hypertension idiopathic dilated cardiomyopathy. 36 Almost half of all those with AF in 
this study had valvular disease compared to 23% in those without AF. Valvular heart 
disease has long been associated with development of AF. Population based estimates 
based on Framingham data revealed that valve disease was associated with a 1.8-fold 






valvular pathology can be related to AF, stenotic left-sided valvular lesions (and in 
particular rheumatic heart disease) have the highest prevalence rates. Severity of 
obstruction follows a dose–response relationship: AF prevalence is 9.1% of patients with 
mild-to-moderate aortic stenosis and 33.7% among those with severe stenosis. 525,526 
Likewise, the prevalence of AF varies with the complexity of rheumatic heart disease: 
from 16% with isolated mitral regurgitation to 29% with isolated mitral stenosis, to 52% 
with coexisting mitral regurgitation and stenosis, and to 70% with mixed mitral and 
tricuspid valve disease.527 
We found low rates of anticoagulation in this cohort. In a prospective study of AF 
patients in Cameroon, only 34% of patients with an indication for oral anticoagulation 
received it, 528 similar to 33% of patients with AF received warfarin in the Heart of 
Soweto study. 518 In this study 52% of our patients with AF received oral anticoagulants. 
In contrast, a much higher percentage of patients received an anticoagulant in Senegal, 
where in a retrospective hospital-based study, anticoagulation with warfarin was 
established in 62% of cases. 529 In the REMEDY registry, 244 40.7% of patients had 
indications for oral anticoagulants and they were prescribed in 69.5% of them. The use of 
oral anticoagulants (OACs) was high in patients with mechanical heart valves (91.6%) 
and AF (68.6%), but low in those with mitral stenosis in sinus rhythm with either dilated 
left atrium or left atrial thrombus (20.3%).  
A study at a private urban referral teaching hospital in Nairobi, Kenya, found that 80% of 
patients with AF and a CHADS2 score of 2 received anticoagulation. 530 Similarly, a 
recent observational multicenter national registry in South Africa indicated that 75% of 






the quality of anti-coagulation control in this study. 
The presence of AF was not associated with all cause death or readmission through 60 
days, but having valvular AF predicted death through 180 days. Eapen and colleagues532 
investigated the associations between AF and early outcomes of patients with heart 
failure. They found AF to be associated with 30-day mortality in patients with preserved 
EF but not in patients with reduced EF.   
Our data should be interpreted in the context of their limitations. The variable timing of 
the electrocardiogram may have affected the specific results obtained, giving that the 
ECGs were accepted if they were recorded + 2 weeks and not necessarily on admission. 
Secondly, our results are drawn from a population of young acute HF patients 
predominantly with systolic dysfunction. Consequently, these findings may not apply to 
older patients or to those with preserved LVEF. Finally the study was conducted in 
selected specialized centers, and only patients who consented to the study were enrolled; 
thus, not all patients admitted with AHF are represented and the study’s generalizability 
may be limited. However, we have increased our understanding of the growing 
importance of cardiovascular disease in this population, who now suffer from double 
burden of communicable and non-communicable diseases.  
 
9.5 Conclusion 
AF is present in one fifth of sub Saharan African patients with AHF. Almost half of the 
AF patients have valvular disease (RHD) and are significantly younger. Valvular AF was 






cause death or readmission through day 60.   The prescription rates of anticoagulation 







10 Chapter 10: NT - Pro BNP and Galectin-3 are Prognostic 
Biomarkers of Acute Heart failure in sub Saharan Africa: 
Lessons from the BAHEF Trial.  
10.1 Introduction 
AHF is a major health issue, accounting for a large proportion of patients admitted to 
hospitals. Patients with recent hospitalizations for AHF are at high risk for future 
cardiovascular events and death.  467 African patients with AHF differ from those in the 
West, in that they are younger in their productive lives, present more acutely, have a 
more severe disease and higher mortality and have predominantly hypertension and 
cardiomyopathy rather than ischaemic heart disease. 44,147,171  
BNP and NT Pro BNP are established serum biomarkers for diagnosis and prognosis in 
acute or chronic HF. 415,426 These peptides have proven utility for confirming the 
diagnosis of AHF in breathless subjects and are predictive of adverse outcomes. 423 In 
addition, high levels of natriuretic peptides are associated with recurrent hospitalization 
and risk of sudden death, 425 and pre discharge BNP level appears to be a strong predictor 
for identifying subsequent death or hospital admission at 6 months. 426,427  
Gal3 is a novel biomarker that is significantly increased in acute and chronic heart 
failure, independent of aetiology. 447 While Gal3 shows promise in detecting long-term 
outcomes, the role of Gal3 levels at admission in diagnosis and early risk stratification in 
patients with AHFS is undefined. 445,447 Plasma Gal3 appears to be a prognostic marker of 
HF outcomes such as death and readmissions for HF, 442,443,533,534 and is associated with 






The combination of NT - pro BNP and galectin-3 has also been shown to identify those at 
greatest death risk among patients with AHF. 442 Patients with the highest quartile of both 
biomarkers had mortality rates as high as 15% within 10 days of presentation, and twice 
the 30-day mortality rate versus the cohort with both markers being low.442 
To the best of our knowledge, the relationship between NT-Pro BNP and galectin 3 and 
outcome has not been studied in SSA patients with AHF.  From pre-specified secondary 
analyses of the BA-HEF study, which included assays of these biomarkers as part of 
patients’ evaluation and follow up, we set out to describe the association between plasma 
levels of NT-Pro BNP and galectin 3 and outcomes (CV death or HF hospitalization) 
through week 24. We also aimed to identify the association between the plasma levels of 
these biomarkers and LVEF, LVEDD, LVESD, which are markers of LV remodeling; as 
well as TAPSE, a marker of RV remodeling, in this cohort of AHF patients. 
10.2 Methods  
The BAHEF study466 was a prospective, randomized, double-blind, placebo controlled 
trial comparing the combination of isorsobide dinitrate and hydralazine (HYIS) with 
placebo. The study aimed to recruit a total of 500 patients from countries in the southern, 
eastern, central and western regions of sub-Saharan Africa. The rationale and design of 
BAHEF as well as the  details of data collection have been previously described in 
chapter 3.  
10.2.1 Statistical Analysis 
The analysis population has been restricted to subjects with available biomarker data and 
further excluding data from one site in Senegal where major protocol non-compliance 






Summary statistics for continuous variables may include the number of non-missing 
observations, mean and standard deviation (SD), median, first and third quartile (Q1, 
Q3), minimum and maximum, as appropriate. Categorical variables are presented with 
absolute and/or relative frequencies (percentages). Relative frequencies are based on all 
non-missing observations for the corresponding variable if not stated otherwise. The 
summary statistics of the biomarker parameters additionally include the geometric mean 
and its corresponding 95% confidence interval (CI). 
Missing values for the six-minute walk test distance, and for dyspnea and general well-
being VAS were imputed by linear interpolation between non-missing observations at the 
closest visit before and after the missing value occurred. For subjects who died, values at 
visits following a death were imputed as zero for six-minute walk test distance and as the 
worst observed value for dyspnea or general well-being VAS. For echocardiographic 
parameters values following a death were imputed as baseline plus or minus the worst 
observed change from baseline across all subjects. Clinically implausible values of 
TAPSE above 50mm have been set to missing for the statistical analysis. Biomarker 
values below the limit of detection (LOD) have been replaced by 0.5*LOD, and values 
above the upper limit of quantification (ULOQ) have been replaced by 1.5*ULOQ. 
Analysis of Covariance (ANCOVA) methods have been applied to evaluate treatment 
differences for changes from baseline with treatment effect adjusted for the 
corresponding baseline values. Results are presented as least square mean differences 
with 95% CIs and p-value. For the biomarker parameters, ANCOVA was applied on log-






treatment difference is presented as the ratio of the baseline adjusted geometric means 
with corresponding 95% CIs. 
Baseline biomarker values and changes from baseline have been further evaluated for 
their association with cardiovascular death or rehospitalization for heart failure through 
week 24 and with cardiovascular death through week 24 as well as with selected 
echocardiographic parameters. These associations were evaluated by fitting Cox 
proportional hazards models and presenting hazard ratios, 95% CIs, and p-values. In 
addition, number of events and the Kaplan-Meier estimate of the event rate are presented 
for each time-to-event endpoint. For change from week 24 to baseline for six-minute 
walk test distance, dyspnea VAS, LVEF, LVEDD, LVESD, and TAPSE, linear 
regression models have been applied to evaluate the association with baseline values as 
well as with change at week 24 for the two biomarkers. Models evaluating the association 
with change from baseline have been adjusted for the baseline values of the respective 
biomarker. Effect sizes are presented as mean differences with 95% CIs and p-values.  
All statistical analyses have been performed using SAS® 9.3 (SAS Institute, Inc., Cary, 
NC, USA). 
10.3 Results 
The BAHEF trial screened 619 patients from nine centres in 6 African countries 
(Mozambique, South Africa, Nigeria, Kenya, Uganda and Senegal).  Data for 14 
randomized patients from one center in Senegal were excluded due to non-compliance 
with the protocol.  Subsequently 133 patients were randomized at the remaining eight 
centers. The primary reasons for exclusion from the study were (1) lack of test results, 






poor, (3) lack of background treatment with ACEI and/or beta-blocker, and (4) liver 
function too poor (5) Not eligible due to low blood pressure. 
Of the 133 patients randomized, 80 had complete data for biomarkers available for 
analysis and their baseline characteristics are outlined in Table 10.1.  Demographic 
characteristics of the patients were similar across participating countries. The 
randomization was blocked by study center. Thus, randomization to the two study arms 















Table 10.1 Baseline characteristics of the study population (restricted  
to biomarker sub set) 
Characteristic Statistic Overall 
(N=83) 
Age, years Mean (SD) 53.1         (15.79) 
Male sex % 48.2 
Weight, kg Mean (SD) 76.5 (18.90) 
Primary cause of 
Heart Failure 
  
  Ischemic heart 
disease 
% 4.9 
  Hypertension % 65.9 
  Idiopathic % 15.9 




  I % 2.0 
  II % 22.4 
  III % 53.1 
  IV % 22.4 







Mean (SD) 24.5(9.87) 
LVIDD, cm 
Screening 
Mean (SD) 6.3 (1.1) 
Blood pressure   
  Systolic Mean (SD) 132.9 (17.55) 




  Diuretic % 80.0 
  ACE inhibitor % 91.3 
  ARB % 3.8 
  Beta Blocker % 28.8 






  Digoxin % 17.5 
  Spironolactone % 10.0 
Race   
  African or 
Black 
% 74.4 
  Colored or 
mixed race 
% 23.1 







Mean (SD) 63.6 (27.40) 
 
 
The mean age of the group (restricted biomarker sub set) was 53.1 + 15.8 years, with 
51.8% being females. Seventy four percent were African/Black and 23.15 were coloured 
or mixed race. The mean period from admission to randomization was 63. 6 + 27.4 hours.  
Most of the patients had hypertension (65.9%) and idiopathic dilated cardiomyopathy 
(15.9%), while ischemic heart disease was present in only 4.9%. Most patients  (75.5%) 
also are in NYHA functional class III and IV. Baseline characteristics were similar in the 
active and the placebo groups. 466  
 The mean LVEF at baseline for the overall group was 24.0 % with no difference 
between those on HYIS and placebo (Table 10.2). The baseline mean LVEDD was 62.7 
+ 8.84 mm while the change from baseline to week 24 was -0.1 + 10.6 mm.  For the 
LVESD, the mean was 55.8 + 9.0 mm with a mean change from baseline to week 24 of -
6.0 + 9.51 mm.  The mean TAPSE at baseline was 20.9 + 5.61 with a mean change 
between baseline and week 24 of 0.3 + 10.31. There was no difference between HYIS 
and placebo in terms of change from baseline to week 24 for LVEF, LVEDD, LVESD 







Table 10.2 Changes from baseline to week 24 in echocardiographic parameter - 
imputed full analysis set (restricted to biomarker sub set) 













      









































      















Mean (SD) 0.8 (9.42) -1.1 (11.67) -0.1 
(10.60) 

















      







































      
































Table 10.3 shows the biomarker levels and their change from baseline to follow up by 
treatment. The mean baseline NT- pro BNP was 3771.13 + 2829.66 pmol/L dropping 
down to 1328.47 + 1369.19 pmol/L by week 24. The mean change in NT Pro BNP from 
baseline to week 24 was - 2258.83 + 2487.88 with no difference between HYIS and 
placebo (p = 0.6425). For galectin-3, the mean at baseline was 8.26 + 7.68 ng/mL and 
came down to 6.18 + 6.03 by week 24 of follow up. The mean change in galectin-3 level 









Table 10.3 Changes in biomarkers from baseline to follow up by treatment - full 
analysis (restricted to biomarker sub set) 
Measure Statistic Placebo 
(n=41) 








NT Pro BNP 
pmol/L 
      
Baseline N 39 41 80   







 Median 3476.00 2158.50 2882.25   







 Min, Max 358.5, 9600.0 430.5, 9600.0 358.5, 
9600.0 
  
 Geom. Mean 3332.18 2303.24 2757.58   









 n (%) < LOD 
(171 pmol/L) 
[1] 
0 (0%) 0 (0%) 0 (0%)   
 n (%) > 
ULOQ (6400 
pmol/L) [1] 
7 (17.9%) 4 (9.8%) 11 (13.8%)   
Follow up N 32 34 66   







 Median 744.75 753.00 744.75   







 Min, Max 211.5, 6314.5 85.5, 4599.5 85.5, 
6314.5 
  
 Geom. Mean 962.06 775.54 860.96   









 n (%) < LOD 
(171 pmol/L) 
[1] 
0 (0%) 1 (2.9%) 1 (1.5%)   
 n (%) > 
ULOQ (6400 
pmol/L) [1] 
0 (0%) 0 (0%) 0 (0%)   
Change to 
week 24 
N 30 33 63 1.10 (0.73, 
1.66) 
0.6425 




















 Min, Max -9009.0, 
717.5 
-8712.0, 287.5 -9009.0, 
717.5 
  
 Geom. Mean 0.28 0.37 0.33   
 95% CI of 
GM 
0.21, 0.39 0.28, 0.49 0.26, 0.40   
       
Galactin 3 
ng/mL 
      
Baseline N 39 41 80   
 Mean (SD) 7.42 (4.628) 9.06 (9.737) 8.26 
(7.680) 
  
 Median 5.88 5.72 5.80   
 Q1, Q3 3.94, 10.20 3.70, 9.07 3.71, 9.65   
 Min, Max 1.8, 24.1 1.9, 45.0 1.8, 45.0   
 Geom. Mean 6.23 6.47 6.35   
 95% CI of 
GM 
5.12, 7.58 5.09, 8.22 5.45, 7.40   
 n (%) < LOD 
(0.29 ng/mL) 
[1] 
0 (0%) 0 (0%) 0 (0%)   
 n (%) > 
ULOQ (30 
ng/mL) [1] 
0 (0%) 2 (4.9%) 2 (2.5%)   
Follow Up N 32 33 65   
 Mean (SD) 6.50 (7.910) 5.88 (3.449) 6.18 
(6.030) 
  
 Median 4.34 4.82 4.66   
 Q1, Q3 3.06, 6.95 3.62, 6.64 3.40, 6.77   
 Min, Max 2.1, 45.0 2.4, 17.9 2.1, 45.0   
 Geom. Mean 4.84 5.18 5.01   
 95% CI of 
GM 
3.82, 6.14 4.37, 6.15 4.35, 5.78   
 n (%) < LOD 
(0.29 ng/mL) 
[1] 
0 (0%) 0 (0%) 0 (0%)   
 n (%) > 
ULOQ (30 
ng/mL) [1] 
1 (3.1%) 0 (0%) 1 (1.5%)   
Change to 
week 24 
N 30 32 62 1.05 (0.81, 
1.36) 
0.6997 
 Mean (SD) 0.20 (6.696) -1.59 (7.505) -0.72 
(7.125) 
  
 Median -0.36 -0.28 -0.28   
 Q1, Q3 -3.06, 0.99 -1.60, 1.17 -2.78, 0.99   
 Min, Max -12.0, 26.1 -39.0, 9.4 -39.0, 26.1   
 Geom. Mean 0.91 0.93 0.92   
 95% CI of 
GM 







The total number of CV death or HF hospitalization through 24 weeks was 9/80 (11.6%) 
while CV deaths through week 24 was 5/80 (6.8%). Using fitting Cox proportional 
hazards models, the associations of baseline biomarker values and changes at week 24 
with cardiovascular death or hospitalization for heart failure and with cardiovascular 
death are shown on Table 10.4. Both NT- pro BNP and galectin 3 at baseline predicted 
combined CV death or HF hospitalization through week 24 (p values = 0.0328 and 
0.0001 respectively) but only galectin 3 at baseline predicted CV death through week 24 ( 
P = 0.0042). Gal3 at baseline also strongly predicted Dyspnea VAS change week 24 to 




















Table 10.4 Associations of biomarker baseline values and changes at week 24 with 
primary end points 
Outcome [1] Covariate Effect size 
for 
a change of 
Effect size 
(95% CI) 
P-value No. events 
(KM rate) 





NT Pro BNP 
at baseline 
Doubling 2.12 (1.06, 
4.22) 
0.0328 9/80 (11.6%) 
 Galectin-3 at 
baseline 
Doubling 2.81 (1.65, 
4.79) 




NT Pro BNP 
at baseline 
Doubling 2.21 (0.85, 
5.71) 
0.1027 5/80 (6.8%) 
 Galectin-3 at 
baseline 
Doubling 2.84 (1.39, 
5.79) 
0.0042 5/80 (6.8%) 
6MWT 
change week 
24 to baseline 
(imputed) 





 NT Pro BNP 


















24 to baseline 
(imputed) 
NT Pro BNP 
at baseline 
Doubling -2.27 (-7.65, 
3.12) 
0.4119  
 NT Pro BNP 
ratio week 24 
to baseline 
Doubling -3.42 (-6.01, -
0.82) 
0.0122  






ratio week 24 
to baseline 




[1] Effect sizes shown are hazard ratios for time-to-event outcomes and mean differences for 
continuous outcomes. In case of continuous outcomes, estimates have been 







For LVEF, LVEDD, LVESD, and TAPSE, linear regression models were applied to 
evaluate the association with baseline values as well as with change at week 24 for the 
two biomarkers (Table 10.5). Models evaluating the association with change from 
baseline have been adjusted for the baseline values of the respective biomarker. While 
NT Pro BNP at baseline only predicted change (week 24 to baseline) in LVEDD, Gal3 at 
baseline predicted changes (week 24 to baseline) in all the tested markers of LV 


















Table 10.5 Association of biomarker baseline values and changes at week 24 with 
echocardiographic parameters 
Outcome [1] Covariate Effect size for 





week 24 to 
baseline 
(imputed) 
BNP at baseline Doubling -2.58 (-5.22, 0.06) 0.0589 
 BNP ratio week 24 
to baseline 
Doubling -1.34 (-3.76, 1.08) 0.2811 
 Galectin-3 at 
baseline 
Doubling -5.15 (-8.19, -2.10) 0.0014 
 Galectin-3 ratio 
week 24 to 
baseline 
Doubling 0.04 (-3.48, 3.57) 0.9807 
LVEDD change 
week 24 to 
baseline 
(imputed) 
BNP at baseline Doubling 2.74 (0.94, 4.53) 0.0038 
 BNP ratio week 24 
to baseline 
Doubling 0.07 (-1.70, 1.85) 0.9359 
 Galectin-3 at 
baseline 
Doubling 4.95 (2.88, 7.02) <.0001 
 Galectin-3 ratio 
week 24 to 
baseline 
Doubling 0.21 (-2.30, 2.71) 0.8719 
LVESD change 
week 24 to 
baseline 
(imputed) 
BNP at baseline Doubling 1.62 (-0.17, 3.41) 0.0795 
 BNP ratio week 24 
to baseline 
Doubling -0.57 (-2.33, 1.18) 0.5251 
 Galectin-3 at 
baseline 
Doubling 3.51 (1.41, 5.61) 0.0016 
 Galectin-3 ratio 
week 24 to 
baseline 
Doubling -1.11 (-3.49, 1.27) 0.3633 
TAPSE change 
week 24 to 
baseline 
(imputed) 
BNP at baseline Doubling -0.95 (-3.73, 1.82) 0.5049 
 BNP ratio week 24 
to baseline 
Doubling -0.54 (-2.23, 1.15) 0.5365 
 Galectin-3 at 
baseline 
Doubling -5.00 (-7.63, -2.38) 0.0007 
 Galectin-3 ratio 
week 24 to 
baseline 
Doubling -0.61 (-2.75, 1.53) 0.5802 
 
[1] Effect sizes shown are mean differences for continuous outcomes. Estimates have been adjust








The BAHEF study showed that in sub-Saharan Africa, HF affects men and women who 
are relatively young (mid fifties) and is mostly caused by hypertension and not ischaemic 
heart disease, as is seen in Western countries. 83 Similar findings were recently reported 
in the sub-Saharan Africa Survey of Heart Failure (THESUS-HF) registry.  36 Both 
studies showed that these patients had predominantly systolic dysfunction and low 
incidence of atrial fibrillation. 
Overall, the BAHEF study did not achieve its primary end point mainly due to poor 
recruitment rate; only 21.5% of screened patients were eligible for entry into the study, 
which reflects the difficulty of recruiting patients for AHF trials in general. The various 
reasons for the poor recruitment into this study have already been enumerated and were 
mostly due to renal and hepatic dysfunction, low blood pressure and procedural 
difficulties. 466  
The African-American Heart Failure Trial (A-HeFT) 465 was similar to BAHEF study but 
focused on chronic HF instead of AHF. Despite the difference in the study population, 
the mean ages of the patients were similar, both for the overall BAHEF patients and for 
the restricted biomarker sub set group. They both had similar mean LVEF of 24% and 
had most of the patients in NYHA functional class III and IV. The mean LVEDD at 
recruitment was 62.7 + 8.8 mm, similar to 65 + 9mm in A-HeFT trial.  However, the A-
HeFT patients had less hypertension, higher incidence of DM and IHD as compared to 
BA-HEF.  






cohort. We are not aware of similar study from sub Saharan Africa. We found both NT 
pro BNP and galectin 3 at baseline to predict the combined outcome of CV death or HF 
hospitalization through week 24, with galectin-3 more predictive than NT-Pro BNP (p 
values = 0.0001 and 0.0328 respectively). When the outcome of CV death alone was 
assessed, only galectin 3 at baseline predicted it through week 24 ( P = 0.0042).  This is 
similar to the findings in the PRIDE study. 442 They have shown that serum galectin-3 
levels were elevated in patients with acute HF, and are prognostic of adverse outcomes 
over a 60-day period after presentation. Similar to our study, they also showed that 
galectin-3 was able to identify those HF patients at risk for short-term death or the 
combination of death or readmission within 60 days better than NT-pro BNP. 442 In a 
meta-analysis of three studies and 893 patients, mentioned in chapter 1 (under diagnosis 
of AHF), DeBoer446 reported that patients with elevated galectin-3 above 17.8 ng/ml were 
nearly three times as likely to suffer short-term re-hospitalization (odds ratio 2.80, 95% 
CI 1.41–5.57, and 3.01, 95% CI 1.79–5.05, for 30- and 90-day readmissions, 
respectively). Also, baseline Gal3 was a predictor of re-hospitalization even after 
adjustment for age, gender, estimated glomerular filtration rates, NYHA functional class, 
LVEF and NT-pro BNP levels. The authors of this meta-analysis concluded that in acute 
HF, an elevated galectin-3 during an emergency department (ED) visits, hospital 
admission, or at hospital discharge is independently associated with early HF 
readmission. These findings are of clinical significance because the results of these 
studies suggest that galectin-3 may identify AHF patients with elevated risk for death and 
re-hospitalization independent of the severity of signs and symptoms at presentation. 






markers may help to tailor the most appropriate treatment strategy on a more 
individualized basis.  
Gal3 at baseline also strongly predicted dyspnea VAS change week 24 to baseline using 
linear regression models in this study. In a study of 115 consecutive patients with acute 
dyspnoea, Shah and colleagues443 found that dyspnoeic patients with HF and Gal3 
concentrations higher than the median value of 15.0 (11.1—19.7) had a 63% 4-year 
mortality rate; compared to patients with concentrations lower than 11.0(9.1—14.4) who 
had a 37% mortality rate (P = 0.003). 
Gal3 has been shown that cardiac macrophages are activated at an early stage in failure-
prone, hypertrophied hearts and that these macrophages express Gal3. 440 It has been 
recently identified to be involved in the pathophysiology of HF through mediation of 
myocardial fibrosis and inflammation, contributing to myocardial remodeling. 533 Given 
mechanistic data in animal models implicating galectin-3 in cardiac remodelling and LV 
dysfunction, identifying associations between galectin-3 levels and cardiac structure and 
function is critically important. Because, measurement of galectin -3 is readily feasible 
and reliable in stored plasma, and its value in diagnosis and prognostication of AHF 
patients, it becomes an important biomarker in the management of AHF patients.  
In this study we examined the associations between biomarker levels and cardiac 
structure and function through markers of LV and RV remodeling. While NT Pro BNP at 
baseline only predicted change (week 24 to baseline) in LVEDD, Galactin-3 at baseline 
predicted changes (week 24 to baseline) in all the tested markers of LV remodeling 






African subjects, Ojji and colleagues showed that NT-pro BNP was significantly 
associated with LVEF (p = 0.01) but not with TAPSE.535 
They also found that NT-pro BNP concentrations were not associated with LV mass 
index, interventricular septal wall thickness or posterior wall thickness in diastole, which 
is similar to findings of other workers. 536 
In the PRIDE study sub analysis, 443 to determine relationships between galectin-3 levels 
and cardiac structure, the authors showed that galectin-3 levels were significantly 
associated with echocardiographic markers of LV filling and diastolic function and 
valvular regurgitation. Similar to our study, they also observed significant association 
between Gal3 and poor RV systolic function (as reflected in fractional area change). In 
this study we used TAPSE to assess RV systolic dysfunction. Poor RV systolic function 
in AHF may reflect elevated LV filling pressures; thus, the association between galectin-
3 levels and markers of poor RV performance reflect similar associations between 
galectin-3 and elevated left sided pressures. It is also possible that similar processes 
occurring in the LV (remodeling, fibrosis, and hypertrophy) may be occurring in the RV.  
Indeed the role of RV structure and function in short and longer term outcomes as well as 
remodeling in AHF is underappreciated, and our findings underscores the need for further 
research to determine the importance of the RV in AHF. 
We suggest that our results provide bases for confirmation through a much bigger study 
on the role of these biomarkers in sub Saharan African patients with AHF. Development 
of bedside kits for NT Pro BNP and galectin -3 for risk stratification and referral to 
appropriate facility for immediate care will go along way in improving morbidity and 






This sub study shares the same limitations with the overall BA-HEF study. 466 In addition 
and specific to biomarker analysis, the relatively small number of patients, with relatively 
limited numbers of events, may be a limitation, as a larger cohort would allow for 
increased scrutiny of short term outcomes. Because lack of complete data we were unable 
to assess the relationship of these biomarkers with LV diastolic function. Finally, patients 
were enrolled based on admission diagnosis and treatment for AHF. While this is highly 
representative of clinical practice, bias may have been introduced in those patients where 
AHF was incorrectly diagnosed, as galectin-3 is known to be elevated in other causes of 
acute dyspnoea.537 
10.5 Conclusions   
In conclusion, we have shown that in sub Saharan African patients with AHF, both NT 
pro BNP and Gal3 at baseline predicted combined CV death or HF hospitalization.. For 
cardiac remodeling, galectin-3 at baseline predicted changes (week 24 to baseline) in all 
the tested markers of LV remodeling and RV remodeling, whereas NT-Pro BNP at 
baseline which only predicted change (week 24 to baseline) in LVEDD. Galectin-3 
provided important and significant prognostic value in identifying patients with AHF at 







11 Chapter 11: Conclusions and Future Perspective 
11.1 Introduction 
There is limited reliable information regarding causes, progression, treatment options and 
outcomes for patients with AHF in SSA. Because the various disease conditions that 
cause heart failure are prevalent in the region, knowledge of the profile of patients and 
distribution of the various aetiologies and outcomes of AHF patients in this part of the 
world is urgently needed. In addition, not much is known about the role of the 
conventional and novel biomarkers in the prognostication of these patients in SSA.  
For SSA with limited available manpower and resources, one of the best ways to address 
the gap in knowledge on AHF was to have well-designed and managed clinical registry.   
Clinical registries provide reliable data about cohorts of patients who are likely to be a 
subset of a larger population with similar disease patterns as well as opportunities for 
physicians and scientists at large to generate knowledge about the current epidemiology, 
actual course and therapies of diseases in the context of their local health care system. 
This information is crucial for an objective estimation of the future health care needs and 
expenditures. 538 They also form the basis of hypothesis formulation for further 
investigation by clinical trials. For all these reasons, a clinical registry of AHF in SSA, 
the THESUS-HF registry was established. The results of THESUS-HF revealed among 
other things that despite the encouraging results of A-HeFT trial, 465 the patients in SSA 
are rarely treated with a combination of hydralazine and nitrates. This information 
formed the bases for the RCT (BAHEF) 466 which investigated the combination treatment 







 In this doctoral work, we sought to address the several gaps in the knowledge about AHF 
in SSA using a clinical registry (THESUS-HF) and an RCT (BAHEF). The main findings 
of our investigations are summarized in the following sections below. We also speculate 
future research directions based on our findings. 
11.2 The demographic and clinical characteristics of patients with AHF.  
Results from both the THESUS registry and BAHEF study (chapter 4) have demonstrated 
that AHF in SSA affects young men and women in their early fifties, predominantly of 
black race. The aetiologies are mainly hypertension, idiopathic dilated cardiomyopathy 
and rheumatic valvular heart disease. HIV infection is as yet not a significant cause of 
AHF in SSA, despite high prevalence of the disease in the continent. Unlike the western 
population, ischemic heart disease was responsible for only a small percentage of AHF.  
Most of the patients present late in NYHA functional class III or IV had significant co-
morbidities, high readmission rates and mortality.  In addition the data from THESUS –
HF showed a high incidence of the use of aspirin in patients with non-ischemic HF, low 
rates of use of beta-blockers and combination of hydralazine and nitrates. 
The findings in THESUS-HF tally with the results of previous smaller studies conducted 
in individual SSA countries. The difference however is that this is a much larger, wider 
study and this therefore makes the findings more credible than the previous smaller 
studies. In view of the credibility of the results of this study, it should be able to spur 
participating and non-participating countries to take appropriate action to prevent the 
emergence of some of the cardiovascular diseases in their countries as their economies 
improve. For example, measures to reduce cigarette smoking, obesity, sedentary habits 






SSA countries. The same goes with the establishment of national programmes to control 
hypertension and diabetes mellitus, two diseases that are able to increase the prevalence 
of ischaemic heart disease in the countries.  
While the experience from THESUS -HF highlights the potential of generating accurate 
and reliable data on AHF and its aetiologies in SSA, the BAHEF study experience 
revealed the challenges of carrying an RCT in SSA. As outlined in chapter 3, this thesis is 
only concerned with the demography and clinical characteristics as well as the biomarker 
aspects of the BAHEF study. The details of the BAHEF study are not part of this work. 
The findings from these 2 studies are needed to assist policy makers to plan health care 
priorities in the region. 
Future perspective in terms of research on the epidemiology and treatment of AHF in 
SSA should study larger samples of AHF and focus more research on the emerging 
causes of AHF (hypertension and ischaemic heart disease) as well as HIV because of its 
importance in the region.  
i. Hypertensive heart failure: There is currently an unmet critical need in HHF to design 
and conduct an African, hospital-based registries to better understand this heterogeneous 
patient population, inform public policy decisions, and guide basic, translational, and 
clinical research. 539 This kind of registry should capture comprehensive and longitudinal 
data including hospital course and post-discharge outcomes over long period of time. 
Future studies should also incorporate quality improvement initiatives focusing on 
continuity of care from initial presentation to the early post-discharge vulnerable period. 






outcomes should be designed that comprehensively and longitudinally capture the burden 
of worsening HF (i.e., quality of life impairments and functional limitations). 539 In 
addition, most AHF patients present to the ED. Conduct of such studies requires the ED 
has an appropriate infrastructure and of teams of qualified investigators and research 
coordinators capable of screening and randomizing patients in early AHFS stages, similar 
to models of thrombolytic therapy trials for acute MI. 71 There is need for extensive 
investment in research facilities in most African countries to allow conduct of RCTs on 
NCDs, including AHF.466 
Results from epidemiological studies and animal research suggest that it may be possible 
to prevent or significantly delay many of the morbid events associated with hypertension 
(including HF) if susceptible individuals can be identified early enough in life. 540 In a 
recent doctoral thesis conducted at the University of Cape Town, D.B Ojji, 541 showed 
that the novel serum biomarker soluble ST2 differentiates hypertensives without LVH 
from those with LVH and hypertensives with LVH from hypertensive HF. This suggests 
that serum soluble ST2 may have the potential of predicting who develops HF among 
hypertensive patients. It is therefore important to note that although markers for early 
detection remain a challenge, efforts should be made to explore combinations of 
genotypic, biochemical, and physiological approaches to define and stratify the 
population at risk. 540 In addition, understanding prehypertension and its early markers 
that establish a biological risk of developing hypertension and target organ damage is an 
important research area. 
ii. Ischaemic heart disease: As discussed in chapter 1, studies from many urban areas in 






that are now leading to a rising prevalence of the major coronary risk factors. 277 There is 
also increase in urbanization leading to concomitant rise in the prevalence of 
hypertension, diabetes and dyslipidaemia, which are important risk factors of ischaemic 
heart disease. 278 At the same time many studies from SSA suggest that the unadjusted 
rates of myocardial infarction and heart failure related to ischemic heart disease remain 
low, particularly among the black African majority population on the continent. In most 
of the reports on IHD from SSA coronary angiographies were not done. It is of 
paramount importance to establish the true prevalence of, as well as the patients’ 
characteristics and outcomes in IHD using appropriate methods that will include coronary 
angiography or highly sensitive biomarkers. Equally important, the current epidemiology 
of IHD in SSA provides an opportunity to conduct public health research on primary and 
secondary prevention policies as well as cost effective treatments on IHD. 288 This should 
be spearheaded by pan African organisations.  
As their economies grow the countries need not go the way of Europe and America 
health wise. This is the one of core messages from these studies to all the health planners 
and health executors in all the SSA countries. Ischaemic heart disease must be prevented 
from becoming an epidemic in all the SSA countries as it presently is in developed 
countries for the simple reason that most SSA countries lack the resources and personnel 
required to handle the disease effectively should its prevalence continue to increase. It is 
therefore imperative that the prevalence of the disease is kept as low as possible in all 
African countries. 
iii. All the three major cardiac manifestations of HIV, namely; HIVAC, pericardial 






in addition, a growing prevalence of asymptomatic ventricular dysfunction, abnormal 
strain patterns, and a higher incidence of diastolic dysfunction is now seen in up to 64%of 
asymptomatic HIV-infected patients on ART. 542 There are significant knowledge gaps in 
HIV related heart disease in Africa. First, more research is needed to understand best 
practices in diagnosis and treating HIVAC in SSA. Second, while an inverse correlation 
between BNP levels and left ventricular function in HIV-infected patients has been seen 
in small case studies, 543 the specificity of BNP for cardiac disease in HIV-infected 
individuals is unclear. 544 There is need to investigate whether this cost-effective and 
simple test may be a useful screening tool for identifying HIVAC. Although soluble ST2 
and GDF-15 have recently been associated with cardiac dysfunction and all-cause 
mortality in a controlled study of HIV infected patients, 545 it will be interesting to assess 
their role in diagnosis and prognostication of HIVAC in SSA. Similarly, it would be 
relevant to explore the combined diagnostic utility of all non-invasive tests including 
ECG, biomarkers and echocardiography to correctly identify or exclude HIV related PH. 
Considering the epidemiological significance of cardiac abnormalities in HIV infected 
individuals and the lack of definitive data on treatment for these patients, further research 
on this is also urgently needed, particularly in SSA.  
11.3 Predictors of outcomes of AHF 
We have enumerated in chapter 1 that AHF is a complex disease and its pathophysiology 
poorly understood. This, together with the lack of understanding of the predictors of 
outcome in AHF are responsible for the lack of progress in its treatment with available 
therapies (diuretics and nitrates), such that outcomes have been largely unchanged over 






term outcomes in patients with AHF from the multicentre THESUS – HF registry. 
Interestingly, we found that despite the differences in age and disease characteristics, the 
main predictors for 6 months mortality and combined 60 days re-admission and death are 
largely similar in sub-Saharan Africa as in the rest of the world, with some exceptions 
such as the association of the HIV status with mortality (chapter 5). We also found simple 
assessments including edema, rales, oxygen saturation, and respiratory rate and asking 
the patient about general well-being are a valuable tools in predicting outcome (chapter 
6). When we looked at the echocardiographic predictors of outcome (chapter 7), we 
found left atrial size and heart rate to predict 60 day readmission or death while heart 
rate, left ventricular posterior wall thickness (PWTd), and presence of aortic stenosis 
were associated with the risk of death at 6 months.  
In this study we also found renal dysfunction is present in one-third of younger non-
ischaemic AHF patients in Africa (chapter 8) but worsening renal function (WRF), is less 
prevalent and has different predictors compared with Western cohorts. Nevertheless, we 
still found WRF to be a strong and independent predictor of death or readmission over 60 
days and all-cause death over 180 days. 
The THESUS-HF registry showed the predictive utility of ECG abnormalities among 
Africans, ECG abnormalities, though non-specific were almost universal, some with 
prognostic value for mortality. 547 In a sub analysis looking specifically at AF (chapter 9), 
it was found to be present in one fifth of AHF patients, and 44% of them had rheumatic 
valvular heart disease, with valvular AF predicting death through day 180. 
Anticoagulation prescription rates were low and decreased progressively over time; only 






In addition to the above areas of concern, the measurement of medication adherence is 
still rare in routine clinical practice and has not been well studied among HF patients in 
SSA. Poor medication adherence leads to increased rates of exacerbation causing 
hospitalizations and increased morbidity. 548 For this reason, medication adherence has 
been called the “next frontier in quality improvement” and is an important part of 
cardiovascular outcomes research. 549 Among heart failure patients, studies of medication 
adherence have also found widely differing rates of non-adherence for the different drugs 
used in HF. 548 It will be very important to develop simple methods to measure the plasma 
levels drugs like ACEI and beta-blocker or use dried blood spot testing (DBS) to assess 
adherence to medications. This is an endeavor that we have already embarked upon with 
a pilot study planned using the BAHEF samples. 
Other potential future areas of research in this area include, investigating whether hand-
held echocardiography, which is available and less expensive, could be used to 
complement other diagnostic and prognostic tools like biomarkers and conventional TTE 
in AHF. The diagnostic capability of hand held echocardiography should be tested 
against conventional TTE in AHF in low resource settings like SSA.  
Several studies have shown that AF in general and valvular AF in particular is associated 
with an increased risk of stroke or systemic embolism.  550 The finding of high prevalence 
of valvular AF and low rates of anticoagulation suggest that many AHF patients in SSA 
could be at risk of stroke and systemic embolism. In the future, 2 important questions 
need to be addressed; first the role of anticoagulation in the prevention of death, stroke 
and systemic embolism, as well as the problem associated with anticoagulation in SSA. 






there is need for an RCT of warfarin versus the new oral anticoagulants (NOACs) in 
valvular AF in the region.  
11.4 NT Pro BNP and Galectin – 3 and Outcomes  
NT-Pro BNP and Gal3 have been well shown to predict adverse outcomes in patients 
with AHF and to also serve as a guide to therapy. 442,552 In a pre-specified secondary 
analyses of the BA-HEF data, we investigated the association between plasma levels of 
NT Pro BPN and galectin 3 and cardiovascular death or heart failure hospitalization as 
well as markers of LV and RV remodeling. We found that both the two biomarker levels 
at baseline predicted combined CV death or HF hospitalization through week 24 and the 
novel biomarker Gal3 is valuable in predicting changes (week 24 to baseline) in markers 
of LV and RV remodeling in African AHF patients. Indeed the role of RV structure and 
function in short and longer term outcomes as well as remodeling in AHF is 
underappreciated, and our findings underscores the need for further research to determine 
the importance of the RV in AHF. We also believe that our results provide bases for 
confirmation through a much bigger study on the role of these biomarkers in SSA 
patients with AHF. This may lead to the development of combined bedside kits for NT 
Pro BNP and Gal3 for risk stratification and referral to appropriate facility for immediate 
care. This will go a long way in improving morbidity and mortality in these patients, 
especially in Africa where resources are scarce.  
In conclusion, several gaps exist in the contemporary knowledge of AHF globally, more 
so in SSA where the disease is prevalent. This work has provided greater insight into 
clinical characteristics of AHF, its aetiologies, outcome predictors and prognostic 






It has also raised some future research questions (Figure 11.1), which we hope to address 
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Beth Davison Momentum Research, Inc, Durham, North Carolina, United States of 
America 
Christopher Edwards Momentum Research, Inc, Durham, North Carolina, United States of 
America 
Gad Cotter Momentum Research, Inc, Durham, North Carolina, United States of 
America 
Karen Sliwa 1) Soweto Cardiovascular Research Unit, Chris Hani Baragwanath
Hospital, University of the Witwatersrand, Johannesburg, South Africa
1) Hatter Institute for Cardiovascular Research in Africa, Cape Heart
Group,University of Cape Town, Cape Town, South Africa
Center investigators 
Mahmoud U. Sani 1) Department of Medicine, Bayero University and Aminu Kano
Teaching Hospital, Kano,Nigeria
1) Department of Medicine, University of Cape Town
Okechukwu S. Ogah Department of Medicine, University College Hospital Ibadan, Ibadan, 
Nigeria 
Ministry of Health, Umuahia, Nigeria 
Anastase DZUDIE Douala General Hospital and Buea Faculty of Medicine, Cameroon 
Charles Mondo Uganda Heart Institute, Uganda 
Dike Ojji University of Abuja Teaching Hospital, Abuja , Nigeria. 
Charles Kouam Department of Medicine, Yaounde General Hospital, Yaounde, 
Cameroon 
Gerald Yonga Department of Medicine, Aga Khan University, Nairobi, Kenya 
Seringe Abdou Ba Department of cardiology, Hôpital Aristide Le Dantec, Dakar, Senegal 
Elijah Ogola Department of Clinical Medicine and Therapeutics, College of Health 
Sciences University of Nairobi, Kenyatta NationalHospital, Nairobi, 
Ken 
Karen Sliwa Soweto Cardiovascular Research Unit, Chris Hani Baragwanath 
Hospital, University of the Witwatersrand, Johannesburg, South Africa 
344 
Statement of originality document: The causes, treatment, and outcome of acute heart failure in 1006 
Africans from 9 countries. (Arch Intern Med 2012; 172:1386-1394) 
Name Responsibility 
Albertino Damasceno, Mondlane Univesity Conceived and designed the research, acquired the 
data, analysed and interpreted the data, handled 
supervision drafted the manuscript 
Bongani Mayosi, University of Cape Town Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Mahmoud Sani, Bayero University Kano Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Okechukwu Ogah, University College Hospital Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Charles Mondo, Uganda Heart institute Acquired the data, analysed and interpreted the data 
Dike Ojji, University of Abuja Acquired the data, analysed and interpreted the data, 
Anastase Dzudie, Douala General Hospital Acquired the data, analysed and interpreted the data 
Charles Kouam Kouam, Douala General Hospital Acquired the data 
Ahmed Suliman, University of Khartoum Acquired the data 
Neshaad Schrueder, University of Cape Town Acquired the data 
Gerald Yonga , Aga Khan University Acquired the data 
Serigne Abdou Ba, University of Dakar Acquired the data 
Fikru Maru, Addis Cardiac Hospital Acquired the data 
Bekele Alemayehu, Addis Cardiac Hospital Acquired the data 
Christopher Edwards, Momentum Research Inc. Performed statistical analysis, analysed and 
interpreted the data 
Beth Davison, Momentum Research Inc. Conceived and designed the research, performed 
statistical analysis, analysed and interpreted the data, 
drafted the manuscript 
Gad Cotter , Momentum Research Inc. Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
funding and supervision 
Karen Sliwa, Hatter Institute, University of Cape Town Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
supervision 
Candidate: I hereby declare that this work is wholly my own 
except where acknowledged as being the work of others (as 
listed above).      I also acknowledge the contribution of 
others (as listed above) to this work in this Statement of 
Originality. 
Dr Mahmoud Sani 2016 
Principal Supervisor: I hereby certify that all 
coauthors have provided their consent for the 
inclusion of the paper in the thesis and that the co-
authors accept the candidate’s contribution to the 
paper as described in this Statement of Originality 
Prof Karen Sliwa 2016 
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Statement of originality document: Bi treatment with hydralazine/nitrates vs. placebo in Africans 
admitted with acute HEart Failure (BA-HEF). Eur J Heart Fail. 2016 May 20. 
Name Responsibility 
Karen Sliwa, Hatter Institute, University of Cape Town Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
supervision 
Albertino Damasceno, Mondlane Univesity Conceived and designed the research, acquired the 
data, analysed and interpreted the data, handled 
supervision drafted the manuscript 
Beth Davison, Momentum Research Inc. Conceived and designed the research, performed 
statistical analysis, analysed and interpreted the data, 
drafted the manuscript 
Bongani Mayosi , University of Cape Town Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Mahmoud Sani, Bayero University Kano Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Okechukwu Ogah, University College Hospital Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Charles Mondo, Uganda Heart institute Acquired the data, analysed and interpreted the data 
Dike Ojji, University of Abuja Acquired the data, analysed and interpreted the data, 
Anastase Dzudie, Douala General Hospital Acquired the data, analysed and interpreted the data 
Charles Kouam Kouam, Douala General Hospital Acquired the data 
Gerald Yonga , Aga Khan University Acquired the data 
Serigne Abdou Ba, University of Dakar Acquired the data 
Elijah Ogola, University of Nairobi Acquired the data, analysed and interpreted the data 
Christopher Edwards, Momentum Research Inc. Performed statistical analysis, analysed and 
interpreted the data 
Gad Cotter, Momentum Research Inc. Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
funding and supervision 
Candidate: I hereby declare that this work is wholly my own 
except where acknowledged as being the work of others (as 
listed above).      I also acknowledge the contribution of 
others (as listed above) to this work in this Statement of 
Originality. 
Dr Mahmoud Sani 2016 
Principal Supervisor: I hereby certify that all 
coauthors have provided their consent for the 
inclusion of the paper in the thesis and that the co-
authors accept the candidate’s contribution to the 
paper as described in this Statement of Originality. 
Prof Karen Sliwa 2016 
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and outcomes in sub-Saharan Africa: results from the THESUS- HF registry.  Eur Heart J. 2013 Oct; 
34(40):3151-3159. 
Name Responsibility 
Karen Sliwa, Hatter Institute, University of Cape Town Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
supervision 
Beth Davison, Momentum Research Inc. Conceived and designed the research, performed 
statistical analysis, analysed and interpreted the data, 
drafted the manuscript 
Bongani Mayosi , University of Cape Town Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Albertino Damasceno, Mondlane Univesity Conceived and designed the research, acquired the 
data, analysed and interpreted the data, handled 
supervision drafted the manuscript 
Mahmoud Sani, Bayero University Kano Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Okechukwu Ogah, University College Hospital Conceived and designed the research, acquired the 
data, analysed and interpreted the data, drafted the 
manuscript 
Charles Mondo, Uganda Heart institute Acquired the data, analysed and interpreted the data 
Dike Ojji, University of Abuja Acquired the data, analysed and interpreted the data, 
Anastase Dzudie, Douala General Hospital Acquired the data, analysed and interpreted the data 
Charles Kouam Kouam, Douala General Hospital Acquired the data 
Ahmed Suliman, University of Khartoum Acquired the data 
Neshaad Schrueder, University of Cape Town Acquired the data 
Gerald Yonga , Aga Khan University Acquired the data 
Serigne Abdou Ba, University of Dakar Acquired the data 
Christopher Edwards, Momentum Research Inc. Performed statistical analysis, analysed and 
interpreted the data 
Gad Cotter , Momentum Research Inc. Conceived and designed the research, analysed and 
interpreted the data, drafted the manuscript, handled 
funding and supervision 
Candidate: I hereby declare that this work is wholly my own 
except where acknowledged as being the work of others (as 
listed above).      I also acknowledge the contribution of 
others (as listed above) to this work in this Statement of 
Originality. 
Dr Mahmoud Sani 2016 
Principal Supervisor: I hereby certify that all 
coauthors have provided their consent for the 
inclusion of the paper in the thesis and that the co-
authors accept the candidate’s contribution to the 
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Prof Karen Sliwa 2016 
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Name Responsibility 
Mahmoud Sani, Bayero University Kano Conceived and designed the research, acquired 
the data, analysed and interpreted the data, 
drafted the manuscript 
Beth Davison, Momentum Research Inc. Conceived and designed the research, performed 
statistical analysis, analysed and interpreted the 
data, drafted the manuscript 
Gad Cotter , Momentum Research Inc. Conceived and designed the research, analysed 
and interpreted the data, drafted the manuscript, 
handled funding and supervision 
Karen Sliwa, Hatter Institute, University of Cape Town Conceived and designed the research, analysed 
and interpreted the data, drafted the manuscript, 
handled supervision 
Christopher Edwards, Momentum Research Inc. Performed statistical analysis, analysed and 
interpreted the data 
Licette Liu, University of Groningen Conceived and designed the research, analysed 
and interpreted the data, drafted the manuscript 
Albertino Damasceno, Mondlane Univesity Conceived and designed the research, acquired 
the data, analysed and interpreted the data, 
handled supervision drafted the manuscript 
Bongani Mayosi , University of Cape Town Conceived and designed the research, acquired 
the data, analysed and interpreted the data, 
drafted the manuscript 
Okechukwu Ogah, University College Hospital Conceived and designed the research, acquired 
the data, analysed and interpreted the data, 
drafted the manuscript 
Charles Mondo, Uganda Heart institute Acquired the data, analysed and interpreted the 
data 
Anastase Dzudie, Douala General Hospital Acquired the data, analysed and interpreted the 
data 
Dike Ojji, University of Abuja Acquired the data, analysed and interpreted the 
data,  
Adrian Voors, University of Groningen Conceived and designed the research, analysed 
and interpreted the data, drafted the manuscript 
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Originality. 
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on Harmonisation Good Clinical Practice (ICH GCP) and Declaration of Helsinki guidelines. 
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4th Floor Chris Barnard !Building 
Dear Prof 511 i wa-Haehn le 
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Tha11k y,011.1 for responding t·o the issues raised by the Faculty of Health Sdences Human Research 
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It is a pleasure to inform you th at the H REC has formil Hy approved the above-rnenti oned study 
once MCC approval i.s r-eceived. 
App:roval 1 s granted for one year tUI the ,30,th Ap1i"I 2013:,  
Please submit a progress fronm, usingi the standardise<il Annual Report Form (IFHS016), i,f the study 
continues beyond the approv.a period. Please submit a Standard Olosure fbrm (FHSOl0) if the study 
is completed within the approval period. 
Please note th.at the ongoing ethical conduct of the study remains. the responsibility of the principal 
I 11 v,estigator. 
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I I Federal Wide Assurance Number: FWAOOOO 1637.
Institutional 1Revi1ew 'Board (IRB) number: lRB00,001938 
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Harmonisa1tion Good Ollnical Praietice (!CH GCP) and Declaration of Helsinki guidelines, 
11.lholffl,H HR C d'OJ.7 /:2.012.- 1011; pril 20:12 
signature removed
The Human Research Ethics Committee granting this approval is in compliance with the ICH 
Harmonised Tripartite Guidelines E6: Note for Guidance on Good Cl in ical Practice (CPMP/ICH/135/95) 
and FDA Code Federal Regulation Part SO, 56 and 312. 




UNIVERSfl'Y OF CAPE TOWN 
' 
Ol March. 2008 
REC REF: 068/2008 
Prof BM Mayosi 
Department of Medicine 
Dear Prof Mayosi 
Health Sciences Faculty 
Research Ethics Comminee 
Room Esi.-24 Groote Schuui Hospital Old Maio Building 
Observatory 7925 
1'tlepbone [02\) 406 63l8 • Facsunik f02l) 406 64t t 
e-mail:shantel.lakay@uct.ac.za 
1ROJECT TITLE: THE SUB-SAHARAN AFRICA SURVEY OF HEART FAILURE (THESUS· 
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2009). 
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Institutional Review Board: TRB00001938 
"Jhig serves to confirm that the Univcnity of Cape Town Research Ethics Committee: complies to the Ethics 
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signature removed
Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 1
Baseline
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute     • PINK — retain at site
Demographics
1 Date of admission: Time: 
2 Date of birth: 
3 Sex:  ■1 Male ■1 Female
4 Race:  ■1 Black ■2 Asian     ■3 Caucasian
5 Height:  ___ ___ ___ cm
6 Weight:  ___ ___ ___ kg
Pre-Admission
1 Number of acute heart failure (AHF) admissions in the last 12 months:  ___ ___
2 Date of last acute heart failure (AHF) admission:  OR  ■96 NA
3 NYHA (New York Heart Association) classification 1 month prior to admission:  ■ I    ■ II    ■ III    ■ IV    ■ NA
ECG (Electrocardiogram)
Please attach copy of admission ECG in the CRF divider pocket.
Baseline Labs  First obtained at Admission
___ ___ /___ ___ ___ /200 ___
day month year
___ ___ /___ ___ ___ /___ ___ ___ ___
day month year
___ ___ : ___ ___
00:00 to 23:59
___ ___ /___ ___ ___ /200 ___
day month year
Lab Value Units
1 Creatinine __________ ■ mg/dL ■ µmol/L
2 BUN (blood urea nitrogen)/urea __________ ■ mg/dL ■ mmol/L
3 Sodium __________ ■ mmol/L ■ mEq/L
4 Glucose __________ ■ mg/dL ■ mmol/L
5 Hemoglobin __________ ■ g/L ■ mmol/L     ■ g/dL
6 Total WBC (white blood count) __________ ■ x10
9/L or 103/mm3
■ /mm3 or /cumm or /µL or /mcL
7 Lymphocytes % __________ %
8 Cholesterol __________ ■ mg/dL ■ mmol/L
9 Triglycerides __________ ■ mg/dL ■ mmol/L
10 Peak CK (creatine kinase) __________ ■ IU/L ■ µkat/L      ■ nkat/L
11 Peak CK-MB (creatinine kinase myocardial band) __________ ■ IU/L ■ µg/L ■ µkat/L     ■ ng/mL■ nkat/L ■ %
12 Peak Troponin __________ ng/mL
13 NT Pro BNP (N Terminal Prohormone B-type
natriuretic peptide) __________ pg/mL OR BNP __________ pg/mL
Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 2
Baseline
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute     • PINK — retain at site
Baseline Characteristics at Time of Admission
1 Diabetes  ................................ ■0 No  ■1 Yes ➞ If Yes: Check all that apply:  ■ Diet     ■ Oral     ■ Insulin
2 Ischemic heart disease  ...... ■0 No  ■1 Yes ➞ If Yes: Check all that apply:
■ History of MI (myocardial infarction)
■ History of CABG (coronary artery bypass graft)
■ History of PCI (percutaneous coronary intervention)
■ Stable angina ➞ If Yes: Canadian Cardiovascular Society
Class. of angina:  ■ I    ■ II    ■ III    ■ IV





■ Other (specify): ____________________________________
4 HIV test positive  ■99 Unknown ■0 No  ■1 Yes ➞ If Yes: Antiretroviral therapy? ■0 No     ■1 Yes
5 Hypertension  ........................ ■0 No  ■1 Yes 
6 Hyperlipidemia  .................... ■0 No  ■1 Yes 
7 Stroke  .................................... ■0 No  ■1 Yes 
8 PVD (peripheral vascular disease) .... ■0 No  ■1 Yes 
9 Smoking  ................................ ■0 No  ■1 Yes 
10 Malignancy  .......................... ■0 No  ■1 Yes 
11 Depression  ............................ ■0 No  ■1 Yes 
12 Dementia  .............................. ■0 No  ■1 Yes 
13 Atrial fibrillation  .................. ■0 No  ■1 Yes 
14 Pacemaker  ............................ ■0 No  ■1 Yes 
15 Pericardial disease  .............. ■0 No  ■1 Yes
16 Cardiomyopathy  .................. ■0 No  ■1 Yes
17 Cor pulmonale  .................... ■0 No  ■1 Yes
18 Ejection fraction:  __________ %

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 4
Hospitalization
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute • PINK — retain at site
Hospital Data  See opposite page for instructions (continued)




































































































































































































Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 5
Outcomes
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute • PINK — retain at site
Outcome
Hospital discharge date:  
Death
1 Date of death:  
2 In hospital at time of death? .................................................. ■0 No ■1 Yes
3 Sudden death?  ........................................................................ ■0 No ■1 Yes
4 During acute heart failure?  .................................................. ■0 No ■1 Yes
5 During acute ischemia?  .......................................................... ■0 No ■1 Yes
6 Associated with arrhythmia?  ................................................ ■0 No ■1 Yes
7 Other cardiac?  .......................................................................... ■0 No ■1 Yes  ➞ Specify:  __________________
8 Non-cardiac?  ............................................................................ ■0 No ■1 Yes  ➞ Specify:  __________________
___ ___ /___ ___ ___ /200 ___
day month year
___ ___ /___ ___ ___ /200 ___
day month year
Rehospitalization Within 6 Months
Rehospitalization #1 Rehospitalization #2 Rehospitalization #3
Admission Date ➞ ___ ___ /___ ___ ___ /200 ___
day month year
___ ___ /___ ___ ___ /200 ___
day month year




Heart Failure ■0 No ■1 Yes ■0 No ■1 Yes ■0 No ■1 Yes
Ischemia ■0 No ■1 Yes ■0 No ■1 Yes ■0 No ■1 Yes
Arrhythmia ■0 No ■1 Yes ■0 No ■1 Yes ■0 No ■1 Yes
Other cardiac
■0 No
■1 Yes ➞ Specify:
______________________
■0 No
■1 Yes ➞ Specify:
______________________
■0 No




■1 Yes ➞ Specify:
______________________
■0 No
■1 Yes ➞ Specify:
______________________
■0 No
■1 Yes ➞ Specify:
______________________
Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 6
Echocardiographic Evaluation
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute     • PINK — retain at site
Echocardiographic Evaluation
Date of echocardiogram ___ ___ /___ ___ ___ /200 ___
day month year
1 Heart rate ___ ___ ___ bpm
Dimensions and LV Function Value
2 Left ventricular size systole _______________ mm
3 Left ventricular size diastole _______________ mm
4 Ejection fraction _______________ %
5 Intra ventricular septum (diastole) _______________ mm
6 Posterior wall (diastole) _______________ mm
Diastolic Function Value
7 Left atrial size, antero-posterior _______________ mm
8 Left atrial size, planimetry _______________ mm2
9 Mitral E-wave _______________ mm/sec
10 E-wave deceleration time _______________ msec
11 Mitral A-wave _______________ mm/sec
12 Mitral A-wave (duration) _______________ msec
Valvular Severity Rheumatic?
13 Aortic stenosis ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
14 Aortic regurgitation ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
15 Mitral stenosis ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
16 Mitral regurgitation ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
17 Tricuspid regurgitation ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
19 Other ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
Pericardial Effusion Severity Tuberculosis?
20 Pericardial effusion ■0 None ■1 Mild    ■2 Moderate    ■3 Severe ■0 No ■1 Yes    ■ NA
21 Other conditions ■0 No ■1 Yes ➞ If Yes: Specify:
22 Other conditions ■0 No ■1 Yes ➞ If Yes: Specify:
Thesus-HF_V1.0_21 MAR 2007 2007 DCRI — Confidential CRF, page 7
Diagnosis
Patient Number: ___ ___ – ___ ___ ___ Patient’s Initials: ___ ___ ___
THESUS-HF
WHITE and YELLOW — Duke Clinical Research Institute     • PINK — retain at site
Diagnosis 
Type of Heart Failure (HF) (please answer all questions):
1 Diastolic dysfunction ■0 No ■1 Yes
2 Systolic dysfunction ■0 No ■1 Yes
3 Dilated—idiopathic cardiomyopathy (CM) ■0 No ■1 Yes
4 Peripartum cardiomyopathy ■0 No ■1 Yes
5 Ischemic heart disease ■0 No ■1 Yes
6 HIV cardiomyopathy ■0 No ■1 Yes
7 Rheumatic heart disease ■0 No ■1 Yes
8 Hypertensive cardiomyopathy (HTN CM) ■0 No     ■1 Yes
9 Endomyocardial fibroelastosis ■0 No ■1 Yes
10 Pericardial effusion/tamponade ■0 No ■1 Yes
11 Other factors ■0 No ■1 Yes ➞ If Yes: Specify:  _______________________
12 Other factors ■0 No ■1 Yes ➞ If Yes: Specify:  _______________________




Patient Number Full Name Phone Number Address ID Number
B-A-HEF CRF
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Date and time of hospital admission:
Gender (check only one): 1 Male 2 Female
Age at screening:
Date and time of start of screening: __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
__ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
Race (check only one): 1 African or black
2 Colored or mixed race






Date and time informed consent signed: __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
3.
Country of Birth:3. _______________________________________________









8 Ndebele  
9 Northern Sotho 
12 Portuguese  
14 Sotho  
16 Swahili  
17 Swazi  
18 Tsonga    
19 Tswana   
10 Oromo  
23 Yoruba   
15 Spanish  21 Wolof  
20 Venda   
22 Xhosa   
24 Zulu   
13 Shona   99 Other: __________
4 Arab 
5 Caucasian or white 
99 Other: _______________
Highest education level completed (check only one):6. 1 None
2 Never in school
3 Primary 
4 Secondary  
5 College  
6 University 
Occupation (nurse, farmer, etc.):7. _______________________________________________
Occupation type (check only one):8. 1 None
2 Unemployed
3 Student 
4 Employed casual   
5 Employed part time  
6 Employed full time  
7 Self employed   
8 Homemaker or housewife   
9 Government grants or pension   
99 Other: _______________
Monthly per capita income:9. 1 None
2 Below 30 USD
3 30 to 99 USD 
4 100 to 999 USD   
5 1000 to 1999 USD   
6 2000 to 4999 USD   
7 more than 5000 USD   
Accommodation type (check only one):10.
1 House or permanent building 
2 Shack on serviced site with sanitation 
3 Shack without sanitation  
4 Traditional housing or hut  
99 Other: _______________
11 Pedi  
If no personal income, income of
household breadwinner. 
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 1: Screening
Hospitalization for Heart Failure in the Past Year
Has the subject been hospitalized (i.e., kept overnight) for heart failure in the past year:
0 No
1 Yes   If Yes: Number of hospitalizations: ________
Date of discharge of last hospitalization: __ __/__ __ __/__ __ __ __
dd mmm        yyyy(not including this hospitalization)
Vital Signs / Physical Assessment
Blood pressure #1:
systolic   diastolic
Heart Rate at screening:
Respiration at screening:
Body temp. at screening:
Weight at screening:
__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F






__ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
Blood pressure #2:
systolic   diastolic
__ __ __/__ __ __ mmHg __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
Blood pressure #3:
systolic   diastolic
__ __ __/__ __ __ mmHg __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
Chest X-Ray
Was a chest x-ray performed? 0 No 1 Yes




Height: __ __ __ . __ cm or __ __ __ . __  in6.
Blood pressures between admission and randomization: 
Body Mass Index (BMI): __ __ . __ 7.
Atrial Fibrillation at Screening
Was the subject in atrial fibrillation/flutter during screening?
0 No 1 Yes 88 Not performed, provide reason: _____________________
B-A-HEF CRF
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_______________Was NT-pro-BNP measured? 0 No 1 Yes If Yes, provide value:
Was Troponin measured? 0 No 1 Yes
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Medical History At Time of Admission
Does the subject have a known current or past history of any of the following disorders/conditions:
3. Hypertension………...…...…………………………………………………………………. 0 No 1 Yes
4. Hyperlipidemia………...………………...………………………………………………….. 0 No 1 Yes
5. Stroke or other cerebrovascular event…………………………………...…...………….. 0 No 1 Yes
6. Cigarette smoking………………………………..…………………………………………. 0 No 1 Yes
7. Depression………..…………………………………………………………………………. 0 No 1 Yes
0 No 1 Yes9. Peripheral vascular disease (PVD)……….……………………………………………….
0 No 1 Yes10. Malignancy……..…………………………………………………………………………….
0 No 1 Yes11. Pacemaker (other than biventricular)……..……………………………………………….…
0 No 1 Yes12. Biventricular pacing………...………………………...……..………………………………
0 No 1 Yes13. Automatic internal cardiac defibrillator (AICD)…….……..………………………………
0 No 1 Yes14. Asthma, bronchitis, chronic obstructive pulmonary disease (COPD)….………………
2. Diabetes mellitus..………………………………………………………………….………. 0 No 1 Yes
If Yes, controlled by: (check all that apply) 1 Insulin 1 Oral antidiabetic agents 1 Diet Only
Visit 1: Screening
0 No 1 Yes15. Dementia...……..…………………………………………………………………………….
0 No 1 Yes16. Pericardial disease………………..……..……………………………………………….…
0 No 1 Yes17. Cardiomyopathy….………...………………………...……..………………………………
0 No 1 Yes24. Cor pulmonale…………………………………..…….……..………………………………
0 No 1 Yes25. Tuberculosis………………………………………………………………….………………
8. HIV test positive..................................................................................
0 No 1 Yes 
77 Unknown 0 No 1 Yes
If Yes, Antiretroviral therapy?
19. Peripartum cardiomyopathy………….……………………………………………………. 0 No 1 Yes
20. HIV cardiomyopathy…..………………...………………………………………………….. 0 No 1 Yes
0 No 1 Yes21. Hypertrophic cardiomyopathy...………………..………………………………………….
22. Endomyocardial fibroelastosis.……………………………………………………………. 0 No 1 Yes
18. Dilated idiopathic cardiomyopathy….…………………………………………….………. 0 No 1 Yes
23. Pericardial effusion/tamponade................................................................................... 0 No 1 Yes
1. Family history of cardiovascular disease..……………………………………….………. 0 No 1 Yes
0 No 1 Yes26. Beta-thalassemia...……………………………..…….……..………………………………
0 No 1 Yes27. Sickle-cell anemia..………………………………………………………….………………
0 No 1 Yes28. Chronic liver disease.……………………………………………………….………………
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Medical History At Time of Admission (continued) 
0 No 1 Yes32. Ischemic heart disease……..………………………...………….…………………………
0 No 1 YesIf Yes, answer the following: 32.1. Myocardial infarction (MI)…...……………
0 No 1 Yes32.2. Coronary artery bypass graft (CABG)…..
0 No 1 Yes32.3. Percutaneous intervention (PCI)...………
0 No 1 Yes33. Atrial fibrillation/flutter..……..…………………………………….…………………………
1 ChronicIf Yes, provide type (check only one): 2 Paroxysmal 3 Persistent 
35. Congestive heart failure (CHF)... 0 No 1 Yes New York Heart Association classification:
(1 month prior to admission) (check only one) 1 I 2 II 3 III 4 IV
36. Angina...………………………..... 0 No 1 Yes Canadian Cardiovascular Society classification:
(check only one) 1 I 2 II 3 III 4 IV
Visit 1: Screening
0 No 1 Yes31. Valvular disease………….....………………………...………….…………………………
0 No 1 YesIf Yes, answer the following: 31.1. Mitral stenosis………………...……………
0 No 1 Yes31.2. Mitral regurgitation…………………….…..
0 No 1 Yes31.3. Aortic stenosis…………………......………
0 No 1 Yes31.4. Aortic regurgitation…………………….…..
0 No 1 Yes31.5. Other (specify):____________________
34. Most recent Ejection Fraction (EF) (if known) ______% Date of assessment: __ __/__ __ __/__ __ __ __
   dd mmm yyyy(including this hospitalization) 
29. Rheumatic heart disease……………..…………………………………...…...………….. 0 No 1 Yes
30. Rheumatic disease……………..…………………….….………………...…...………….. 0 No 1 Yes
0 No 1 YesIf Yes, answer the following: 30.1. Scleroderma (systemic sclerosis).………
0 No 1 Yes30.2. Mixed connective tissue disease...….…..
0 No 1 Yes30.3. Systemic lupus erythematosus.....………
0 No 1 Yes30.4. Rheumatoid arthritis………………….…..
0 No 1 Yes30.7. Other (specify):____________________
0 No 1 Yes30.5. Systemic necrotizing vasculitis…..….…..
0 No 1 Yes30.6. Idiopathic inflammatory myositis...….…..
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 1: Screening
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes 88 NA
Echocardiographic Evaluation
Date and time of echocardiogram: __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
1.  Heart Rate: __ __ __ bpm
Valvular Severity Rheumatic?
18. Aortic Stenosis:
0 None/trace 1 Mild 2 Moderate  3 Severe 0 No  1 Yes19. Aortic Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes20. Mitral Stenosis:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes21. Mitral Regurgitation:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes22. Tricuspid Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes23. Other:
Pericardial Effusion Severity
0 None 1 Mild 2 Moderate  3 Severe24. Pericardial effusion:
25. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
26. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
Left Heart Dimensions and LV Function
2. Left ventricular size systole:
3. Left ventricular size diastole:
4. Ejection Fraction:      __ __ %
5. Intra ventricular septum (diastole):
6. Posterior wall (diastole):
Diastolic Function
7. Left atrial size, antero-posterior:
8. Left atrial size, planimetry:
9. Mitral E-wave velocity:
10. E-wave deceleration time:
11. Mitral A-wave velocity:










































99 Other: ____________ 
0 None 1 Mild 2 Moderate  3 Severe13. Dilatation right ventricle:
Right Heart Dimensions and Function Severity
 3 Severe14. Dilatation right atrium: 0 None 1 Mild 2 Moderate
15. Tricuspid regurgitation (TR) velocity: __________
1 cm/sec
99 other: __________
16. Right ventricular systolic pressure (RVSP): __________ mmHg
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 2: Randomization
Eligibility 
Did the subject meet all screening eligibility criteria?
1 Yes
0 No, If No, specify criteria not met:
Inclusion criteria number(s): _____, _____, _____, _____, ____
Exclusion criteria number(s): _____, _____, _____, _____, ____
Randomization (Visit 2) Date
Date study drug first dispensed: __ __/__ __ __/__ __ __ __
dd mmm        yyyy
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F






6 Minute Walk Test and Subject Self-Report of Symptoms
6MWT Distance:
Dyspnea VAS:
__ __ __ __ m
__ __ __ mm
1.
2.
General Well-Being VAS: __ __ __ mm3.
Biomarker Samples
Were samples for biomarker assays drawn? 0 No 1 Yes, Date:
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
__ __/__ __ __/__ __ __ __
dd mmm        yyyy
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
Final V2.0 13 February 2013 Confidential
CRF, Page 9
Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 2: Randomization
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 3: Discharge or Day 7
Subject Status
Did the subject attend the scheduled visit?2.
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F






6 Minute Walk Test and Subject Self-Report of Symptoms
6MWT Distance:
Dyspnea VAS:
__ __ __ __ m
__ __ __ mm
1.
2.
General Well-Being VAS: __ __ __ mm3.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
Provide the type of assessment performed:1. 1 Discharge 2 Day 7
Discharge from Index Hospitalization 
Was the subject discharged prior to Week 24?
0 No
2 Yes, Discharge date: __ __/__ __ __/__ __ __ __
dd          mmm    yyyy
1 Yes, Due to Death, Complete Death Page
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 3: Discharge or Day 7
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 4: Week 2
Subject Status
Did the subject attend the scheduled visit?1.
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F






Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
Rehospitalization Details
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 4: Week 2
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 5: Week 4
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 5: Week 4
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 6: Week 8
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
6 Minute Walk Test and Subject Self-Report of Symptoms
6MWT Distance:
Dyspnea VAS:
__ __ __ __ m
__ __ __ mm
1.
2.
General Well-Being VAS: __ __ __ mm3.
Visit 6: Week 8
Biomarker Samples
Were samples for biomarker assays drawn? 0 No 1 Yes, Date: __ __/__ __ __/__ __ __ __
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 6: Week 8
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 7: Week 12
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 7: Week 12
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 8: Week 16
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 8: Week 16
Route Medication




























































































































































Final V2.0 13 February 2013 Confidential
CRF, Page 23
Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 9: Week 20
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 9: Week 20
Route Medication
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 10: Week 24
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log1.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
6 Minute Walk Test and Subject Self-Report of Symptoms
6MWT Distance:
Dyspnea VAS:
__ __ __ __ m
__ __ __ mm
1.
2.
General Well-Being VAS: __ __ __ mm3.
Visit 10: Week 24
Biomarker Samples
Were samples for biomarker assays drawn? 0 No 1 Yes, Date: __ __/__ __ __/__ __ __ __
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Visit 10: Week 24
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes 88 NA
Echocardiographic Evaluation
Date and time of echocardiogram: __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
1.  Heart Rate: __ __ __ bpm
Valvular Severity Rheumatic?
18. Aortic Stenosis:
0 None/trace 1 Mild 2 Moderate  3 Severe 0 No  1 Yes19. Aortic Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes20. Mitral Stenosis:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes21. Mitral Regurgitation:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes22. Tricuspid Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes23. Other:
Pericardial Effusion Severity
0 None 1 Mild 2 Moderate  3 Severe24. Pericardial effusion:
25. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
26. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
Left Heart Dimensions and LV Function
2. Left ventricular size systole:
3. Left ventricular size diastole:
4. Ejection Fraction:      __ __ %
5. Intra ventricular septum (diastole):
6. Posterior wall (diastole):
Diastolic Function
7. Left atrial size, antero-posterior:
8. Left atrial size, planimetry:
9. Mitral E-wave velocity:
10. E-wave deceleration time:
11. Mitral A-wave velocity:










































99 Other: ____________ 
0 None 1 Mild 2 Moderate  3 Severe13. Dilatation right ventricle:
Right Heart Dimensions and Function Severity
 3 Severe14. Dilatation right atrium: 0 None 1 Mild 2 Moderate
15. Tricuspid regurgitation (TR) velocity: __________
1 cm/sec
99 other: __________
16. Right ventricular systolic pressure (RVSP): __________ mmHg
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Visit 10: Week 24
Route Medication
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Study Drug Accountability Log





1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __

















Study Drug Kit Label(s)
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __





Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __





Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
__ __/__ __ __/__ __ __ __






__ __/__ __ __/__ __ __ __
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Study Drug Accountability  
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __















Study Drug Kit Label(s)
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __





Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __





Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
__ __/__ __ __/__ __ __ __






__ __/__ __ __/__ __ __ __






__ __/__ __ __/__ __ __ __
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Study Drug Accountability Log
Study Drug Accountability  
1 Subject withdrew consent
2 Death
99 Other (specify): __________
3 Study drug intolerability 
Was study drug dispensed?
0 No, specify:
1 Yes, provide details →
__ __/__ __ __/__ __ __ __















Study Drug Kit Label(s)
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
Affix study drug kit
 label(s) here
ISDN or placebo
__ __/__ __ __/__ __ __ __






__ __/__ __ __/__ __ __ __






__ __/__ __ __/__ __ __ __
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to study drug Was this event 
serious?
Stop date or ongoing 
at final exam
__ __/__ __ __/__ __ __ __











__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam




   interrupted









__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily





__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily





__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily
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to study drug Was this event 
serious?
Stop date or ongoing 
at final exam
__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
0 No 1 Yes, If Yes. Provide details below:
X
5 Temporarily
   interrupted





__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily





__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily





__ __/__ __ __/__ __ __ __














__ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
OR
1 Ongoing at final exam
X
5 Temporarily
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Rehospitalization Form
Rehospitalization Details
Was the subject discharged?
0 No, due to death Complete Death Page
1 Yes If Yes, record discharge date:
Date of hospital admission: __ __/__ __ __/__ __ __ __
dd mmm        yyyy
1.
Provide primary cause of hospitalization:2.
3.
__ __/__ __ __/__ __ __ __
dd mmm        yyyy
Provide the type of rehospitalization:4. 1 Planned
2 Unplanned, Please report event on SAE Form
Did heart failure contribute to rehospitalization?5. 0 No 1 Yes
Did renal impairment contribute to rehospitalization?6. 0 No 1 Yes
Describe the hospital course: ____________________________________________________________7.
____________________________________________________________________________________
____________________________________________________________________________________
Physical Examination on Presentation
Diagnostic Findings
ECG:                                                                   __________________________________________________________________
________________________________________________________________________________________________________
Chest x-ray:                                                         __________________________________________________________________
________________________________________________________________________________________________________













systolic   diastolic
Heart Rate:
Respiration:
__ __ __ bpm





Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
Edema:
Rales:
Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3






1 Normal 2 Abnormal 
1 Normal 2 Abnormal
1 Normal 2 Abnormal
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Rehospitalization Form
Medication Details
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Rehospitalization Form
Rehospitalization Details
Was the subject discharged?
0 No, due to death Complete Death Page
1 Yes If Yes, record discharge date:
Date of hospital admission: __ __/__ __ __/__ __ __ __
dd mmm        yyyy
1.
Provide primary cause of hospitalization:2.
3.
__ __/__ __ __/__ __ __ __
dd mmm        yyyy
Provide the type of rehospitalization:4. 1 Planned
2 Unplanned, Please report event on SAE Form
Did heart failure contribute to rehospitalization?5. 0 No 1 Yes
Did renal impairment contribute to rehospitalization?6. 0 No 1 Yes











Physical Examination on Presentation
Blood pressure:
systolic   diastolic
Heart Rate:
Respiration:
__ __ __ bpm





Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
Edema:
Rales:
Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3







ECG:                                                                   __________________________________________________________________
________________________________________________________________________________________________________
Chest x-ray:                                                         __________________________________________________________________
________________________________________________________________________________________________________
Echo:                                                                   __________________________________________________________________
________________________________________________________________________________________________________
Other: __________________________________________________________________________________________________
1 Normal 2 Abnormal 
1 Normal 2 Abnormal
1 Normal 2 Abnormal
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Rehospitalization Form
Medication Details
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Did the subject die between signing informed consent and completing the study?
0 No
1 Yes, Complete the following section and report event on SAE Form.
__ __/__ __ __/__ __ __ __
dd          mmm    yyyy
0 No 
1 Yes Complete Rehospitalization Form
77 Unknown, subject lost to follow up or withdrew consent from review of records
Provide primary cause of death:2.
Did the death occur in hospital?3.
Date of death:1.






Describe the pertinent clinical history as is relates to the cause of death: __________________________5.
1 Heart failure/pump failure 
2 Sudden death
3 Cerebral vascular accident (CVA)/stroke  
4 Sepsis 
99 Other: __________________________
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Did the subject withdraw consent from participating in any aspects of the study?
Withdrawal of Consent
Subject Status
1. Withdrawal of consent date: __ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
1 Yes, Please enter date of withdrawal of consent
1 Not willing to receive any additional study drug
Withdrawal of Consent Details  
2. Level of withdrawal of consent (check all that apply):
1 Not willing to provide any additional laboratory samples (blood draws and urine samples)
1 Not willing to provide detailed information about symptoms or be examined for study purposes.
1 Not willing to be contacted to check on progress.
1 Not willing to allow use of information from hospital records or health registration system to check 
on progress.
0 No
3. Did the subject re-consent to any of the levels above?
1 Yes, Please provide the level(s) the subject is now willing to  participate (check all that apply):
0 No
1 Now willing to receive any additional study drug
1 Now willing to provide any additional laboratory samples (blood draws and urine samples)
1 Now willing to provide detailed information about symptoms or be examined for study purposes.
1 Now willing to be contacted to check on progress.
1 Now willing to allow use of information from hospital records or health registration system to 
check on progress.
B-A-HEF CRF
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2. End of study date: __ __/__ __ __/__ __ __ __
   dd        mmm            yyyy
1. Did the subject complete the double blind phase of the study? 1 Yes, completed Week 24 Visit
0 No
If No, choose primary reason (check only one)
3 Subject was lost to follow-up, enter date last known alive below
1 Subject withdrew consent from follow-up, enter date subject 
withdrew below and fill out Withdrawal of Consent Page
2 Death, enter date subject died below and fill out Death Page
I have reviewed and found all the case report form data pertaining to this subject to be complete and accurate.
Investigator: __________________________________ Date: __ __/__ __ __/__ __ __ __
   dd        mmm            yyyySignature of Investigator
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Unscheduled Visit: Early Termination of Study Drug
Vital Signs / Physical Assessment
Blood pressure:





__ __ __ bpm
__ __ __/__ __ __ mmHg
__ __ breaths/min
__ __ __ . __ °C or __ __ __ . __  °F







Has the subject been rehospitalized since the last assessment?
0 No 
1 Yes Complete Rehospitalization Page
Physician Assessment     (Check only one answer per question)
1. Dyspnea on exertion: 0 None 1 Mild 2 Moderate 3 Severe (including dyspnea at rest)
2. Orthopnea: 0 None 1 1 pillow (10 cm) 2 2 pillows (20 cm) 3 > 30 degrees
3. Edema:
4. Rales:
5. Jugular venous pulse (JVP):
0 0 1 1 + 2 2+ 3 3+
0 No rales 1 Rales < 1/3 2 Rales 1/3-2/3 3 Rales > 2/3
0 < 6 cm 1 6-10 cm 2 > 10 cm 88 Not Evaluable
Was study drug accountability performed? 0 No 1 Yes If Yes, complete the Study Drug Accountability Log
88 NA, subject still hospitalized
Were there any Adverse Events since the last assessment?
Record all medications on Concomitant Medication Log
1.
Adverse Events
0 No 1 Yes
If Yes, complete the Non-Serious Adverse Events CRF page or the Serious Adverse Event Form, as applicable.
Reason for dose change:3. 1 As per protocol
2 Adverse Event
88 Not Applicable
99 Other (specify): ________________________
Subject Status
Did the subject attend the scheduled visit?1.
Date of assessment: __ __/__ __ __/__ __ __ __






If No, provide source of information for this report:
0 No 1 Yes
3 Subject’s neighbor/friend
4 Health care provider
5 Public death registry 
6 Other physician
7 Other (specify): 
1 Alive
2 Dead Complete Death page
77 Unknown 
If indirect contact, provide the subject status:
Study Drug Administration 
2 Two tablets 3x daily
1 One tablet 3x daily
Dose level assigned: 0 None2. HYD or placebo:
2 Two tablets 3x daily
1 One tablet 3x daily
0 NoneISDN or placebo:
B-A-HEF CRF
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
6 Minute Walk Test and Subject Self-Report of Symptoms
6MWT Distance:
Dyspnea VAS:
__ __ __ __ m
__ __ __ mm
1.
2.
General Well-Being VAS: __ __ __ mm3.
Unscheduled Visit: Early Termination of Study Drug
Biomarker Samples
Were samples for biomarker assays drawn? 0 No 1 Yes, Date: __ __/__ __ __/__ __ __ __
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Unscheduled Visit: Early Termination of Study Drug
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes 88 NA
Echocardiographic Evaluation
Date and time of echocardiogram: __ __/__ __ __/__ __ __ __ __ __ : __ __
dd mmm        yyyy     24 hr clock
1.  Heart Rate: __ __ __ bpm
Valvular Severity Rheumatic?
18. Aortic Stenosis:
0 None/trace 1 Mild 2 Moderate  3 Severe 0 No  1 Yes19. Aortic Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes20. Mitral Stenosis:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes21. Mitral Regurgitation:
1 Mild 2 Moderate  3 Severe 0 No  1 Yes22. Tricuspid Regurgitation:
0 None 1 Mild 2 Moderate  3 Severe 0 No  1 Yes23. Other:
Pericardial Effusion Severity
0 None 1 Mild 2 Moderate  3 Severe24. Pericardial effusion:
25. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
26. Other Conditions: 0 No  1 Yes è Specify: _______________________________________
Left Heart Dimensions and LV Function
2. Left ventricular size systole:
3. Left ventricular size diastole:
4. Ejection Fraction:      __ __ %
5. Intra ventricular septum (diastole):
6. Posterior wall (diastole):
Diastolic Function
7. Left atrial size, antero-posterior:
8. Left atrial size, planimetry:
9. Mitral E-wave velocity:
10. E-wave deceleration time:
11. Mitral A-wave velocity:










































99 Other: ____________ 
0 None 1 Mild 2 Moderate  3 Severe13. Dilatation right ventricle:
Right Heart Dimensions and Function Severity
 3 Severe14. Dilatation right atrium: 0 None 1 Mild 2 Moderate
15. Tricuspid regurgitation (TR) velocity: __________
1 cm/sec
99 other: __________
16. Right ventricular systolic pressure (RVSP): __________ mmHg
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Site Number: __ __ __ __ Subject Number: __ __ __  Subject Initials: __ __ __
Concomitant Medication Log – Early Termination of Study Drug
















99 Other: ________ ________
1 mg
99 other
__________
Other
Other
Other
1 QD
2 BID
99 Other: ________
3 TID
________________ ________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________ ________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________ ________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
________________
1 IV
2 PO
99 Other: ________
________
1 mg
99 other
__________
1 QD
2 BID
99 Other: ________
3 TID
2 PO
99 Other: ________
2 PO
99 Other: ________
Digoxin
Aldosterone 
Blockers
2 PO
99 Other: ________
